Reduced size self-delivering rnai compounds

ABSTRACT

The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.

RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. §120, as aContinuation in Part, of U.S. application Ser. No. 13/120,342 entitled“Reduced Size Self-delivering RNAi Compounds,” filed on Mar. 22, 2011,which is a national stage filing under 35 U.S.C. §371 of internationalapplication PCT/US2009/005247, filed Sep. 22, 2009, which was publishedunder PCT Article 21(20) in English, and claims the benefit under 35U.S.C. §119(e) of U.S. provisional application Ser. No. U.S. 61/192,954,entitled “Chemically Modified Polynucleotides and Methods of Using theSame,” filed on Sep. 22, 2008, U.S. 61/149,946, entitled “Minimum LengthTriggers of RNA Interference,” filed on Feb. 4, 2009, and U.S.61/224,031, entitled “Minimum Length Triggers of RNA Interference,”filed on Jul. 8, 2009, the disclosure of each of which is incorporatedby reference herein in its entirety.

FIELD OF INVENTION

The invention pertains to the field of RNA interference (RNAi). Theinvention more specifically relates to nucleic acid molecules withimproved in vivo delivery properties without the use of a deliveringagent and their use in efficient gene silencing.

BACKGROUND OF INVENTION

Complementary oligonucleotide sequences are promising therapeutic agentsand useful research tools in elucidating gene functions. However, priorart oligonucleotide molecules suffer from several problems that mayimpede their clinical development, and frequently make it difficult toachieve intended efficient inhibition of gene expression (includingprotein synthesis) using such compositions in vivo.

A major problem has been the delivery of these compounds to cells andtissues. Conventional double-stranded RNAi compounds, 19-29 bases long,form a highly negatively-charged rigid helix of approximately 1.5 by10-15 nm in size. This rod type molecule cannot get through thecell-membrane and as a result has very limited efficacy both in vitroand in vivo. As a result, all conventional RNAi compounds require somekind of a delivery vehicle to promote their tissue distribution andcellular uptake. This is considered to be a major limitation of the RNAitechnology.

There have been previous attempts to apply chemical modifications tooligonucleotides to improve their cellular uptake properties. One suchmodification was the attachment of a cholesterol molecule to theoligonucleotide. A first report on this approach was by Letsinger etal., in 1989. Subsequently, ISIS Pharmaceuticals, Inc. (Carlsbad,Calif.) reported on more advanced techniques in attaching thecholesterol molecule to the oligonucleotide (Manoharan, 1992).

With the discovery of siRNAs in the late nineties, similar types ofmodifications were attempted on these molecules to enhance theirdelivery profiles. Cholesterol molecules conjugated to slightly modified(Soutschek, 2004) and heavily modified (Wolfrum, 2007) siRNAs appearedin the literature. Yamada et al., 2008 also reported on the use ofadvanced linker chemistries which further improved cholesterol mediateduptake of siRNAs. In spite of all this effort, the uptake of these typesof compounds appears to be inhibited in the presence of biologicalfluids resulting in highly limited efficacy in gene silencing in vivo,limiting the applicability of these compounds in a clinical setting.

Therefore, it would be of great benefit to improve upon the prior artoligonucleotides by designing oligonucleotides that have improveddelivery properties in vivo and are clinically meaningful.

SUMMARY OF INVENTION

Described herein are asymmetric chemically modified nucleic acidmolecules with minimal double stranded regions, and the use of suchmolecules in gene expression modulation. RNAi molecules associated withthe invention contain single stranded regions and double strandedregions, and can contain a variety of chemical modifications within boththe single stranded and double stranded regions of the molecule.Additionally, the RNAi molecules can be attached to a hydrophobicconjugate such as a conventional and advanced sterol-type molecule. Thisnew class of RNAi molecules has superior efficacy both in vitro and invivo than previously described RNAi molecules.

Aspects of the invention relate to an isolated nucleic acid moleculehaving a guide strand of 18-23 nucleotides in length that hascomplementarity to a miRNA sequence and a passenger strand of 8-16nucleotides in length. The guide strand and the passenger strand formthe nucleic acid molecule such that the nucleic acid has a doublestranded region and a single stranded region, wherein the singlestranded region is the 3′ end of the guide strand and is 2-13nucleotides in length and comprises at least two phosphorothioatemodifications. At least 50% of the pyrimidines in the nucleic acidmolecule are modified.

In some embodiments the nucleotide in position one of the guide strandhas a 2′-O-methyl modification. For example, the nucleotide in positionone of the guide strand may be a 5P-2′O-methyl U.

In other embodiments, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,98% or 99% of the pyrimidines in the nucleic acid molecule are modified.100% of the pyrimidines in the nucleic acid molecule are modified inother embodiments. The modified pyrimidines may be, for instance,2′fluoro or 2′O methyl modified.

In some embodiments at least one U or C includes a hydrophobicmodification. In other embodiments a plurality of U's and/or C's includea hydrophobic modification. The hydrophobic modification may be, forinstance, a methyl or ethyl hydrophobic base modification.

The guide strand may include a number of phosphate backbonemodifications, such as phosphorothioate modifications. The guide strandcontains 6-8 phosphorothioate modifications in some embodiments. Inother embodiments the 3′ terminal 10 nucleotides of the guide strandinclude at least eight phosphorothioate modifications. In yet otherembodiments the guide strand includes 4-14 phosphate modifications.These modifications may be on the single stranded region, the doublestranded region or both.

The nucleic acid molecule includes a single stranded and a doublestranded region. The single stranded region of the guide strand, in someembodiments, is 6 nucleotides long. In other embodiments the singlestranded region of the guide strand is 8 nucleotides long. The doublestranded region may be 12-14 or 13 nucleotides long in otherembodiments.

Optionally, the double stranded nucleic acid molecule has one end thatis blunt or includes a one nucleotide overhang.

The passenger strand is linked at the 3′ end to a lipophilic groupaccording to some embodiments. The lipophilic group may be a sterol,such as cholesterol.

The isolated double stranded nucleic acid molecule in some embodimentsis an miRNA mimic. The miRNA sequence to which the guide strand iscomplementary in the miRNA mimic is a miRNA recognition element. In someembodiments the miRNA mimic is a mimic of an miRNA selected from thegroup consisting of miR21, miR 139, miR 7, miR29, miR 122, miR 302-367cluster, miR 221, miR-96, miR 126, miR 225 and miR 206.

In other embodiments the isolated double stranded nucleic acid moleculeis an miRNA inhibitor. The miRNA sequence to which the guide strand iscomplementary in the miRNA inhibitor is an antisense strand of a maturemiRNA. In some embodiments the guide strand is at least 50% chemicallymodified. In other embodiments the mature miRNA is miR 17-92.

According to aspects of the invention, a method for modulatingmiRNA-mediated gene expression in a mammalian cell is provided. Themethod involves contacting the mammalian cell with an isolated doublestranded nucleic acid molecule described herein in an effective amountto modulate miRNA-mediated gene expression. In some embodimentsmiRNA-mediated gene expression in the mammalian cell is reduced. Inother embodiments miRNA-mediated gene expression in the mammalian cellis increased. The mammalian cell may contacted with the isolated nucleicacid in vivo, ex vivo, or in vitro.

The invention also involves in other aspects a method for modulatingmiRNA-mediated gene expression in a stem cell. The method involvescontacting the stem cell with an isolated double stranded nucleic acidmolecule described herein in an effective amount to modulatemiRNA-mediated gene expression in the stem cell. The methods are usefulfor example in promoting or inhibiting stem cell differentiation, tissueremodeling, organ preservation etc.

Each of the limitations of the invention can encompass variousembodiments of the invention. It is, therefore, anticipated that each ofthe limitations of the invention involving any one element orcombinations of elements can be included in each aspect of theinvention. This invention is not limited in its application to thedetails of construction and the arrangement of components set forth inthe following description or illustrated in the drawings. The inventionis capable of other embodiments and of being practiced or of beingcarried out in various ways.

BRIEF DESCRIPTION OF DRAWINGS

The accompanying drawings are not intended to be drawn to scale. In thedrawings, each identical or nearly identical component that isillustrated in various figures is represented by a like numeral. Forpurposes of clarity, not every component may be labeled in everydrawing. In the drawings:

FIG. 1 is a schematic depicting proposed structures of asymmetric doublestranded RNA molecules (adsRNA). Bold lines represent sequences carryingmodification patterns compatible with RISC loading. Striped linesrepresent polynucleotides carrying modifications compatible withpassenger strands. Plain lines represent a single strandedpolynucleotide with modification patterns optimized for cell interactionand uptake. FIG. 1A depicts adsRNA with extended guide or passengerstrands; FIG. 1B depicts adsRNA with length variations of a cellpenetrating polynucleotide; FIG. 1C depicts adsRNA with 3′ and 5′conjugates; FIG. 1D depicts adsRNAs with mismatches.

FIG. 2 is a schematic depicting asymmetric dsRNA molecules withdifferent chemical modification patterns. Several examples of chemicalmodifications that might be used to increase hydrophobicity are shownincluding 4-pyridyl, 2-pyridyl, isobutyl and indolyl based position 5uridine modifications.

FIG. 3 is a schematic depicting the use of dsRNA binding domains,protamine (or other Arg rich peptides), spermidine or similar chemicalstructures to block duplex charge to facilitate cellular entry.

FIG. 4 is a schematic depicting positively charged chemicals that mightbe used for polynucleotide charge blockage.

FIG. 5 is a schematic depicting examples of structural and chemicalcompositions of single stranded RISC entering polynucleotides. Thecombination of one or more modifications including 2′d, 2′Ome, 2′F,hydrophobic and phosphorothioate modifications can be used to optimizesingle strand entry into the RISC.

FIG. 6 is a schematic depicting examples of structural and chemicalcomposition of RISC substrate inhibitors. Combinations of one or morechemical modifications can be used to mediate efficient uptake andefficient binding to preloaded RISC complex.

FIG. 7 is a schematic depicting structures of polynucleotides withsterol type molecules attached, where R represent a polycarbonic tail of9 carbons or longer. FIG. 7A depicts an adsRNA molecule; FIG. 7B depictsan siRNA molecule of approximately 17-30 bp long; FIG. 7C depicts a RISCentering strand; FIG. 7D depicts a substrate analog strand. Chemicalmodification patterns, as depicted in FIG. 7, can be optimized topromote desired function.

FIG. 8 is a schematic depicting examples of naturally occurringphytosterols with a polycarbon chain that is longer than 8, attached atposition 17. More than 250 different types of phytosterols are known.

FIG. 9 is a schematic depicting examples of sterol-like structures, withvariations in the size of the polycarbon chains attached at position 17.

FIG. 10 presents schematics and graphs demonstrating that the percentageof liver uptake and plasma clearance of lipid emulsions containingsterol type molecules is directly affected by the size of the polycarbonchain attached at position 17. This figure is adapted from Martins etal, Journal of Lipid Research (1998).

FIG. 11 is a schematic depicting micelle formation. FIG. 11A depicts apolynucleotide with a hydrophobic conjugate; FIG. 11B depicts linoleicacid; FIG. 11C depicts a micelle formed from a mixture ofpolynucleotides containing hydrophobic conjugates combined with fattyacids.

FIG. 12 is a schematic depicting how alteration in lipid composition canaffect pharmacokinetic behavior and tissue distribution ofhydrophobically modified and/or hydrophobically conjugatedpolynucleotides. In particular, use of lipid mixtures enriched inlinoleic acid and cardiolipin results in preferential uptake bycardiomyocites.

FIG. 13 is a schematic showing examples of RNAi constructs and controlsused to target MAP4K4 expression. RNAi construct 12083 corresponds toSEQ ID NOs:597 and 598. RNAi construct 12089 corresponds to SEQ IDNO:599.

FIG. 14 is a graph showing MAP4K4 expression following transfection withRNAi constructs associated with the invention. RNAi constructs testedwere: 12083 (Nicked), 12085 (13 nt Duplex), 12089 (No Stem Pairing) and12134 (13 nt miniRNA). Results of transfection were compared to anuntransfected control sample. RNAi construct 12083 corresponds to SEQ IDNOs:597 and 598. RNAi construct 12085 corresponds to SEQ ID NOs:600 and601. RNAi construct 12089 corresponds to SEQ ID NO:599. RNAi construct12134 corresponds to SEQ ID NOs:602 and 603.

FIG. 15 is a graph showing expression of MAP4K4 24 hourspost-transfection with RNAi constructs associated with the invention.RNAi constructs tested were: 11546 (MAP4K4 rxRNA), 12083 (MAP4K4 NickedConstruct), 12134 (12 bp soloRNA) and 12241 (14/3/14 soloRNA). Resultsof transfection were compared to a filler control sample. RNAi construct11546 corresponds to SEQ ID NOs:604 and 605. RNAi construct 12083corresponds to SEQ ID NOs:597 and 598. RNAi construct 12134 correspondsto SEQ ID NOs:602 and 603. RNAi construct 12241 corresponds to SEQ IDNOs:606 and 607.

FIG. 16 presents a graph and several tables comparing parametersassociated with silencing of MAP4K4 expression following transfectionwith RNAi constructs associated with the invention. The rxRNA constructcorresponds to SEQ ID NOs:604 and 605. The 14-3-14 soloRNA constructcorresponds to SEQ ID NOs:606 and 607. The 13/19 duplex (nickedconstruct) corresponds to SEQ ID NOs:597 and 598. The 12-bp soloRNAconstruct corresponds to SEQ ID NOs:602 and 603.

FIG. 17 is a schematic showing examples of RNAi constructs and controlsused to target SOD1 expression. The 12084 RNAi construct corresponds toSEQ ID NOs:612 and 613.

FIG. 18 is a graph showing SOD1 expression following transfection withRNAi constructs associated with the invention. RNAi constructs testedwere: 12084 (Nicked), 12086 (13 nt Duplex), 12090 (No Stem Pairing) and12035 (13 nt MiniRNA). Results of transfection were compared to anuntransfected control sample. The 12084 RNAi construct corresponds toSEQ ID NOs:612 and 613. The 12086 RNAi construct corresponds to SEQ IDNOs:608 and 609. The 12035 RNAi construct corresponds to SEQ ID NOs:610and 611.

FIG. 19 is a graph showing expression of SOD1 24 hours post-transfectionwith RNAi constructs associated with the invention. RNAi constructstested were: 10015 (SOD1 rxRNA) and 12084 (SOD1 Nicked Construct).Results of transfection were compared to a filler control sample. The10015 RNAi construct corresponds to SEQ ID NOs:614 and 615. The 12084RNAi construct corresponds to SEQ ID NOs:612 and 613.

FIG. 20 is a schematic indicating that RNA molecules with doublestranded regions that are less than 10 nucleotides are not cleaved byDicer.

FIG. 21 is a schematic revealing a hypothetical RNAi model for RNAinduced gene silencing.

FIG. 22 is a graph showing chemical optimization of asymmetric RNAicompounds. The presence of chemical modifications, in particular 2′F UC,phosphorothioate modifications on the guide strand, and complete CU2′OMe modification of the passenger strands results in development offunctional compounds. Silencing of MAP4K4 following lipid-mediatedtransfection is shown using RNAi molecules with specific modifications.RNAi molecules tested had sense strands that were 13 nucleotides longand contained the following modifications: unmodified; C and U 2′OMe; Cand U 2′OMe and 3′ Chl; rxRNA 2′OMe pattern; or full 2′OMe, exceptbase 1. Additionally, the guide (anti-sense) strands of the RNAimolecules tested contained the following modifications: unmodified;unmodified with 5′P; C and U 2′F; C and U 2′F with 8 PS 3′ end; andunmodified (17 nt length). Results for rxRNA 12/10 Duplex and negativecontrols are also shown.

FIG. 23 demonstrates that the chemical modifications described hereinsignificantly increase in vitro efficacy in un-assisted delivery of RNAimolecules in HeLa cells. The structure and sequence of the compoundswere not altered; only the chemical modification patterns of themolecules were modified. Compounds lacking 2′F, 2′O-me, phosphorothioatemodification, or cholesterol conjugates were completely inactive inpassive uptake. A combination of all 4 of these types of modificationsproduced the highest levels of activity (compound 12386).

FIG. 24 is a graph showing MAP4K4 expression in Hela cells followingpassive uptake transfection of: NT Accell modified siRNA, MAP4K4 AccellsiRNA, Non-Chl nanoRNA (12379) and sd-nanoRNA (12386).

FIG. 25 is a graph showing expression of MAP4K4 in HeLa cells followingpassive uptake transfection of various concentrations of RNA moleculescontaining the following parameters: Nano Lead with no 3′Chl; Nano Lead;Accell MAP4K4; 21 mer GS with 8 PS tail; 21 mer GS with 12 PS tail; and25 mer GS with 12 PS tail.

FIG. 26 is a graph demonstrating that reduction in oligonucleotidecontent increases the efficacy of unassisted uptake. Similar chemicalmodifications were applied to asymmetric compounds, traditional siRNAcompounds and 25 mer RNAi compounds. The asymmetric small compoundsdemonstrated the most significant efficacy.

FIG. 27 is a graph demonstrating the importance of phosphorothioatecontent for un-assisted delivery. FIG. 27A demonstrates the results of asystematic screen that revealed that the presence of at least 2-12phosphorothioates in the guide strand significantly improves uptake; insome embodiments, 4-8 phosphorothioate modifications were found to bepreferred. FIG. 27B reveals that the presence or absence ofphosphorothioate modifications in the sense strand did not alterefficacy.

FIG. 28 is a graph showing expression of MAP4K4 in primary mousehepatocytes following passive uptake transfection of: AccellMedia-Ctrl-UTC; MM APOB Alnylam; Active APOB Alnylam; nanoRNA withoutchl; nanoRNA MAP4K4; Mouse MAP4K4 Accell Smartpool; DY547 AccellControl; Luc Ctrl rxRNA with Dy547; MAP4K4 rxRNA with DY547; and ASStrand Alone (nano).

FIG. 29 is a graph showing expression of ApoB in mouse primaryhepatocytes following passive uptake transfection of: AccellMedia-Ctrl-UTC; MM APOB Alnylam; Active APOB Alnylam; nanoRNA withoutchl; nanoRNA MAP4K4; Mouse MAP4K4 Accell Smartpool; DY547 AccellControl; Luc Ctrl rxRNA with Dy547; MAP4K4 rxRNA with DY547; and ASStrand Alone (nano).

FIG. 30 is a graph showing expression of MAP4K4 in primary humanhepatocytes following passive uptake transfection of: 11550 MAP4K4rxRNA; 12544 MM MAP4K4 nanoRNA; 12539 Active MAP4K4 nanoRNA; AccellMedia; and UTC.

FIG. 31 is a graph showing ApoB expression in primary human hepatocytesfollowing passive uptake transfection of: 12505 Active ApoB chol-siRNA;12506 mM ApoB chol-siRNA; Accell Media; and UTC.

FIG. 32 is an image depicting localization of sd-rxRNA^(nano)localization.

FIG. 33 is an image depicting localization of Chol-siRNA (Alnylam).

FIG. 34 is a schematic of 1^(st) generation (G1) sd-rxRNA^(nano)molecules associated with the invention indicating regions that aretargeted for modification, and functions associated with differentregions of the molecules.

FIG. 35 depicts modification patterns that were screened foroptimization of sd-rxRNA^(nano) (G1). The modifications that werescreened included, on the guide strand, lengths of 19, 21 and 25nucleotides, phosphorothioate modifications of 0-18 nucleotides, andreplacement of 2′F modifications with 2′OMe, 5 Methyl C and/or riboThymidine modifications. Modifications on the sense strand that werescreened included nucleotide lengths of 11, 13 and 19 nucleotides,phosphorothioate modifications of 0-4 nucleotides and 2′OMemodifications.

FIG. 36 is a schematic depicting modifications of sd-rxRNA^(nano) thatwere screened for optimization.

FIG. 37 is a graph showing percent MAP4K4 expression in Hek293 cellsfollowing transfection of: Risc Free siRNA; rxRNA; Nano (unmodified); GSalone; Nano Lead (no Chl); Nano (GS: (3) 2′OMe at positions 1, 18, and19, 8 PS, 19 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS,21 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 21 nt);and Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 25 nt);

FIG. 38 is a graph showing percent MAP4K4 expression in HeLa cellsfollowing passive uptake transfection of: GS alone; Nano Lead; Nano (GS:(3) 2′OMe at positions 1, 18, and 19, 8 PS, 19 nt); Nano (GS: (3) 2′OMeat positions 1, 18, and 19, 8 PS, 21 nt); Nano (GS: (3) 2′OMe atpositions 1, 18, and 19, 12 PS, 21 nt); Nano (GS: (3) 2′OMe at positions1, 18, and 19, 12 PS, 25 nt).

FIG. 39 is a graph showing percent MAP4K4 expression in Hek293 cellsfollowing lipid mediated transfection of: Guide Strand alone (GS: 8PS,19 nt); Guide Strand alone (GS: 18PS, 19 nt); Nano (GS: no PS, 19 nt);Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt);Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS,19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 40 is a graph showing percent MAP4K4 expression in Hek293 cellsfollowing lipid mediated transfection of: Guide Strand alone (GS: 8PS,19 nt); Guide Strand alone (GS: 18PS, 19 nt); Nano (GS: no PS, 19 nt);Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt);Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS,19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 41 is a graph showing percent MAP4K4 expression in HeLa cellsfollowing passive uptake transfection of: Nano Lead (no Chl); GuideStrand alone (18 PS); Nano (GS: 0 PS, 19 nt); Nano (GS: 2 PS, 19 nt);Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18PS, 19 nt).

FIG. 42 is a graph showing percent MAP4K4 expression in HeLa cellsfollowing passive uptake transfection of: Nano Lead (no Chl); GuideStrand alone (18 PS); Nano (GS: 0 PS, 19 nt); Nano (GS: 2 PS, 19 nt);Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18PS, 19 nt).

FIG. 43 is a schematic depicting guide strand chemical modificationsthat were screened for optimization.

FIG. 44 is a graph showing percent MAP4K4 expression in Hek293 cellsfollowing reverse transfection of: RISC free siRNA; GS only (2′F C andUs); GS only (2′OMe C and Us); Nano Lead (2′F C and Us); nano (GS: (3)2′OMe, positions 16-18); nano (GS: (3) 2′OMe, positions 16, 17 and 19);nano (GS: (4) 2′OMe, positions 11, 16-18); nano (GS: (10) 2′OMe, C andUs); nano (GS: (6) 2′OMe, positions 1 and 5-9); nano (GS: (3) 2′OMe,positions 1, 18 and 19); and nano (GS: (5) 2′OMe Cs).

FIG. 45 is a graph demonstrating efficacy of various chemicalmodification patterns. In particular, 2-OMe modification in positions 1and 11-18 was well tolerated. 2′OMe modifications in the seed arearesulted in a slight reduction of efficacy (but were still highlyefficient). Ribo-modifications in the seed were well tolerated. Thisdata enabled the generation of self delivering compounds with reduced orno 2′F modifications. This is significant because 2′F modifications maybe associated with toxicity in vivo.

FIG. 46 is a schematic depicting sense strand modifications.

FIG. 47 is a graph demonstrating sense strand length optimization. Asense strand length between 10-15 bases was found to be optimal in thisassay. Increasing sense strand length resulted in a reduction of passiveuptake of these compounds but may be tolerated for other compounds.Sense strands containing LNA modification demonstrated similar efficacyto non-LNA containing compounds. In some embodiments, the addition ofLNA or other thermodynamically stabilizing compounds can be beneficial,resulting in converting non-functional sequences into functionalsequences.

FIG. 48 is a graph showing percent MAP4K4 expression in HeLa cellsfollowing passive uptake transfection of: Guide Strand Alone (2′F C andU); Nano Lead; Nano Lead (No Chl); Nano (SS: 11 nt 2′OMe C and Us, Chl);Nano (SS: lint, complete 2′OMe, Chl); Nano (SS: 19 nt, 2′OMe C and Us,Chl); Nano (SS: 19 nt, 2′OMe C and Us, no Chi).

FIG. 49 is a graph showing percent MAP4K4 expression in HeLa cellsfollowing passive uptake transfection of: Nano Lead (No Chl); Nano (SSno PS); Nano Lead (SS:2 PS); Nano (SS:4 PS).

FIG. 50 is a schematic depicting a sd-rxRNA^(nano) second generation (GMlead molecule.

FIG. 51 presents a graph indicating EC50 values for MAP4K4 silencing inthe presence of sd-rxRNA, and images depicting localization ofDY547-labeled rxRNA^(ori) and DY547-labeled sd-rxRNA.

FIG. 52 is a graph showing percent MAP4K4 expression in HeLa cells inthe presence of optimized sd-rxRNA molecules.

FIG. 53 is a graph depicting the relevance of chemistry content inoptimization of sd-rxRNA efficacy.

FIG. 54 presents schematics of sterol-type molecules and a graphrevealing that sd-rxRNA compounds are fully functional with a variety oflinker chemistries. GII asymmetric compounds were synthesized withsterol type molecules attached through TEG and amino caproic acidlinkers. Both linkers showed identical potency. This functionalityindependent of linker chemistry indicates a significant differencebetween the molecules described herein and previously describedmolecules, and offers significant advantages for the molecules describedherein in terms of scale up and synthesis.

FIG. 55 demonstrates the stability of chemically modified sd-rxRNAcompounds in human serum in comparison to non modified RNA. Theoligonucleotides were incubated in 75% serum at 37° C. for the number ofhours indicated. The level of degradation was determined by running thesamples on non-denaturing gels and staining with SYBGR.

FIG. 56 is a graph depicting optimization of cellular uptake of sd-rxRNAthrough minimizing oligonucleotide content.

FIG. 57 is a graph showing percent MAP4K4 expression after spontaneouscellular uptake of sd-rxRNA in mouse PEC-derived macrophages, and phaseand fluorescent images showing localization of sd-rxRNA.

FIG. 58 is a graph showing percent MAP4K4 expression after spontaneouscellular uptake of sd-rxRNA (targeting) and sd-rxRNA (mismatch) in mouseprimary hepatocytes, and phase and fluorescent images showinglocalization of sd-rxRNA.

FIG. 59 presents images depicting localization of DY547-labeled sd-rxRNAdelivered to RPE cells with no formulation.

FIG. 60 is a graph showing silencing of MAP4K4 expression in RPE cellstreated with sd-rxRNA^(nano) without formulation.

FIG. 61 presents a graph and schematics of RNAi compounds showing thechemical/structural composition of highly effective sd-rxRNA compounds.Highly effective compounds were found to have the followingcharacteristics: antisense strands of 17-21 nucleotides, sense strandsof 10-15 nucleotides, single-stranded regions that contained 2-12phosphorothioate modifications, preferentially 6-8 phosphorothioatemodifications, and sense strands in which the majority of nucleotideswere 2′OMe modified, with or without phosphorothioate modification. Anylinker chemistry can be used to attach these molecules to hydrophobicmoieties such as cholesterol at the 3′ end of the sense strand. VersionGIIa-b of these RNA compounds demonstrate that elimination of 2′Fcontent has no impact on efficacy.

FIG. 62 presents a graph and schematics of RNAi compounds demonstratingthe superior performance of sd-rxRNA compounds compared to compoundspublished by Wolfrum et. al. Nature Biotech, 2007. Both generation I andII compounds (GI and GIIa) developed herein show great efficacy. Bycontrast, when the chemistry described in Wolfrum et al. (all oligoscontain cholesterol conjugated to the 3′ end of the sense strand) wasapplied to the same sequence in a context of conventional siRNA (19 bpduplex with two overhang) the compound was practically inactive. Thesedata to emphasize the significance of the combination of chemicalmodifications and asymmetrical molecules described herein, producinghighly effective RNA compounds.

FIG. 63 presents images showing that sd-rxRNA accumulates inside cellswhile other less effective conjugate RNAs accumulate on the surface ofcells.

FIG. 64 presents images showing that sd-rxRNA molecules, but not othermolecules, are internalized into cells within minutes.

FIG. 65 presents images demonstrating that sd-rxRNA compounds havedrastically better cellular and tissue uptake characteristics whencompared to conventional cholesterol conjugated siRNAs (such as thosepublished by Soucheck et al). FIG. 65A,B compare uptake in RPE cells,FIG. 65C,D compare uptake upon local administration to skin and FIG.65E,F compare uptake by the liver upon systemic administration. Thelevel of uptake is at least an order of magnitude higher for thesd-rxRNA compounds relative to the regular siRNA-cholesterol compounds.

FIG. 66 presents images depicting localization of rxRNA^(ori) andsd-rxRNA following local delivery.

FIG. 67 presents images depicting localization of sd-rxRNA and otherconjugate RNAs following local delivery.

FIG. 68 presents a graph revealing the results of a screen performedwith sd-rxRNAGII chemistry to identify functional compounds targetingthe SPP1 gene. Multiple effective compounds were identified, with 14131being the most effective. The compounds were added to A-549 cells andthe level of the ratio of SPP1/PPIB was determined by B-DNA after 48hours.

FIG. 69 presents a graph and several images demonstrating efficientcellular uptake of sd-rxRNA within minutes of exposure. This is a uniquecharacteristics of the sd-rxRNA compounds described herein, not observedwith any other RNAi compounds. The Soutschek et al. compound was used asa negative control.

FIG. 70 presents a graph and several images demonstrating efficientuptake and silencing of sd-rxRNA compounds in multiple cell types withmultiple sequences. In each case silencing was confirmed by looking attarget gene expression using a Branched DNA assay.

FIG. 71 presents a graph revealing that sd-rxRNA is active in thepresence and absence of serum. A slight reduction in efficacy (2-5 fold)was observed in the presence of serum. This minimal reduction inefficacy in the presence of serum differentiates the sd-rxRNA compoundsdescribed herein from previously described RNAi compounds, which had agreater reduction in efficacy, and thus creates a foundation for in vivoefficacy of the sd-rxRNA molecules described herein.

FIG. 72 presents images demonstrating efficient tissue penetration andcellular uptake upon single intradermal injection of sd-rxRNA compoundsdescribed herein. This represents a model for local delivery of sd-rxRNAcompounds as well as an effective demonstration of delivery of sd-rxRNAcompounds and silencing of genes in dermatological applications.

FIG. 73 presents images and a graph demonstrating efficient cellularuptake and in vivo silencing with sd-rxRNA following intradermalinjection.

FIG. 74 presents graphs demonstrating that sd-rxRNA compounds haveimproved blood clearance and induce effective gene silencing in vivo inthe liver upon systemic administration.

FIG. 75 presents a graph demonstrating that the presence of 5-Methyl Cin an RNAi compound resulted in an increase in potency of lipid mediatedtransfection, demonstrating that hydrophobic modification of Cs and Usin the content of RNAi compounds can be beneficial. In some embodiments,these types of modifications can be used in the context of 2′ ribosemodified bases to insure optimal stability and efficacy.

FIG. 76 presents a graph showing percent MAP4K4 expression in HeLa cellsfollowing passive uptake transfection of: Guide strand alone; Nano Lead;Nano Lead (No cholesterol); Guide Strand w/5MeC and 2′F Us Alone; NanoLead w/GS 5MeC and 2′F Us; Nano Lead w/GS riboT and 5 Methyl Cs; andNano Lead w/Guide dT and 5 Methyl Cs.

FIG. 77 presents images comparing localization of sd-rxRNA and other RNAconjugates following systemic delivery to the liver.

FIG. 78 presents schematics demonstrating 5-uridyl modifications withimproved hydrophobicity characteristics. Incorporation of suchmodifications into sd-rxRNA compounds can increase cellular and tissueuptake properties. FIG. 78B presents a new type of RNAi compoundmodification which can be applied to compounds to improve cellularuptake and pharmacokinetic behavior. This type of modification, whenapplied to sd-rxRNA compounds, may contribute to making such compoundsorally available.

FIG. 79 presents schematics revealing the structures of synthesizedmodified sterol type molecules, where the length and structure of theC17 attached tail is modified. Without wishing to be bound by anytheory, the length of the C17 attached tail may contribute to improvingin vitro and in vivo efficacy of sd-rxRNA compounds.

FIG. 80 presents a schematic demonstrating the lithocholic acid route tolong side chain cholesterols.

FIG. 81 presents a schematic demonstrating a route to 5-uridylphosphoramidite synthesis.

FIG. 82 presents a schematic demonstrating synthesis of tri-functionalhydroxyprolinol linker for 3′-cholesterol attachment.

FIG. 83 presents a schematic demonstrating synthesis of solid supportfor the manufacture of a shorter asymmetric RNAi compound strand.

FIG. 84 demonstrates SPPI sd-rxRNA compound selection. Sd-rxRNAcompounds targeting SPP1 were added to A549 cells (using passivetransfection) and the level of SPP1 expression was evaluated after 48hours. Several novel compounds effective in SPP1 silencing wereidentified, the most potent of which was compound 14131.

FIG. 85 demonstrates independent validation of sd-rxRNA compounds 14116,14121, 14131, 14134, 14139, 14149, and 14152 efficacy in SPP1 silencing.

FIG. 86 demonstrates results of sd-rxRNA compound screens to identifysd-rxRNA compounds functional in CTGF knockdown.

FIG. 87 demonstrates results of sd-rxRNA compound screens to identifysd-rxRNA functional in CTGF knockdown.

FIG. 88 demonstrates a systematic screen identifying the minimal lengthof the asymmetric compounds. The passenger strand of 10-19 bases washybridized to a guide strand of 17-25 bases. In this assay, compoundswith duplex regions as short as 10 bases were found to be effective ininducing.

FIG. 89 demonstrates that positioning of the sense strand relative tothe guide strand is critical for RNAi Activity. In this assay, a bluntend was found to be optimal, a 3′ overhang was tolerated, and a 5′overhang resulted in complete loss of functionality.

FIG. 90 demonstrates that the guide strand, which has homology to thetarget only at nucleotides 2-17, resulted in effective RNAi whenhybridized with sense strands of different lengths. The compounds wereintroduced into HeLa cells via lipid mediated transfection.

FIG. 91 is a schematic depicting a panel of sterol-type molecules whichcan be used as a hydrophobic entity in place of cholesterol. In someinstances, the use of sterol-type molecules comprising longer chainsresults in generation of sd-rxRNA compounds with significantly bettercellular uptake and tissue distribution properties.

FIG. 92 presents schematics depicting a panel of hydrophobic moleculeswhich might be used as a hydrophobic entity in place of cholesterol.These list just provides representative examples; any small moleculewith substantial hydrophobicity can be used.

DETAILED DESCRIPTION

Aspects of the invention relate to methods and compositions involved ingene silencing. The invention is based at least in part on thesurprising discovery that asymmetric nucleic acid molecules with adouble stranded region of a minimal length such as 8-14 nucleotides, areeffective in silencing gene expression. Molecules with such a shortdouble stranded region have not previously been demonstrated to beeffective in mediating RNA interference. It had previously been assumedthat that there must be a double stranded region of 19 nucleotides orgreater. The molecules described herein are optimized through chemicalmodification, and in some instances through attachment of hydrophobicconjugates.

The invention is based at least in part on another surprising discoverythat asymmetric nucleic acid molecules with reduced double strandedregions are much more effectively taken up by cells compared toconventional siRNAs. These molecules are highly efficient in silencingof target gene expression and offer significant advantages overpreviously described RNAi molecules including high activity in thepresence of serum, efficient self delivery, compatibility with a widevariety of linkers, and reduced presence or complete absence of chemicalmodifications that are associated with toxicity.

In contrast to single-stranded polynucleotides, duplex polynucleotideshave been difficult to deliver to a cell as they have rigid structuresand a large number of negative charges which makes membrane transferdifficult. Unexpectedly, it was found that the polynucleotides of thepresent invention, although partially double-stranded, are recognized invivo as single-stranded and, as such, are capable of efficiently beingdelivered across cell membranes. As a result the polynucleotides of theinvention are capable in many instances of self delivery. Thus, thepolynucleotides of the invention may be formulated in a manner similarto conventional RNAi agents or they may be delivered to the cell orsubject alone (or with non-delivery type carriers) and allowed to selfdeliver. In one embodiment of the present invention, self deliveringasymmetric double-stranded RNA molecules are provided in which oneportion of the molecule resembles a conventional RNA duplex and a secondportion of the molecule is single stranded.

The polynucleotides of the invention are referred to herein as isolateddouble stranded or duplex nucleic acids, oligonucleotides orpolynucleotides, nano molecules, nano RNA, sd-rxRNA^(nano), sd-rxRNA orRNA molecules of the invention.

The oligonucleotides of the invention in some aspects have a combinationof asymmetric structures including a double stranded region and a singlestranded region of 5 nucleotides or longer, specific chemicalmodification patterns and are conjugated to lipophilic or hydrophobicmolecules. This new class of RNAi like compounds have superior efficacyin vitro and in vivo. Based on the data described herein it is believedthat the reduction in the size of the rigid duplex region in combinationwith phosphorothioate modifications applied to a single stranded regionare new and important for achieving the observed superior efficacy.Thus, the RNA molecules described herein are different in both structureand composition as well as in vitro and in vivo activity.

In a preferred embodiment the RNAi compounds of the invention comprisean asymmetric compound comprising a duplex region (required forefficient RISC entry of 10-15 bases long) and single stranded region of4-12 nucleotides long; with a 13 nucleotide duplex. A 6 nucleotidesingle stranded region is preferred in some embodiments. The singlestranded region of the new RNAi compounds also comprises 2-12phosphorothioate internucleotide linkages (referred to asphosphorothioate modifications). 6-8 phosphorothioate internucleotidelinkages are preferred in some embodiments. Additionally, the RNAicompounds of the invention also include a unique chemical modificationpattern, which provides stability and is compatible with RISC entry. Thecombination of these elements has resulted in unexpected propertieswhich are highly useful for delivery of RNAi reagents in vitro and invivo.

The chemically modification pattern, which provides stability and iscompatible with RISC entry includes modifications to the sense, orpassenger, strand as well as the antisense, or guide, strand. Forinstance the passenger strand can be modified with any chemical entitieswhich confirm stability and do not interfere with activity. Suchmodifications include 2′ ribo modifications (O-methyl, 2′ F, 2 deoxy andothers) and backbone modification like phosphorothioate modifications. Apreferred chemical modification pattern in the passenger strand includesO-methyl modification of C and U nucleotides within the passenger strandor alternatively the passenger strand may be completely O-methylmodified.

The guide strand, for example, may also be modified by any chemicalmodification which confirms stability without interfering with RISCentry. A preferred chemical modification pattern in the guide strandincludes the majority of C and U nucleotides being 2′ F modified and the5′ end being phosphorylated. Another preferred chemical modificationpattern in the guide strand includes 2′Omethyl modification of position1 and C/U in positions 11-18 and 5′ end chemical phosphorylation. Yetanother preferred chemical modification pattern in the guide strandincludes 2′Omethyl modification of position 1 and C/U in positions 11-18and 5′ end chemical phosphorylation and 2′F modification of C/U inpositions 2-10.

It was surprisingly discovered according to the invention that theabove-described chemical modification patterns of the oligonucleotidesof the invention are well tolerated and actually improved efficacy ofasymmetric RNAi compounds. See, for instance, FIG. 22.

It was also demonstrated experimentally herein that the combination ofmodifications to RNAi when used together in a polynucleotide results inthe achievement of optimal efficacy in passive uptake of the RNAi.Elimination of any of the described components (Guide strandstabilization, phosphorothioate stretch, sense strand stabilization andhydrophobic conjugate) or increase in size results in sub-optimalefficacy and in some instances complete lost of efficacy. Thecombination of elements results in development of compound, which isfully active following passive delivery to cells such as HeLa cells.(FIG. 23). The degree to which the combination of elements results inefficient self delivery of RNAi molecules was completely unexpected.

The data shown in FIGS. 26, 27 and 43 demonstrated the importance of thevarious modifications to the RNAi in achieving stabilization andactivity. For instance, FIG. 26 demonstrates that use off asymmetricconfiguration is important in getting efficacy in passive uptake. Whenthe same chemical composition is applied to compounds of traditionalconfigurations (19-21 bases duplex and 25 mer duplex) the efficacy wasdrastically decreased in a length dependent manner FIG. 27 demonstrateda systematic screen of the impact of phosphorothioate chemicalmodifications on activity. The sequence, structure, stabilizationchemical modifications, hydrophobic conjugate were kept constant andcompound phosphorothioate content was varied (from 0 to 18 PS bond).Both compounds having no phosphorothioate linkages and having 18phosphorothioate linkages were completely inactive in passive uptake.Compounds having 2-16 phosphorothioate linkages were active, withcompounds having 4-10 phosphorothioate being the most active compounds.

The data in the Examples presented below demonstrates high efficacy ofthe oligonucleotides of the invention both in vitro in variety of celltypes (supporting data) and in vivo upon local and systemicadministration. For instance, the data compares the ability of severalcompetitive RNAi molecules having different chemistries to silence agene. Comparison of sd-rxRNA (oligonucleotides of the invention) withRNAs described in Soucheck et al. and Wolfrum at al., as applied to thesame targeting region, demonstrated that only sd-rxRNA chemistry showeda significant functionality in passive uptake. The composition of theinvention achieved EC50 values of 10-50 pM. This level of efficacy isun-attainable with conventional chemistries like those described inSauthceck at al and Accell. Similar comparisons were made in othersystems, such as in vitro (RPE cell line), in vivo upon localadministration (wounded skin) and systemic (50 mg/kg) as well as othergenes (FIGS. 65 and 68). In each case the oligonucleotides of theinvention achieved better results. FIG. 64 includes data demonstratingefficient cellular uptake and resulting silencing by sd-rxRNA compoundsonly after 1 minute of exposure. Such an efficacy is unique to thiscomposition and have not been seen with other types of molecules in thisclass. FIG. 70 demonstrates efficient uptake and silencing of sd-rxRNAcompounds in multiple cell types with multiple sequences. The sd-rxRNAcompounds are also active in cells in presence and absence of serum andother biological liquids. FIG. 71 demonstrates only a slight reductionin activity in the presence of serum. This ability to function inbiologically aggressive environment effectively further differentiatessd-rxRNA compounds from other compounds described previously in thisgroup, like Accell and Soucheck et al, in which uptake is drasticallyinhibited in a presence of serum.

Significant amounts of data also demonstrate the in vivo efficacy of thecompounds of the invention. For instance FIGS. 72-74 involve multipleroutes of in vivo delivery of the compounds of the invention resultingin significant activity. FIG. 72, for example, demonstrates efficienttissue penetration and cellular uptake upon single intradermalinjection. This is a model for local delivery of sd-rxRNA compounds aswell as an effective delivery mode for sd-rxRNA compounds and silencinggenes in any dermatology applications. FIG. 73 demonstrated efficienttissue penetration, cellular uptake and silencing upon local in vivointradermal injection of sd-rxRNA compounds. The data of FIG. 74demonstrate that sd-rxRNA compounds result in highly effective liveruptake upon IV administration. Comparison to Souicheck at al moleculeshowed that the level of liver uptake at identical dose level was quitesurprisingly, at least 50 fold higher with the sd-rxRNA compound thanthe Souicheck at al molecule.

The sd-rxRNA can be further improved in some instances by improving thehydrophobicity of compounds using of novel types of chemistries. Forexample one chemistry is related to use of hydrophobic basemodifications. Any base in any position might be modified, as long asmodification results in an increase of the partition coefficient of thebase. The preferred locations for modification chemistries are positions4 and 5 of the pyrimidines. Preferably the base modification is a methylor ethyl modification. The major advantage of these positions is (a)ease of synthesis and (b) lack of interference with base-pairing and Aform helix formation, which are essential for RISC complex loading andtarget recognition. Examples of these chemistries is shown in FIGS.75-83. A version of sd-rxRNA compounds where multiple deoxy Uridines arepresent without interfering with overall compound efficacy was used. Inaddition major improvement in tissue distribution and cellular uptakemight be obtained by optimizing the structure of the hydrophobicconjugate. In some of the preferred embodiment the structure of sterolis modified to alter (increase/decrease) C17 attached chain. This typeof modification results in significant increase in cellular uptake andimprovement of tissue uptake prosperities in vivo.

This invention is not limited in its application to the details ofconstruction and the arrangement of components set forth in thefollowing description or illustrated in the drawings. The invention iscapable of other embodiments and of being practiced or of being carriedout in various ways. Also, the phraseology and terminology used hereinis for the purpose of description and should not be regarded aslimiting. The use of “including,” “comprising,” or “having,”“containing,” “involving,” and variations thereof herein, is meant toencompass the items listed thereafter and equivalents thereof as well asadditional items.

Thus, aspects of the invention relate to isolated double strandednucleic acid molecules comprising a guide (antisense) strand and apassenger (sense) strand. As used herein, the term “double-stranded”refers to one or more nucleic acid molecules in which at least a portionof the nucleomonomers are complementary and hydrogen bond to form adouble-stranded region. In some embodiments, the length of the guidestrand ranges from 16-29 nucleotides long. In certain embodiments, theguide strand is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or29 nucleotides long. The guide strand has complementarity to a targetgene. Complementarity between the guide strand and the target gene mayexist over any portion of the guide strand. Complementarity as usedherein may be perfect complementarity or less than perfectcomplementarity as long as the guide strand is sufficientlycomplementary to the target that it mediates RNAi. In some embodimentscomplementarity refers to less than 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%,or 1% mismatch between the guide strand and the target. Perfectcomplementarity refers to 100% complementarity. Thus the invention hasthe advantage of being able to tolerate sequence variations that mightbe expected due to genetic mutation, strain polymorphism, orevolutionary divergence. For example, siRNA sequences with insertions,deletions, and single point mutations relative to the target sequencehave also been found to be effective for inhibition. Moreover, not allpositions of a siRNA contribute equally to target recognition.Mismatches in the center of the siRNA are most critical and essentiallyabolish target RNA cleavage. Mismatches upstream of the center orupstream of the cleavage site referencing the antisense strand aretolerated but significantly reduce target RNA cleavage. Mismatchesdownstream of the center or cleavage site referencing the antisensestrand, preferably located near the 3′ end of the antisense strand, e.g.1, 2, 3, 4, 5 or 6 nucleotides from the 3′ end of the antisense strand,are tolerated and reduce target RNA cleavage only slightly.

While not wishing to be bound by any particular theory, in someembodiments, the guide strand is at least 16 nucleotides in length andanchors the Argonaute protein in RISC. In some embodiments, when theguide strand loads into RISC it has a defined seed region and targetmRNA cleavage takes place across from position 10-11 of the guidestrand. In some embodiments, the 5′ end of the guide strand is or isable to be phosphorylated. The nucleic acid molecules described hereinmay be referred to as minimum trigger RNA.

In some embodiments, the length of the passenger strand ranges from 8-14nucleotides long. In certain embodiments, the passenger strand is 8, 9,10, 11, 12, 13 or 14 nucleotides long. The passenger strand hascomplementarity to the guide strand. Complementarity between thepassenger strand and the guide strand can exist over any portion of thepassenger or guide strand. In some embodiments, there is 100%complementarity between the guide and passenger strands within thedouble stranded region of the molecule.

Aspects of the invention relate to double stranded nucleic acidmolecules with minimal double stranded regions. In some embodiments theregion of the molecule that is double stranded ranges from 8-14nucleotides long. In certain embodiments, the region of the moleculethat is double stranded is 8, 9, 10, 11, 12, 13 or 14 nucleotides long.In certain embodiments the double stranded region is 13 nucleotideslong. There can be 100% complementarity between the guide and passengerstrands, or there may be one or more mismatches between the guide andpassenger strands. In some embodiments, on one end of the doublestranded molecule, the molecule is either blunt-ended or has aone-nucleotide overhang. The single stranded region of the molecule isin some embodiments between 4-12 nucleotides long. For example thesingle stranded region can be 4, 5, 6, 7, 8, 9, 10, 11 or 12 nucleotideslong. However, in certain embodiments, the single stranded region canalso be less than 4 or greater than 12 nucleotides long. In certainembodiments, the single stranded region is 6 nucleotides long.

RNAi constructs associated with the invention can have a thermodynamicstability (ΔG) of less than −13 kkal/mol. In some embodiments, thethermodynamic stability (ΔG) is less than −20 kkal/mol. In someembodiments there is a loss of efficacy when (ΔG) goes below −21kkal/mol. In some embodiments a (ΔG) value higher than −13 kkal/mol iscompatible with aspects of the invention. Without wishing to be bound byany theory, in some embodiments a molecule with a relatively higher (ΔG)value may become active at a relatively higher concentration, while amolecule with a relatively lower (ΔG) value may become active at arelatively lower concentration. In some embodiments, the (ΔG) value maybe higher than −9 kkcal/mol. The gene silencing effects mediated by theRNAi constructs associated with the invention, containing minimal doublestranded regions, are unexpected because molecules of almost identicaldesign but lower thermodynamic stability have been demonstrated to beinactive (Rana et al 2004).

Without wishing to be bound by any theory, results described hereinsuggest that a stretch of 8-10 bp of dsRNA or dsDNA will be structurallyrecognized by protein components of RISC or co-factors of RISC.Additionally, there is a free energy requirement for the triggeringcompound that it may be either sensed by the protein components and/orstable enough to interact with such components so that it may be loadedinto the Argonaute protein. If optimal thermodynamics are present andthere is a double stranded portion that is preferably at least 8nucleotides then the duplex will be recognized and loaded into the RNAimachinery.

In some embodiments, thermodynamic stability is increased through theuse of LNA bases. In some embodiments, additional chemical modificationsare introduced. Several non-limiting examples of chemical modificationsinclude: 5′ Phosphate, 2′-O-methyl, 2′-O-ethyl, 2′-fluoro,ribothymidine, C-5 propynyl-dC (pdC) and C-5 propynyl-dU (pdU); C-5propynyl-C (pC) and C-5 propynyl-U (pU); 5-methyl C, 5-methyl U,5-methyl dC, 5-methyl dU methoxy, (2,6-diaminopurine),5′-Dimethoxytrityl-N4-ethyl-2′-deoxyCytidine and MGB (minor groovebinder). It should be appreciated that more than one chemicalmodification can be combined within the same molecule.

Molecules associated with the invention are optimized for increasedpotency and/or reduced toxicity. For example, nucleotide length of theguide and/or passenger strand, and/or the number of phosphorothioatemodifications in the guide and/or passenger strand, can in some aspectsinfluence potency of the RNA molecule, while replacing 2′-fluoro (2′F)modifications with 2′-O-methyl (2′OMe) modifications can in some aspectsinfluence toxicity of the molecule. Specifically, reduction in 2′Fcontent of a molecule is predicted to reduce toxicity of the molecule.The Examples section presents molecules in which 2′F modifications havebeen eliminated, offering an advantage over previously described RNAicompounds due to a predicted reduction in toxicity. Furthermore, thenumber of phosphorothioate modifications in an RNA molecule caninfluence the uptake of the molecule into a cell, for example theefficiency of passive uptake of the molecule into a cell. Preferredembodiments of molecules described herein have no 2′F modification andyet are characterized by equal efficacy in cellular uptake and tissuepenetration. Such molecules represent a significant improvement overprior art, such as molecules described by Accell and Wolfrum, which areheavily modified with extensive use of 2′F.

In some embodiments, a guide strand is approximately 18-19 nucleotidesin length and has approximately 2-14 phosphate modifications. Forexample, a guide strand can contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14 or more than 14 nucleotides that are phosphate-modified. Theguide strand may contain one or more modifications that confer increasedstability without interfering with RISC entry. The phosphate modifiednucleotides, such as phosphorothioate modified nucleotides, can be atthe 3′ end, 5′ end or spread throughout the guide strand. In someembodiments, the 3′ terminal 10 nucleotides of the guide strand contains1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 phosphorothioate modified nucleotides.The guide strand can also contain 2′F and/or 2′OMe modifications, whichcan be located throughout the molecule. In some embodiments, thenucleotide in position one of the guide strand (the nucleotide in themost 5′ position of the guide strand) is 2′OMe modified and/orphosphorylated. C and U nucleotides within the guide strand can be 2′Fmodified. For example, C and U nucleotides in positions 2-10 of a 19 ntguide strand (or corresponding positions in a guide strand of adifferent length) can be 2′F modified. C and U nucleotides within theguide strand can also be 2′OMe modified. For example, C and Unucleotides in positions 11-18 of a 19 nt guide strand (or correspondingpositions in a guide strand of a different length) can be 2′OMemodified. In some embodiments, the nucleotide at the most 3′ end of theguide strand is unmodified. In certain embodiments, the majority of Csand Us within the guide strand are 2′F modified and the 5′ end of theguide strand is phosphorylated. In other embodiments, position 1 and theCs or Us in positions 11-18 are 2′OMe modified and the 5′ end of theguide strand is phosphorylated. In other embodiments, position 1 and theCs or Us in positions 11-18 are 2′OMe modified, the 5′ end of the guidestrand is phosphorylated, and the Cs or Us in position 2-10 are 2′Fmodified.

In some aspects, an optimal passenger strand is approximately 11-14nucleotides in length. The passenger strand may contain modificationsthat confer increased stability. One or more nucleotides in thepassenger strand can be 2′OMe modified. In some embodiments, one or moreof the C and/or U nucleotides in the passenger strand is 2′OMe modified,or all of the C and U nucleotides in the passenger strand are 2′OMemodified. In certain embodiments, all of the nucleotides in thepassenger strand are 2′OMe modified. One or more of the nucleotides onthe passenger strand can also be phosphate-modified such asphosphorothioate modified. The passenger strand can also contain 2′ribo, 2′F and 2 deoxy modifications or any combination of the above. Asdemonstrated in the Examples, chemical modification patterns on both theguide and passenger strand are well tolerated and a combination ofchemical modifications is shown herein to lead to increased efficacy andself-delivery of RNA molecules.

Aspects of the invention relate to RNAi constructs that have extendedsingle-stranded regions relative to double stranded regions, as comparedto molecules that have been used previously for RNAi. The singlestranded region of the molecules may be modified to promote cellularuptake or gene silencing. In some embodiments, phosphorothioatemodification of the single stranded region influences cellular uptakeand/or gene silencing. The region of the guide strand that isphosphorothioate modified can include nucleotides within both the singlestranded and double stranded regions of the molecule. In someembodiments, the single stranded region includes 2-12 phosphorothioatemodifications. For example, the single stranded region can include 2, 3,4, 5, 6, 7, 8, 9, 10, 11, or 12 phosphorothioate modifications. In someinstances, the single stranded region contains 6-8 phosphorothioatemodifications.

Molecules associated with the invention are also optimized for cellularuptake. In RNA molecules described herein, the guide and/or passengerstrands can be attached to a conjugate. In certain embodiments theconjugate is hydrophobic. The hydrophobic conjugate can be a smallmolecule with a partition coefficient that is higher than 10. Theconjugate can be a sterol-type molecule such as cholesterol, or amolecule with an increased length polycarbon chain attached to C17, andthe presence of a conjugate can influence the ability of an RNA moleculeto be taken into a cell with or without a lipid transfection reagent.The conjugate can be attached to the passenger or guide strand through ahydrophobic linker. In some embodiments, a hydrophobic linker is 5-12Cin length, and/or is hydroxypyrrolidine-based. In some embodiments, ahydrophobic conjugate is attached to the passenger strand and the CUresidues of either the passenger and/or guide strand are modified. Insome embodiments, at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%or 95% of the CU residues on the passenger strand and/or the guidestrand are modified. In some aspects, molecules associated with theinvention are self-delivering (sd). As used herein, “self-delivery”refers to the ability of a molecule to be delivered into a cell withoutthe need for an additional delivery vehicle such as a transfectionreagent.

Aspects of the invention relate to selecting molecules for use in RNAi.Based on the data described herein, molecules that have a doublestranded region of 8-14 nucleotides can be selected for use in RNAi. Insome embodiments, molecules are selected based on their thermodynamicstability (ΔG). In some embodiments, molecules will be selected thathave a (ΔG) of less than −13 kkal/mol. For example, the (ΔG) value maybe −13, −14, −15, −16, −17, −18, −19, −21, −22 or less than −22kkal/mol. In other embodiments, the (ΔG) value may be higher than −13kkal/mol. For example, the (ΔG) value may be −12, −11, −10, −9, −8, −7or more than −7 kkal/mol. It should be appreciated that ΔG can becalculated using any method known in the art. In some embodiments ΔG iscalculated using Mfold, available through the Mfold internet site(http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi). Methods forcalculating ΔG are described in, and are incorporated by reference from,the following references: Zuker, M. (2003) Nucleic Acids Res.,31(13):3406-15; Mathews, D. H., Sabina, J., Zuker, M. and Turner, D. H.(1999) J. Mol. Biol. 288:911-940; Mathews, D. H., Disney, M. D., Childs,J. L., Schroeder, S. J., Zuker, M., and Turner, D. H. (2004) Proc. Natl.Acad. Sci. 101:7287-7292; Duan, S., Mathews, D. H., and Turner, D. H.(2006) Biochemistry 45:9819-9832; Wuchty, S., Fontana, W., Hofacker, I.L., and Schuster, P. (1999) Biopolymers 49:145-165.

Aspects of the invention relate to using nucleic acid moleculesdescribed herein, with minimal double stranded regions and/or with a(ΔG) of less than −13 kkal/mol, for gene silencing. RNAi molecules canbe administered in vivo or in vitro, and gene silencing effects can beachieved in vivo or in vitro.

In certain embodiments, the polynucleotide contains 5′- and/or 3′-endoverhangs. The number and/or sequence of nucleotides overhang on one endof the polynucleotide may be the same or different from the other end ofthe polynucleotide. In certain embodiments, one or more of the overhangnucleotides may contain chemical modification(s), such asphosphorothioate or 2′-OMe modification.

In certain embodiments, the polynucleotide is unmodified. In otherembodiments, at least one nucleotide is modified. In furtherembodiments, the modification includes a 2′-H or 2′-modified ribosesugar at the 2nd nucleotide from the 5′-end of the guide sequence. The“2nd nucleotide” is defined as the second nucleotide from the 5′-end ofthe polynucleotide.

As used herein, “2′-modified ribose sugar” includes those ribose sugarsthat do not have a 2′-OH group. “2′-modified ribose sugar” does notinclude 2′-deoxyribose (found in unmodified canonical DNA nucleotides).For example, the 2′-modified ribose sugar may be 21-O-alkyl nucleotides,2′-deoxy-2′-fluoro nucleotides, 2′-deoxy nucleotides, or combinationthereof.

In certain embodiments, the 2′-modified nucleotides are pyrimidinenucleotides (e.g., C/U). Examples of 2′-O-alkyl nucleotides include2′-O-methyl nucleotides, or 2′-O-allyl nucleotides.

In certain embodiments, the miniRNA polynucleotide of the invention withthe above-referenced 5′-end modification exhibits significantly (e.g.,at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90% or more) less “off-target” gene silencing when compared tosimilar constructs without the specified 5′-end modification, thusgreatly improving the overall specificity of the RNAi reagent ortherapeutics.

As used herein, “off-target” gene silencing refers to unintended genesilencing due to, for example, spurious sequence homology between theantisense (guide) sequence and the unintended target mRNA sequence.

According to this aspect of the invention, certain guide strandmodifications further increase nuclease stability, and/or lowerinterferon induction, without significantly decreasing RNAi activity (orno decrease in RNAi activity at all).

In some embodiments, the 5′-stem sequence may comprise a 2′-modifiedribose sugar, such as 2′-O-methyl modified nucleotide, at the 2^(nd)nucleotide on the 5′-end of the polynucleotide and, in some embodiments,no other modified nucleotides. The hairpin structure having suchmodification may have enhanced target specificity or reduced off-targetsilencing compared to a similar construct without the 2′-O-methylmodification at said position.

Certain combinations of specific 5′-stem sequence and 3′-stem sequencemodifications may result in further unexpected advantages, as partlymanifested by enhanced ability to inhibit target gene expression,enhanced serum stability, and/or increased target specificity, etc.

In certain embodiments, the guide strand comprises a 2′-O-methylmodified nucleotide at the 2^(nd) nucleotide on the 5′-end of the guidestrand and no other modified nucleotides.

In other aspects, the miniRNA structures of the present inventionmediates sequence-dependent gene silencing by a microRNA mechanism. Asused herein, the term “microRNA” (“miRNA”), also referred to in the artas “small temporal RNAs” (“stRNAs”), refers to a small (10-50nucleotide) RNA which are genetically encoded (e.g., by viral,mammalian, or plant genomes) and are capable of directing or mediatingRNA silencing. An “miRNA disorder” shall refer to a disease or disordercharacterized by an aberrant expression or activity of an miRNA.

miRNAs are important modulators of cellular homeostasis anddifferention. Reduced levels of miRNA expression or excessive expressionof miRNA have been shown to be involved in many diseases. microRNAs areinvolved in down-regulating target genes in critical pathways, such asdevelopment and cancer, in mice, worms and mammals. In particularsignificant reduction of different miRNA expression is related to tumordevelopment and progression. Gene silencing through a microRNA mechanismis achieved by specific yet, in some cases, imperfect base-pairing ofthe miRNA and its target messenger RNA (mRNA). Various mechanisms may beused in microRNA-mediated down-regulation of target mRNA expression.

miRNAs are noncoding RNAs of approximately 22 nucleotides which canregulate gene expression at the post transcriptional or translationallevel during plant and animal development. One common feature of miRNAsis that they are all excised from an approximately 70 nucleotideprecursor RNA stem-loop termed pre-miRNA, probably by Dicer, an RNaseIII-type enzyme, or a homolog thereof. Naturally-occurring miRNAs areexpressed by endogenous genes in vivo and are processed from a hairpinor stem-loop precursor (pre-miRNA or pri-miRNAs) by Dicer or otherRNAses. miRNAs can exist transiently in vivo as a double-stranded duplexbut only one strand is taken up by the RISC complex to direct genesilencing.

In some embodiments a version of sd-rxRNA compounds, which are effectivein cellular uptake and modulating miRNA activity are described.Essentially the compounds are similar to RISC entering version but largestrand chemical modification patterns are optimized in the way to blockcleavage and act as an effective inhibitor of the RISC action. Forexample, the compound might be completely or mostly O-methyl modifiedwith the PS content described previously. For these types of compoundsthe 5′ phosphorylation is not necessary. The presence of double strandedregion is preferred as it is promotes cellular uptake and efficient RISCloading.

Finding a way to modulate miRNA expression is an important unresolvedproblem in miRNA based drug development. The invention describes novelmiRNA modulating compounds (miRNA mimics and miRNA inhibitors). ThemiRNA modulating compounds of the invention have the same basicstructural properties described herein for self delivering RNA.Exemplary, non-limiting, sequences of the miRNA modulating compounds ofthe invention are shown in Tables 4-5.

In general, the miRNA modulating compounds have two strands, a guide (orantisense) strand that is 18-23 bases long and a passenger (or sense)strand that is 8-16 bases long. The size difference of the two strandsresults in a double stranded and a single strand region of the molecule.In some embodiments the single stranded region is substantiallymodified, for example, with phosphorothioates. The presence of thisphosphorothioated region is believed to be important for improved PK/PD,tissue distribution and cellular uptake properties of these molecules.

In some instances it is preferred that the first position of the guidestrand has a 2′O-methyl modification such as a 5P-2 o-methyl U. Thepresence of this modification in the guide strand further promotes theassociation with and loading into RISC complex.

Preferably both strands of the miRNA modulators are extensivelymodified, as described herein. For instance many of the pyrimidines arepreferably 2′ modified. These modifications contribute to the stabilityof the molecule.

Additionally the overall hydrophobicity of the miRNA modulatingcompounds of the invention is increased to enhance cellular entry. Thismay be accomplished through the presence of some hydrophobicmodification in the bases. For instance, position 5 or 4 of uridines andcytidine may include hydrophobic base modifications. These modificationsincrease and promote RISC association, stability, specificity andcellular entry. An example of a preferred hydrophobic base modificationis methyl or ethyl. The presence of these type of modifications appearto not interfere with RISC entry of the miRNA modulating compounds andactually seem to promotes RISC entry.

In addition to hydrophobic base modification, other hydrophobic moietiesmay be linked to the molecule. A preferred location for linkage ofhydrophobic moieties is the 3′ end position of the passenger strand.

The compounds of the invention having these structural properties areexcellent modulators of miRNA expression in vivo. Administration ofthese compounds is expected to mimic natural miRNA expression in atargeted cells or inhibit undesirable miRNA, depending on thespecificity of the guide strand. These compounds are useful inmodulating miRNA level and activity in many tissues, such as brain,spinal cord, tumors, liver, lung, kidney skin, heart, vasculature, andspleen. Additionally these compounds may be used ex vivo and in primary,dentritic or stem cells to modulate cellular properties prior tointroduction or reintroduction of the cells into a subject. For instancethey may be used in dendritic cells or primary tumors to help with acancer vaccine development. The compounds may be used in stem cells ortissues or organs ex vivo or in vitro to promote or stop stem cellsdifferentiation, tissue remodeling, organ preservation and many otherapplications.

The miRNA modulating compounds of the invention are miRNA mimics ormiRNA inhibitors. An miRNA mimic as used herein refers to a doublestranded nucleic acid having a guide strand that has a nucleic acidsequence that is similar, or in some cases identical, to a guide strandof a naturally occurring mature miRNA. Naturally occurring miRNA areprocessed from long nucleic acids having secondary structural properties(referred to as pri-miRNA and pre-miRNA) to produce naturally occurringmature miRNA. The mature miRNA is a double stranded molecule of about 22nucleotides in length having a guide strand that binds to an miRNArecognition element (MRE) in the 3′ untranslated region (UTR) of atarget mRNA (in a RISC complex) and suppresses its translation orinitiates degradation of the mRNA.

The miRNA mimic of the invention includes a guide strand that isidentical to or similar to the sequence of a guide strand of a naturallyoccurring mature miRNA. Identical to the sequence, as used herein refersto the same nucleic acid bases in the nucleotide as are found in themature miRNA. Similar to the sequence, in this context, refers to anucleic acid molecule having a sequence which is less than identical butat least 75% homologous to the mature miRNA. In some instances “similarto the sequence” refers to a sequence which is less than identical butat least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99% homologous to the mature miRNA. In some cases the sequenceof the miRNA mimic may include the same bases, but the base of the mimicmay be modified, i.e. hydrophobically modified. In other cases the mimicmay include one or more different bases or nucleotides than thenaturally occurring mature miRNA.

The guide strand of the miRNA mimic is complementary to a miRNArecognition element (MRE). “Complementary to a miRNA recognitionelement” as used herein refers to base complementarity between at least6 or 7 nucleotides of the miRNA mimic guide strand (preferably the 5′end of the guide strand) and the MRE. The region of complementarity isreferred to as the seed region. In some embodiments the seed region orregion of complementarity is 6, 7, 8, 9, 10, 11, 12 or 13 nucleotides inlength. The complementarity of the seed region may be perfect (100%) ormay be less i.e. greater than 90%, 95%, 96%, 97%, 98%, or 99%, butpreferably is 100%. The complementarity between the entire miRNA and theMRE may be greater than 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, or 99%.

The miRNA mimics of the invention are useful for mimicking the activityof any naturally occurring miRNA. Non-limiting examples include: miR21,miR 139, miR 7, miR29, miR 122, miR 302-367 cluster, miR 221, miR-96,miR 126, miR 225 and miR 206.

An miRNA inhibitor as used herein refers to a double stranded nucleicacid having a guide strand that has a nucleic acid sequence that iscomplementary to a guide strand or antisense strand of a naturallyoccurring mature miRNA. “Complementary to an antisense strand of anaturally occurring mature miRNA” as used herein refers to basecomplementarity between the guide strand of the inhibitor and theantisense strand of the naturally occurring mature miRNA. In someembodiments the complementarity may be perfect (100%) or may be lessthan perfect i.e. greater than 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%complementarity. The guide strand of the miRNA inhibitor is extensivelychemically modified (i.e. with O-methyls or other modification), toprevent its entry into RISC. The association of the miRNA inhibitorguide strand with the naturally occurring (or miRNA mimic guide strand)miRNA loaded RISC is enhanced by the chemical modifications and sequencecomplementarily, such that it competes for binding with the naturallyoccurring mRNA.

The structure and function of miRNAs has been the subject of extensiveresearch and several miRNAs have been sequenced and investigatedregarding their function in human disease. Some non-limiting examples ofknown human miRNAs, the expression of which can be modulated with agentsand methods provided herein are let-7, let-7a-1, let-7a-2, let-7a-3,let-7b, let-7c, let-7d, let-7e, let-7f-1, let-7f-2, let-7g, let-7i,mir-1, mir-10, mir-100, mir-101, mir-101-1, mir-101-2, mir-103,mir-103-1, mir-103-2, mir-105, mir-105-1, mir-105-2, mir-106a, mir-106b,mir-107, mir-10a, mir-10b, mir-1-1, mir-1-2, mir-124, mir-124-1,mir-124-2, mir-124-3, mir-125, mir-125a, mir-125b-1, mir-125b-2,mir-128, mir-128a, mir-128b, mir-129, mir-129-1, mir-129-2, mir-130,mir-130a, mir-130b, mir-132, mir-132, mir-133, mir-133a-1, mir-133a-2,mir-133b, mir-135, mir-135a-1, mir-135a-2, mir-135b, mir-138, mir-138-1,mir-138-2, mir-141, mir-146, mir-146a, mir-146b, mir-147, mir-147a,mir-147b, mir-148, mir-148a, mir-148b, mir-15, mir-151, mir-152,mir-153, mir-153-1, mir-153-2, mir-154, mir-154, mir-15a, mir-15b,mir-16-1, mir-16-2, mir-17, mir-181, mir-181a-1, mir-181a-2, mir-181b-1,mir-181b-2, mir-181c, mir-181d, mir-188, mir-188, mir-18a, mir-18b,mir-19, mir-190, mir-190, mir-190b, mir-192, mir-192, mir-193, mir-193a,mir-193b, mir-194, mir-194-1, mir-194-2, mir-195, mir-196, mir-196a-1,mir-196a-2, mir-196b, mir-199, mir-199a-1, mir-199a-2, mir-199b,mir-19a, mir-19b-1, mir-19b-2, mir-200a, mir-200b, mir-200c, mir-204,mir-204, mir-206, mir-208, mir-208, mir-208b, mir-20a, mir-20b, mir-211,mir-212, mir-215, mir-216, mir-216a, mir-216b, mir-218, mir-218-1,mir-218-2, mir-219, mir-219-1, mir-219-2, mir-220, mir-220, mir-220b,mir-221, mir-221, mir-222, mir-23, mir-23a, mir-23b, mir-24, mir-24-1,mir-24-2, mir-25, mir-25, mir-26, mir-26a-1, mir-26a-2, mir-26b, mir-27,mir-27a, mir-27b, mir-28, mir-28, mir-29, mir-290, mir-29a, mir-29b-1,mir-29b-2, mir-29c, mir-30, mir-300, mir-301a, mir-301b, mir-302,mir-302a, mir-302b, mir-302c, mir-302d, mir-30a, mir-30b, mir-30c-1,mir-30c-2, mir-30d, mir-30e, mir-323, mir-329, mir-329-1, mir-329-2,mir-33, mir-33a, mir-33b, mir-34, mir-34a, mir-34b, mir-34c, mir-365,mir-365-1, mir-365-2, mir-368, mir-369, mir-371, mir-372, mir-374,mir-374a, mir-374b, mir-376a-1, mir-376a-2, mir-376b, mir-376c, mir-377,mir-379, mir-379, mir-380, mir-381, mir-382, mir-409, mir-410, mir-411,mir-421, mir-429, mir-449, mir-449a, mir-449b, mir-450, mir-450a-1,mir-450a-2, mir-450b, mir-453, mir-487a, mir-487b, mir-494, mir-495,mir-496, mir-500, mir-500, mir-501, mir-502, mir-506, mir-506, mir-507,mir-508, mir-509, mir-509-1, mir-509-2, mir-509-3, mir-510, mir-511,mir-511-1, mir-511-2, mir-512, mir-512-1, mir-512-2, mir-513, mir-513-1,mir-513-2, mir-514-1, mir-514-2, mir-514-3, mir-515, mir-515-1,mir-515-2, mir-516a-1, mir-516a-2, mir-516b-1, mir-516b-2, mir-517a,mir-517b, mir-517c, mir-518a-1, mir-518a-2, mir-518b, mir-518c,mir-518d, mir-518e, mir-518f, mir-519a-1, mir-519a-2, mir-519b,mir-519c, mir-519d, mir-519e, mir-520a, mir-520b, mir-520c, mir-520d,mir-520e, mir-520f, mir-520g, mir-520h, mir-521-1, mir-521-2, mir-522,mir-523, mir-524, mir-525, mir-526a-1, mir-526a-2, mir-526b, mir-527,mir-532, mir-539, mir-543, mir-545, mir-548, mir-548a-1, mir-548a-2,mir-548a-3, mir-548b, mir-548c, mir-548d-1, mir-548d-2, mir-550,mir-550-1, mir-550-2, mir-551, mir-551a, mir-551b, mir-570, mir-579,mir-603, mir-655, mir-656, mir-660, mir-7, mir-7-1, mir-7-2, mir-7-3,mir-758, mir-8, mir-891, mir-891a, mir-891b, mir-892, mir-892a,mir-892b, mir-9, mir-9-1, mir-9-2, mir-92a-1, mir-92a-2, mir-92b,mir-93, mir-9-3, mir-941, mir-941-1, mir-941-2, mir-941-3, mir-941-4,mir-95, mir-95, mir-98, mir-99, mir-99a, mir-99b. Sequence, structuralinformation, and functions of these and other miRNAs are well known tothose of skill in the art and are described, for example, in the miRBasedatabase, Release 16, September 2010, accessible at www.mirbase.org, anddescribed in more detail in “miRBase: tools for microRNA genomics” byGriffiths-Jones S, Saini H K, van Dongen S, Enright A J, Nucleic AcidsRes. 2008 36:D154-D158; “miRBase: microRNA sequences, targets and genenomenclature” by Griffiths-Jones S, Grocock R J, van Dongen S, BatemanA, Enright A J, Nucleic Acids Res. 2006 34:D140-D144; and “The miRNARegistry” by Griffiths-Jones S, Nucleic Acids Res. 2004 32:D109-D111.The entire contents of miRBase, Release 16, September 2010, and thethree references provided immediately above are incorporated herein intheir entirety by reference for disclosure of miRNA sequences,structure, and function.

In some embodiments, the miRNA that is modulated using an agent ormethod provided herein is an miRNA that is implicated or known to beinvolved in the pathogenesis or the progression of a human disease, forexample, in a cancer or neoplastic disease. miRNAs implicated or knownto be involved in the pathogenesis or the progression of a human diseaseare well known to those of skill in the art and include, but are notlimited to the miRNAs described in the Human mRNA & Disease Database(HMDD), Release January 2011, accessible at202.38.126.151/hmdd/mirna/md/, and described in more detail in Lu M,Zhang Q, Deng M, Miao J, Guo Y, et al. (2008) An Analysis of HumanMicroRNA and Disease Associations. PLoS ONE 3(10): e3420; themir2disease base, Release March 2011, accessible at www.mir2disease.org,and described in more detail in Jiang Q., Wang Y., Hao Y., Juan L., TengM., Zhang X., Li M., Wang G., Liu Y., (2009) miR2Disease: a manuallycurated database for microRNA deregulation in human disease. NucleicAcids Res 37:D98-104; the entire contents of each database and referenceare incorporated herein by reference.

In some embodiments, an miRNA modulating agent or method is providedthat targets a particular miRNA or a particular miRNA cluster. Forexample, in some embodiments, the target miRNA is mir139 (e.g., miRBaseaccession: MI0000261). Mir139 has been described to act as a tumorsuppressor and aberrant expression of mir139 has been reported to beassociated with leukemia, for example, chronic lymphocytic leukemia, andwith certain carcinomas, for example, adenocarcinoma, epithelial ovariancarcinoma, gastric carcinoma, and non-small cell lung carcinoma. In someembodiments, a miRNA modulating agent or method provided herein isuseful for the alleviation of a disease or condition associated withaberrant mir139.

In some embodiments, the target miRNA is let-7 (e.g., miRBase accession:MI0000060-MI0000068). Let-7 has been reported to act as a tumorsuppressor and aberrant expression of let-7 has been reported to beassociated with tumorigenesis and tumor progression. In someembodiments, a let-7 mimic as provided herein is introduced into aneoplastic cell or tissue, for example, into a tumor cell or tumortissue to alleviate tumor growth and/or any associated disease orcondition. In some embodiments, introduction of a let-7 mimic into atumor results in tumor regression.

In some embodiments, the target miRNA is mir-29 (e.g., miRBaseaccession: MI0000087, MI0000105, MI0000107). Aberrant expression ofmir-29 has been reported to be associated with abnormal cell or tissueproliferation. For example, lack of miR-29a and/or miR-29b is implicatedin progression of HCV infection, fibrosis or neuron remodeling anddegeneration during Alzeheimer's disease. In some embodiments,introduction of a mir-29 mimic into an affected cell or tissue of adiseased subject is of therapeutic benefit in neurological disorders,liver and pulmonary fibrosis, HCV or other liver infection, cardiachypertension and other indications with a reported involvement ofmir-29. In some embodiments, introduction of a mir-29 mimic, as providedherein, for example, of a mir-29b mimic, can result in PDPNdownregulation, which is involved in glioblastoma progression. In someembodiments, introduction of a mir-29 mimic as provided herein into aglioblastoma cell or tissue, for example, brain tissue of a glioblastomapatient, results in arrest or delay of tumor progression, tumorregression, or an alleviation of the disease state.

In some embodiments, the target miRNA is mir-133 (e.g., miRBaseaccession: MI0000450, MI0000451, MI0000822). Aberrant expression ofmiR-133 has been reported to be associated with CTGF downregulation aswell as downregulation of molecular signaling pathways implicated infibrosis. In some embodiments, a mir-133 mimic provided herein is usedas an anti-fibrotic agent.

In some embodiments, the target miRNA is a miRNA of the mir-302-367cluster, comprising mir-302a-mir302d and mir-367 (e.g., miRBaseaccession: MI0000738, MI0000772, MI0000773, MI0000775). Aberrantexpression of the miRNA 302-367 cluster has been reported to beassociated with inhibition of HDac2-regulated reprogramming of somaticcells into pluripotent stem cells. In some embodiments, introduction ofa mimic of a miRNA in the miRNA 302-367 cluster into somatic stem cellssupports or enhances the reprogramming of the somatic cells intopluripotent stem cells, which can be used for regenerative medicineapproaches, and organ and tissue development.

In some embodiments, the target miRNA is mir-221 (e.g., miRBaseaccession: MI0000298). Mir-221 has been reported to act as a tumorsuppressor, and aberrant expression of mir-221 has been reported to beassociated with glioblastoma progression. In some embodiments,introduction, e.g., by direct injection or intrabrain infusion of amir-221 mimic provided herein is used to treat or alleviate a symptomobserved in glioblastoma patients.

In some embodiments, the target miRNA is mir-96 (e.g., miRBaseaccession: MI0000098). Mir-96 has been reported to be involved in hairgrowth regulation and aberrant expression of mir-96 has been reported tobe associated with alopecia, for example, or chemotherapy-inducedalopecia. In some embodiments, a mir-96 mimic as provided herein is usedto treat alopecia.

In some embodiments, the target miRNA is mir-126, mir-335, or mir-206(e.g., miRBase accession: MI0000471, MI0000816, MI0000490). These miRNAsare potent suppressors of tumor metastasis formation or maturation. Forexample, mir-126 has been reported to suppress endothelium cellularrecruitment and, thus, metastasis maturation. In some embodiment,introduction of a mir-126, mir-335, or mir-206 mimic as provided hereininto a primary tumor, or systemic administration to a subject having atumor results in a partial or complete inhibition of metastasisformation.

In some embodiments, the target miRNA is a miRNA of the mir-17-92cluster, comprising mir-17, mir-18a, mir-19a, mir-20a, mir-19b-1, andmir-92a-1 (e.g., miRBase accession: MI0000071, MI0000072, MI0000073,MI0000076, MI0000074, MI0000093). The mir-17-92 cluster has beenreported to act as an oncogene and overexpression of the cluster, or ofany member of the cluster has been reported to be associated withtumorigenesis. In some embodiments, a miRNA inhibitory agent targetingthe mir-17-92 cluster as provided herein is administered to a tumor cellor tissue, or systemically, to a patient diagnosed with or suspected tohave a tumor. Another pathway that uses small RNAs as sequence-specificregulators is the RNA interference (RNAi) pathway, which is anevolutionarily conserved response to the presence of double-stranded RNA(dsRNA) in the cell. The dsRNAs are cleaved into ˜20-base pair (bp)duplexes of small-interfering RNAs (siRNAs) by Dicer. These small RNAsget assembled into multiprotein effector complexes called RNA-inducedsilencing complexes (RISCs). The siRNAs then guide the cleavage oftarget mRNAs with perfect complementarity.

Some aspects of biogenesis, protein complexes, and function are sharedbetween the siRNA pathway and the miRNA pathway. The subjectsingle-stranded polynucleotides may mimic the dsRNA in the siRNAmechanism, or the microRNA in the miRNA mechanism.

In certain embodiments, the modified RNAi constructs may have improvedstability in serum and/or cerebral spinal fluid compared to anunmodified RNAi constructs having the same sequence.

In certain embodiments, the structure of the RNAi construct does notinduce interferon response in primary cells, such as mammalian primarycells, including primary cells from human, mouse and other rodents, andother non-human mammals. In certain embodiments, the RNAi construct mayalso be used to inhibit expression of a target gene in an invertebrateorganism.

To further increase the stability of the subject constructs in vivo, the3′-end of the hairpin structure may be blocked by protective group(s).For example, protective groups such as inverted nucleotides, invertedabasic moieties, or amino-end modified nucleotides may be used. Invertednucleotides may comprise an inverted deoxynucleotide. Inverted abasicmoieties may comprise an inverted deoxyabasic moiety, such as a3′,3′-linked or 5′,5′-linked deoxyabasic moiety.

The RNAi constructs of the invention are capable of inhibiting thesynthesis of any target protein encoded by target gene(s). The inventionincludes methods to inhibit expression of a target gene either in a cellin vitro, or in vivo. As such, the RNAi constructs of the invention areuseful for treating a patient with a disease characterized by theoverexpression of a target gene.

The target gene can be endogenous or exogenous (e.g., introduced into acell by a virus or using recombinant DNA technology) to a cell. Suchmethods may include introduction of RNA into a cell in an amountsufficient to inhibit expression of the target gene. By way of example,such an RNA molecule may have a guide strand that is complementary tothe nucleotide sequence of the target gene, such that the compositioninhibits expression of the target gene.

The invention also relates to vectors expressing the nucleic acids ofthe invention, and cells comprising such vectors or the nucleic acids.The cell may be a mammalian cell in vivo or in culture, such as a humancell.

The invention further relates to compositions comprising the subjectRNAi constructs, and a pharmaceutically acceptable carrier or diluent.

Another aspect of the invention provides a method for inhibiting theexpression of a target gene in a mammalian cell, comprising contactingthe mammalian cell with any of the subject RNAi constructs.

The method may be carried out in vitro, ex vivo, or in vivo, in, forexample, mammalian cells in culture, such as a human cell in culture.

The target cells (e.g., mammalian cell) may be contacted in the presenceof a delivery reagent, such as a lipid (e.g., a cationic lipid) or aliposome.

Another aspect of the invention provides a method for inhibiting theexpression of a target gene in a mammalian cell, comprising contactingthe mammalian cell with a vector expressing the subject RNAi constructs.

In one aspect of the invention, a longer duplex polynucleotide isprovided, including a first polynucleotide that ranges in size fromabout 16 to about 30 nucleotides; a second polynucleotide that ranges insize from about 26 to about 46 nucleotides, wherein the firstpolynucleotide (the antisense strand) is complementary to both thesecond polynucleotide (the sense strand) and a target gene, and whereinboth polynucleotides form a duplex and wherein the first polynucleotidecontains a single stranded region longer than 6 bases in length and ismodified with alternative chemical modification pattern, and/or includesa conjugate moiety that facilitates cellular delivery. In thisembodiment, between about 40% to about 90% of the nucleotides of thepassenger strand between about 40% to about 90% of the nucleotides ofthe guide strand, and between about 40% to about 90% of the nucleotidesof the single stranded region of the first polynucleotide are chemicallymodified nucleotides.

In an embodiment, the chemically modified nucleotide in thepolynucleotide duplex may be any chemically modified nucleotide known inthe art, such as those discussed in detail above. In a particularembodiment, the chemically modified nucleotide is selected from thegroup consisting of 2′ F modified nucleotides, 2′-O-methyl modified and2′ deoxy nucleotides. In another particular embodiment, the chemicallymodified nucleotides results from “hydrophobic modifications” of thenucleotide base. In another particular embodiment, the chemicallymodified nucleotides are phosphorothioates. In an additional particularembodiment, chemically modified nucleotides are combination ofphosphorothioates, 2′-O-methyl, 2′ deoxy, hydrophobic modifications andphosphorothioates. As these groups of modifications refer tomodification of the ribose ring, back bone and nucleotide, it isfeasible that some modified nucleotides will carry a combination of allthree modification types.

In another embodiment, the chemical modification is not the same acrossthe various regions of the duplex. In a particular embodiment, the firstpolynucleotide (the passenger strand), has a large number of diversechemical modifications in various positions. For this polynucleotide upto 90% of nucleotides might be chemically modified and/or havemismatches introduced.

In another embodiment, chemical modifications of the first or secondpolynucleotide include, but not limited to, 5′ position modification ofUridine and Cytosine (4-pyridyl, 2-pyridyl, indolyl, phenyl (C₆H₅OH);tryptophanyl (C8H6N)CH2CH(NH2)CO), isobutyl, butyl, aminobenzyl; phenyl;naphthyl, etc), where the chemical modification might alter base pairingcapabilities of a nucleotide. For the guide strand an important featureof this aspect of the invention is the position of the chemicalmodification relative to the 5′ end of the antisense and sequence. Forexample, chemical phosphorylation of the 5′ end of the guide strand isusually beneficial for efficacy. O-methyl modifications in the seedregion of the sense strand (position 2-7 relative to the 5′ end) are notgenerally well tolerated, whereas 2′F and deoxy are well tolerated. Themid part of the guide strand and the 3′ end of the guide strand are morepermissive in a type of chemical modifications applied. Deoxymodifications are not tolerated at the 3′ end of the guide strand.

A unique feature of this aspect of the invention involves the use ofhydrophobic modification on the bases. In one embodiment, thehydrophobic modifications are preferably positioned near the 5′ end ofthe guide strand, in other embodiments, they localized in the middle ofthe guides strand, in other embodiment they localized at the 3′ end ofthe guide strand and yet in another embodiment they are distributedthought the whole length of the polynucleotide. The same type ofpatterns is applicable to the passenger strand of the duplex.

The other part of the molecule is a single stranded region. The singlestranded region is expected to range from 7 to 40 nucleotides.

In one embodiment, the single stranded region of the firstpolynucleotide contains modifications selected from the group consistingof between 40% and 90% hydrophobic base modifications, between 40%-90%phosphorothioates, between 40%-90% modification of the ribose moiety,and any combination of the preceding.

Efficiency of guide strand (first polynucleotide) loading into the RISCcomplex might be altered for heavily modified polynucleotides, so in oneembodiment, the duplex polynucleotide includes a mismatch betweennucleotide 9, 11, 12, 13, or 14 on the guide strand (firstpolynucleotide) and the opposite nucleotide on the sense strand (secondpolynucleotide) to promote efficient guide strand loading.

More detailed aspects of the invention are described in the sectionsbelow.

Duplex Characteristics

Double-stranded oligonucleotides of the invention may be formed by twoseparate complementary nucleic acid strands. Duplex formation can occureither inside or outside the cell containing the target gene.

As used herein, the term “duplex” includes the region of thedouble-stranded nucleic acid molecule(s) that is (are) hydrogen bondedto a complementary sequence. Double-stranded oligonucleotides of theinvention may comprise a nucleotide sequence that is sense to a targetgene and a complementary sequence that is antisense to the target gene.The sense and antisense nucleotide sequences correspond to the targetgene sequence, e.g., are identical or are sufficiently identical toeffect target gene inhibition (e.g., are about at least about 98%identical, 96% identical, 94%, 90% identical, 85% identical, or 80%identical) to the target gene sequence.

In certain embodiments, the double-stranded oligonucleotide of theinvention is double-stranded over its entire length, i.e., with nooverhanging single-stranded sequence at either end of the molecule,i.e., is blunt-ended. In other embodiments, the individual nucleic acidmolecules can be of different lengths. In other words, a double-strandedoligonucleotide of the invention is not double-stranded over its entirelength. For instance, when two separate nucleic acid molecules are used,one of the molecules, e.g., the first molecule comprising an antisensesequence, can be longer than the second molecule hybridizing thereto(leaving a portion of the molecule single-stranded). Likewise, when asingle nucleic acid molecule is used a portion of the molecule at eitherend can remain single-stranded.

In one embodiment, a double-stranded oligonucleotide of the inventioncontains mismatches and/or loops or bulges, but is double-stranded overat least about 70% of the length of the oligonucleotide. In anotherembodiment, a double-stranded oligonucleotide of the invention isdouble-stranded over at least about 80% of the length of theoligonucleotide. In another embodiment, a double-strandedoligonucleotide of the invention is double-stranded over at least about90%-95% of the length of the oligonucleotide. In another embodiment, adouble-stranded oligonucleotide of the invention is double-stranded overat least about 96%-98% of the length of the oligonucleotide. In certainembodiments, the double-stranded oligonucleotide of the inventioncontains at least or up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, or 15 mismatches.

Modifications

The nucleotides of the invention may be modified at various locations,including the sugar moiety, the phosphodiester linkage, and/or the base.

Sugar moieties include natural, unmodified sugars, e.g., monosaccharide(such as pentose, e.g., ribose, deoxyribose), modified sugars and sugaranalogs. In general, possible modifications of nucleomonomers,particularly of a sugar moiety, include, for example, replacement of oneor more of the hydroxyl groups with a halogen, a heteroatom, analiphatic group, or the functionalization of the hydroxyl group as anether, an amine, a thiol, or the like.

One particularly useful group of modified nucleomonomers are 2′-O-methylnucleotides. Such 2′-O-methyl nucleotides may be referred to as“methylated,” and the corresponding nucleotides may be made fromunmethylated nucleotides followed by alkylation or directly frommethylated nucleotide reagents. Modified nucleomonomers may be used incombination with unmodified nucleomonomers. For example, anoligonucleotide of the invention may contain both methylated andunmethylated nucleomonomers.

Some exemplary modified nucleomonomers include sugar- orbackbone-modified ribonucleotides. Modified ribonucleotides may containa non-naturally occurring base (instead of a naturally occurring base),such as uridines or cytidines modified at the 5′-position, e.g.,5′-(2-amino)propyl uridine and 5′-bromo uridine; adenosines andguanosines modified at the 8-position, e.g., 8-bromo guanosine; deazanucleotides, e.g., 7-deaza-adenosine; and N-alkylated nucleotides, e.g.,N6-methyl adenosine. Also, sugar-modified ribonucleotides may have the2′-OH group replaced by a H, alxoxy (or OR), R or alkyl, halogen, SH,SR, amino (such as NH₂, NHR, NR₂,), or CN group, wherein R is loweralkyl, alkenyl, or alkynyl.

Modified ribonucleotides may also have the phosphodiester groupconnecting to adjacent ribonucleotides replaced by a modified group,e.g., of phosphorothioate group. More generally, the various nucleotidemodifications may be combined.

Although the antisense (guide) strand may be substantially identical toat least a portion of the target gene (or genes), at least with respectto the base pairing properties, the sequence need not be perfectlyidentical to be useful, e.g., to inhibit expression of a target gene'sphenotype. Generally, higher homology can be used to compensate for theuse of a shorter antisense gene. In some cases, the antisense strandgenerally will be substantially identical (although in antisenseorientation) to the target gene.

The use of 2′-O-methyl modified RNA may also be beneficial incircumstances in which it is desirable to minimize cellular stressresponses. RNA having 2′-O-methyl nucleomonomers may not be recognizedby cellular machinery that is thought to recognize unmodified RNA. Theuse of 2′-O-methylated or partially 2′-O-methylated RNA may avoid theinterferon response to double-stranded nucleic acids, while maintainingtarget RNA inhibition. This may be useful, for example, for avoiding theinterferon or other cellular stress responses, both in short RNAi (e.g.,siRNA) sequences that induce the interferon response, and in longer RNAisequences that may induce the interferon response.

Overall, modified sugars may include D-ribose, 2′-O-alkyl (including2′-O-methyl and 2′-O-ethyl), i.e., 2′-alkoxy, 2′-amino, 2′-S-alkyl,2′-halo (including 2′-fluoro), 2′-methoxyethoxy, 2′-allyloxy(—OCH₂CH═CH₂), 2′-propargyl, 2′-propyl, ethynyl, ethenyl, propenyl, andcyano and the like. In one embodiment, the sugar moiety can be a hexoseand incorporated into an oligonucleotide as described (Augustyns, K., etal., Nucl. Acids. Res. 18:4711 (1992)). Exemplary nucleomonomers can befound, e.g., in U.S. Pat. No. 5,849,902, incorporated by referenceherein.

The term “alkyl” includes saturated aliphatic groups, includingstraight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl,hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups(isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups(cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkylsubstituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.In certain embodiments, a straight chain or branched chain alkyl has 6or fewer carbon atoms in its backbone (e.g., C₁-C₆ for straight chain,C₃-C₆ for branched chain), and more preferably 4 or fewer. Likewise,preferred cycloalkyls have from 3-8 carbon atoms in their ringstructure, and more preferably have 5 or 6 carbons in the ringstructure. The term C₁-C₆ includes alkyl groups containing 1 to 6 carbonatoms.

Moreover, unless otherwise specified, the term alkyl includes both“unsubstituted alkyls” and “substituted alkyls,” the latter of whichrefers to alkyl moieties having independently selected substituentsreplacing a hydrogen on one or more carbons of the hydrocarbon backbone.Such substituents can include, for example, alkenyl, alkynyl, halogen,hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy,aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl,alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano,amino (including alkyl amino, dialkylamino, arylamino, diarylamino, andalkylarylamino), acylamino (including alkylcarbonylamino,arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl,alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl,sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido,heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.Cycloalkyls can be further substituted, e.g., with the substituentsdescribed above. An “alkylaryl” or an “arylalkyl” moiety is an alkylsubstituted with an aryl (e.g., phenylmethyl (benzyl)). The term “alkyl”also includes the side chains of natural and unnatural amino acids. Theterm “n-alkyl” means a straight chain (i.e., unbranched) unsubstitutedalkyl group.

The term “alkenyl” includes unsaturated aliphatic groups analogous inlength and possible substitution to the alkyls described above, but thatcontain at least one double bond. For example, the term “alkenyl”includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl,butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.),branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups(cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl,cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, andcycloalkyl or cycloalkenyl substituted alkenyl groups. In certainembodiments, a straight chain or branched chain alkenyl group has 6 orfewer carbon atoms in its backbone (e.g., C₂-C₆ for straight chain,C₃-C₆ for branched chain). Likewise, cycloalkenyl groups may have from3-8 carbon atoms in their ring structure, and more preferably have 5 or6 carbons in the ring structure. The term C₂-C₆ includes alkenyl groupscontaining 2 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkenyl includes both“unsubstituted alkenyls” and “substituted alkenyls,” the latter of whichrefers to alkenyl moieties having independently selected substituentsreplacing a hydrogen on one or more carbons of the hydrocarbon backbone.Such substituents can include, for example, alkyl groups, alkynylgroups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy,alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl,arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl,dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate,phosphonato, phosphinato, cyano, amino (including alkyl amino,dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino(including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido),amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro,trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromaticor heteroaromatic moiety.

The term “alkynyl” includes unsaturated aliphatic groups analogous inlength and possible substitution to the alkyls described above, butwhich contain at least one triple bond. For example, the term “alkynyl”includes straight-chain alkynyl groups (e.g., ethynyl, propynyl,butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.),branched-chain alkynyl groups, and cycloalkyl or cycloalkenylsubstituted alkynyl groups. In certain embodiments, a straight chain orbranched chain alkynyl group has 6 or fewer carbon atoms in its backbone(e.g., C₂-C₆ for straight chain, C₃-C₆ for branched chain). The termC₂-C₆ includes alkynyl groups containing 2 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkynyl includes both“unsubstituted alkynyls” and “substituted alkynyls,” the latter of whichrefers to alkynyl moieties having independently selected substituentsreplacing a hydrogen on one or more carbons of the hydrocarbon backbone.Such substituents can include, for example, alkyl groups, alkynylgroups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy,alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl,arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl,dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate,phosphonato, phosphinato, cyano, amino (including alkyl amino,dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino(including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido),amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro,trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromaticor heteroaromatic moiety.

Unless the number of carbons is otherwise specified, “lower alkyl” asused herein means an alkyl group, as defined above, but having from oneto five carbon atoms in its backbone structure. “Lower alkenyl” and“lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.

The term “alkoxy” includes substituted and unsubstituted alkyl, alkenyl,and alkynyl groups covalently linked to an oxygen atom. Examples ofalkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy,and pentoxy groups. Examples of substituted alkoxy groups includehalogenated alkoxy groups. The alkoxy groups can be substituted withindependently selected groups such as alkenyl, alkynyl, halogen,hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy,aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl,alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano,amino (including alkyl amino, dialkylamino, arylamino, diarylamino, andalkylarylamino), acylamino (including alkylcarbonylamino,arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulffiydryl,alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl,sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido,heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties.Examples of halogen substituted alkoxy groups include, but are notlimited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy,chloromethoxy, dichloromethoxy, trichloromethoxy, etc.

The term “heteroatom” includes atoms of any element other than carbon orhydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur andphosphorus.

The term “hydroxy” or “hydroxyl” includes groups with an —OH or —O⁻(with an appropriate counterion).

The term “halogen” includes fluorine, bromine, chlorine, iodine, etc.The term “perhalogenated” generally refers to a moiety wherein allhydrogens are replaced by halogen atoms.

The term “substituted” includes independently selected substituentswhich can be placed on the moiety and which allow the molecule toperform its intended function. Examples of substituents include alkyl,alkenyl, alkynyl, aryl, (CR′R″)₀₋₃NR′R″, (CR′R″)₀₋₃CN, NO₂, halogen,(CR′R″)₀₋₃C(halogen)₃, (CR′R″)₀₋₃CH(halogen)₂, (CR′R″)₀₋₃CH₂(halogen),(CR′R″)₀₋₃CONR′R″, (CR′R″)₀₋₃S(O)₁₋₂NR′R″, (CR′R″)₀₋₃CHO,(CR′R″)₀₋₃O(CR′R″)₀₋₃H, (CR′R″)₀₋₃S(O)₀₋₂R′, (CR′R″)₀₋₃O(CR′R″)₀₋₃H,(CR′R″)₀₋₃COR′, (CR′R″)₀₋₃CO₂R′, or (CR′R″)₀₋₃₀R′ groups; wherein eachR′ and R″ are each independently hydrogen, a C₁-C₅ alkyl, C₂-C₅ alkenyl,C₂-C₅ alkynyl, or aryl group, or R′ and R″ taken together are abenzylidene group or a —(CH₂)₂O(CH₂)₂— group.

The term “amine” or “amino” includes compounds or moieties in which anitrogen atom is covalently bonded to at least one carbon or heteroatom.The term “alkyl amino” includes groups and compounds wherein thenitrogen is bound to at least one additional alkyl group. The term“dialkyl amino” includes groups wherein the nitrogen atom is bound to atleast two additional alkyl groups.

The term “ether” includes compounds or moieties which contain an oxygenbonded to two different carbon atoms or heteroatoms. For example, theterm includes “alkoxyalkyl,” which refers to an alkyl, alkenyl, oralkynyl group covalently bonded to an oxygen atom which is covalentlybonded to another alkyl group.

The term “base” includes the known purine and pyrimidine heterocyclicbases, deazapurines, and analogs (including heterocyclic substitutedanalogs, e.g., aminoethyoxy phenoxazine), derivatives (e.g., 1-alkyl-,1-alkenyl-, heteroaromatic- and 1-alkynyl derivatives) and tautomersthereof. Examples of purines include adenine, guanine, inosine,diaminopurine, and xanthine and analogs (e.g., 8-oxo-N⁶-methyladenine or7-diazaxanthine) and derivatives thereof. Pyrimidines include, forexample, thymine, uracil, and cytosine, and their analogs (e.g.,5-methylcytosine, 5-methyluracil, 5-(1-propynyl)uracil,5-(1-propynyl)cytosine and 4,4-ethanocytosine). Other examples ofsuitable bases include non-purinyl and non-pyrimidinyl bases such as2-aminopyridine and triazines.

In a preferred embodiment, the nucleomonomers of an oligonucleotide ofthe invention are RNA nucleotides. In another preferred embodiment, thenucleomonomers of an oligonucleotide of the invention are modified RNAnucleotides. Thus, the oligunucleotides contain modified RNAnucleotides.

The term “nucleoside” includes bases which are covalently attached to asugar moiety, preferably ribose or deoxyribose. Examples of preferrednucleosides include ribonucleosides and deoxyribonucleosides.Nucleosides also include bases linked to amino acids or amino acidanalogs which may comprise free carboxyl groups, free amino groups, orprotecting groups. Suitable protecting groups are well known in the art(see P. G. M. Wuts and T. W. Greene, “Protective Groups in OrganicSynthesis”, 2^(nd) Ed., Wiley-Interscience, New York, 1999).

The term “nucleotide” includes nucleosides which further comprise aphosphate group or a phosphate analog.

As used herein, the term “linkage” includes a naturally occurring,unmodified phosphodiester moiety (—O—(PO²⁻)—O—) that covalently couplesadjacent nucleomonomers. As used herein, the term “substitute linkage”includes any analog or derivative of the native phosphodiester groupthat covalently couples adjacent nucleomonomers. Substitute linkagesinclude phosphodiester analogs, e.g., phosphorothioate,phosphorodithioate, and P-ethyoxyphosphodiester, P-ethoxyphosphodiester,P-alkyloxyphosphotriester, methylphosphonate, and nonphosphoruscontaining linkages, e.g., acetals and amides. Such substitute linkagesare known in the art (e.g., Bjergarde et al. 1991. Nucleic Acids Res.19:5843; Caruthers et al. 1991. Nucleosides Nucleotides. 10:47). Incertain embodiments, non-hydrolizable linkages are preferred, such asphosphorothiate linkages.

In certain embodiments, oligonucleotides of the invention comprisehydrophobically modified nucleotides or “hydrophobic modifications.” Asused herein “hydrophobic modifications” refers to bases that aremodified such that (1) overall hydrophobicity of the base issignificantly increased, and/or (2) the base is still capable of formingclose to regular Watson-Crick interaction. Several non-limiting examplesof base modifications include 5-position uridine and cytidinemodifications such as methyl, ethyl, phenyl, 4-pyridyl, 2-pyridyl,indolyl, and isobutyl, phenyl (C6H5OH); tryptophanyl(C8H6N)CH2CH(NH2)CO), butyl, aminobenzyl; and naphthyl.

In certain embodiments, oligonucleotides of the invention comprise 3′and 5′ termini (except for circular oligonucleotides). In oneembodiment, the 3′ and 5′ termini of an oligonucleotide can besubstantially protected from nucleases e.g., by modifying the 3′ or 5′linkages (e.g., U.S. Pat. No. 5,849,902 and WO 98/13526). For example,oligonucleotides can be made resistant by the inclusion of a “blockinggroup.” The term “blocking group” as used herein refers to substituents(e.g., other than OH groups) that can be attached to oligonucleotides ornucleomonomers, either as protecting groups or coupling groups forsynthesis (e.g., FITC, propyl (CH₂—CH₂—CH₃), glycol (—O—CH₂—CH₂—O—)phosphate (PO₃ ²⁻), hydrogen phosphonate, or phosphoramidite). “Blockinggroups” also include “end blocking groups” or “exonuclease blockinggroups” which protect the 5′ and 3′ termini of the oligonucleotide,including modified nucleotides and non-nucleotide exonuclease resistantstructures.

Exemplary end-blocking groups include cap structures (e.g., a7-methylguanosine cap), inverted nucleomonomers, e.g., with 3′-3′ or5′-5′ end inversions (see, e.g., Ortiagao et al. 1992. Antisense Res.Dev. 2:129), methylphosphonate, phosphoramidite, non-nucleotide groups(e.g., non-nucleotide linkers, amino linkers, conjugates) and the like.The 3′ terminal nucleomonomer can comprise a modified sugar moiety. The3′ terminal nucleomonomer comprises a 3′-O that can optionally besubstituted by a blocking group that prevents 3′-exonuclease degradationof the oligonucleotide. For example, the 3′-hydroxyl can be esterifiedto a nucleotide through a 3′→3′ internucleotide linkage. For example,the alkyloxy radical can be methoxy, ethoxy, or isopropoxy, andpreferably, ethoxy. Optionally, the 3′→3′linked nucleotide at the 3′terminus can be linked by a substitute linkage. To reduce nucleasedegradation, the 5′ most 3′→5′ linkage can be a modified linkage, e.g.,a phosphorothioate or a P-alkyloxyphosphotriester linkage. Preferably,the two 5′ most 3′→5′ linkages are modified linkages. Optionally, the 5′terminal hydroxy moiety can be esterified with a phosphorus containingmoiety, e.g., phosphate, phosphorothioate, or P-ethoxyphosphate.

Another type of conjugates that can be attached to the end (3′ or 5′end), the loop region, or any other parts of the miniRNA might include asterol, sterol type molecule, peptide, small molecule, protein, etc. Insome embodiments, a miniRNA may contain more than one conjugates (sameor different chemical nature). In some embodiments, the conjugate ischolesterol.

Another way to increase target gene specificity, or to reduce off-targetsilencing effect, is to introduce a 2′-modification (such as the 2′-Omethyl modification) at a position corresponding to the second 5′-endnucleotide of the guide sequence. This allows the positioning of this2′-modification in the Dicer-resistant hairpin structure, thus enablingone to design better RNAi constructs with less or no off-targetsilencing.

In one embodiment, a hairpin polynucleotide of the invention cancomprise one nucleic acid portion which is DNA and one nucleic acidportion which is RNA. Antisense (guide) sequences of the invention canbe “chimeric oligonucleotides” which comprise an RNA-like and a DNA-likeregion.

The language “RNase H activating region” includes a region of anoligonucleotide, e.g., a chimeric oligonucleotide, that is capable ofrecruiting RNase H to cleave the target RNA strand to which theoligonucleotide binds. Typically, the RNase activating region contains aminimal core (of at least about 3-5, typically between about 3-12, moretypically, between about 5-12, and more preferably between about 5-10contiguous nucleomonomers) of DNA or DNA-like nucleomonomers. (See,e.g., U.S. Pat. No. 5,849,902). Preferably, the RNase H activatingregion comprises about nine contiguous deoxyribose containingnucleomonomers.

The language “non-activating region” includes a region of an antisensesequence, e.g., a chimeric oligonucleotide, that does not recruit oractivate RNase H. Preferably, a non-activating region does not comprisephosphorothioate DNA. The oligonucleotides of the invention comprise atleast one non-activating region. In one embodiment, the non-activatingregion can be stabilized against nucleases or can provide specificityfor the target by being complementary to the target and forming hydrogenbonds with the target nucleic acid molecule, which is to be bound by theoligonucleotide.

In one embodiment, at least a portion of the contiguous polynucleotidesare linked by a substitute linkage, e.g., a phosphorothioate linkage.

In certain embodiments, most or all of the nucleotides beyond the guidesequence (2′-modified or not) are linked by phosphorothioate linkages.Such constructs tend to have improved pharmacokinetics due to theirhigher affinity for serum proteins. The phosphorothioate linkages in thenon-guide sequence portion of the polynucleotide generally do notinterfere with guide strand activity, once the latter is loaded intoRISC.

Antisense (guide) sequences of the present invention may include“morpholino oligonucleotides.” Morpholino oligonucleotides are non-ionicand function by an RNase H-independent mechanism. Each of the 4 geneticbases (Adenine, Cytosine, Guanine, and Thymine/Uracil) of the morpholinooligonucleotides is linked to a 6-membered morpholine ring. Morpholinooligonucleotides are made by joining the 4 different subunit types by,e.g., non-ionic phosphorodiamidate inter-subunit linkages. Morpholinooligonucleotides have many advantages including: complete resistance tonucleases (Antisense & Nucl. Acid Drug Dev. 1996. 6:267); predictabletargeting (Biochemica Biophysica Acta. 1999. 1489:141); reliableactivity in cells (Antisense & Nucl. Acid Drug Dev. 1997. 7:63);excellent sequence specificity (Antisense & Nucl. Acid Drug Dev. 1997.7:151); minimal non-antisense activity (Biochemica Biophysica Acta.1999. 1489:141); and simple osmotic or scrape delivery (Antisense &Nucl. Acid Drug Dev. 1997. 7:291). Morpholino oligonucleotides are alsopreferred because of their non-toxicity at high doses. A discussion ofthe preparation of morpholino oligonucleotides can be found in Antisense& Nucl. Acid Drug Dev. 1997. 7:187.

The chemical modifications described herein are believed, based on thedata described herein, to promote single stranded polynucleotide loadinginto the RISC. Single stranded polynucleotides have been shown to beactive in loading into RISC and inducing gene silencing. However, thelevel of activity for single stranded polynucleotides appears to be 2 to4 orders of magnitude lower when compared to a duplex polynucleotide.

The present invention provides a description of the chemicalmodification patterns, which may (a) significantly increase stability ofthe single stranded polynucleotide (b) promote efficient loading of thepolynucleotide into the RISC complex and (c) improve uptake of thesingle stranded nucleotide by the cell. FIG. 5 provides somenon-limiting examples of the chemical modification patterns which may bebeneficial for achieving single stranded polynucleotide efficacy insidethe cell. The chemical modification patterns may include combination ofribose, backbone, hydrophobic nucleoside and conjugate type ofmodifications. In addition, in some of the embodiments, the 5′ end ofthe single polynucleotide may be chemically phosphorylated.

In yet another embodiment, the present invention provides a descriptionof the chemical modifications patterns, which improve functionality ofRISC inhibiting polynucleotides. Single stranded polynucleotides havebeen shown to inhibit activity of a preloaded RISC complex through thesubstrate competition mechanism. For these types of molecules,conventionally called antagomers, the activity usually requires highconcentration and in vivo delivery is not very effective. The presentinvention provides a description of the chemical modification patterns,which may (a) significantly increase stability of the single strandedpolynucleotide (b) promote efficient recognition of the polynucleotideby the RISC as a substrate and/or (c) improve uptake of the singlestranded nucleotide by the cell. FIG. 6 provides some non-limitingexamples of the chemical modification patterns that may be beneficialfor achieving single stranded polynucleotide efficacy inside the cell.The chemical modification patterns may include combination of ribose,backbone, hydrophobic nucleoside and conjugate type of modifications.

The modifications provided by the present invention are applicable toall polynucleotides. This includes single stranded RISC enteringpolynucleotides, single stranded RISC inhibiting polynucleotides,conventional duplexed polynucleotides of variable length (15-40 bp),asymmetric duplexed polynucleotides, and the like. Polynucleotides maybe modified with wide variety of chemical modification patterns,including 5′ end, ribose, backbone and hydrophobic nucleosidemodifications.

Synthesis

Oligonucleotides of the invention can be synthesized by any method knownin the art, e.g., using enzymatic synthesis and/or chemical synthesis.The oligonucleotides can be synthesized in vitro (e.g., using enzymaticsynthesis and chemical synthesis) or in vivo (using recombinant DNAtechnology well known in the art).

In a preferred embodiment, chemical synthesis is used for modifiedpolynucleotides. Chemical synthesis of linear oligonucleotides is wellknown in the art and can be achieved by solution or solid phasetechniques. Preferably, synthesis is by solid phase methods.Oligonucleotides can be made by any of several different syntheticprocedures including the phosphoramidite, phosphite triester,H-phosphonate, and phosphotriester methods, typically by automatedsynthesis methods.

Oligonucleotide synthesis protocols are well known in the art and can befound, e.g., in U.S. Pat. No. 5,830,653; WO 98/13526; Stec et al. 1984.J. Am. Chem. Soc. 106:6077; Stec et al. 1985. J. Org. Chem. 50:3908;Stec et al. J. Chromatog. 1985. 326:263; LaPlanche et al. 1986. Nucl.Acid. Res. 1986. 14:9081; Fasman G. D., 1989. Practical Handbook ofBiochemistry and Molecular Biology. 1989. CRC Press, Boca Raton, Fla.;Lamone. 1993. Biochem. Soc. Trans. 21:1; U.S. Pat. No. 5,013,830; U.S.Pat. No. 5,214,135; U.S. Pat. No. 5,525,719; Kawasaki et al. 1993. J.Med. Chem. 36:831; WO 92/03568; U.S. Pat. No. 5,276,019; and U.S. Pat.No. 5,264,423.

The synthesis method selected can depend on the length of the desiredoligonucleotide and such choice is within the skill of the ordinaryartisan. For example, the phosphoramidite and phosphite triester methodcan produce oligonucleotides having 175 or more nucleotides, while theH-phosphonate method works well for oligonucleotides of less than 100nucleotides. If modified bases are incorporated into theoligonucleotide, and particularly if modified phosphodiester linkagesare used, then the synthetic procedures are altered as needed accordingto known procedures. In this regard, Uhlmann et al. (1990, ChemicalReviews 90:543-584) provide references and outline procedures for makingoligonucleotides with modified bases and modified phosphodiesterlinkages. Other exemplary methods for making oligonucleotides are taughtin Sonveaux. 1994. “Protecting Groups in Oligonucleotide Synthesis”;Agrawal. Methods in Molecular Biology 26:1. Exemplary synthesis methodsare also taught in “Oligonucleotide Synthesis—A Practical Approach”(Gait, M. J. IRL Press at Oxford University Press. 1984). Moreover,linear oligonucleotides of defined sequence, including some sequenceswith modified nucleotides, are readily available from several commercialsources.

The oligonucleotides may be purified by polyacrylamide gelelectrophoresis, or by any of a number of chromatographic methods,including gel chromatography and high pressure liquid chromatography. Toconfirm a nucleotide sequence, especially unmodified nucleotidesequences, oligonucleotides may be subjected to DNA sequencing by any ofthe known procedures, including Maxam and Gilbert sequencing, Sangersequencing, capillary electrophoresis sequencing, the wandering spotsequencing procedure or by using selective chemical degradation ofoligonucleotides bound to Hybond paper. Sequences of shortoligonucleotides can also be analyzed by laser desorption massspectroscopy or by fast atom bombardment (McNeal, et al., 1982, J. Am.Chem. Soc. 104:976; Viari, et al., 1987, Biomed. Environ. Mass Spectrom.14:83; Grotjahn et al., 1982, Nuc. Acid Res. 10:4671). Sequencingmethods are also available for RNA oligonucleotides.

The quality of oligonucleotides synthesized can be verified by testingthe oligonucleotide by capillary electrophoresis and denaturing stronganion HPLC (SAX-HPLC) using, e.g., the method of Bergot and Egan. 1992.J. Chrom. 599:35.

Other exemplary synthesis techniques are well known in the art (see,e.g., Sambrook et al., Molecular Cloning: a Laboratory Manual, SecondEdition (1989); DNA Cloning, Volumes I and II (DN Glover Ed. 1985);Oligonucleotide Synthesis (M J Gait Ed, 1984; Nucleic Acid Hybridisation(B D Hames and S J Higgins eds. 1984); A Practical Guide to MolecularCloning (1984); or the series, Methods in Enzymology (Academic Press,Inc.)).

In certain embodiments, the subject RNAi constructs or at least portionsthereof are transcribed from expression vectors encoding the subjectconstructs. Any art recognized vectors may be use for this purpose. Thetranscribed RNAi constructs may be isolated and purified, before desiredmodifications (such as replacing an unmodified sense strand with amodified one, etc.) are carried out.

Delivery/Carrier Uptake of Oligonucleotides by Cells

Oligonucleotides and oligonucleotide compositions are contacted with(i.e., brought into contact with, also referred to herein asadministered or delivered to) and taken up by one or more cells or acell lysate. The term “cells” includes prokaryotic and eukaryotic cells,preferably vertebrate cells, and, more preferably, mammalian cells. In apreferred embodiment, the oligonucleotide compositions of the inventionare contacted with human cells.

Oligonucleotide compositions of the invention can be contacted withcells in vitro, e.g., in a test tube or culture dish, (and may or maynot be introduced into a subject) or in vivo, e.g., in a subject such asa mammalian subject. Oligonucleotides are taken up by cells at a slowrate by endocytosis, but endocytosed oligonucleotides are generallysequestered and not available, e.g., for hybridization to a targetnucleic acid molecule. In one embodiment, cellular uptake can befacilitated by electroporation or calcium phosphate precipitation.However, these procedures are only useful for in vitro or ex vivoembodiments, are not convenient and, in some cases, are associated withcell toxicity.

In another embodiment, delivery of oligonucleotides into cells can beenhanced by suitable art recognized methods including calcium phosphate,DMSO, glycerol or dextran, electroporation, or by transfection, e.g.,using cationic, anionic, or neutral lipid compositions or liposomesusing methods known in the art (see e.g., WO 90/14074; WO 91/16024; WO91/17424; U.S. Pat. No. 4,897,355; Bergan et al. 1993. Nucleic AcidsResearch. 21:3567). Enhanced delivery of oligonucleotides can also bemediated by the use of vectors (See e.g., Shi, Y. 2003. Trends Genet2003 Jan. 19:9; Reichhart J. M et al. Genesis. 2002. 34(1-2):1604, Yu etal. 2002. Proc. Natl. Acad. Sci. USA 99:6047; Sui et al. 2002. Proc.Natl. Acad. Sci. USA 99:5515) viruses, polyamine or polycationconjugates using compounds such as polylysine, protamine, or Ni,N12-bis(ethyl) spermine (see, e.g., Bartzatt, R. et al. 1989.Biotechnol. Appl. Biochem. 11:133; Wagner E. et al. 1992. Proc. Natl.Acad. Sci. 88:4255).

In certain embodiments, the miniRNA of the invention may be delivered byusing various beta-glucan containing particles, such as those describedin US 2005/0281781 A1, WO 2006/007372, and WO 2007/050643 (allincorporated herein by reference). In certain embodiments, thebeta-glucan particle is derived from yeast. In certain embodiments, thepayload trapping molecule is a polymer, such as those with a molecularweight of at least about 1000 Da, 10,000 Da, 50,000 Da, 100 kDa, 500kDa, etc. Preferred polymers include (without limitation) cationicpolymers, chitosans, or PEI (polyethylenimine), etc.

Such beta-glucan based delivery system may be formulated for oraldelivery, where the orally delivered beta-glucan/miniRNA constructs maybe engulfed by macrophages or other related phagocytic cells, which mayin turn release the miniRNA constructs in selected in vivo sites.Alternatively or in addition, the miniRNA may changes the expression ofcertain macrophage target genes.

The optimal protocol for uptake of oligonucleotides will depend upon anumber of factors, the most crucial being the type of cells that arebeing used. Other factors that are important in uptake include, but arenot limited to, the nature and concentration of the oligonucleotide, theconfluence of the cells, the type of culture the cells are in (e.g., asuspension culture or plated) and the type of media in which the cellsare grown.

Encapsulating Agents

Encapsulating agents entrap oligonucleotides within vesicles. In anotherembodiment of the invention, an oligonucleotide may be associated with acarrier or vehicle, e.g., liposomes or micelles, although other carrierscould be used, as would be appreciated by one skilled in the art.Liposomes are vesicles made of a lipid bilayer having a structuresimilar to biological membranes. Such carriers are used to facilitatethe cellular uptake or targeting of the oligonucleotide, or improve theoligonucleotide's pharmacokinetic or toxicologic properties.

For example, the oligonucleotides of the present invention may also beadministered encapsulated in liposomes, pharmaceutical compositionswherein the active ingredient is contained either dispersed or variouslypresent in corpuscles consisting of aqueous concentric layers adherentto lipidic layers. The oligonucleotides, depending upon solubility, maybe present both in the aqueous layer and in the lipidic layer, or inwhat is generally termed a liposomic suspension. The hydrophobic layer,generally but not exclusively, comprises phospholipids such as lecithinand sphingomyelin, steroids such as cholesterol, more or less ionicsurfactants such as diacetylphosphate, stearylamine, or phosphatidicacid, or other materials of a hydrophobic nature. The diameters of theliposomes generally range from about 15 nm to about 5 microns.

A “hydrophobic modified polynucleotide” as used herein is apolynucleotide of the invention (i.e. sd-rxRNA) that has at least onemodification that renders the polynucleotide more hydrophobic than thepolynucleotide was prior to modification. The modification may beachieved by attaching (covalently or non-covalently) a hydrophobicmolecule to the polynucleotide. In some instances the hydrophobicmolecule is or includes a lipophilic group.

The term “lipophilic group” means a group that has a higher affinity forlipids than its affinity for water. Examples of lipophilic groupsinclude, but are not limited to, cholesterol, a cholesteryl or modifiedcholesteryl residue, adamantine, dihydrotesterone, long chain alkyl,long chain alkenyl, long chain alkynyl, olely-lithocholic, cholenic,oleoyl-cholenic, palmityl, heptadecyl, myrisityl, bile acids, cholicacid or taurocholic acid, deoxycholate, oleyl litocholic acid, oleoylcholenic acid, glycolipids, phospholipids, sphingolipids, isoprenoids,such as steroids, vitamins, such as vitamin E, fatty acids eithersaturated or unsaturated, fatty acid esters, such as triglycerides,pyrenes, porphyrines, Texaphyrine, adamantane, acridines, biotin,coumarin, fluorescein, rhodamine, Texas-Red, digoxygenin,dimethoxytrityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, cyaninedyes (e.g. Cy3 or Cy5), Hoechst 33258 dye, psoralen, or ibuprofen. Thecholesterol moiety may be reduced (e.g. as in cholestan) or may besubstituted (e.g. by halogen). A combination of different lipophilicgroups in one molecule is also possible.

The hydrophobic molecule may be attached at various positions of thepolynucleotide. As described above, the hydrophobic molecule may belinked to the terminal residue of the polynucleotide such as the 3′ of5′-end of the polynucleotide. Alternatively, it may be linked to aninternal nucleotide or a nucleotide on a branch of the polynucleotide.The hydrophobic molecule may be attached, for instance to a 2′-positionof the nucleotide. The hydrophobic molecule may also be linked to theheterocyclic base, the sugar or the backbone of a nucleotide of thepolynucleotide.

The hydrophobic molecule may be connected to the polynucleotide by alinker moiety. Optionally the linker moiety is a non-nucleotidic linkermoiety. Non-nucleotidic linkers are e.g. abasic residues (dSpacer),oligoethyleneglycol, such as triethyleneglycol (spacer 9) orhexaethylenegylcol (spacer 18), or alkane-diol, such as butanediol. Thespacer units are preferably linked by phosphodiester or phosphorothioatebonds. The linker units may appear just once in the molecule or may beincorporated several times, e.g. via phosphodiester, phosphorothioate,methylphosphonate, or amide linkages.

Typical conjugation protocols involve the synthesis of polynucleotidesbearing an aminolinker at one or more positions of the sequence,however, a linker is not required. The amino group is then reacted withthe molecule being conjugated using appropriate coupling or activatingreagents. The conjugation reaction may be performed either with thepolynucleotide still bound to a solid support or following cleavage ofthe polynucleotide in solution phase. Purification of the modifiedpolynucleotide by HPLC typically results in a pure material.

In some embodiments the hydrophobic molecule is a sterol type conjugate,a PhytoSterol conjugate, cholesterol conjugate, sterol type conjugatewith altered side chain length, fatty acid conjugate, any otherhydrophobic group conjugate, and/or hydrophobic modifications of theinternal nucleoside, which provide sufficient hydrophobicity to beincorporated into micelles.

For purposes of the present invention, the term “sterols”, refers orsteroid alcohols are a subgroup of steroids with a hydroxyl group at the3-position of the A-ring. They are amphipathic lipids synthesized fromacetyl-coenzyme A via the HMG-CoA reductase pathway. The overallmolecule is quite flat. The hydroxyl group on the A ring is polar. Therest of the aliphatic chain is non-polar. Usually sterols are consideredto have an 8 carbon chain at position 17.

For purposes of the present invention, the term “sterol type molecules”,refers to steroid alcohols, which are similar in structure to sterols.The main difference is the structure of the ring and number of carbonsin a position 21 attached side chain.

For purposes of the present invention, the term “PhytoSterols” (alsocalled plant sterols) are a group of steroid alcohols, phytochemicalsnaturally occurring in plants. There are more then 200 different knownPhytoSterols

For purposes of the present invention, the term “Sterol side chain”refers to a chemical composition of a side chain attached at theposition 17 of sterol-type molecule. In a standard definition sterolsare limited to a 4 ring structure carrying a 8 carbon chain at position17. In this invention, the sterol type molecules with side chain longerand shorter than conventional are described. The side chain may branchedor contain double back bones.

Thus, sterols useful in the invention, for example, includecholesterols, as well as unique sterols in which position 17 hasattached side chain of 2-7 or longer then 9 carbons. In a particularembodiment, the length of the polycarbon tail is varied between 5 and 9carbons. FIG. 9 demonstrates that there is a correlation between plasmaclearance, liver uptake and the length of the polycarbon chain. Suchconjugates may have significantly better in vivo efficacy, in particulardelivery to liver. These types of molecules are expected to work atconcentrations 5 to 9 fold lower then oligonucleotides conjugated toconventional cholesterols.

Alternatively the polynucleotide may be bound to a protein, peptide orpositively charged chemical that functions as the hydrophobic molecule.The proteins may be selected from the group consisting of protamine,dsRNA binding domain, and arginine rich peptides. Exemplary positivelycharged chemicals include spermine, spermidine, cadaverine, andputrescine.

In another embodiment hydrophobic molecule conjugates may demonstrateeven higher efficacy when it is combined with optimal chemicalmodification patterns of the polynucleotide (as described herein indetail), containing but not limited to hydrophobic modifications,phosphorothioate modifications, and 2′ ribo modifications.

In another embodiment the sterol type molecule may be a naturallyoccurring PhytoSterols such as those shown in FIG. 8. The polycarbonchain may be longer than 9 and may be linear, branched and/or containdouble bonds. Some PhytoSterol containing polynucleotide conjugates maybe significantly more potent and active in delivery of polynucleotidesto various tissues. Some PhytoSterols may demonstrate tissue preferenceand thus be used as a way to delivery RNAi specifically to particulartissues.

Targeting Agents

The delivery of oligonucleotides can also be improved by targeting theoligonucleotides to a cellular receptor. The targeting moieties can beconjugated to the oligonucleotides or attached to a carrier group (i.e.,poly(L-lysine) or liposomes) linked to the oligonucleotides. This methodis well suited to cells that display specific receptor-mediatedendocytosis.

For instance, oligonucleotide conjugates to 6-phosphomannosylatedproteins are internalized 20-fold more efficiently by cells expressingmannose 6-phosphate specific receptors than free oligonucleotides. Theoligonucleotides may also be coupled to a ligand for a cellular receptorusing a biodegradable linker. In another example, the delivery constructis mannosylated streptavidin which forms a tight complex withbiotinylated oligonucleotides. Mannosylated streptavidin was found toincrease 20-fold the internalization of biotinylated oligonucleotides.(Vlassov et al. 1994. Biochimica et Biophysica Acta 1197:95-108).

In addition specific ligands can be conjugated to the polylysinecomponent of polylysine-based delivery systems. For example,transferrin-polylysine, adenovirus-polylysine, and influenza virushemagglutinin HA-2 N-terminal fusogenic peptides-polylysine conjugatesgreatly enhance receptor-mediated DNA delivery in eucaryotic cells.Mannosylated glycoprotein conjugated to poly(L-lysine) in aveolarmacrophages has been employed to enhance the cellular uptake ofoligonucleotides. Liang et al. 1999. Pharmazie 54:559-566.

Because malignant cells have an increased need for essential nutrientssuch as folic acid and transferrin, these nutrients can be used totarget oligonucleotides to cancerous cells. For example, when folic acidis linked to poly(L-lysine) enhanced oligonucleotide uptake is seen inpromyelocytic leukaemia (HL-60) cells and human to melanoma (M-14)cells. Ginobbi et al. 1997. Anticancer Res. 17:29. In another example,liposomes coated with maleylated bovine serum albumin, folic acid, orferric protoporphyrin IX, show enhanced cellular uptake ofoligonucleotides in murine macrophages, KB cells, and 2.2.15 humanhepatoma cells. Liang et al. 1999. Pharmazie 54:559-566.

Liposomes naturally accumulate in the liver, spleen, andreticuloendothelial system (so-called, passive targeting). By couplingliposomes to various ligands such as antibodies are protein A, they canbe actively targeted to specific cell populations. For example, proteinA-bearing liposomes may be pretreated with H-2K specific antibodieswhich are targeted to the mouse major histocompatibility complex-encodedH-2K protein expressed on L cells. (Vlassov et al. 1994. Biochimica etBiophysica Acta 1197:95-108).

Other in vitro and/or in vivo delivery of RNAi reagents are known in theart, and can be used to deliver the subject RNAi constructs. See, forexample, U.S. patent application publications 20080152661, 20080112916,20080107694, 20080038296, 20070231392, 20060240093, 20060178327,20060008910, 20050265957, 20050064595, 20050042227, 20050037496,20050026286, 20040162235, 20040072785, 20040063654, 20030157030, WO2008/036825, WO04/065601, and AU2004206255B2, just to name a few (allincorporated by reference).

Administration

The optimal course of administration or delivery of the oligonucleotidesmay vary depending upon the desired result and/or on the subject to betreated. As used herein “administration” refers to contacting cells witholigonucleotides and can be performed in vitro or in vivo. The dosage ofoligonucleotides may be adjusted to optimally reduce expression of aprotein translated from a target nucleic acid molecule, e.g., asmeasured by a readout of RNA stability or by a therapeutic response,without undue experimentation.

For example, expression of the protein encoded by the nucleic acidtarget can be measured to determine whether or not the dosage regimenneeds to be adjusted accordingly. In addition, an increase or decreasein RNA or protein levels in a cell or produced by a cell can be measuredusing any art recognized technique. By determining whether transcriptionhas been decreased, the effectiveness of the oligonucleotide in inducingthe cleavage of a target RNA can be determined.

Any of the above-described oligonucleotide compositions can be usedalone or in conjunction with a pharmaceutically acceptable carrier. Asused herein, “pharmaceutically acceptable carrier” includes appropriatesolvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents, and the like. The useof such media and agents for pharmaceutical active substances is wellknown in the art. Except insofar as any conventional media or agent isincompatible with the active ingredient, it can be used in thetherapeutic compositions. Supplementary active ingredients can also beincorporated into the compositions.

Oligonucleotides may be incorporated into liposomes or liposomesmodified with polyethylene glycol or admixed with cationic lipids forparenteral administration. Incorporation of additional substances intothe liposome, for example, antibodies reactive against membrane proteinsfound on specific target cells, can help target the oligonucleotides tospecific cell types.

Moreover, the present invention provides for administering the subjectoligonucleotides with an osmotic pump providing continuous infusion ofsuch oligonucleotides, for example, as described in Rataiczak et al.(1992 Proc. Natl. Acad. Sci. USA 89:11823-11827). Such osmotic pumps arecommercially available, e.g., from Alzet Inc. (Palo Alto, Calif.).Topical administration and parenteral administration in a cationic lipidcarrier are preferred.

With respect to in vivo applications, the formulations of the presentinvention can be administered to a patient in a variety of forms adaptedto the chosen route of administration, e.g., parenterally, orally, orintraperitoneally. Parenteral administration, which is preferred,includes administration by the following routes: intravenous;intramuscular; interstitially; intraarterially; subcutaneous; intraocular; intrasynovial; trans epithelial, including transdermal;pulmonary via inhalation; ophthalmic; sublingual and buccal; topically,including ophthalmic; dermal; ocular; rectal; and nasal inhalation viainsufflation.

Pharmaceutical preparations for parenteral administration includeaqueous solutions of the active compounds in water-soluble orwater-dispersible form. In addition, suspensions of the active compoundsas appropriate oily injection suspensions may be administered. Suitablelipophilic solvents or vehicles include fatty oils, for example, sesameoil, or synthetic fatty acid esters, for example, ethyl oleate ortriglycerides. Aqueous injection suspensions may contain substanceswhich increase the viscosity of the suspension include, for example,sodium carboxymethyl cellulose, sorbitol, or dextran, optionally, thesuspension may also contain stabilizers. The oligonucleotides of theinvention can be formulated in liquid solutions, preferably inphysiologically compatible buffers such as Hank's solution or Ringer'ssolution. In addition, the oligonucleotides may be formulated in solidform and redissolved or suspended immediately prior to use. Lyophilizedforms are also included in the invention.

Pharmaceutical preparations for topical administration includetransdermal patches, ointments, lotions, creams, gels, drops, sprays,suppositories, liquids and powders. In addition, conventionalpharmaceutical carriers, aqueous, powder or oily bases, or thickenersmay be used in pharmaceutical preparations for topical administration.

Pharmaceutical preparations for oral administration include powders orgranules, suspensions or solutions in water or non-aqueous media,capsules, sachets or tablets. In addition, thickeners, flavoring agents,diluents, emulsifiers, dispersing aids, or binders may be used inpharmaceutical preparations for oral administration.

For transmucosal or transdermal administration, penetrants appropriateto the barrier to be permeated are used in the formulation. Suchpenetrants are known in the art, and include, for example, fortransmucosal administration bile salts and fusidic acid derivatives, anddetergents. Transmucosal administration may be through nasal sprays orusing suppositories. For oral administration, the oligonucleotides areformulated into conventional oral administration forms such as capsules,tablets, and tonics. For topical administration, the oligonucleotides ofthe invention are formulated into ointments, salves, gels, or creams asknown in the art.

Drug delivery vehicles can be chosen e.g., for in vitro, for systemic,or for topical administration. These vehicles can be designed to serveas a slow release reservoir or to deliver their contents directly to thetarget cell. An advantage of using some direct delivery drug vehicles isthat multiple molecules are delivered per uptake. Such vehicles havebeen shown to increase the circulation half-life of drugs that wouldotherwise be rapidly cleared from the blood stream. Some examples ofsuch specialized drug delivery vehicles which fall into this categoryare liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, andbioadhesive microspheres.

The described oligonucleotides may be administered systemically to asubject. Systemic absorption refers to the entry of drugs into the bloodstream followed by distribution throughout the entire body.Administration routes which lead to systemic absorption include:intravenous, subcutaneous, intraperitoneal, and intranasal. Each ofthese administration routes delivers the oligonucleotide to accessiblediseased cells. Following subcutaneous administration, the therapeuticagent drains into local lymph nodes and proceeds through the lymphaticnetwork into the circulation. The rate of entry into the circulation hasbeen shown to be a function of molecular weight or size. The use of aliposome or other drug carrier localizes the oligonucleotide at thelymph node. The oligonucleotide can be modified to diffuse into thecell, or the liposome can directly participate in the delivery of eitherthe unmodified or modified oligonucleotide into the cell.

The chosen method of delivery will result in entry into cells. Preferreddelivery methods include liposomes (10-400 nm), hydrogels,controlled-release polymers, and other pharmaceutically applicablevehicles, and microinjection or electroporation (for ex vivotreatments).

The pharmaceutical preparations of the present invention may be preparedand formulated as emulsions. Emulsions are usually heterogeneous systemsof one liquid dispersed in another in the form of droplets usuallyexceeding 0.1 μm in diameter. The emulsions of the present invention maycontain excipients such as emulsifiers, stabilizers, dyes, fats, oils,waxes, fatty acids, fatty alcohols, fatty esters, humectants,hydrophilic colloids, preservatives, and anti-oxidants may also bepresent in emulsions as needed. These excipients may be present as asolution in either the aqueous phase, oily phase or itself as a separatephase.

Examples of naturally occurring emulsifiers that may be used in emulsionformulations of the present invention include lanolin, beeswax,phosphatides, lecithin and acacia. Finely divided solids have also beenused as good emulsifiers especially in combination with surfactants andin viscous preparations. Examples of finely divided solids that may beused as emulsifiers include polar inorganic solids, such as heavy metalhydroxides, nonswelling clays such as bentonite, attapulgite, hectorite,kaolin, montrnorillonite, colloidal aluminum silicate and colloidalmagnesium aluminum silicate, pigments and nonpolar solids such as carbonor glyceryl tristearate.

Examples of preservatives that may be included in the emulsionformulations include methyl paraben, propyl paraben, quaternary ammoniumsalts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boricacid. Examples of antioxidants that may be included in the emulsionformulations include free radical scavengers such as tocopherols, alkylgallates, butylated hydroxyanisole, butylated hydroxytoluene, orreducing agents such as ascorbic acid and sodium metabisulfite, andantioxidant synergists such as citric acid, tartaric acid, and lecithin.

In one embodiment, the compositions of oligonucleotides are formulatedas microemulsions. A microemulsion is a system of water, oil andamphiphile which is a single optically isotropic and thermodynamicallystable liquid solution. Typically microemulsions are prepared by firstdispersing an oil in an aqueous surfactant solution and then adding asufficient amount of a 4th component, generally an intermediatechain-length alcohol to form a transparent system.

Surfactants that may be used in the preparation of microemulsionsinclude, but are not limited to, ionic surfactants, non-ionicsurfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fattyacid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate(MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate(PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate(MO750), decaglycerol sequioleate (S0750), decaglycerol decaoleate(DA0750), alone or in combination with cosurfactants. The cosurfactant,usually a short-chain alcohol such as ethanol, 1-propanol, and1-butanol, serves to increase the interfacial fluidity by penetratinginto the surfactant film and consequently creating a disordered filmbecause of the void space generated among surfactant molecules.

Microemulsions may, however, be prepared without the use ofcosurfactants and alcohol-free self-emulsifying microemulsion systemsare known in the art. The aqueous phase may typically be, but is notlimited to, water, an aqueous solution of the drug, glycerol, PEG300,PEG400, polyglycerols, propylene glycols, and derivatives of ethyleneglycol. The oil phase may include, but is not limited to, materials suchas Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain(C₈-C₁₂) mono, di, and tri-glycerides, polyoxyethylated glyceryl fattyacid esters, fatty alcohols, polyglycolized glycerides, saturatedpolyglycolized C₈-C₁₀ glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drugsolubilization and the enhanced absorption of drugs. Lipid basedmicroemulsions (both oil/water and water/oil) have been proposed toenhance the oral bioavailability of drugs.

Microemulsions offer improved drug solubilization, protection of drugfrom enzymatic hydrolysis, possible enhancement of drug absorption dueto surfactant-induced alterations in membrane fluidity and permeability,ease of preparation, ease of oral administration over solid dosageforms, improved clinical potency, and decreased toxicity (Constantinideset al., Pharmaceutical Research, 1994, 11:1385; Ho et al., J. Pharm.Sci., 1996, 85:138-143). Microemulsions have also been effective in thetransdermal delivery of active components in both cosmetic andpharmaceutical applications. It is expected that the microemulsioncompositions and formulations of the present invention will facilitatethe increased systemic absorption of oligonucleotides from thegastrointestinal tract, as well as improve the local cellular uptake ofoligonucleotides within the gastrointestinal tract, vagina, buccalcavity and other areas of administration.

In an embodiment, the present invention employs various penetrationenhancers to affect the efficient delivery of nucleic acids,particularly oligonucleotides, to the skin of animals. Evennon-lipophilic drugs may cross cell membranes if the membrane to becrossed is treated with a penetration enhancer. In addition toincreasing the diffusion of non-lipophilic drugs across cell membranes,penetration enhancers also act to enhance the permeability of lipophilicdrugs.

Five categories of penetration enhancers that may be used in the presentinvention include: surfactants, fatty acids, bile salts, chelatingagents, and non-chelating non-surfactants. Other agents may be utilizedto enhance the penetration of the administered oligonucleotides include:glycols such as ethylene glycol and propylene glycol, pyrrols such as2-15 pyrrol, azones, and terpenes such as limonene, and menthone.

The oligonucleotides, especially in lipid formulations, can also beadministered by coating a medical device, for example, a catheter, suchas an angioplasty balloon catheter, with a cationic lipid formulation.Coating may be achieved, for example, by dipping the medical device intoa lipid formulation or a mixture of a lipid formulation and a suitablesolvent, for example, an aqueous-based buffer, an aqueous solvent,ethanol, methylene chloride, chloroform and the like. An amount of theformulation will naturally adhere to the surface of the device which issubsequently administered to a patient, as appropriate. Alternatively, alyophilized mixture of a lipid formulation may be specifically bound tothe surface of the device. Such binding techniques are described, forexample, in K. Ishihara et al., Journal of Biomedical MaterialsResearch, Vol. 27, pp. 1309-1314 (1993), the disclosures of which areincorporated herein by reference in their entirety.

The useful dosage to be administered and the particular mode ofadministration will vary depending upon such factors as the cell type,or for in vivo use, the age, weight and the particular animal and regionthereof to be treated, the particular oligonucleotide and deliverymethod used, the therapeutic or diagnostic use contemplated, and theform of the formulation, for example, suspension, emulsion, micelle orliposome, as will be readily apparent to those skilled in the art.Typically, dosage is administered at lower levels and increased untilthe desired effect is achieved. When lipids are used to deliver theoligonucleotides, the amount of lipid compound that is administered canvary and generally depends upon the amount of oligonucleotide agentbeing administered. For example, the weight ratio of lipid compound tooligonucleotide agent is preferably from about 1:1 to about 15:1, with aweight ratio of about 5:1 to about 10:1 being more preferred. Generally,the amount of cationic lipid compound which is administered will varyfrom between about 0.1 milligram (mg) to about 1 gram (g). By way ofgeneral guidance, typically between about 0.1 mg and about 10 mg of theparticular oligonucleotide agent, and about 1 mg to about 100 mg of thelipid compositions, each per kilogram of patient body weight, isadministered, although higher and lower amounts can be used.

The agents of the invention are administered to subjects or contactedwith cells in a biologically compatible form suitable for pharmaceuticaladministration. By “biologically compatible form suitable foradministration” is meant that the oligonucleotide is administered in aform in which any toxic effects are outweighed by the therapeuticeffects of the oligonucleotide. In one embodiment, oligonucleotides canbe administered to subjects. Examples of subjects include mammals, e.g.,humans and other primates; cows, pigs, horses, and farming(agricultural) animals; dogs, cats, and other domesticated pets; mice,rats, and transgenic non-human animals.

Administration of an active amount of an oligonucleotide of the presentinvention is defined as an amount effective, at dosages and for periodsof time necessary to achieve the desired result. For example, an activeamount of an oligonucleotide may vary according to factors such as thetype of cell, the oligonucleotide used, and for in vivo uses the diseasestate, age, sex, and weight of the individual, and the ability of theoligonucleotide to elicit a desired response in the individual.Establishment of therapeutic levels of oligonucleotides within the cellis dependent upon the rates of uptake and efflux or degradation.Decreasing the degree of degradation prolongs the intracellularhalf-life of the oligonucleotide. Thus, chemically-modifiedoligonucleotides, e.g., with modification of the phosphate backbone, mayrequire different dosing.

The exact dosage of an oligonucleotide and number of doses administeredwill depend upon the data generated experimentally and in clinicaltrials. Several factors such as the desired effect, the deliveryvehicle, disease indication, and the route of administration, willaffect the dosage. Dosages can be readily determined by one of ordinaryskill in the art and formulated into the subject pharmaceuticalcompositions. Preferably, the duration of treatment will extend at leastthrough the course of the disease symptoms.

Dosage regime may be adjusted to provide the optimum therapeuticresponse. For example, the oligonucleotide may be repeatedlyadministered, e.g., several doses may be administered daily or the dosemay be proportionally reduced as indicated by the exigencies of thetherapeutic situation. One of ordinary skill in the art will readily beable to determine appropriate doses and schedules of administration ofthe subject oligonucleotides, whether the oligonucleotides are to beadministered to cells or to subjects.

Physical methods of introducing nucleic acids include injection of asolution containing the nucleic acid, bombardment by particles coveredby the nucleic acid, soaking the cell or organism in a solution of thenucleic acid, or electroporation of cell membranes in the presence ofthe nucleic acid. A viral construct packaged into a viral particle wouldaccomplish both efficient introduction of an expression construct intothe cell and transcription of nucleic acid encoded by the expressionconstruct. Other methods known in the art for introducing nucleic acidsto cells may be used, such as lipid-mediated carrier transport,chemical-mediated transport, such as calcium phosphate, and the like.Thus the nucleic acid may be introduced along with components thatperform one or more of the following activities: enhance nucleic aciduptake by the cell, inhibit annealing of single strands, stabilize thesingle strands, or other-wise increase inhibition of the target gene.

Nucleic acid may be directly introduced into the cell (i.e.,intracellularly); or introduced extracellularly into a cavity,interstitial space, into the circulation of an organism, introducedorally or by inhalation, or may be introduced by bathing a cell ororganism in a solution containing the nucleic acid. Vascular orextravascular circulation, the blood or lymph system, and thecerebrospinal fluid are sites where the nucleic acid may be introduced.

The cell with the target gene may be derived from or contained in anyorganism. The organism may a plant, animal, protozoan, bacterium, virus,or fungus. The plant may be a monocot, dicot or gymnosperm; the animalmay be a vertebrate or invertebrate. Preferred microbes are those usedin agriculture or by industry, and those that are pathogenic for plantsor animals.

Alternatively, vectors, e.g., transgenes encoding a siRNA of theinvention can be engineered into a host cell or transgenic animal usingart recognized techniques.

Another use for the nucleic acids of the present invention (or vectorsor transgenes encoding same) is a functional analysis to be carried outin eukaryotic cells, or eukaryotic non-human organisms, preferablymammalian cells or organisms and most preferably human cells, e.g. celllines such as HeLa or 293 or rodents, e.g. rats and mice. Byadministering a suitable nucleic acid of the invention which issufficiently complementary to a target mRNA sequence to directtarget-specific RNA interference, a specific knockout or knockdownphenotype can be obtained in a target cell, e.g. in cell culture or in atarget organism.

Thus, a further subject matter of the invention is a eukaryotic cell ora eukaryotic non-human organism exhibiting a target gene-specificknockout or knockdown phenotype comprising a fully or at least partiallydeficient expression of at least one endogenous target gene wherein saidcell or organism is transfected with at least one vector comprising DNAencoding an RNAi agent capable of inhibiting the expression of thetarget gene. It should be noted that the present invention allows atarget-specific knockout or knockdown of several different endogenousgenes due to the specificity of the RNAi agent.

Gene-specific knockout or knockdown phenotypes of cells or non-humanorganisms, particularly of human cells or non-human mammals may be usedin analytic to procedures, e.g. in the functional and/or phenotypicalanalysis of complex physiological processes such as analysis of geneexpression profiles and/or proteomes. Preferably the analysis is carriedout by high throughput methods using oligonucleotide based chips.

Therapeutic Use

By inhibiting the expression of a gene, the oligonucleotide compositionsof the present invention can be used to treat any disease involving theexpression of a protein. Examples of diseases that can be treated byoligonucleotide compositions, just to illustrate, include: cancer,retinopathies, autoimmune diseases, inflammatory diseases (i.e., ICAM-1related disorders, Psoriasis, Ulcerative Colitus, Crohn's disease),viral diseases (i.e., HIV, Hepatitis C), miRNA disorders, andcardiovascular diseases.

In one embodiment, in vitro treatment of cells with oligonucleotides canbe used for ex vivo therapy of cells removed from a subject (e.g., fortreatment of leukemia or viral infection) or for treatment of cellswhich did not originate in the subject, but are to be administered tothe subject (e.g., to eliminate transplantation antigen expression oncells to be transplanted into a subject). In addition, in vitrotreatment of cells can be used in non-therapeutic settings, e.g., toevaluate gene function, to study gene regulation and protein synthesisor to evaluate improvements made to oligonucleotides designed tomodulate gene expression or protein synthesis. In vivo treatment ofcells can be useful in certain clinical settings where it is desirableto inhibit the expression of a protein. There are numerous medicalconditions for which antisense therapy is reported to be suitable (see,e.g., U.S. Pat. No. 5,830,653) as well as respiratory syncytial virusinfection (WO 95/22,553) influenza virus (WO 94/23,028), andmalignancies (WO 94/08,003). Other examples of clinical uses ofantisense sequences are reviewed, e.g., in Glaser. 1996. GeneticEngineering News 16:1. Exemplary targets for cleavage byoligonucleotides include, e.g., protein kinase Ca, ICAM-1, c-raf kinase,p53, c-myb, and the bcr/abl fusion gene found in chronic myelogenousleukemia.

The subject nucleic acids can be used in RNAi-based therapy in anyanimal having RNAi pathway, such as human, non-human primate, non-humanmammal, non-human vertebrates, rodents (mice, rats, hamsters, rabbits,etc.), domestic livestock animals, pets (cats, dogs, etc.), Xenopus,fish, insects (Drosophila, etc.), and worms (C. elegans), etc.

The invention provides methods for inhibiting or preventing in asubject, a disease or condition associated with an aberrant or unwantedtarget gene expression or activity, by administering to the subject anucleic acid of the invention. If appropriate, subjects are firsttreated with a priming agent so as to be more responsive to thesubsequent RNAi therapy. Subjects at risk for a disease which is causedor contributed to by aberrant or unwanted target gene expression oractivity can be identified by, for example, any or a combination ofdiagnostic or prognostic assays known in the art. Administration of aprophylactic agent can occur prior to the manifestation of symptomscharacteristic of the target gene aberrancy, such that a disease ordisorder is prevented or, alternatively, delayed in its progression.Depending on the type of target gene aberrancy, for example, a targetgene, target gene agonist or target gene antagonist agent can be usedfor treating the subject.

In another aspect, the invention pertains to methods of modulatingtarget gene expression, protein expression or activity for therapeuticpurposes. Accordingly, in an exemplary embodiment, the methods of theinvention involve contacting a cell capable of expressing target genewith a nucleic acid of the invention that is specific for the targetgene or protein (e.g., is specific for the mRNA encoded by said gene orspecifying the amino acid sequence of said protein) such that expressionor one or more of the activities of target protein is modulated. Thesemethods can be performed in vitro (e.g., by culturing the cell with theagent), in vivo (e.g., by administering the agent to a subject), or exvivo. The subjects may be first treated with a priming agent so as to bemore responsive to the subsequent RNAi therapy if desired. As such, thepresent invention provides methods of treating a subject afflicted witha disease or disorder characterized by aberrant or unwanted expressionor activity of a target gene polypeptide or nucleic acid moleculeInhibition of target gene activity is desirable in situations in whichtarget gene is abnormally unregulated and/or in which decreased targetgene activity is likely to have a beneficial effect.

Thus the therapeutic agents of the invention can be administered tosubjects to treat (prophylactically or therapeutically) disordersassociated with aberrant or unwanted target gene activity. Inconjunction with such treatment, pharmacogenomics (i.e., the study ofthe relationship between an individual's genotype and that individual'sresponse to a foreign compound or drug) may be considered. Differencesin metabolism of therapeutics can lead to severe toxicity or therapeuticfailure by altering the relation between dose and blood concentration ofthe pharmacologically active drug. Thus, a physician or clinician mayconsider applying knowledge obtained in relevant pharmacogenomicsstudies in determining whether to administer a therapeutic agent as wellas tailoring the dosage and/or therapeutic regimen of treatment with atherapeutic agent. Pharmacogenomics deals with clinically significanthereditary variations in the response to drugs due to altered drugdisposition and abnormal action in affected persons.

For the purposes of the invention, ranges may be expressed herein asfrom “about” one particular value, and/or to “about” another particularvalue. When such a range is expressed, another embodiment includes fromthe one particular value and/or to the other particular value.Similarly, when values are expressed as approximations, by use of theantecedent “about,” it will be understood that the particular valueforms another embodiment. It will be further understood that theendpoints of each of the ranges are significant both in relation to theother endpoint, and independently of the other endpoint.

Moreover, for the purposes of the present invention, the term “a” or“an” entity refers to one or more of that entity; for example, “aprotein” or “a nucleic acid molecule” refers to one or more of thosecompounds or at least one compound. As such, the terms “a” (or “an”),“one or more” and “at least one” can be used interchangeably herein. Itis also to be noted that the terms “comprising”, “including”, and“having” can be used interchangeably. Furthermore, a compound “selectedfrom the group consisting of” refers to one or more of the compounds inthe list that follows, including mixtures (i.e., combinations) of two ormore of the compounds. According to the present invention, an isolated,or biologically pure, protein or nucleic acid molecule is a compoundthat has to been removed from its natural milieu. As such, “isolated”and “biologically pure” do not necessarily reflect the extent to whichthe compound has been purified. An isolated compound of the presentinvention can be obtained from its natural source, can be produced usingmolecular biology techniques or can be produced by chemical synthesis.

The present invention is further illustrated by the following Examples,which in no way should be construed as further limiting. The entirecontents of all of the references (including literature references,issued patents, published patent applications, and co-pending patentapplications) cited throughout this application are hereby expresslyincorporated by reference.

EXAMPLES Example 1 Inhibition of Gene Expression using Minimum LengthTrigger RNAs

Transfection of Minimum Length Trigger (mlt) RNA

mltRNA constructs were chemically synthesized (Integrated DNATechnologies, Coralville, Iowa) and transfected into HEK293 cells (ATCC,Manassas, Va.) using the Lipofectamine RNAiMAX (Invitrogen, Carlsbad,Calif.) reagent according to manufacturer's instructions. In brief, RNAwas diluted to a 12× concentration and then combined with a 12×concentration of Lipofectamine RNAiMAX to complex. The RNA andtransfection reagent were allowed to complex at room temperature for 20minutes and make a 6× concentration. While complexing, HEK293 cells werewashed, trypsinized and counted. The cells were diluted to aconcentration recommended by the manufacturer and previously describedconditions which was at 1×10⁵ cells/ml. When RNA had completedcomplexing with the RNAiMAX transfection reagent, 20 ul of the complexeswere added to the appropriate well of the 96-well plate in triplicate.Cells were added to each well (100 ul volume) to make the final cellcount per well at 1×10⁴ cells/well. The volume of cells diluted the 6×concentration of complex to 1× which was equal to a concentration noted(between 10-0.05 nM). Cells were incubated for 24 or 48 hours undernormal growth conditions.

After 24 or 48 hour incubation cells were lysed and gene silencingactivity was measured using the QuantiGene assay (Panomics, Freemont,Calif.) which employs bDNA hybridization technology. The assay wascarried out according to manufacturer's instructions.

ΔG calculation

ΔG was calculated using Mfold, available through the Mfold internet site(http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi). Methods forcalculating ΔG are described in, and are incorporated by reference from,the following references: Zuker, M. (2003) Nucleic Acids Res.,31(13):3406-15; Mathews, D. H., Sabina, J., Zuker, M. and Turner, D. H.(1999) J. Mol. Biol. 288:911-940; Mathews, D. H., Disney, M. D., Childs,J. L., Schroeder, S. J., Zuker, M., and Turner, D. H. (2004) Proc. Natl.Acad. Sci. 101:7287-7292; Duan, S., Mathews, D. H., and Turner, D. H.(2006) Biochemistry 45:9819-9832; Wuchty, S., Fontana, W., Hofacker, I.L., and Schuster, P. (1999) Biopolymers 49:145-165.

Example 2 Optimization of sd-rxRNA^(nano) Molecules for Gene Silencing

Asymmetric double stranded RNAi molecules, with minimal double strandedregions, were developed herein and are highly effective at genesilencing. These molecules can contain a variety of chemicalmodifications on the sense and/or anti-sense strands, and can beconjugated to sterol-like compounds such as cholesterol.

FIGS. 1-3 present schematics of RNAi molecules associated with theinvention. In the asymmetric molecules, which contain a sense andanti-sense strand, either of the strands can be the longer strand.Either strand can also contain a single-stranded region. There can alsobe mismatches between the sense and anti-sense strand, as indicated inFIG. 1D. Preferably, one end of the double-stranded molecule is eitherblunt-ended or contains a short overhang such as an overhang of onenucleotide. FIG. 2 indicates types of chemical modifications applied tothe sense and anti-sense strands including 2′F, 2′OMe, hydrophobicmodifications and phosphorothioate modifications. Preferably, the singlestranded region of the molecule contains multiple phosphorothioatemodifications. Hydrophobicity of molecules can be increased using suchcompounds as 4-pyridyl at 5-U, 2-pyridyl at 5-U, isobutyl at 5-U andindolyl at 5-U (FIG. 2). Proteins or peptides such as protamine (orother Arg rich peptides), spermidine or other similar chemicalstructures can also be used to block duplex charge and facilitatecellular entry (FIG. 3). Increased hydrophobicity can be achievedthrough either covalent or non-covalent modifications. Severalpositively charged chemicals, which might be used for polynucleotidecharge blockage are depicted in FIG. 4.

Chemical modifications of polynucleotides, such as the guide strand in aduplex molecule, can facilitate RISC entry. FIG. 5 depicts singlestranded polynucleotides, representing a guide strand in a duplexmolecule, with a variety of chemical modifications including 2′d, 2′OMe,2′F, hydrophobic modifications, phosphorothioate modifications, andattachment of conjugates such as “X” in FIG. 5, where X can be a smallmolecule with high affinity to a PAZ domain, or sterol-type entity.Similarly, FIG. 6 depicts single stranded polynucleotides, representinga passenger strand in a duplex molecule, with proposed structural andchemical compositions of RISC substrate inhibitors. Combinations ofchemical modifications can ensure efficient uptake and efficient bindingto preloaded RISC complexes.

FIG. 7 depicts structures of polynucleotides with sterol-type moleculesattached, where R represents a polycarbonic tail of 9 carbons or longer.FIG. 8 presents examples of naturally occurring phytosterols with apolycarbon chain longer than 8 attached at position 17. More than 250different types of phytosterols are known. FIG. 9 presents examples ofsterol-like structures with variations in the sizes of the polycarbonchains attached at position 17. FIG. 91 presents further examples ofsterol-type molecules that can be used as a hydrophobic entity in placeof cholesterol. FIG. 92 presents further examples of hydrophobicmolecules that might be used as hydrophobic entities in place ofcholestesterol. Optimization of such characteristics can improve uptakeproperties of the RNAi molecules. FIG. 10 presents data adapted fromMartins et al. (J Lipid Research), showing that the percentage of liveruptake and plasma clearance of lipid emulsions containing sterol-typemolecules is directly affected by the size of the attached polycarbonchain at position 17. FIG. 11 depicts a micelle formed from a mixture ofpolynucleotides attached to hydrophobic conjugates and fatty acids. FIG.12 describes how alteration in lipid composition can affectpharmacokinetic behavior and tissue distribution of hydrophobicallymodified and/or hydrophobically conjugated polynucleotides. Inparticular, the use of lipid mixtures that are enriched in linoleic acidand cardiolipin results in preferential uptake by cardiomyocites.

FIG. 13 depicts examples of RNAi constructs and controls designed totarget MAP4K4 expression. FIGS. 14 and 15 reveal that RNAi constructswith minimal duplex regions (such as duplex regions of approximately 13nucleotides) are effective in mediating RNA silencing in cell culture.Parameters associated with these RNA molecules are shown in FIG. 16.FIG. 17 depicts examples of RNAi constructs and controls designed totarget SOD1 expression. FIGS. 18 and 19 reveal the results of genesilencing experiments using these RNAi molecules to target SOD1 incells. FIG. 20 presents a schematic indicating that RNA molecules withdouble stranded regions that are less than 10 nucleotides are notcleaved by Dicer, and FIG. 21 presents a schematic of a hypotheticalRNAi model for RNA induced gene silencing.

The RNA molecules described herein were subject to a variety of chemicalmodifications on the sense and antisense strands, and the effects ofsuch modifications were observed. RNAi molecules were synthesized andoptimized through testing of a variety of modifications. In firstgeneration optimization, the sense (passenger) and anti-sense (guide)strands of the sd-rxRNA^(nano) molecules were modified for examplethrough incorporation of C and U 2′OMe modifications, 2′F modifications,phosphorothioate modifications, phosphorylation, and conjugation ofcholesterol. Molecules were tested for inhibition of MAP4K4 expressionin cells including HeLa, primary mouse hepatocytes and primary humanhepatocytes through both lipid-mediated and passive uptake transfection.

FIG. 22 reveals that chemical modifications can enhance gene silencing.In particular, modifying the guide strand with 2′F UC modifications, andwith a stretch of phosphorothioate modifications, combined with completeCU O′Me modification of the passenger strands, resulted in moleculesthat were highly effective in gene silencing. The effect of chemicalmodification on in vitro efficacy in un-assisted delivery in HeLa cellswas also examined FIG. 23 reveals that compounds lacking any of 2′F,2′OMe, a stretch of phosphorothioate modifications, or cholesterolconjugates, were completely inactive in passive uptake. A combination ofall 4 types of chemical modifications, for example in compound 12386,was found to be highly effective in gene silencing. FIG. 24 also showsthe effectiveness of compound 12386 in gene silencing.

Optimization of the length of the oligonucleotide was also investigated.FIGS. 25 and 26 reveal that oligonucleotides with a length of 21nucleotides were more effective than oligonucleotides with a length of25 nucleotides, indicating that reduction in the size of an RNA moleculecan improve efficiency, potentially by assisting in its uptake.Screening was also conducted to optimize the size of the duplex regionof double stranded RNA molecules. FIG. 88 reveals that compounds withduplexes of 10 nucleotides were effective in inducing gene silencing.Positioning of the sense strand relative to the guide strand can also becritical for silencing gene expression (FIG. 89). In this assay, a bluntend was found to be most effective. 3′ overhangs were tolerated, but 5′overhangs resulted in a complete loss of functionality. The guide strandcan be effective in gene silencing when hybridized to a sense strand ofvarying lengths (FIG. 90). In this assay presented in FIG. 90, thecompounds were introduced into HeLa cells via lipid mediatedtransfection.

The importance of phosphorothioate content of the RNA molecule forunassisted delivery was also investigated. FIG. 27 presents the resultsof a systematic screen that identified that the presence of at least2-12 phosphorothioates in the guide strand as being highly advantageousfor achieving uptake, with 4-8 being the preferred number. FIG. 27 alsoshows that presence or absence of phosphorothioate modifications in thesense strand did not alter efficacy.

FIGS. 28-29 reveal the effects of passive uptake of RNA compounds ongene silencing in primary mouse hepatocytes. nanoRNA molecules werefound to be highly effective, especially at a concentration of 1 μM(FIG. 28). FIGS. 30 and 31 reveal that the RNA compounds associated withthe invention were also effective in gene silencing following passiveuptake in primary human hepatocytes. The cellular localization of theRNA molecules associated with the invention was examined and compared tothe localization of Chol-siRNA (Alnylam) molecules, as shown in FIGS. 32and 33.

A summary of 1^(st) generation sd-rxRNA molecules is presented in FIG.21. Chemical modifications were introduced into the RNA molecules, atleast in part, to increase potency, such as through optimization ofnucleotide length and phosphorothioate content, to reduce toxicity, suchas through replacing 2′F modifications on the guide strand with othermodifications, to improve delivery such as by adding or conjugating theRNA molecules to linker and sterol modalities, and to improve the easeof manufacturing the RNA molecules. FIG. 35 presents schematicdepictions of some of the chemical modifications that were screened in1^(st) generation molecules. Parameters that were optimized for theguide strand included nucleotide length (e.g., 19, 21 and 25nucleotides), phosphorothioate content (e.g., 0-18 phosphorothioatelinkages) and replacement of 2′F groups with 2′OMe and 5 Me C orriboThymidine. Parameters that were optimized for the sense strandincluded nucleotide length (e.g., 11, 13 and 19 nucleotides),phosphorothioate content (e.g., 0-4 phosphorothioate linkages), and2′OMe modifications. FIG. 36 summarizes parameters that were screened.For example, the nucleotide length and the phosphorothioate tail lengthwere modified and screened for optimization, as were the additions of2′OMe C and U modifications. Guide strand length and the length of thephosphorothioate modified stretch of nucleotides were found to influenceefficacy (FIGS. 37-38). Phosphorothioate modifications were tolerated inthe guide strand and were found to influence passive uptake (FIGS.39-42).

FIG. 43 presents a schematic revealing guide strand chemicalmodifications that were screened. FIGS. 44 and 45 reveal that 2′OMemodifications were tolerated in the 3′ end of the guide strand. Inparticular, 2′OMe modifications in positions 1 and 11-18 were welltolerated. The 2′OMe modifications in the seed area were tolerated butresulted in slight reduction of efficacy. Ribo-modifications in the seedwere also well tolerated. These data indicate that the moleculesassociated with the invention offer the significant advantage of havingreduced or no 2′F modification content. This is advantageous because 2′Fmodifications are thought to generate toxicity in vivo. In someinstances, a complete substitution of 2′F modifications with 2′OMe wasfound to lead to some reduction in potency. However, the 2′ OMesubstituted molecules were still very active. A molecule with 50%reduction in 2′F content (including at positions 11, 16-18 which werechanged to 2′OMe modifications), was found to have comparable efficacyto a compound with complete 2′F C and U modification. 2′OMe modificationin position was found in some instances to reduce efficacy, althoughthis can be at least partially compensated by 2′OMe modification inposition 1 (with chemical phosphate). In some instances, 5 Me C and/orribothymidine substitution for 2′F modifications led to a reduction inpassive uptake efficacy, but increased potency in lipid mediatedtransfections compared to 2′F modifications. Optimization results forlipid mediated transfection were not necessarily the same as for passiveuptake.

Modifications to the sense strand were also developed and tested, asdepicted in FIG. 46. FIG. 47 reveals that in some instances, a sensestrand length between 10-15 bases was found to be optimal. For themolecules tested in FIG. 47, an increase in the sense strand lengthresulted in reduction of passive uptake, however an increase in sensestrand length may be tolerated for some compounds. FIG. 47 also revealsthat LNA modification of the sense strand demonstrated similar efficacyto non-LNA containing compounds. In general, the addition of LNA orother thermodynamically stabilizing compounds has been found to bebeneficial, in some instances resulting in converting non-functionalsequences to functional sequences. FIG. 48 also presents data on sensestrand length optimization, while FIG. 49 shows that phosphorothioatemodification of the sense strand is not required for passive uptake.

Based on the above-described optimization experiments, 2^(nd) generationRNA molecules were developed. As shown in FIG. 50, these moleculescontained reduced phosphorothioate modification content and reduced 2′Fmodification content, relative to 1^(st) generation RNA molecules.Significantly, these RNA molecules exhibit spontaneous cellular uptakeand efficacy without a delivery vehicle (FIG. 51). These molecules canachieve self-delivery (i.e., with no transfection reagent) and followingself-delivery can exhibit nanomolar activity in cell culture. Thesemolecules can also be delivered using lipid-mediated transfection, andexhibit picomolar activity levels following transfection. Significantly,these molecules exhibit highly efficient uptake, 95% by most cells incell culture, and are stable for more than three days in the presence of100% human serum. These molecules are also highly specific and exhibitlittle or no immune induction. FIGS. 52 and 53 reveal the significanceof chemical modifications and the configurations of such modificationsin influencing the properties of the RNA molecules associated with theinvention.

Linker chemistry was also tested in conjunction with the RNA moleculesassociated with the invention. As depicted in FIG. 54, 2^(nd) generationRNA molecules were synthesized with sterol-type molecules attachedthrough TEG and amino caproic acid linkers. Both linkers showedidentical potency. This functionality of the RNA molecules, independentof linker chemistry offers additional advantages in terms of scale upand synthesis and demonstrates that the mechanism of function of theseRNA molecules is very different from other previously described RNAmolecules.

Stability of the chemically modified sd-rxRNA molecules described hereinin human serum is shown in FIG. 55 in comparison to unmodified RNA. Theduplex molecules were incubated in 75% serum at 37° C. for the indicatedperiods of time. The level of degradation was determined by running thesamples on non-denaturing gels and staining with SYBGR.

FIGS. 56 and 57 present data on cellular uptake of the sd-rxRNAmolecules. FIG. 56 shows that minimizing the length of the RNA moleculeis importance for cellular uptake, while FIG. 57 presents data showingtarget gene silencing after spontaneous cellular uptake in mousePEC-derived macrophages. FIG. 58 demonstrates spontaneous uptake andtarget gene silencing in primary cells. FIG. 59 shows the results ofdelivery of sd-rxRNA molecules associated with the invention to RPEcells with no formulation. Imaging with Hoechst and DY547 reveals theclear presence of a signal representing the RNA molecule in the sd-rxRNAsample, while no signal is detectable in the other samples including thesamples competing a competing conjugate, an rxRNA, and an untransfectedcontrol. FIG. 60 reveals silencing of target gene expression in RPEcells treated with sd-rxRNA molecules associated with the inventionfollowing 24-48 hours without any transfection formulation.

FIG. 61 shows further optimization of the chemical/structuralcomposition of sd-rxRNA compounds. In some instances, preferredproperties included an antisense strand that was 17-21 nucleotides long,a sense strand that was 10-15 nucleotides long, phosphorothioatemodification of 2-12 nucleotides within the single stranded region ofthe molecule, preferentially phosphorothioate modification of 6-8nucleotides within the single stranded region, and 2′OMe modification atthe majority of positions within the sense strand, with or withoutphosphorothioate modification. Any linker chemistry can be used toattach the hydrophobic moiety, such as cholesterol, to the 3′ end of thesense strand. Version GIIb molecules, as shown in FIG. 61, have no 2′Fmodifications. Significantly, there is was no impact on efficacy inthese molecules.

FIG. 62 demonstrates the superior performance of sd-rxRNA compoundscompared to compounds published by Wolfrum et. al. Nature Biotech, 2007.Both generation I and II compounds (GI and GIIa) developed herein showgreat efficacy in reducing target gene expression. By contrast, when thechemistry described in Wolfrum et al. (all oligos contain cholesterolconjugated to the 3′ end of the sense strand) was applied to the samesequence in a context of conventional siRNA (19 bp duplex with twooverhang) the compound was practically inactive. These data emphasizethe significance of the combination of chemical modifications andassymetrical molecules described herein, producing highly effective RNAcompounds.

FIG. 63 shows localization of sd-rxRNA molecules developed hereincompared to localization of other RNA molecules such as those describedin Soutschek et al. (2004) Nature, 432:173. sd-rxRNA moleculesaccumulate inside the cells whereas competing conjugate RNAs accumulateon the surface of cells. Significantly, FIG. 64 shows that sd-rxRNAmolecules, but not competitor molecules such as those described inSoutschek et al. are internalized within minutes. FIG. 65 compareslocalization of sd-rxRNA molecules compared to regularsiRNA-cholesterol, as described in Soutschek et al. A signalrepresenting the RNA molecule is clearly detected for the sd-rxRNAmolecule in tissue culture RPE cells, following local delivery tocompromised skin, and following systemic delivery where uptake to theliver is seen. In each case, no signal is detected for the regularsiRNA-cholesterol molecule. The sd-rxRNA molecule thus has drasticallybetter cellular and tissue uptake characteristics when compared toconventional cholesterol conjugated siRNAs such as those described inSoutschek et al. The level of uptake is at least order of magnitudehigher and is due at least in part to the unique combination ofchemistries and conjugated structure. Superior delivery of sd-rxRNArelative to previously described RNA molecules is also demonstrated inFIGS. 66 and 67.

Based on the analysis of 2^(nd) generation RNA molecules associated withthe invention, a screen was performed to identify functional moleculesfor targeting the SPP1/PPIB gene. As revealed in FIG. 68, severaleffective molecules were identified, with 14131 being the mosteffective. The compounds were added to A-549 cells and then the level ofSPP1/PPIB ratio was determined by B-DNA after 48 hours.

FIG. 69 reveals efficient cellular uptake of sd-rxRNA within minutes ofexposure. This is a unique characteristics of these molecules, notobserved with any other RNAi compounds. Compounds described in Soutscheket al. were used as negative controls. FIG. 70 reveals that the uptakeand gene silencing of the sd-rxRNA is effective in multiple differentcell types including SH-SY5Y neuroblastoma derived cells, ARPE-19(retinal pigment epithelium) cells, primary hepatocytes, and primarymacrophages. In each case silencing was confirmed by looking at targetgene expression by a Branched DNA assay.

FIG. 70 reveals that sd-rxRNA is active in the presence or absence ofserum. While a slight reduction in efficacy (2-5 fold) was observed inthe presence of serum, this small reduction in efficacy in the presenceof serum differentiate the sd-rxRNA molecules from previously describedmolecules which exhibited a larger reduction in efficacy in the presenceof serum. This demonstrated level of efficacy in the presence of serumcreates a foundation for in vivo efficacy.

FIG. 72 reveals efficient tissue penetration and cellular uptake uponsingle intradermal injection. This data indicates the potential of thesd-rxRNA compounds described herein for silencing genes in anydermatology applications, and also represents a model for local deliveryof sd-rxRNA compounds. FIG. 73 also demonstrates efficient cellularuptake and in vivo silencing with sd-rxRNA following intradermalinjection. Silencing is determined as the level of MAP4K4 knockdown inseveral individual biopsies taken from the site of injection as comparedto biopsies taken from a site injected with a negative control. FIG. 74reveals that sd-rxRNA compounds has improved blood clearance and inducedeffective gene silencing in vivo in the liver upon systemicadministration. In comparison to the RNA molecules described bySoutschek et al., the level of liver uptake at identical dose level isat least 50 fold higher with the sd-rxRNA molecules. The uptake resultsin productive silencing. sd-rxRNA compounds are also characterized byimproved blood clearance kinetics.

The effect of 5-Methyl C modifications was also examined. FIG. 75demonstrates that the presence of 5-Methyl C in an RNAi moleculeresulted in increased potency in lipid mediated transfection. Thissuggests that hydrophobic modification of Cs and Us in an RNAi moleculecan be beneficial. These types of modifications can also be used in thecontext 2′ ribose modified bases to ensure optimal stability andefficacy. FIG. 76 presents data showing that incorporation of 5-Methyl Cand/or ribothymidine in the guide strand can in some instances reduceefficacy.

FIG. 77 reveals that sd-rxRNA molecules are more effective thancompetitor molecules such as molecules described in Soutschek et al., insystemic delivery to the liver. A signal representing the RNA moleculeis clearly visible in the sample containing sd-rxRNA, while no signalrepresenting the RNA molecule is visible in the sample containing thecompetitor RNA molecule.

The addition of hydrophobic conjugates to the sd-rxRNA molecules wasalso explored (FIGS. 78-83). FIG. 78 presents schematics demonstrating5-uridyl modifications with improved hydrophobicity characteristics.Incorporation of such modifications into sd-rxRNA compounds can increasecellular and tissue uptake properties. FIG. 78B presents a new type ofRNAi compound modification which can be applied to compounds to improvecellular uptake and pharmacokinetic behavior. Significantly, this typeof modification, when applied to sd-rxRNA compounds, may contribute tomaking such compounds orally available. FIG. 79 presents schematicsrevealing the structures of synthesized modified sterol-type molecules,where the length and structure of the C17 attached tail is modified.Without wishing to be bound by any theory, the length of the C17attached tail may contribute to improving in vitro and in vivo efficacyof sd-rxRNA compounds.

FIG. 80 presents a schematic demonstrating the lithocholic acid route tolong side chain cholesterols. FIG. 81 presents a schematic demonstratinga route to 5-uridyl phosphoramidite synthesis. FIG. 82 presents aschematic demonstrating synthesis of tri-functional hydroxyprolinollinker for 3′-cholesterol attachment. FIG. 83 presents a schematicdemonstrating synthesis of solid support for the manufacture of ashorter asymmetric RNAi compound strand.

A screen was conducted to identify compounds that could effectivelysilence expression of SPP1 (Osteopontin). Compounds targeting SPP1 wereadded to A549 cells (using passive transfection), and the level of SPP1expression was evaluated at 48 hours. Several novel compounds effectivein SPP1 silencing were identified. Compounds that were effective insilencing of SPP1 included 14116, 14121, 14131, 14134, 14139, 14149, and14152 (FIGS. 84-86). The most potent compound in this assay was 14131(FIG. 84). The efficacy of these sd-rxRNA compounds in silencing SPP1expression was independently validated (FIG. 85).

A similar screen was conducted to identify compounds that couldeffectively silence expression of CTGF (FIGS. 86-87). Compounds thatwere effective in silencing of CTGF included 14017, 14013, 14016, 14022,14025, 14027.

Methods

Transfection of sd-rxRNA^(nano)

Lipid Mediated Transfection

sd-rxRNA^(nano) constructs were chemically synthesized (Dharmacon,Lafayette, Colo.) and transfected into HEK293 cells (ATCC, Manassas,Va.) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, Calif.)according to the manufacturer's instructions. In brief, RNA was dilutedto a 12× concentration in Opti-MEM®1 Reduced Serum Media (Invitrogen,Carlsbad, Calif.) and then combined with a 12× concentration ofLipofectamine RNAiMAX. The RNA and transfection reagent were allowed tocomplex at room temperature for 20 minutes and make a 6× concentration.While complexing, HEK293 cells were washed, trypsinized and counted. Thecells were diluted to a concentration recommended by the manufacturerand previously described of 1×10⁵ cells/ml. When RNA had completedcomplexing with the RNAiMAX transfection reagent, 20 ul of the complexeswere added to the appropriate well of the 96-well plate in triplicate.Cells were added to each well (100 ul volume) to make the final cellcount per well 1×10⁴ cells/well. The volume of cells diluted the 6×concentration of complex to 1× (between 10-0.05 nM). Cells wereincubated for 24 or 48 hours under normal growth conditions. After 24 or48 hour incubation, cells were lysed and gene silencing activity wasmeasured using the QuantiGene assay (Panomics, Freemont, Calif.) whichemploys bDNA hybridization technology. The assay was carried outaccording to manufacturer's instructions.

Passive Uptake Transfection

sd-rxRNA^(nano) constructs were chemically synthesized (Dharmacon,Lafayette, Colo.). 24 hours prior to transfection, HeLa cells (ATCC,Manassas, Va.) were plated at 1×10⁴ cells/well in a 96 well plate undernormal growth conditions (DMEM, 10% FBS and 1% Penicillin andStreptomycin). Prior to transfection of HeLa cells, sd-rxRNA^(nano) werediluted to a final concentration of 0.01 uM to 1 uM in Accell siRNADelivery Media (Dharmacon, Lafayette, Colo.). Normal growth media wasaspirated off cells and 100 uL of Accell Delivery media containing theappropriate concentration of sd-rxRNAnano was applied to the cells. 48hours post transfection, delivery media was aspirated off the cells andnormal growth media was applied to cells for an additional 24 hours.

After 48 or 72 hour incubation, cells were lysed and gene silencingactivity was measured using the QuantiGene assay (Panomics, Freemont,Calif.) according to manufacturer's instructions.

TABLE 1 Oligo Accession Gene ID Number Number number Gene Name SymbolAPOB-10167-20-12138 12138 NM_000384 Apolipoprotein B (including APOBAg(x) antigen) APOB-10167-20-12139 12139 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) MAP4K4-2931-13-12266 12266 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-16-12293 12293 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-16-12383 12383 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-16-12384 12384 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-16-12385 12385 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-16-12386 12386 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-16-12387 12387 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-15-12388 12388 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-13-12432 12432 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-13-12266.2 12266.2 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 APOB--21-12434 12434 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) APOB--21-12435 12435 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) MAP4K4-2931-16-1245112451 NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase KinaseKinase 4 (MAP4K4), transcript variant 1 MAP4K4-2931-16-12452 12452NM_004834 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4(MAP4K4), transcript variant 1 MAP4K4-2931-16-12453 12453 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-17-12454 12454 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-17-12455 12455 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-19-12456 12456 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 --27-12480 12480 --27-12481 12481APOB-10167-21-12505 12505 NM_000384 Apolipoprotein B (including APOBAg(x) antigen) APOB-10167-21-12506 12506 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) MAP4K4-2931-16-12539 12539 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 APOB-10167-21-12505.2 12505.2 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) APOB-10167-21-12506.212506.2 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen)MAP4K4--13-12565 12565 MAP4K4 MAP4K4-2931-16-12386.2 12386.2 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 MAP4K4-2931-13-12815 12815 NM_004834Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4),transcript variant 1 APOB--13-12957 12957 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) MAP4K4--16-12983 12983 Mitogen-ActivatedProtein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcriptvariant 1 MAP4K4--16-12984 12984 Mitogen-Activated Protein Kinase MAP4K4Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-1298512985 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4(MAP4K4), transcript variant 1 MAP4K4--16-12986 12986 Mitogen-ActivatedProtein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcriptvariant 1 MAP4K4--16-12987 12987 Mitogen-Activated Protein Kinase MAP4K4Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-1298812988 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4(MAP4K4), transcript variant 1 MAP4K4--16-12989 12989 Mitogen-ActivatedProtein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcriptvariant 1 MAP4K4--16-12990 12990 Mitogen-Activated Protein Kinase MAP4K4Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-1299112991 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4(MAP4K4), transcript variant 1 MAP4K4--16-12992 12992 Mitogen-ActivatedProtein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcriptvariant 1 MAP4K4--16-12993 12993 Mitogen-Activated Protein Kinase MAP4K4Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1 MAP4K4--16-1299412994 Mitogen-Activated Protein Kinase MAP4K4 Kinase Kinase Kinase 4(MAP4K4), transcript variant 1 MAP4K4--16-12995 12995 Mitogen-ActivatedProtein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcriptvariant 1 MAP4K4-2931-19-13012 13012 NM_004834 Mitogen-Activated ProteinKinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1MAP4K4-2931-19-13016 13016 NM_004834 Mitogen-Activated Protein KinaseMAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcript variant 1PPIB--13-13021 13021 NM_000942 Peptidylprolyl Isomerase B PPIB(cyclophilin B) pGL3-1172-13-13038 13038 U47296 Cloning vectorpGL3-Control pGL3 pGL3-1172-13-13040 13040 U47296 Cloning vectorpGL3-Control pGL3 --16-13047 13047 SOD1-530-13-13090 13090 NM_000454Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1(adult)) SOD1-523-13-13091 13091 NM_000454 Superoxide Dismutase 1,soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-535-13-1309213092 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophiclateral sclerosis 1 (adult)) SOD1-536-13-13093 13093 NM_000454Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1(adult)) SOD1-396-13-13094 13094 NM_000454 Superoxide Dismutase 1,soluble SOD1 (amyotrophic lateral sclerosis 1 (adult)) SOD1-385-13-1309513095 NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophiclateral sclerosis 1 (adult)) SOD1-195-13-13096 13096 NM_000454Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1(adult)) APOB-4314-13-13115 13115 NM_000384 Apolipoprotein B (includingAPOB Ag(x) antigen) APOB-3384-13-13116 13116 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) APOB-3547-13-13117 13117 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) APOB-4318-13-13118 13118NM_000384 Apolipoprotein B (including APOB Ag(x) antigen)APOB-3741-13-13119 13119 NM_000384 Apolipoprotein B (including APOBAg(x) antigen) PPIB--16-13136 13136 NM_000942 Peptidylprolyl Isomerase BPPIB (cyclophilin B) APOB-4314-15-13154 13154 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) APOB-3547-15-13155 13155 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) APOB-4318-15-13157 13157NM_000384 Apolipoprotein B (including APOB Ag(x) antigen)APOB-3741-15-13158 13158 NM_000384 Apolipoprotein B (including APOBAg(x) antigen) APOB--13-13159 13159 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) APOB--15-13160 13160 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) SOD1-530-16-13163 13163NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateralsclerosis 1 (adult)) SOD1-523-16-13164 13164 NM_000454 SuperoxideDismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult))SOD1-535-16-13165 13165 NM_000454 Superoxide Dismutase 1, soluble SOD1(amyotrophic lateral sclerosis 1 (adult)) SOD1-536-16-13166 13166NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateralsclerosis 1 (adult)) SOD1-396-16-13167 13167 NM_000454 SuperoxideDismutase 1, soluble SOD1 (amyotrophic lateral sclerosis 1 (adult))SOD1-385-16-13168 13168 NM_000454 Superoxide Dismutase 1, soluble SOD1(amyotrophic lateral sclerosis 1 (adult)) SOD1-195-16-13169 13169NM_000454 Superoxide Dismutase 1, soluble SOD1 (amyotrophic lateralsclerosis 1 (adult)) pGL3-1172-16-13170 13170 U47296 Cloning vectorpGL3-Control pGL3 pGL3-1172-16-13171 13171 U47296 Cloning vectorpGL3-Control pGL3 MAP4k4-2931-19-13189 13189 NM_004834 Mitogen-ActivatedProtein Kinase MAP4k4 Kinase Kinase Kinase 4 (MAP4K4), transcriptvariant 1 CTGF-1222-13-13190 13190 NM_001901.2 connective tissue growthfactor CTGF CTGF-813-13-13192 13192 NM_001901.2 connective tissue growthfactor CTGF CTGF-747-13-13194 13194 NM_001901.2 connective tissue growthfactor CTGF CTGF-817-13-13196 13196 NM_001901.2 connective tissue growthfactor CTGF CTGF-1174-13-13198 13198 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1005-13-13200 13200 NM_001901.2 connectivetissue growth factor CTGF CTGF-814-13-13202 13202 NM_001901.2 connectivetissue growth factor CTGF CTGF-816-13-13204 13204 NM_001901.2 connectivetissue growth factor CTGF CTGF-1001-13-13206 13206 NM_001901.2connective tissue growth factor CTGF CTGF-1173-13-13208 13208NM_001901.2 connective tissue growth factor CTGF CTGF-749-13-13210 13210NM_001901.2 connective tissue growth factor CTGF CTGF-792-13-13212 13212NM_001901.2 connective tissue growth factor CTGF CTGF-1162-13-1321413214 NM_001901.2 connective tissue growth factor CTGF CTGF-811-13-1321613216 NM_001901.2 connective tissue growth factor CTGF CTGF-797-13-1321813218 NM_001901.2 connective tissue growth factor CTGFCTGF-1175-13-13220 13220 NM_001901.2 connective tissue growth factorCTGF CTGF-1172-13-13222 13222 NM_001901.2 connective tissue growthfactor CTGF CTGF-1177-13-13224 13224 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1176-13-13226 13226 NM_001901.2 connectivetissue growth factor CTGF CTGF-812-13-13228 13228 NM_001901.2 connectivetissue growth factor CTGF CTGF-745-13-13230 13230 NM_001901.2 connectivetissue growth factor CTGF CTGF-1230-13-13232 13232 NM_001901.2connective tissue growth factor CTGF CTGF-920-13-13234 13234 NM_001901.2connective tissue growth factor CTGF CTGF-679-13-13236 13236 NM_001901.2connective tissue growth factor CTGF CTGF-992-13-13238 13238 NM_001901.2connective tissue growth factor CTGF CTGF-1045-13-13240 13240NM_001901.2 connective tissue growth factor CTGF CTGF-1231-13-1324213242 NM_001901.2 connective tissue growth factor CTGF CTGF-991-13-1324413244 NM_001901.2 connective tissue growth factor CTGF CTGF-998-13-1324613246 NM_001901.2 connective tissue growth factor CTGFCTGF-1049-13-13248 13248 NM_001901.2 connective tissue growth factorCTGF CTGF-1044-13-13250 13250 NM_001901.2 connective tissue growthfactor CTGF CTGF-1327-13-13252 13252 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1196-13-13254 13254 NM_001901.2 connectivetissue growth factor CTGF CTGF-562-13-13256 13256 NM_001901.2 connectivetissue growth factor CTGF CTGF-752-13-13258 13258 NM_001901.2 connectivetissue growth factor CTGF CTGF-994-13-13260 13260 NM_001901.2 connectivetissue growth factor CTGF CTGF-1040-13-13262 13262 NM_001901.2connective tissue growth factor CTGF CTGF-1984-13-13264 13264NM_001901.2 connective tissue growth factor CTGF CTGF-2195-13-1326613266 NM_001901.2 connective tissue growth factor CTGFCTGF-2043-13-13268 13268 NM_001901.2 connective tissue growth factorCTGF CTGF-1892-13-13270 13270 NM_001901.2 connective tissue growthfactor CTGF CTGF-1567-13-13272 13272 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1780-13-13274 13274 NM_001901.2 connectivetissue growth factor CTGF CTGF-2162-13-13276 13276 NM_001901.2connective tissue growth factor CTGF CTGF-1034-13-13278 13278NM_001901.2 connective tissue growth factor CTGF CTGF-2264-13-1328013280 NM_001901.2 connective tissue growth factor CTGFCTGF-1032-13-13282 13282 NM_001901.2 connective tissue growth factorCTGF CTGF-1535-13-13284 13284 NM_001901.2 connective tissue growthfactor CTGF CTGF-1694-13-13286 13286 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1588-13-13288 13288 NM_001901.2 connectivetissue growth factor CTGF CTGF-928-13-13290 13290 NM_001901.2 connectivetissue growth factor CTGF CTGF-1133-13-13292 13292 NM_001901.2connective tissue growth factor CTGF CTGF-912-13-13294 13294 NM_001901.2connective tissue growth factor CTGF CTGF-753-13-13296 13296 NM_001901.2connective tissue growth factor CTGF CTGF-918-13-13298 13298 NM_001901.2connective tissue growth factor CTGF CTGF-744-13-13300 13300 NM_001901.2connective tissue growth factor CTGF CTGF-466-13-13302 13302 NM_001901.2connective tissue growth factor CTGF CTGF-917-13-13304 13304 NM_001901.2connective tissue growth factor CTGF CTGF-1038-13-13306 13306NM_001901.2 connective tissue growth factor CTGF CTGF-1048-13-1330813308 NM_001901.2 connective tissue growth factor CTGFCTGF-1235-13-13310 13310 NM_001901.2 connective tissue growth factorCTGF CTGF-868-13-13312 13312 NM_001901.2 connective tissue growth factorCTGF CTGF-1131-13-13314 13314 NM_001901.2 connective tissue growthfactor CTGF CTGF-1043-13-13316 13316 NM_001901.2 connective tissuegrowth factor CTGF CTGF-751-13-13318 13318 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1227-13-13320 13320 NM_001901.2 connectivetissue growth factor CTGF CTGF-867-13-13322 13322 NM_001901.2 connectivetissue growth factor CTGF CTGF-1128-13-13324 13324 NM_001901.2connective tissue growth factor CTGF CTGF-756-13-13326 13326 NM_001901.2connective tissue growth factor CTGF CTGF-1234-13-13328 13328NM_001901.2 connective tissue growth factor CTGF CTGF-916-13-13330 13330NM_001901.2 connective tissue growth factor CTGF CTGF-925-13-13332 13332NM_001901.2 connective tissue growth factor CTGF CTGF-1225-13-1333413334 NM_001901.2 connective tissue growth factor CTGF CTGF-445-13-1333613336 NM_001901.2 connective tissue growth factor CTGF CTGF-446-13-1333813338 NM_001901.2 connective tissue growth factor CTGF CTGF-913-13-1334013340 NM_001901.2 connective tissue growth factor CTGF CTGF-997-13-1334213342 NM_001901.2 connective tissue growth factor CTGF CTGF-277-13-1334413344 NM_001901.2 connective tissue growth factor CTGFCTGF-1052-13-13346 13346 NM_001901.2 connective tissue growth factorCTGF CTGF-887-13-13348 13348 NM_001901.2 connective tissue growth factorCTGF CTGF-914-13-13350 13350 NM_001901.2 connective tissue growth factorCTGF CTGF-1039-13-13352 13352 NM_001901.2 connective tissue growthfactor CTGF CTGF-754-13-13354 13354 NM_001901.2 connective tissue growthfactor CTGF CTGF-1130-13-13356 13356 NM_001901.2 connective tissuegrowth factor CTGF CTGF-919-13-13358 13358 NM_001901.2 connective tissuegrowth factor CTGF CTGF-922-13-13360 13360 NM_001901.2 connective tissuegrowth factor CTGF CTGF-746-13-13362 13362 NM_001901.2 connective tissuegrowth factor CTGF CTGF-993-13-13364 13364 NM_001901.2 connective tissuegrowth factor CTGF CTGF-825-13-13366 13366 NM_001901.2 connective tissuegrowth factor CTGF CTGF-926-13-13368 13368 NM_001901.2 connective tissuegrowth factor CTGF CTGF-923-13-13370 13370 NM_001901.2 connective tissuegrowth factor CTGF CTGF-866-13-13372 13372 NM_001901.2 connective tissuegrowth factor CTGF CTGF-563-13-13374 13374 NM_001901.2 connective tissuegrowth factor CTGF CTGF-823-13-13376 13376 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1233-13-13378 13378 NM_001901.2 connectivetissue growth factor CTGF CTGF-924-13-13380 13380 NM_001901.2 connectivetissue growth factor CTGF CTGF-921-13-13382 13382 NM_001901.2 connectivetissue growth factor CTGF CTGF-443-13-13384 13384 NM_001901.2 connectivetissue growth factor CTGF CTGF-1041-13-13386 13386 NM_001901.2connective tissue growth factor CTGF CTGF-1042-13-13388 13388NM_001901.2 connective tissue growth factor CTGF CTGF-755-13-13390 13390NM_001901.2 connective tissue growth factor CTGF CTGF-467-13-13392 13392NM_001901.2 connective tissue growth factor CTGF CTGF-995-13-13394 13394NM_001901.2 connective tissue growth factor CTGF CTGF-927-13-13396 13396NM_001901.2 connective tissue growth factor CTGF SPP1-1025-13-1339813398 NM_000582.2 Osteopontin SPP1 SPP1-1049-13-13400 13400 NM_000582.2Osteopontin SPP1 SPP1-1051-13-13402 13402 NM_000582.2 Osteopontin SPP1SPP1-1048-13-13404 13404 NM_000582.2 Osteopontin SPP1 SPP1-1050-13-1340613406 NM_000582.2 Osteopontin SPP1 SPP1-1047-13-13408 13408 NM_000582.2Osteopontin SPP1 SPP1-800-13-13410 13410 NM_000582.2 Osteopontin SPP1SPP1-492-13-13412 13412 NM_000582.2 Osteopontin SPP1 SPP1-612-13-1341413414 NM_000582.2 Osteopontin SPP1 SPP1-481-13-13416 13416 NM_000582.2Osteopontin SPP1 SPP1-614-13-13418 13418 NM_000582.2 Osteopontin SPP1SPP1-951-13-13420 13420 NM_000582.2 Osteopontin SPP1 SPP1-482-13-1342213422 NM_000582.2 Osteopontin SPP1 SPP1-856-13-13424 13424 NM_000582.2Osteopontin SPP1 SPP1-857-13-13426 13426 NM_000582.2 Osteopontin SPP1SPP1-365-13-13428 13428 NM_000582.2 Osteopontin SPP1 SPP1-359-13-1343013430 NM_000582.2 Osteopontin SPP1 SPP1-357-13-13432 13432 NM_000582.2Osteopontin SPP1 SPP1-858-13-13434 13434 NM_000582.2 Osteopontin SPP1SPP1-1012-13-13436 13436 NM_000582.2 Osteopontin SPP1 SPP1-1014-13-1343813438 NM_000582.2 Osteopontin SPP1 SPP1-356-13-13440 13440 NM_000582.2Osteopontin SPP1 SPP1-368-13-13442 13442 NM_000582.2 Osteopontin SPP1SPP1-1011-13-13444 13444 NM_000582.2 Osteopontin SPP1 SPP1-754-13-1344613446 NM_000582.2 Osteopontin SPP1 SPP1-1021-13-13448 13448 NM_000582.2Osteopontin SPP1 SPP1-1330-13-13450 13450 NM_000582.2 Osteopontin SPP1SPP1-346-13-13452 13452 NM_000582.2 Osteopontin SPP1 SPP1-869-13-1345413454 NM_000582.2 Osteopontin SPP1 SPP1-701-13-13456 13456 NM_000582.2Osteopontin SPP1 SPP1-896-13-13458 13458 NM_000582.2 Osteopontin SPP1SPP1-1035-13-13460 13460 NM_000582.2 Osteopontin SPP1 SPP1-1170-13-1346213462 NM_000582.2 Osteopontin SPP1 SPP1-1282-13-13464 13464 NM_000582.2Osteopontin SPP1 SPP1-1537-13-13466 13466 NM_000582.2 Osteopontin SPP1SPP1-692-13-13468 13468 NM_000582.2 Osteopontin SPP1 SPP1-840-13-1347013470 NM_000582.2 Osteopontin SPP1 SPP1-1163-13-13472 13472 NM_000582.2Osteopontin SPP1 SPP1-789-13-13474 13474 NM_000582.2 Osteopontin SPP1SPP1-841-13-13476 13476 NM_000582.2 Osteopontin SPP1 SPP1-852-13-1347813478 NM_000582.2 Osteopontin SPP1 SPP1-209-13-13480 13480 NM_000582.2Osteopontin SPP1 SPP1-1276-13-13482 13482 NM_000582.2 Osteopontin SPP1SPP1-137-13-13484 13484 NM_000582.2 Osteopontin SPP1 SPP1-711-13-1348613486 NM_000582.2 Osteopontin SPP1 SPP1-582-13-13488 13488 NM_000582.2Osteopontin SPP1 SPP1-839-13-13490 13490 NM_000582.2 Osteopontin SPP1SPP1-1091-13-13492 13492 NM_000582.2 Osteopontin SPP1 SPP1-884-13-1349413494 NM_000582.2 Osteopontin SPP1 SPP1-903-13-13496 13496 NM_000582.2Osteopontin SPP1 SPP1-1090-13-13498 13498 NM_000582.2 Osteopontin SPP1SPP1-474-13-13500 13500 NM_000582.2 Osteopontin SPP1 SPP1-575-13-1350213502 NM_000582.2 Osteopontin SPP1 SPP1-671-13-13504 13504 NM_000582.2Osteopontin SPP1 SPP1-924-13-13506 13506 NM_000582.2 Osteopontin SPP1SPP1-1185-13-13508 13508 NM_000582.2 Osteopontin SPP1 SPP1-1221-13-1351013510 NM_000582.2 Osteopontin SPP1 SPP1-347-13-13512 13512 NM_000582.2Osteopontin SPP1 SPP1-634-13-13514 13514 NM_000582.2 Osteopontin SPP1SPP1-877-13-13516 13516 NM_000582.2 Osteopontin SPP1 SPP1-1033-13-1351813518 NM_000582.2 Osteopontin SPP1 SPP1-714-13-13520 13520 NM_000582.2Osteopontin SPP1 SPP1-791-13-13522 13522 NM_000582.2 Osteopontin SPP1SPP1-813-13-13524 13524 NM_000582.2 Osteopontin SPP1 SPP1-939-13-1352613526 NM_000582.2 Osteopontin SPP1 SPP1-1161-13-13528 13528 NM_000582.2Osteopontin SPP1 SPP1-1164-13-13530 13530 NM_000582.2 Osteopontin SPP1SPP1-1190-13-13532 13532 NM_000582.2 Osteopontin SPP1 SPP1-1333-13-1353413534 NM_000582.2 Osteopontin SPP1 SPP1-537-13-13536 13536 NM_000582.2Osteopontin SPP1 SPP1-684-13-13538 13538 NM_000582.2 Osteopontin SPP1SPP1-707-13-13540 13540 NM_000582.2 Osteopontin SPP1 SPP1-799-13-1354213542 NM_000582.2 Osteopontin SPP1 SPP1-853-13-13544 13544 NM_000582.2Osteopontin SPP1 SPP1-888-13-13546 13546 NM_000582.2 Osteopontin SPP1SPP1-1194-13-13548 13548 NM_000582.2 Osteopontin SPP1 SPP1-1279-13-1355013550 NM_000582.2 Osteopontin SPP1 SPP1-1300-13-13552 13552 NM_000582.2Osteopontin SPP1 SPP1-1510-13-13554 13554 NM_000582.2 Osteopontin SPP1SPP1-1543-13-13556 13556 NM_000582.2 Osteopontin SPP1 SPP1-434-13-1355813558 NM_000582.2 Osteopontin SPP1 SPP1-600-13-13560 13560 NM_000582.2Osteopontin SPP1 SPP1-863-13-13562 13562 NM_000582.2 Osteopontin SPP1SPP1-902-13-13564 13564 NM_000582.2 Osteopontin SPP1 SPP1-921-13-1356613566 NM_000582.2 Osteopontin SPP1 SPP1-154-13-13568 13568 NM_000582.2Osteopontin SPP1 SPP1-217-13-13570 13570 NM_000582.2 Osteopontin SPP1SPP1-816-13-13572 13572 NM_000582.2 Osteopontin SPP1 SPP1-882-13-1357413574 NM_000582.2 Osteopontin SPP1 SPP1-932-13-13576 13576 NM_000582.2Osteopontin SPP1 SPP1-1509-13-13578 13578 NM_000582.2 Osteopontin SPP1SPP1-157-13-13580 13580 NM_000582.2 Osteopontin SPP1 SPP1-350-13-1358213582 NM_000582.2 Osteopontin SPP1 SPP1-511-13-13584 13584 NM_000582.2Osteopontin SPP1 SPP1-605-13-13586 13586 NM_000582.2 Osteopontin SPP1SPP1-811-13-13588 13588 NM_000582.2 Osteopontin SPP1 SPP1-892-13-1359013590 NM_000582.2 Osteopontin SPP1 SPP1-922-13-13592 13592 NM_000582.2Osteopontin SPP1 SPP1-1169-13-13594 13594 NM_000582.2 Osteopontin SPP1SPP1-1182-13-13596 13596 NM_000582.2 Osteopontin SPP1 SPP1-1539-13-1359813598 NM_000582.2 Osteopontin SPP1 SPP1-1541-13-13600 13600 NM_000582.2Osteopontin SPP1 SPP1-427-13-13602 13602 NM_000582.2 Osteopontin SPP1SPP1-533-13-13604 13604 NM_000582.2 Osteopontin SPP1 APOB--13-1376313763 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen)APOB--13-13764 13764 NM_000384 Apolipoprotein B (including APOB Ag(x)antigen) MAP4K4--16-13766 13766 MAP4K4 PPIB--13-13767 13767 NM_000942peptidylprolyl isomerase B PPIB (cyclophilin B) PPIB--15-13768 13768NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B) PPIB--17-1376913769 NM_000942 peptidylprolyl isomerase B PPIB (cyclophilin B)MAP4K4--16-13939 13939 MAP4K4 APOB-4314-16-13940 13940 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) APOB-4314-17-13941 13941NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--16-1394213942 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen)APOB--18-13943 13943 NM_000384 Apolipoprotein B (including APOB Ag(x)antigen) APOB--17-13944 13944 NM_000384 Apolipoprotein B (including APOBAg(x) antigen) APOB--19-13945 13945 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) APOB-4314-16-13946 13946 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) APOB-4314-17-13947 13947NM_000384 Apolipoprotein B (including APOB Ag(x) antigen) APOB--16-1394813948 NM_000384 Apolipoprotein B (including APOB Ag(x) antigen)APOB--17-13949 13949 NM_000384 Apolipoprotein B (including APOB Ag(x)antigen) APOB--16-13950 13950 NM_000384 Apolipoprotein B (including APOBAg(x) antigen) APOB--18-13951 13951 NM_000384 Apolipoprotein B(including APOB Ag(x) antigen) APOB--17-13952 13952 NM_000384Apolipoprotein B (including APOB Ag(x) antigen) APOB--19-13953 13953NM_000384 Apolipoprotein B (including APOB Ag(x) antigen)MAP4K4--16-13766.2 13766.2 MAP4K4 CTGF-1222-16-13980 13980 NM_001901.2connective tissue growth factor CTGF CTGF-813-16-13981 13981 NM_001901.2connective tissue growth factor CTGF CTGF-747-16-13982 13982 NM_001901.2connective tissue growth factor CTGF CTGF-817-16-13983 13983 NM_001901.2connective tissue growth factor CTGF CTGF-1174-16-13984 13984NM_001901.2 connective tissue growth factor CTGF CTGF-1005-16-1398513985 NM_001901.2 connective tissue growth factor CTGF CTGF-814-16-1398613986 NM_001901.2 connective tissue growth factor CTGF CTGF-816-16-1398713987 NM_001901.2 connective tissue growth factor CTGFCTGF-1001-16-13988 13988 NM_001901.2 connective tissue growth factorCTGF CTGF-1173-16-13989 13989 NM_001901.2 connective tissue growthfactor CTGF CTGF-749-16-13990 13990 NM_001901.2 connective tissue growthfactor CTGF CTGF-792-16-13991 13991 NM_001901.2 connective tissue growthfactor CTGF CTGF-1162-16-13992 13992 NM_001901.2 connective tissuegrowth factor CTGF CTGF-811-16-13993 13993 NM_001901.2 connective tissuegrowth factor CTGF CTGF-797-16-13994 13994 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1175-16-13995 13995 NM_001901.2 connectivetissue growth factor CTGF CTGF-1172-16-13996 13996 NM_001901.2connective tissue growth factor CTGF CTGF-1177-16-13997 13997NM_001901.2 connective tissue growth factor CTGF CTGF-1176-16-1399813998 NM_001901.2 connective tissue growth factor CTGF CTGF-812-16-1399913999 NM_001901.2 connective tissue growth factor CTGF CTGF-745-16-1400014000 NM_001901.2 connective tissue growth factor CTGFCTGF-1230-16-14001 14001 NM_001901.2 connective tissue growth factorCTGF CTGF-920-16-14002 14002 NM_001901.2 connective tissue growth factorCTGF CTGF-679-16-14003 14003 NM_001901.2 connective tissue growth factorCTGF CTGF-992-16-14004 14004 NM_001901.2 connective tissue growth factorCTGF CTGF-1045-16-14005 14005 NM_001901.2 connective tissue growthfactor CTGF CTGF-1231-16-14006 14006 NM_001901.2 connective tissuegrowth factor CTGF CTGF-991-16-14007 14007 NM_001901.2 connective tissuegrowth factor CTGF CTGF-998-16-14008 14008 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1049-16-14009 14009 NM_001901.2 connectivetissue growth factor CTGF CTGF-1044-16-14010 14010 NM_001901.2connective tissue growth factor CTGF CTGF-1327-16-14011 14011NM_001901.2 connective tissue growth factor CTGF CTGF-1196-16-1401214012 NM_001901.2 connective tissue growth factor CTGF CTGF-562-16-1401314013 NM_001901.2 connective tissue growth factor CTGF CTGF-752-16-1401414014 NM_001901.2 connective tissue growth factor CTGF CTGF-994-16-1401514015 NM_001901.2 connective tissue growth factor CTGFCTGF-1040-16-14016 14016 NM_001901.2 connective tissue growth factorCTGF CTGF-1984-16-14017 14017 NM_001901.2 connective tissue growthfactor CTGF CTGF-2195-16-14018 14018 NM_001901.2 connective tissuegrowth factor CTGF CTGF-2043-16-14019 14019 NM_001901.2 connectivetissue growth factor CTGF CTGF-1892-16-14020 14020 NM_001901.2connective tissue growth factor CTGF CTGF-1567-16-14021 14021NM_001901.2 connective tissue growth factor CTGF CTGF-1780-16-1402214022 NM_001901.2 connective tissue growth factor CTGFCTGF-2162-16-14023 14023 NM_001901.2 connective tissue growth factorCTGF CTGF-1034-16-14024 14024 NM_001901.2 connective tissue growthfactor CTGF CTGF-2264-16-14025 14025 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1032-16-14026 14026 NM_001901.2 connectivetissue growth factor CTGF CTGF-1535-16-14027 14027 NM_001901.2connective tissue growth factor CTGF CTGF-1694-16-14028 14028NM_001901.2 connective tissue growth factor CTGF CTGF-1588-16-1402914029 NM_001901.2 connective tissue growth factor CTGF CTGF-928-16-1403014030 NM_001901.2 connective tissue growth factor CTGFCTGF-1133-16-14031 14031 NM_001901.2 connective tissue growth factorCTGF CTGF-912-16-14032 14032 NM_001901.2 connective tissue growth factorCTGF CTGF-753-16-14033 14033 NM_001901.2 connective tissue growth factorCTGF CTGF-918-16-14034 14034 NM_001901.2 connective tissue growth factorCTGF CTGF-744-16-14035 14035 NM_001901.2 connective tissue growth factorCTGF CTGF-466-16-14036 14036 NM_001901.2 connective tissue growth factorCTGF CTGF-917-16-14037 14037 NM_001901.2 connective tissue growth factorCTGF CTGF-1038-16-14038 14038 NM_001901.2 connective tissue growthfactor CTGF CTGF-1048-16-14039 14039 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1235-16-14040 14040 NM_001901.2 connectivetissue growth factor CTGF CTGF-868-16-14041 14041 NM_001901.2 connectivetissue growth factor CTGF CTGF-1131-16-14042 14042 NM_001901.2connective tissue growth factor CTGF CTGF-1043-16-14043 14043NM_001901.2 connective tissue growth factor CTGF CTGF-751-16-14044 14044NM_001901.2 connective tissue growth factor CTGF CTGF-1227-16-1404514045 NM_001901.2 connective tissue growth factor CTGF CTGF-867-16-1404614046 NM_001901.2 connective tissue growth factor CTGFCTGF-1128-16-14047 14047 NM_001901.2 connective tissue growth factorCTGF CTGF-756-16-14048 14048 NM_001901.2 connective tissue growth factorCTGF CTGF-1234-16-14049 14049 NM_001901.2 connective tissue growthfactor CTGF CTGF-916-16-14050 14050 NM_001901.2 connective tissue growthfactor CTGF CTGF-925-16-14051 14051 NM_001901.2 connective tissue growthfactor CTGF CTGF-1225-16-14052 14052 NM_001901.2 connective tissuegrowth factor CTGF CTGF-445-16-14053 14053 NM_001901.2 connective tissuegrowth factor CTGF CTGF-446-16-14054 14054 NM_001901.2 connective tissuegrowth factor CTGF CTGF-913-16-14055 14055 NM_001901.2 connective tissuegrowth factor CTGF CTGF-997-16-14056 14056 NM_001901.2 connective tissuegrowth factor CTGF CTGF-277-16-14057 14057 NM_001901.2 connective tissuegrowth factor CTGF CTGF-1052-16-14058 14058 NM_001901.2 connectivetissue growth factor CTGF CTGF-887-16-14059 14059 NM_001901.2 connectivetissue growth factor CTGF CTGF-914-16-14060 14060 NM_001901.2 connectivetissue growth factor CTGF CTGF-1039-16-14061 14061 NM_001901.2connective tissue growth factor CTGF CTGF-754-16-14062 14062 NM_001901.2connective tissue growth factor CTGF CTGF-1130-16-14063 14063NM_001901.2 connective tissue growth factor CTGF CTGF-919-16-14064 14064NM_001901.2 connective tissue growth factor CTGF CTGF-922-16-14065 14065NM_001901.2 connective tissue growth factor CTGF CTGF-746-16-14066 14066NM_001901.2 connective tissue growth factor CTGF CTGF-993-16-14067 14067NM_001901.2 connective tissue growth factor CTGF CTGF-825-16-14068 14068NM_001901.2 connective tissue growth factor CTGF CTGF-926-16-14069 14069NM_001901.2 connective tissue growth factor CTGF CTGF-923-16-14070 14070NM_001901.2 connective tissue growth factor CTGF CTGF-866-16-14071 14071NM_001901.2 connective tissue growth factor CTGF CTGF-563-16-14072 14072NM_001901.2 connective tissue growth factor CTGF CTGF-823-16-14073 14073NM_001901.2 connective tissue growth factor CTGF CTGF-1233-16-1407414074 NM_001901.2 connective tissue growth factor CTGF CTGF-924-16-1407514075 NM_001901.2 connective tissue growth factor CTGF CTGF-921-16-1407614076 NM_001901.2 connective tissue growth factor CTGF CTGF-443-16-1407714077 NM_001901.2 connective tissue growth factor CTGFCTGF-1041-16-14078 14078 NM_001901.2 connective tissue growth factorCTGF CTGF-1042-16-14079 14079 NM_001901.2 connective tissue growthfactor CTGF CTGF-755-16-14080 14080 NM_001901.2 connective tissue growthfactor CTGF CTGF-467-16-14081 14081 NM_001901.2 connective tissue growthfactor CTGF CTGF-995-16-14082 14082 NM_001901.2 connective tissue growthfactor CTGF CTGF-927-16-14083 14083 NM_001901.2 connective tissue growthfactor CTGF SPP1-1091-16-14131 14131 NM_000582.2 Osteopontin SPP1PPIB--16-14188 14188 NM_000942 peptidylprolyl isomerase B PPIB(cyclophilin B) PPIB--17-14189 14189 NM_000942 peptidylprolyl isomeraseB PPIB (cyclophilin B) PPIB--18-14190 14190 NM_000942 peptidylprolylisomerase B PPIB (cyclophilin B) pGL3-1172-16-14386 14386 U47296 Cloningvector pGL3-Control pGL3 pGL3-1172-16-14387 14387 U47296 Cloning vectorpGL3-Control pGL3 MAP4K4-2931-25-14390 14390 NM_004834 Mitogen-ActivatedProtein Kinase MAP4K4 Kinase Kinase Kinase 4 (MAP4K4), transcriptvariant 1 miR-122--23-14391 14391 miR-122 14084 NM_000582.2 OsteopontinSPP1 14085 NM_000582.2 Osteopontin SPP1 14086 NM_000582.2 OsteopontinSPP1 14087 NM_000582.2 Osteopontin SPP1 14088 NM_000582.2 OsteopontinSPP1 14089 NM_000582.2 Osteopontin SPP1 14090 NM_000582.2 OsteopontinSPP1 14091 NM_000582.2 Osteopontin SPP1 14092 NM_000582.2 OsteopontinSPP1 14093 NM_000582.2 Osteopontin SPP1 14094 NM_000582.2 OsteopontinSPP1 14095 NM_000582.2 Osteopontin SPP1 14096 NM_000582.2 OsteopontinSPP1 14097 NM_000582.2 Osteopontin SPP1 14098 NM_000582.2 OsteopontinSPP1 14099 NM_000582.2 Osteopontin SPP1 14100 NM_000582.2 OsteopontinSPP1 14101 NM_000582.2 Osteopontin SPP1 14102 NM_000582.2 OsteopontinSPP1 14103 NM_000582.2 Osteopontin SPP1 14104 NM_000582.2 OsteopontinSPP1 14105 NM_000582.2 Osteopontin SPP1 14106 NM_000582.2 OsteopontinSPP1 14107 NM_000582.2 Osteopontin SPP1 14108 NM_000582.2 OsteopontinSPP1 14109 NM_000582.2 Osteopontin SPP1 14110 NM_000582.2 OsteopontinSPP1 14111 NM_000582.2 Osteopontin SPP1 14112 NM_000582.2 OsteopontinSPP1 14113 NM_000582.2 Osteopontin SPP1 14114 NM_000582.2 OsteopontinSPP1 14115 NM_000582.2 Osteopontin SPP1 14116 NM_000582.2 OsteopontinSPP1 14117 NM_000582.2 Osteopontin SPP1 14118 NM_000582.2 OsteopontinSPP1 14119 NM_000582.2 Osteopontin SPP1 14120 NM_000582.2 OsteopontinSPP1 14121 NM_000582.2 Osteopontin SPP1 14122 NM_000582.2 OsteopontinSPP1 14123 NM_000582.2 Osteopontin SPP1 14124 NM_000582.2 OsteopontinSPP1 14125 NM_000582.2 Osteopontin SPP1 14126 NM_000582.2 OsteopontinSPP1 14127 NM_000582.2 Osteopontin SPP1 14128 NM_000582.2 OsteopontinSPP1 14129 NM_000582.2 Osteopontin SPP1 14130 NM_000582.2 OsteopontinSPP1 14132 NM_000582.2 Osteopontin SPP1 14133 NM_000582.2 OsteopontinSPP1 14134 NM_000582.2 Osteopontin SPP1 14135 NM_000582.2 OsteopontinSPP1 14136 NM_000582.2 Osteopontin SPP1 14137 NM_000582.2 OsteopontinSPP1 14138 NM_000582.2 Osteopontin SPP1 14139 NM_000582.2 OsteopontinSPP1 14140 NM_000582.2 Osteopontin SPP1 14141 NM_000582.2 OsteopontinSPP1 14142 NM_000582.2 Osteopontin SPP1 14143 NM_000582.2 OsteopontinSPP1 14144 NM_000582.2 Osteopontin SPP1 14145 NM_000582.2 OsteopontinSPP1 14146 NM_000582.2 Osteopontin SPP1 14147 NM_000582.2 OsteopontinSPP1 14148 NM_000582.2 Osteopontin SPP1 14149 NM_000582.2 OsteopontinSPP1 14150 NM_000582.2 Osteopontin SPP1 14151 NM_000582.2 OsteopontinSPP1 14152 NM_000582.2 Osteopontin SPP1 14153 NM_000582.2 OsteopontinSPP1 14154 NM_000582.2 Osteopontin SPP1 14155 NM_000582.2 OsteopontinSPP1 14156 NM_000582.2 Osteopontin SPP1 14157 NM_000582.2 OsteopontinSPP1 14158 NM_000582.2 Osteopontin SPP1 14159 NM_000582.2 OsteopontinSPP1 14160 NM_000582.2 Osteopontin SPP1 14161 NM_000582.2 OsteopontinSPP1 14162 NM_000582.2 Osteopontin SPP1 14163 NM_000582.2 OsteopontinSPP1 14164 NM_000582.2 Osteopontin SPP1 14165 NM_000582.2 OsteopontinSPP1 14166 NM_000582.2 Osteopontin SPP1 14167 NM_000582.2 OsteopontinSPP1 14168 NM_000582.2 Osteopontin SPP1 14169 NM_000582.2 OsteopontinSPP1 14170 NM_000582.2 Osteopontin SPP1 14171 NM_000582.2 OsteopontinSPP1 14172 NM_000582.2 Osteopontin SPP1 14173 NM_000582.2 OsteopontinSPP1 14174 NM_000582.2 Osteopontin SPP1 14175 NM_000582.2 OsteopontinSPP1 14176 NM_000582.2 Osteopontin SPP1 14177 NM_000582.2 OsteopontinSPP1 14178 NM_000582.2 Osteopontin SPP1 14179 NM_000582.2 OsteopontinSPP1 14180 NM_000582.2 Osteopontin SPP1 14181 NM_000582.2 OsteopontinSPP1 14182 NM_000582.2 Osteopontin SPP1 14183 NM_000582.2 OsteopontinSPP1 14184 NM_000582.2 Osteopontin SPP1 14185 NM_000582.2 OsteopontinSPP1 14186 NM_000582.2 Osteopontin SPP1 14187 NM_000582.2 OsteopontinSPP1

TABLE 2 SEQ Oligo ID ID Number # AntiSense Backbone AntiSense ChemistryAntiSense Sequence NO: APOB-10167-20-12138 12138 ooooooooooooooooooo00000000000000000000m AUUGGUAUUCAGUGUGAUG 1 APOB-10167-20-12139 12139ooooooooooooooooooo 00000000000000000000m AUUCGUAUUGAGUCUGAUC 2MAP4K4-2931-16-12293 12293 ooooooooooooooooooo Pf000fffff0f0000fff0UAGACUUCCACAGAACUCU 3 MAP4K4-2931-16-12383 12383 ooooooooooooooooooo0000000000000000000 UAGACUUCCACAGAACUCU 4 MAP4K4-2931-16-12384 12384ooooooooooooooooooo P0000000000000000000 UAGACUUCCACAGAACUCU 5MAP4K4-2931-16-12385 12385 ooooooooooooooooooo Pf000fffff0f0000fff0UAGACUUCCACAGAACUCU 6 MAP4K4-2931-16-12386 12386 oooooooooossssssssoPf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 7 MAP4K4-2931-16-12387 12387oooooooooosssssssso P0000000000000000000 UAGACUUCCACAGAACUCU 8MAP4K4-2931-15-12388 12388 ooooooooooooooooo 00000000000000000UAGACUUCCACAGAACU 9 APOB-21-12434 12434 ooooooooooooooooooooo0000000000000000000m AUUGGUAUUCAGUGUGAUG 10 AC APOB-21-12435 12435ooooooooooooooooooooo 0000000000000000000m AUUCGUAUUGAGUCUGAUC 11 ACMAP4K4-2931-16-12451 12451 oooooooooosssssssso Pf000fffff0f0000ffmmUAGACUUCCACAGAACUCU 12 MAP4K4-2931-16-12452 12452 oooooooooossssssssoPm000fffff0f0000ffmm UAGACUUCCACAGAACUCU 13 MAP4K4-2931-16-12453 12453oooooosssssssssssso Pm000fffff0f0000ffmm UAGACUUCCACAGAACUCU 14MAP4K4-2931-17-12454 12454 oooooooooooosssssssso Pm000fffff0f0000ffffmmUAGACUUCCACAGAACUCU 15 UC MAP4K4-2931-17-12455 12455oooooooosssssssssssso Pm000fffff0f0000ffffmm UAGACUUCCACAGAACUCU 16 UCMAP4K4-2931-19-12456 12456 oooooooooooossssssssssssoPm000fffff0f0000ffffff UAGACUUCCACAGAACUCU 17 00mm UCAAAGapob-10167-21-12505 12505 oooooooooooooooooooos 00000000000000000000mAUUGGUAUUCAGUGUGAUG 18 AC APOB-10167-21-12506 12506oooooooooooooooooooos 00000000000000000000m AUUCGUAUUGAGUCUGAUC 19 ACMAP4K4-2931-16-12539 12539 ooooooooooossssssss Pf000fffff0f0000fff0UAGACUUCCACAGAACUCU 20 APOB-10167-21-12505.2 12505.2ooooooooooooooooooooo 00000000000000000000m AUUGGUAUUCAGUGUGAUG 21 ACAPOB-10167-21-12506.2 12506.2 ooooooooooooooooooooo00000000000000000000m AUUCGUAUUGAGUCUGAUC 22 AC MAP4K4-2931-16-12386.212386.2 oooooooooosssssssso Pf000fffff0f0000fff0 UAGACUUCCACAGAACUCU 23MAP4K4--16-12983 12983 oooooooooooosssssso Pm000fffff0m0000mmm0uagacuuccacagaacucu 24 MAP4K4--16-12984 12984 oooooooooooossssssPm000fffff0m0000mmm0 uagacuuccacagaacucu 25 MAP4K4--16-12985 12985oooooooooooosssssso Pm000fffff0m0000mmm0 uagacuuccacagaacucu 26MAP4K4--16-12986 12986 oooooooooosssssssso Pf000fffff0f0000fff0UAGACUUCCACAGAACUCU 27 MAP4K4--16-12987 12987 ooooooooooooossssssP0000f00ff0m0000m0m0 UagacUUccacagaacUcU 28 MAP4K4--16-12988 12988ooooooooooooossssss P0000f00ff0m0000m0m0 UagacUUccacagaacUcu 29MAP4K4--16-12989 12989 ooooooooooooossssss P0000ff0ff0m0000m0m0UagacuUccacagaacUcu 30 MAP4K4--16-12990 12990 ooooooooooooossssssPf0000ff000000000m00 uagaCuuCCaCagaaCuCu 31 MAP4K4--16-12991 12991ooooooooooooossssss Pf0000fff00m00000mm0 uagaCuucCacagaaCucu 32MAP4K4--16-12992 12992 ooooooooooooossssss Pf000fffff0000000m00uagacuuccaCagaaCuCu 33 MAP4K4--16-12993 12993 ooooooooooooossssssP0000000000000000000 UagaCUUCCaCagaaCUCU 34 MAP4K4--16-12994 12994ooooooooooooossssss P0000f0f0f0000000m00 UagacUcCcaCagaaCuCu 35MAP4K4--16-12995 12995 oooooooooooosssssso Pf000fffff0000000000uagacuuccaCagaaCUCU 36 --16-13047 13047 oooooooooooossssssPm000000000m0000mmm0 UAGACUUCCACAGAACUCU 37 PPIB--16-13136 13136oooooooooooossssss Pm0fffff0f00mm000mm0 UGUUUUUGUAGCCAAAUCC 38SOD1-530-16-13163 13163 oooooooooooosssssso Pm0ffffffff0mmmmm0m0UACUUUCUUCAUUUCCACC 39 SOD1-523-16-13164 13164 oooooooooooossssssoPmff0fffff0fmmmm0mm0 UUCAUUUCCACCUUUGCCC 40 SOD1-535-16-13165 13165oooooooooooosssssso Pmfff0f0ffffmmmm0mm0 CUUUGUACUUUCUUCAUUU 41SOD1-536-16-13166 13166 oooooooooooosssssso Pmffff0f0fffmmmmm0m0UCUUUGUACUUUCUUCAUU 42 SOD1-396-16-13167 13167 oooooooooooossssssoPmf00f00ff0f0mm0mmm0 UCAGCAGUCACAUUGCCCA 43 SOD1-385-16-13168 13168oooooooooooosssssso Pmff0fff000fmmmm00m0 AUUGCCCAAGUCUCCAACA 44SOD1-195-16-13169 13169 oooooooooooosssssso Pmfff0fff0000mm00m00UUCUGCUCGAAAUUGAUGA 45 pGL3-1172-16-13170 13170 oooooooooooossssssoPm00ff0f0ffm0ff00mm0 AAAUCGUAUUUGUCAAUCA 46 pGL3-1172-16-13171 13171ooooooooooooossssss Pm00ff0f0ffm0ff00mm0 AAAUCGUAUUUGUCAAUCA 47MAP4k4-2931-19-13189 13189 ooooooooooooooooooo 0000000000000000000UAGACUUCCACAGAACUCU 48 MAP4K4--16-13766 13766 oooooooooooossssssoPm000fffff0m0000mmm0 UAGACUUCCACAGAACUCU 49 MAP4K4--16-13939 13939oooooooooooosssssso m000f0ffff0m0m00m0m UAGACAUCCUACACAGCAC 50APOB-4314-16-13940 13940 oooooooooooosssssso Pm0fffffff000mmmmm00UGUUUCUCCAGAUCCUUGC 51 APOB-4314-17-13941 13941 oooooooooooossssssoPm0fffffff000mmmmm00 UGUUUCUCCAGAUCCUUGC 52 APOB-16-13942 13942oooooooooooosssssso Pm00f000f000mmm0mmm0 UAGCAGAUGAGUCCAUUUG 53APOB--18-13943 13943 oooooooooooooooosssssso Pm00f000f000mmm0mmm0UAGCAGAUGAGUCCAUUUG 54 0000 GAGA APOB--17-13944 13944oooooooooooosssssso Pm00f000f000mmm0mmm0 UAGCAGAUGAGUCCAUUUG 55APOB--19-13945 13945 oooooooooooooooosssssso Pm00f000f000mmm0mmm0UAGCAGAUGAGUCCAUUUG 56 0000 GAGA APOB-4314-16-13946 13946oooooooooooosssssso Pmf0ff0ffffmmm000mm0 AUGUUGUUUCUCCAGAUCC 57APOB-4314-17-13947 13947 oooooooooooosssssso Pmf0ff0ffffmmm000mm0AUGUUGUUUCUCCAGAUCC 58 APOB--16-13948 13948 oooooooooooossssssoPm0fff000000mmmm0m00 UGUUUGAGGGACUCUGUGA 59 APOB--17-13949 13949oooooooooooosssssso Pm0fff000000mmmm0m00 UGUUUGAGGGACUCUGUGA 60APOB--16-13950 13950 oooooooooooosssssso Pmff00f0fff00m0m00m0AUUGGUAUUCAGUGUGAUG 61 APOB--18-13951 13951 oooooooooooooooossssssoPmff00f0fff00m0m00m0 AUUGGUAUUCAGUGUGAUG 62 0m00 ACAC APOB--17-1395213952 oooooooooooosssssso Pmff00f0fff00m0m00m0 AUUGGUAUUCAGUGUGAUG 63APOB--19-13953 13953 oooooooooooooooosssssso Pmff00f0fff00m0m00m0AUUGGUAUUCAGUGUGAUG 64 0m00 ACAC MAP4K4--16-13766.2 13766.2oooooooooooosssssso Pm000fffff0m0000mmm0 UAGACUUCCACAGAACUCU 65CTGF-1222-16-13980 13980 oooooooooooosssssso Pm0f0ffffffm0m00m0m0UACAUCUUCCUGUAGUACA 66 CTGF-813-16-13981 13981 oooooooooooossssssoPm0f0ffff0mmmm0m000 AGGCGCUCCACUCUGUGGU 67 CTGF-747-16-13982 13982oooooooooooosssssso Pm0ffffff00mm0m0000 UGUCUUCCAGUCGGUAAGC 68CTGF-817-16-13983 13983 oooooooooooosssssso Pm00f000f0fmmm0mmmm0GAACAGGCGCUCCACUCUG 69 CTGF-1174-16-13984 13984 oooooooooooossssssoPm00ff0f00f00m000m00 CAGUUGUAAUGGCAGGCAC 70 CTGF-1005-16-13985 13985oooooooooooosssssso Pmff000000mmm000mm0 AGCCAGAAAGCUCAAACUU 71CTGF-814-16-13986 13986 oooooooooooosssssso Pm000f0ffff0mmmm0m00CAGGCGCUCCACUCUGUGG 72 CTGF-816-16-13987 13987 oooooooooooossssssoPm0f000f0ffmm0mmmm00 AACAGGCGCUCCACUCUGU 73 CTGF-1001-16-13988 13988oooooooooooosssssso Pm0000fff000mmm00m0 AGAAAGCUCAAACUUGAUA 74CTGF-1173-16-13989 13989 oooooooooooosssssso Pmff0f00f00m000m0m0AGUUGUAAUGGCAGGCACA 75 CTGF-749-16-13990 13990 oooooooooooossssssoPmf0ffffff00mm00m00 CGUGUCUUCCAGUCGGUAA 76 CTGF-792-16-13991 13991oooooooooooosssssso Pm00ff000f00mm00mmm0 GGACCAGGCAGUUGGCUCU 77CTGF-1162-16-13992 13992 oooooooooooosssssso Pm000f0f000mmmm00m00CAGGCACAGGUCUUGAUGA 78 CTGF-811-16-13993 13993 oooooooooooossssssoPmf0ffff0ffmm0m00mm0 GCGCUCCACUCUGUGGUCU 79 CTGF-797-16-13994 13994oooooooooooosssssso Pm0fff000ff000m00mm0 GGUCUGGACCAGGCAGUUG 80CTGF-1175-16-13995 13995 oooooooooooosssssso Pmf00ff0f00m00m000m0ACAGUUGUAAUGGCAGGCA 81 CTGF-1172-16-13996 13996 oooooooooooossssssoPmff0f00f00m000m0m00 GUUGUAAUGGCAGGCACAG 82 CTGF-1177-16-13997 13997oooooooooooosssssso Pm00f00ff0f00m00m000 GGACAGUUGUAAUGGCAGG 83CTGF-1176-16-13998 13998 oooooooooooosssssso Pm0f00ff0f00m00m0000GACAGUUGUAAUGGCAGGC 84 CTGF-812-16-13999 13999 oooooooooooossssssoPm0f0ffff0fmmm0m00m0 GGCGCUCCACUCUGUGGUC 85 CTGF-745-16-14000 14000oooooooooooosssssso Pmfffff00ff00m000mm0 UCUUCCAGUCGGUAAGCCG 86CTGF-1230-16-14001 14001 oooooooooooosssssso Pm0fffff0f0m0mmmmmm0UGUCUCCGUACAUCUUCCU 87 CTGF-920-16-14002 14002 oooooooooooossssssoPmffff0f0000mmm00m0 AGCUUCGCAAGGCCUGACC 88 CTGF-679-16-14003 14003oooooooooooosssssso Pm0ffffff0f00m0mmm0 CACUCCUCGCAGCAUUUCC 89CTGF-992-16-14004 14004 oooooooooooosssssso Pm00fff00f000mmm0000AAACUUGAUAGGCUUGGAG 90 CTGF-1045-16-14005 14005 oooooooooooossssssoPmffff0f0000mmm00mm0 ACUCCACAGAAUUUAGCUC 91 CTGF-1231-16-14006 14006oooooooooooosssssso Pmf0fffff0f0m0mmmmm0 AUGUCUCCGUACAUCUUCC 92CTGF-991-16-14007 14007 oooooooooooosssssso Pm0fff00f000mmm00000AACUUGAUAGGCUUGGAGA 93 CTGF-998-16-14008 14008 oooooooooooossssssoPm00fff000fmm00m0000 AAGCUCAAACUUGAUAGGC 94 CTGF-1049-16-14009 14009oooooooooooosssssso Pmf0f0ffff0m0000mmm0 ACAUACUCCACAGAAUUUA 95CTGF-1044-16-14010 14010 oooooooooooosssssso Pmfff0f0000mmm00mmm0CUCCACAGAAUUUAGCUCG 96 CTGF-1327-16-14011 14011 oooooooooooossssssoPm0f0ff0ff0000mm0mm0 UGUGCUACUGAAAUCAUUU 97 CTGF-1196-16-14012 14012oooooooooooosssssso Pm0000f0ff0mm0mmmmm0 AAAGAUGUCAUUGUCUCCG 98CTGF-562-16-14013 14013 oooooooooooosssssso Pmf0f0ff00f0mmm0m000GUGCACUGGUACUUGCAGC 99 CTGF-752-16-14014 14014 oooooooooooossssssoPm00f0f0fffmmm00mm00 AAACGUGUCUUCCAGUCGG 100 CTGF-994-16-14015 14015oooooooooooosssssso Pmf000fff00m000mmm00 UCAAACUUGAUAGGCUUGG 101CTGF-1040-16-14016 14016 oooooooooooosssssso Pmf0000fff00mmm00m00ACAGAAUUUAGCUCGGUAU 102 CTGF-1984-16-14017 14017 oooooooooooossssssoPmf0f0ffff0mmm0m00m0 UUACAUUCUACCUAUGGUG 103 CTGF-2195-16-14018 14018oooooooooooosssssso Pm00ff00ff00mm0m0m00 AAACUGAUCAGCUAUAUAG 104CTGF-2043-16-14019 14019 oooooooooooosssssso Pm0fff000f0000mmmmm0UAUCUGAGCAGAAUUUCCA 105 CTGF-1892-16-14020 14020 oooooooooooossssssoPmf00fff000m00mm0m00 UUAACUUAGAUAACUGUAC 106 CTGF-1567-16-14021 14021oooooooooooosssssso Pm0ff0fff0f0m0000m00 UAUUACUCGUAUAAGAUGC 107CTGF-1780-16-14022 14022 oooooooooooosssssso Pm00ff0fff00mmm00mm0AAGCUGUCCAGUCUAAUCG 108 CTGF-2162-16-14023 14023 oooooooooooossssssoPm00f00000fm0mmm0mm0 UAAUAAAGGCCAUUUGUUC 109 CTGF-1034-16-14024 14024oooooooooooosssssso Pmff00fff00m0m0mmmm0 UUUAGCUCGGUAUGUCUUC 110CTGF-2264-16-14025 14025 oooooooooooosssssso Pmf0fffff00m000m0000ACACUCUCAACAAAUAAAC 111 CTGF-1032-16-14026 14026 oooooooooooossssssoPm00fff00f0m0mmmmm00 UAGCUCGGUAUGUCUUCAU 112 CTGF-1535-16-14027 14027oooooooooooosssssso Pm00fffffff0mm00m0m0 UAACCUUUCUGCUGGUACC 113CTGF-1694-16-14028 14028 oooooooooooosssssso Pmf000000f00mmm00mm0UUAAGGAACAACUUGACUC 114 CTGF-1588-16-14029 14029 oooooooooooossssssoPmf0f0ffff000m00m000 UUACACUUCAAAUAGCAGG 115 CTGF-928-16-14030 14030oooooooooooosssssso Pmff000ff00mmmm0m000 UCCAGGUCAGCUUCGCAAG 116CTGF-1133-16-14031 14031 oooooooooooosssssso Pmffffff0f00mmmm0mm0CUUCUUCAUGACCUCGCCG 117 CTGF-912-16-14032 14032 oooooooooooossssssoPm000fff00fm0m0m0m00 AAGGCCUGACCAUGCACAG 118 CTGF-753-16-14033 14033oooooooooooosssssso Pm000f0f0ffmmmm00mm0 CAAACGUGUCUUCCAGUCG 119CTGF-918-16-14034 14034 oooooooooooosssssso Pmfff0f0000mmm00mm00CUUCGCAAGGCCUGACCAU 120 CTGF-744-16-14035 14035 oooooooooooossssssoPmffff00ff00m000mm00 CUUCCAGUCGGUAAGCCGC 121 CTGF-466-16-14036 14036oooooooooooosssssso Pmf00ffff0f00mm00mm0 CCGAUCUUGCGGUUGGCCG 122CTGF-917-16-14037 14037 oooooooooooosssssso Pmff0f0000fmm00mm0m0UUCGCAAGGCCUGACCAUG 123 CTGF-1038-16-14038 14038 oooooooooooossssssoPm00fff00fmm0m0m00 AGAAUUUAGCUCGGUAUGU 124 CTGF-1048-16-14039 14039oooooooooooosssssso Pm0f0ffff0f0000mmm00 CAUACUCCACAGAAUUUAG 125CTGF-1235-16-14040 14040 oooooooooooosssssso Pm0ff0f0ffmmm0m0m0UGCCAUGUCUCCGUACAUC 126 CTGF-868-16-14041 14041 oooooooooooossssssoPm000f0ff0fm0mm00m00 GAGGCGUUGUCAUUGGUAA 127 CTGF-1131-16-14042 14042oooooooooooosssssso Pmffff0f00fmmm0mm0m0 UCUUCAUGACCUCGCCGUC 128CTGF-1043-16-14043 14043 oooooooooooosssssso Pmff0f0000fmm00mmm00UCCACAGAAUUUAGCUCGG 129 CTGF-751-16-14044 14044 oooooooooooossssssoPm0f0f0ffffmm00mm000 AACGUGUCUUCCAGUCGGU 130 CTGF-1227-16-14045 14045oooooooooooosssssso Pmfff0f0f0fmmmmmm0m0 CUCCGUACAUCUUCCUGUA 131CTGF-867-16-14046 14046 oooooooooooosssssso Pm0f0ff0ff0mm00m000AGGCGUUGUCAUUGGUAAC 132 CTGF-1128-16-14047 14047 oooooooooooossssssoPmf0f00ffff0mm0mm000 UCAUGACCUCGCCGUCAGG 133 CTGF-756-16-14048 14048oooooooooooosssssso Pm0ff000f0f0mmmmmm00 GGCCAAACGUGUCUUCCAG 134CTGF-1234-16-14049 14049 oooooooooooosssssso Pmff0f0ffffmm0m0mm0GCCAUGUCUCCGUACAUCU 135 CTGF-916-16-14050 14050 oooooooooooossssssoPmf0f0000ffm00mm0m00 UCGCAAGGCCUGACCAUGC 136 CTGF-925-16-14051 14051oooooooooooosssssso Pm0ff00fffmm0000m0 AGGUCAGCUUCGCAAGGCC 137CTGF-1225-16-14052 14052 oooooooooooosssssso Pmf0f0f0fffmmmm0m000CCGUACAUCUUCCUGUAGU 138 CTGF-445-16-14053 14053 oooooooooooossssssoPm00ff0000fm0m000000 GAGCCGAAGUCACAGAAGA 139 CTGF-446-16-14054 14054oooooooooooosssssso Pm000ff0000mm0m00000 GGAGCCGAAGUCACAGAAG 140CTGF-913-16-14055 14055 oooooooooooosssssso Pm0000fff00mm0m0m0m0CAAGGCCUGACCAUGCACA 141 CTGF-997-16-14056 14056 oooooooooooossssssoPmfff000ffm00m000m0 AGCUCAAACUUGAUAGGCU 142 CTGF-277-16-14057 14057oooooooooooosssssso Pmf0f00ffff00mm00m00 CUGCAGUUCUGGCCGACGG 143CTGF-1052-16-14058 14058 oooooooooooosssssso Pm0f0f0f0ffmm0m00000GGUACAUACUCCACAGAAU 144 CTGF-887-16-14059 14059 oooooooooooossssssoPmf0fffffff00mmm0m00 CUGCUUCUCUAGCCUGCAG 145 CTGF-914-16-14060 14060oooooooooooosssssso Pmf0000fff00mm0m0m00 GCAAGGCCUGACCAUGCAC 146CTGF-1039-16-14061 14061 oooooooooooosssssso Pm0000fff00mmm00m0m0CAGAAUUUAGCUCGGUAUG 147 CTGF-754-16-14062 14062 oooooooooooossssssoPmf000f0f0fmmmmm00m0 CCAAACGUGUCUUCCAGUC 148 CTGF-1130-16-14063 14063oooooooooooosssssso Pmfff0f00ffmmmm0mm0 CUUCAUGACCUCGCCGUCA 149CTGF-919-16-14064 14064 oooooooooooosssssso Pmffff0f0000mmm00mm0GCUUCGCAAGGCCUGACCA 150 CTGF-922-16-14065 14065 oooooooooooossssssoPmf00ffff0f0000mmm00 UCAGCUUCGCAAGGCCUGA 151 CTGF-746-16-14066 14066oooooooooooosssssso Pmffffff00fm0m000m0 GUCUUCCAGUCGGUAAGCC 152CTGF-993-16-14067 14067 oooooooooooosssssso Pm000fff00f000mmm000CAAACUUGAUAGGCUUGGA 153 CTGF-825-16-14068 14068 oooooooooooossssssoPm0ffff0000m000m0m0 AGGUCUUGGAACAGGCGCU 154 CTGF-926-16-14069 14069oooooooooooosssssso Pm000ff00ffmmm00000 CAGGUCAGCUUCGCAAGGC 155CTGF-923-16-14070 14070 oooooooooooosssssso Pmff00ffff0m0000mmm0GUCAGCUUCGCAAGGCCUG 156 CTGF-866-16-14071 14071 oooooooooooossssssoPm0f0ff0ff0mm00m00m0 GGCGUUGUCAUUGGUAACC 157 CTGF-563-16-14072 14072oooooooooooosssssso Pmf0f0ff00m0mmm0m00 CGUGCACUGGUACUUGCAG 158CTGF-823-16-14073 14073 oooooooooooosssssso Pmffff0000f000m0mmm0GUCUUGGAACAGGCGCUCC 159 CTGF-1233-16-14074 14074 oooooooooooossssssoPmf0f0fffff0m0m0mmm0 CCAUGUCUCCGUACAUCUU 160 CTGF-924-16-14075 14075oooooooooooosssssso Pm0ff00ffff0m0000mm0 GGUCAGCUUCGCAAGGCCU 161CTGF-921-16-14076 14076 oooooooooooosssssso Pm00ffff0f0000mmm000CAGCUUCGCAAGGCCUGAC 162 CTGF-443-16-14077 14077 oooooooooooossssssoPmff0000ff0m00000000 GCCGAAGUCACAGAAGAGG 163 CTGF-1041-16-14078 14078oooooooooooosssssso Pm0f0000fff00mmm00m0 CACAGAAUUUAGCUCGGUA 164CTGF-1042-16-14079 14079 oooooooooooosssssso Pmf0f0000ffm00mmm000CCACAGAAUUUAGCUCGGU 165 CTGF-755-16-14080 14080 oooooooooooossssssoPmff000f0f0mmmmmm000 GCCAAACGUGUCUUCCAGU 166 CTGF-467-16-14081 14081oooooooooooosssssso Pmf0f00ffff0m0mm00m0 GCCGAUCUUGCGGUUGGCC 167CTGF-995-16-14082 14082 oooooooooooosssssso Pmff000fff00m000mmm0CUCAAACUUGAUAGGCUUG 168 CTGF-927-16-14083 14083 oooooooooooossssssoPmf000ff00fmmm0m0000 CCAGGUCAGCUUCGCAAGG 169 SPP1-1091-16-14131 14131oooooooooooosssssso Pmff00ff000m0m0000m0 UUUGACUAAAUGCAAAGUG 170PPIB--16-14188 14188 oooooooooooosssssso Pm0fffff0f00mm000mm0UGUUUUUGUAGCCAAAUCC 171 PPIB--17-14189 14189 oooooooooooossssssoPm0fffff0f00mm000mm0 UGUUUUUGUAGCCAAAUCC 172 PPIB--18-14190 14190oooooooooooosssssso Pm0fffff0f00mm000mm0 UGUUUUUGUAGCCAAAUCC 173pGL3-1172-16-14386 14386 oooooooooooosssssso Pm00ff0f0ffm0mm00mm0AAAUCGUAUUUGUCAAUCA 174 pGL3-1172-16-14387 14387 oooooooooooossssssoPm00ff0f0ffm0mm00mm0 AAAUCGUAUUUGUCAAUCA 175 miR-122--23-14391 1439114084 oooooooooooosssssso Pmff00fff0f000000m00 UCUAAUUCAUGAGAAAUAC 61614085 oooooooooooosssssso Pm00ff00fffm000000m0 UAAUUGACCUCAGAAGAUG 61714086 oooooooooooosssssso Pmff00ff00fmmm000000 UUUAAUUGACCUCAGAAGA 61814087 oooooooooooosssssso Pm0ff00ffff000000m00 AAUUGACCUCAGAAGAUGC 61914088 oooooooooooosssssso Pmf00ff00ffmm0000000 UUAAUUGACCUCAGAAGAU 62014089 oooooooooooosssssso Pmff00ffff000000m0m0 AUUGACCUCAGAAGAUGCA 62114090 oooooooooooosssssso Pmf0fff00ff00mmm0mm0 UCAUCCAGCUGACUCGUUU 62214091 oooooooooooosssssso Pm0fff0ff0000m00m00 AGAUUCAUCAGAAUGGUGA 62314092 oooooooooooosssssso Pm00ffff00fmm0m000m0 UGACCUCAGUCCAUAAACC 62414093 oooooooooooosssssso Pm0f00f0000mmm0mm000 AAUGGUGAGACUCAUCAGA 62514094 oooooooooooosssssso Pmff00ffff00mmm0m000 UUUGACCUCAGUCCAUAAA 62614095 oooooooooooosssssso Pmff0f00ff0m0000mmm0 UUCAUGGCUGUGAAAUUCA 62714096 oooooooooooosssssso Pm00f00f0000mmm0mm00 GAAUGGUGAGACUCAUCAG 62814097 oooooooooooosssssso Pm00ffffff0mmm0m0m00 UGGCUUUCCGCUUAUAUAA 62914098 oooooooooooosssssso Pmf00ffffff0mmm0m0m0 UUGGCUUUCCGCUUAUAUA 63014099 oooooooooooosssssso Pmf0fff0f0f00mm0m000 UCAUCCAUGUGGUCAUGGC 63114100 oooooooooooosssssso Pmf0f00ff0f00mmmmm00 AUGUGGUCAUGGCUUUCGU 63214101 oooooooooooosssssso Pmf00ff0f00mmmmm0mm0 GUGGUCAUGGCUUUCGUUG 63314102 oooooooooooosssssso Pmff00fffffmmmm0m00 AUUGGCUUUCCGCUUAUAU 63414103 oooooooooooosssssso Pm00f0f0000mmmm000m0 AAAUACGAAAUUUCAGGUG 63514104 oooooooooooosssssso Pm000f0f0000mmmm000 AGAAAUACGAAAUUUCAGG 63614105 oooooooooooosssssso Pm00ff0f00fmmmm0mm00 UGGUCAUGGCUUUCGUUGG 63714106 oooooooooooosssssso Pmf0ff0fff0m0m00mm00 AUAUCAUCCAUGUGGUCAU 63814107 oooooooooooosssssso Pm0f0f0000fmmmm000m00 AAUACGAAAUUUCAGGUGU 63914108 oooooooooooosssssso Pm0ff000000mm0mmm00 AAUCAGAAGGCGCGUUCAG 64014109 oooooooooooosssssso Pmfff0f000000m0m0000 AUUCAUGAGAAAUACGAAA 64114110 oooooooooooosssssso Pmf0fff0f0000000m000 CUAUUCAUGAGAGAAUAAC 64214111 oooooooooooosssssso Pmfff0ff000mmm0mmm00 UUUCGUUGGACUUACUUGG 64314112 oooooooooooosssssso Pmf0fffff0fm0mm00mm0 UUGCUCUCAUCAUUGGCUU 64414113 oooooooooooosssssso Pmff00fffffmmmmmmm0 UUCAACUCCUCGCUUUCCA 64514114 oooooooooooosssssso Pm00ff0ff00mm0m0mm00 UGACUAUCAAUCACAUCGG 64614115 oooooooooooosssssso Pm0f0f0ff0mmm00mmm0 AGAUGCACUAUCUAAUUCA 64714116 oooooooooooosssssso Pm0f000f0f0m0mmm00m0 AAUAGAUACACAUUCAACC 64814117 oooooooooooosssssso Pmffffff0f0000m000m0 UUCUUCUAUAGAAUGAACA 64914118 oooooooooooosssssso Pm0ff0ff000m00mm0m00 AAUUGCUGGACAACCGUGG 65014119 oooooooooooosssssso Pmf0ffffff0m0m0m0000 UCGCUUUCCAUGUGUGAGG 65114120 oooooooooooosssssso Pm00fff000fm0mmm0m00 UAAUCUGGACUGCUUGUGG 65214121 oooooooooooosssssso Pmf0f0fff00mm00m0000 ACACAUUCAACCAAUAAAC 65314122 oooooooooooosssssso Pmfff0ffff0m00mm0mm0 ACUCGUUUCAUAACUGUCC 65414121 oooooooooooosssssso Pmf00fff000mm0mmm0m0 AUAAUCUGGACUGCUUGUG 65514124 oooooooooooosssssso Pmffff0fff0m0m00mmm0 UUUCCGCUUAUAUAAUCUG 65614125 oooooooooooosssssso Pm0fff00ff00m0m00m00 UGUUUAACUGGUAUGGCAC 65714126 oooooooooooosssssso Pm0f0000f000m0m000m0 UAUAGAAUGAACAUAGACA 65814127 oooooooooooosssssso Pmffffff00fm0m0mmm0 UUUCCUUGGUCGGCGUUUG 65914128 oooooooooooosssssso Pmf0f0f0ff0mmm00mmm0 GUAUGCACCAUUCAACUCC 66014129 oooooooooooosssssso Pmf00ff0ff0m0m0m0mm0 UCGGCCAUCAUAUGUGUCU 66114130 oooooooooooosssssso Pm0fff000ff0mmm0m000 AAUCUGGACUGCUUGUGGC 66214132 oooooooooooosssssso Pmf0ff0000f0mmm0mm00 ACAUCGGAAUGCUCAUUGC 66314133 oooooooooooosssssso Pm00fffff00mm0mm00m0 AAGUUCCUGACUAUCAAUC 66414134 oooooooooooosssssso Pmf00ff000f0m0000m00 UUGACUAAAUGCAAAGUGA 66514135 oooooooooooosssssso Pm0fff0ff000mm00m00 AGACUCAUCAGACUGGUGA 66614136 oooooooooooosssssso Pmf0f0f0f0fmm0mm0m00 UCAUAUGUGUCUACUGUGG 66714137 oooooooooooosssssso Pmf0fffff0fmm0m00m00 AUGUCCUCGUCUGUAGCAU 66814138 oooooooooooosssssso Pm00fff0f00mm00mmmm0 GAAUUCACGGCUGACUUUG 66914139 oooooooooooosssssso Pmf0fffff000mmm000m0 UUAUUUCCAGACUCAAAUA 67014140 oooooooooooosssssso Pm000ff0f000mm000mm0 GAAGCCACAAACUAAACUA 67114141 oooooooooooosssssso Pmffff0ff000mmm0mmm0 CUUUCGUUGGACUUACUUG 67214142 oooooooooooosssssso Pmfff0f0000mmmmmm000 GUCUGCGAAACUUCUUAGA 67314143 oooooooooooosssssso Pm0f0fff0ff0mmmmm0m0 AAUGCUCAUUGCUCUCAUC 67414144 oooooooooooosssssso Pmf0f0ff0ffm00mmm0m0 AUGCACUAUCUAAUUCAUG 67514145 oooooooooooosssssso Pmff0f0f0f0mm0mmm000 CUUGUAUGCACCAUUCAAC 67614146 oooooooooooosssssso Pm00fff0ffm0m00mm00 UGACUCGUUUCAUAACUGU 67714147 oooooooooooosssssso Pmff00f0fffm00mm0mm0 UUCAGCACUCUGGUCAUCC 67814148 oooooooooooosssssso Pm00fff0f00mm0m00000 AAAUUCAUGGCUGUGGAAU 67914149 oooooooooooosssssso Pmf0fff00ff00m000mm0 ACAUUCAACCAAUAAACUG 68014150 oooooooooooosssssso Pm0f0f0fff00mm00m000 UACACAUUCAACCAAUAAA 68114151 oooooooooooosssssso Pmff00ff0ffmmm000mm0 AUUAGUUAUUUCCAGACUC 68214152 oooooooooooosssssso Pmffff0fff0m00000000 UUUCUAUUCAUGAGAGAAU 68314153 oooooooooooosssssso Pmff00ff0ff00m000mm0 UUCGGUUGCUGGCAGGUCC 68414154 oooooooooooosssssso Pm0f0f0f0000m00m0mm0 CAUGUGUGAGGUGAUGUCC 68514155 oooooooooooosssssso Pmf0ff0fff00mmmmmm00 GCACCAUUCAACUCCUCGC 68614156 oooooooooooosssssso Pm0fff00ff00mmm0mmm0 CAUCCAGCUGACUCGUUUC 68714157 oooooooooooosssssso Pmfffff0fff0m0m00mm0 CUUUCCGCUUAUAUAAUCU 68814158 oooooooooooosssssso Pm0ff0f0ff0000m0mmm0 AAUCACAUCGGAAUGCUCA 68914159 oooooooooooosssssso Pmf0f0ff00fm0mmmmm00 ACACAUUAGUUAUUUCCAG 69014160 oooooooooooosssssso Pmfff0f0000m000m0m00 UUCUAUAGAAUGAACAUAG 69114161 oooooooooooosssssso Pm0f00f00f00mmm0m0m0 UACAGUGAUAGUUUGCAUU 69214162 oooooooooooosssssso Pmf000f00ff00m0mm0m0 AUAAGCAAUUGACACCACC 69314163 oooooooooooosssssso Pmff0ff00ff0mm000m00 UUUAUUAAUUGCUGGACAA 69414164 oooooooooooosssssso Pmf0ff0000fmmmm0000 UCAUCAGAGUCGUUCGAGU 69514165 oooooooooooosssssso Pmf000ff0f0mm0mm0mm0 AUAAACCACACUAUCACCU 69614166 oooooooooooosssssso Pmf0ff0ff00mmmmmm0m0 UCAUCAUUGGCUUUCCGCU 69714167 oooooooooooosssssso Pmfffff00fm0mm00mm0 AGUUCCUGACUAUCAAUCA 69814168 oooooooooooosssssso Pmff0f00ff00mmmm0000 UUCACGGCUGACUUUGGAA 69914169 oooooooooooosssssso Pmffff0f00f00m000mm0 UUCUCAUGGUAGUGAGUUU 70014170 oooooooooooosssssso Pm0ff00fff0mmm00mm00 AAUCAGCCUGUUUAACUGG 70114171 oooooooooooosssssso Pm0ffff00f0mmmm00mm0 GGUUUCAGCACUCUGGUCA 70214172 oooooooooooosssssso Pmff0000f0fmm0mm0mm0 AUCGGAAUGCUCAUUGCUC 70314173 oooooooooooosssssso Pm00ff0f0000mmm0m000 UGGCUGUGGAAUUCACGGC 70414174 oooooooooooosssssso Pm000f00ff00m0mm0mm0 UAAGCAAUUGACACCACCA 70514175 oooooooooooosssssso Pm00fffff0f00m00m000 CAAUUCUCAUGGUAGUGAG 70614176 oooooooooooosssssso Pm00fffff0fm000mmm00 UGGCUUUCGUUGGACUUAC 70714177 oooooooooooosssssso Pm0ff00f00fm00mmm0m0 AAUCAGUGACCAGUUCAUC 70814178 oooooooooooosssssso Pmfff0f000mm0m0mm00 AGUCCAUAAACCACACUAU 70914179 oooooooooooosssssso Pm00f0ffff00mm0mmm00 CAGCACUCUGGUCAUCCAG 71014180 oooooooooooosssssso Pm0ff00ff0f0mm0000m0 UAUCAAUCACAUCGGAAUG 71114181 oooooooooooosssssso Pmfff0f00ff00mmmm000 AUUCACGGCUGACUUUGGA 71214182 oooooooooooosssssso Pmf000f0f0f0mmm00mm0 AUAGAUACACAUUCAACCA 71314183 oooooooooooosssssso Pmffff000ffm000m0000 UUUCCAGACUCAAAUAGAU 71414184 oooooooooooosssssso Pmf00ff0ff000m00mm00 UUAAUUGCUGGACAACCGU 71514185 oooooooooooosssssso Pm0ff00ff0fm000m00m0 UAUUAAUUGCUGGACAACC 71614186 oooooooooooosssssso Pmff0fff000mm00m000 AGUCGUUCGAGUCAAUGGA 71714187 oooooooooooosssssso Pmff0ff00f000mmm0m00 GUUGCUGGCAGGUCCGUGG 718TABLE 2: Antisense backbone, chemistry, and sequence information. o:phosphodiester; s: phosphorothioate; P: 5′ phosphorylation; 0: 2′-OH; F:2′-fluoro; m: 2′ O-methyl; +: LNA modification. Capital letters in thesequence signify riobonucleotides, lower case letters signifydeoxyribonucleotides.

TABLE 3 Sense backbone, chemistry, and sequence information. OHang SEQOligo Sense Sense ID ID Number Number Chem. Backbone Sense ChemistrySense Sequence NO: APOB-10167- 12138 chl ooooooooooooo 00000000000000000GUCAUCACACUGAA 176 20-12138 ooooooso 000 UACCAAU APOB-10167- 12139 chlooooooooooooo 00000000000000000 GUGAUCAGACUCAA 177 20-12139 ooooooso 000UACGAAU MAP4K4-2931- 12266 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA178 13-12266 MAP4K4-2931- 12293 chl oooooooooosso mm0m00000mmm0CUGUGGAAGUCUA 179 16-12293 MAP4K4-2931- 12383 chl ooooooooooooomm0m00000mmm0 CUGUGGAAGUCUA 180 16-12383 MAP4K4-2931- 12384 chlooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 181 16-12384 MAP4K4-2931-12385 chl ooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 182 16-12385MAP4K4-2931- 12386 chl oooooooooosso 0mm0m00000mmm0 CUGUGGAAGUCUA 18316-12386 MAP4K4-2931- 12387 chl ooooooooooooo mm0m00000mmm0CUGUGGAAGUCUA 184 16-12387 MAP4K4-2931- 12388 chl ooooooooooooomm0m00000mmm0 CUGUGGAAGUCUA 185 15-12388 MAP4K4-2931- 12432 chlooooooooooooo DY547mm0m00000mmm0 CUGUGGAAGUCUA 186 13-12432 MAP4K4-2931-12266.2 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 187 13-12266.2APOB--21- 12434 chl ooooooooooooo 00000000000000000 GUCAUCACACUGAA 18812434 ooooooso 000 UACCAAU APOB--21- 12435 chl oooooooooooooDY547000000000000 GUGAUCAGACUCAA 189 12435 ooooooso 00000000 UACGAAUMAP4K4-2931- 12451 chl oooooooooooss 0mm0m00000mmm0 CUGUGGAAGUCUA 19016-12451 MAP4K4-2931- 12452 chl oooooooooooss mm0m00000mmm0CUGUGGAAGUCUA 191 16-12452 MAP4K4-2931- 12453 chl ooooooooooossmm0m00000mmm0 CUGUGGAAGUCUA 192 16-12453 MAP4K4-2931- 12454 chloooooooooooss 0mm0m00000mmm0 CUGUGGAAGUCUA 193 17-12454 MAP4K4-2931-12455 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 194 17-12455MAP4K4-2931- 12456 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 19519-12456 --27-12480 12480 chl ooooooooooooo DY547mm0f000f0055UCAUAGGUAACCUC 196 ooooooooooosso f5f00mm00000m000 UGGUUGAAAGUGA--27-12481 12481 chl ooooooooooooo DY547mm05f05000f0 CGGCUACAGGUGCU 197ooooooooooosso 5ff0m00000000m00 UAUGAAGAAAGUA APOB-10167- 12505 chlooooooooooooo 00000000000000000 GUCAUCACACUGAA 198 21-12505 ooooooos0000 UACCAAU APOB-10167- 12506 chl ooooooooooooo 00000000000000000GUGAUCAGACUCAA 199 21-12506 ooooooos 0000 UACGAAU MAP4K4-2931- 12539 chloooooooooooss DY547mm0m00000mmm0 CUGUGGAAGUCUA 200 16-12539 APOB-10167-12505.2 chl ooooooooooooo 00000000000000000 GUCAUCACACUGAA 20121-12505.2 ooooooso 000 UACCAAU APOB-10167- 12506.2 chl ooooooooooooo00000000000000000 GUGAUCAGACUCAA 202 21-12506.2 ooooooso 000 UACGAAUMAP4K4--13- 12565 Chl ooooooooooooo m0m0000m0mmm0 UGUAGGAUGUCUA 20312565 MAP4K4-2931- 12386.2 chl ooooooooooooo 0mm0m00000mmm0CUGUGGAAGUCUA 204 16-12386.2 MAP4K4-2931- 12815 chl ooooooooooooom0m0m0m0m0m0m0m0m CUGUGGAAGUCUA 205 13-12815 0m0m0m0m0 APOB--13- 12957Chl oooooooooooss 0mmmmmmmmmmmmm ACUGAAUACCAAU 206 12957 TEG MAP4K4--16-12983 chl oooooooooooss mm0m00000mmm0 CUGUGGAAGUCUA 207 12983MAP4K4--16- 12984 Chl oooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 20812984 MAP4K4--16- 12985 chl oooooooooosso mmmmmmmmmmmmm CUGUGGAAGUCUA209 12985 MAP4K4--16- 12986 chl oooooooooosso mmmmmmmmmmmmmCUGUGGAAGUCUA 210 12986 MAP4K4--16- 12987 chl oooooooooossomm0m00000mmm0 CUGUGGAAGUCUA 211 12987 MAP4K4--16- 12988 chloooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 212 12988 MAP4K4--16- 12989chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 213 12989 MAP4K4--16-12990 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 214 12990MAP4K4--16- 12991 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 21512991 MAP4K4--16- 12992 chl oooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA216 12992 MAP4K4--16- 12993 chl oooooooooosso mm0m00000mmm0CUGUGGAAGUCUA 217 12993 MAP4K4--16- 12994 chl oooooooooossomm0m00000mmm0 CUGUGGAAGUCUA 218 12994 MAP4K4--16- 12995 chloooooooooosso mm0m00000mmm0 CUGUGGAAGUCUA 219 12995 MAP4K4-2931- 13012chl ooooooooooooo 00000000000000000 AGAGUUCUGUGGAA 220 19-13012 oooooo0000 GUCUA MAP4K4-2931- 13016 chl ooooooooooooo DY547000000000000AGAGUUCUGUGGAA 221 19-13016 oooooo 000000000 GUCUA PPIB--13- 13021 Chlooooooooooooo 0mmm00mm0m000 AUUUGGCUACAAA 222 13021 pGL3-1172- 13038 chlooooooooooooo 00m000m0m00mmm ACAAAUACGAUUU 223 13-13038 pGL3-1172- 13040chl ooooooooooooo DY5470m000m0m00mmm ACAAAUACGAUUU 224 13-13040--16-13047 13047 Chl oooooooooooooo mm0m00000mmm0 CUGUGGAAGUCUA 225SOD1-530-13- 13090 chl ooooooooooooo 00m00000000m0 AAUGAAGAAAGUA 22613090 SOD1-523-13- 13091 chl ooooooooooooo 000m00000m000 AGGUGGAAAUGAA227 13091 SOD1-535-13- 13092 chl ooooooooooooo 000000m0m0000AGAAAGUACAAAG 228 13092 SOD1-536-13- 13093 chl ooooooooooooo00000m0m00000 GAAAGUACAAAGA 229 13093 SOD1-396-13- 13094 chlooooooooooooo 0m0m00mm0mm00 AUGUGACUGCUGA 230 13094 SOD1-385-13- 13095chl ooooooooooooo 000mmm000m00m AGACUUGGGCAAU 231 13095 SOD1-195-13-13096 chl ooooooooooooo 0mmmm000m0000 AUUUCGAGCAGAA 232 13096 APOB-4314-13115 Chl ooooooooooooo 0mmm0000000m0 AUCUGGAGAAACA 233 13-13115APOB-3384- 13116 Chl ooooooooooooo mm0000m000000 UCAGAACAAGAAA 23413-13116 APOB-3547- 13117 Chl ooooooooooooo 00mmm0mmm0mm0 GACUCAUCUGCUA235 13-13117 APOB-4318- 13118 Chl ooooooooooooo 0000000m00m0mGGAGAAACAACAU 236 13-13118 APOB-3741- 13119 Chl ooooooooooooo00mmmmmm000m0 AGUCCCUCAAACA 237 13-13119 PPIB--16- 13136 Chloooooooooooooo 00mm0m00000m0 GGCUACAAAAACA 238 13136 APOB-4314- 13154chl oooooooooooooo 000mmm0000000m0 AGAUCUGGAGAAACA 239 15-13154APOB-3547- 13155 chl oooooooooooooo m000mmm0mmm0mm0 UGGACUCAUCUGCUA 24015-13155 APOB-4318- 13157 chl oooooooooooooo mm0000000m00m0mCUGGAGAAACAACAU 241 15-13157 APOB-3741- 13158 chl oooooooooooooo0000mmmmmm000m0 AGAGUCCCUCAAACA 242 15-13158 APOB--13- 13159 chloooooooooooo 0mm000m0mm00m ACUGAAUACCAAU 243 13159 APOB--15- 13160 chloooooooooooooo 0m0mm000m0mm00m ACACUGAAUACCAAU 244 13160 SOD1-530-16-13163 chl ooooooooooooo 00m00000000m0 AAUGAAGAAAGUA 245 13163SOD1-523-16- 13164 chl ooooooooooooo 000m00000m000 AGGUGGAAAUGAA 24613164 SOD1-535-16- 13165 chl ooooooooooooo 000000m0m0000 AGAAAGUACAAAG247 13165 SOD1-536-16- 13166 chl ooooooooooooo 00000m0m00000GAAAGUACAAAGA 248 13166 SOD1-396-16- 13167 chl ooooooooooooo0m0m00mm0mm00 AUGUGACUGCUGA 249 13167 SOD1-385-16- 13168 chlooooooooooooo 000mmm000m00m AGACUUGGGCAAU 250 13168 SOD1-195-16- 13169chl ooooooooooooo 0mmmm000m0000 AUUUCGAGCAGAA 251 13169 pGL3-1172- 13170chl ooooooooooooo 0m000m0m00mmm ACAAAUACGAUUU 252 16-13170 pGL3-1172-13171 chl ooooooooooooo DY5470m000m0m00mmm ACAAAUACGAUUU 253 16-13171MAP4k4-2931- 13189 chl ooooooooooooo 00000000000000000 AGAGUUCUGUGGAA254 19-13189 oooooo 0000 GUCUA CTGF-1222- 13190 Chl ooooooooooooo0m0000000m0m0 ACAGGAAGAUGUA 255 13-13190 CTGF-813-13- 13192 Chlooooooooooooo 000m0000m0mmm GAGUGGAGCGCCU 256 13192 CTGF-747-13- 13194Chl ooooooooooooo m00mm000000m0 CGACUGGAAGACA 257 13194 CTGF-817-13-13196 Chl ooooooooooooo 0000m0mmm0mmm GGAGCGCCUGUUC 258 13196 CTGF-1174-13198 Chl ooooooooooooo 0mm0mm0m00mm0 GCCAUUACAACUG 259 13-13198CTGF-1005- 13200 Chl ooooooooooooo 000mmmmmm00mm GAGCUUUCUGGCU 26013-13200 CTGF-814-13- 13202 Chl ooooooooooooo 00m0000m0mmm0AGUGGAGCGCCUG 261 13202 CTGF-816-13- 13204 Chl ooooooooooooom0000m0mmm0mm UGGAGCGCCUGUU 262 13204 CTGF-1001- 13206 Chl ooooooooooooo0mmm000mmmmmm GUUUGAGCUUUCU 263 13-13206 CTGF-1173- 13208 Chlooooooooooooo m0mm0mm0m00mm UGCCAUUACAACU 264 13-13208 CTGF-749-13-13210 Chl ooooooooooooo 0mm000000m0m0 ACUGGAAGACACG 265 13210CTGF-792-13- 13212 Chl ooooooooooooo 00mm0mmm00mmm AACUGCCUGGUCC 26613212 CTGF-1162- 13214 Chl ooooooooooooo 000mmm0m0mmm0 AGACCUGUGCCUG 26713-13214 CTGF-811-13- 13216 Chl ooooooooooooo m0000m0000m0mCAGAGUGGAGCGC 268 13216 CTGF-797-13- 13218 Chl ooooooooooooommm00mmm000mm CCUGGUCCAGACC 269 13218 CTGF-1175- 13220 Chl ooooooooooooomm0mm0m00mm0m CCAUUACAACUGU 270 13-13220 CTGF-1172- 13222 Chlooooooooooooo mm0mm0mm0m00m CUGCCAUUACAAC 271 13-13222 CTGF-1177- 13224Chl ooooooooooooo 0mm0m00mm0mmm AUUACAACUGUCC 272 13-13224 CTGF-1176-13226 Chl ooooooooooooo m0mm0m00mm0mm CAUUACAACUGUC 273 13-13226CTGF-812-13- 13228 Chl ooooooooooooo 0000m0000m0mm AGAGUGGAGCGCC 27413228 CTGF-745-13- 13230 Chl ooooooooooooo 0mm00mm000000 ACCGACUGGAAGA275 13230 CTGF-1230- 13232 Chl ooooooooooooo 0m0m0m00000m0 AUGUACGGAGACA276 13-13232 CTGF-920-13- 13234 Chl ooooooooooooo 0mmmm0m0000mmGCCUUGCGAAGCU 277 13234 CTGF-679-13- 13236 Chl ooooooooooooo0mm0m000000m0 GCUGCGAGGAGUG 278 13236 CTGF-992-13- 13238 Chlooooooooooooo 0mmm0mm000mmm GCCUAUCAAGUUU 279 13238 CTGF-1045- 13240 Chlooooooooooooo 00mmmm0m0000m AAUUCUGUGGAGU 280 13-13240 CTGF-1231- 13242Chl ooooooooooooo m0m0m00000m0m UGUACGGAGACAU 281 13-13242 CTGF-991-13-13244 Chl ooooooooooooo 00mmm0mm000mm AGCCUAUCAAGUU 282 13244CTGF-998-13- 13246 Chl ooooooooooooo m000mmm000mmm CAAGUUUGAGCUU 28313246 CTGF-1049- 13248 Chl ooooooooooooo mm0m0000m0m0m CUGUGGAGUAUGU 28413-13248 CTGF-1044- 13250 Chl ooooooooooooo 000mmmm0m0000 AAAUUCUGUGGAG285 13-13250 CTGF-1327- 13252 Chl ooooooooooooo mmmm00m00m0m0UUUCAGUAGCACA 286 13-13252 CTGF-1196- 13254 Chl ooooooooooooom00m00m0mmmmm CAAUGACAUCUUU 287 13-13254 CTGF-562-13- 13256 Chlooooooooooooo 00m0mm00m0m0m AGUACCAGUGCAC 288 13256 CTGF-752-13- 13258Chl ooooooooooooo 000000m0m0mmm GGAAGACACGUUU 289 13258 CTGF-994-13-13260 Chl ooooooooooooo mm0mm000mmm00 CUAUCAAGUUUGA 290 13260 CTGF-1040-13262 Chl ooooooooooooo 00mm000mmmm0m AGCUAAAUUCUGU 291 13-13262CTGF-1984- 13264 Chl ooooooooooooo 000m0000m0m00 AGGUAGAAUGUAA 29213-13264 CTGF-2195- 13266 Chl ooooooooooooo 00mm00mm00mmm AGCUGAUCAGUUU293 13-13266 CTGF-2043- 13268 Chl ooooooooooooo mmmm0mmm000m0UUCUGCUCAGAUA 294 13-13268 CTGF-1892- 13270 Chl ooooooooooooomm0mmm000mm00 UUAUCUAAGUUAA 295 13-13270 CTGF-1567- 13272 Chlooooooooooooo m0m0m000m00m0 UAUACGAGUAAUA 296 13-13272 CTGF-1780- 13274Chl ooooooooooooo 00mm000m00mmm GACUGGACAGCUU 297 13-13274 CTGF-2162-13276 Chl ooooooooooooo 0m00mmmmm0mm0 AUGGCCUUUAUUA 298 13-13276CTGF-1034- 13278 Chl ooooooooooooo 0m0mm000mm000 AUACCGAGCUAAA 29913-13278 CTGF-2264- 13280 Chl ooooooooooooo mm0mm00000m0m UUGUUGAGAGUGU300 13-13280 CTGF-1032- 13282 Chl ooooooooooooo 0m0m0mm000mm0ACAUACCGAGCUA 301 13-13282 CTGF-1535- 13284 Chl ooooooooooooo00m0000000mm0 AGCAGAAAGGUUA 302 13-13284 CTGF-1694- 13286 Chlooooooooooooo 00mm0mmmmmm00 AGUUGUUCCUUAA 303 13-13286 CTGF-1588- 13288Chl ooooooooooooo 0mmm0000m0m00 AUUUGAAGUGUAA 304 13-13288 CTGF-928-13-13290 Chl ooooooooooooo 000mm00mmm000 AAGCUGACCUGGA 305 13290 CTGF-1133-13292 Chl ooooooooooooo 00mm0m0000000 GGUCAUGAAGAAG 306 13-13292CTGF-912-13- 13294 Chl ooooooooooooo 0m00mm000mmmm AUGGUCAGGCCUU 30713294 CTGF-753-13- 13296 Chl ooooooooooooo 00000m0m0mmm0 GAAGACACGUUUG308 13296 CTGF-918-13- 13298 Chl ooooooooooooo 000mmmm0m0000AGGCCUUGCGAAG 309 13298 CTGF-744-13- 13300 Chl ooooooooooooom0mm0mm00000 UACCGACUGGAAG 310 13300 CTGF-466-13- 13302 Chlooooooooooooo 0mm0m0000mm0 ACCGCAAGAUCGG 311 13302 CTGF-917-13- 13304Chl ooooooooooooo m000mmmm0m000 CAGGCCUUGCGAA 312 13304 CTGF-1038- 13306Chl ooooooooooooo m000mm000mmmm CGAGCUAAAUUCU 313 13-13306 CTGF-1048-13308 Chl ooooooooooooo mmm0m0000m0m0 UCUGUGGAGUAUG 314 13-13308CTGF-1235- 13310 Chl ooooooooooooo m00000m0m00m0 CGGAGACAUGGCA 31513-13310 CTGF-868-13- 13312 Chl ooooooooooooo 0m00m00m0mmmmAUGACAACGCCUC 316 13312 CTGF-1131- 13314 Chl ooooooooooooo 0000mm0m00000GAGGUCAUGAAGA 317 13-13314 CTGF-1043- 13316 Chl ooooooooooooom000mmmm0m000 UAAAUUCUGUGGA 318 13-13316 CTGF-751-13- 13318 Chlooooooooooooo m000000m0m0mm UGGAAGACACGUU 319 13318 CTGF-1227- 13320 Chlooooooooooooo 0000m0m0m0000 AAGAUGUACGGAG 320 13-13320 CTGF-867-13-13322 Chl ooooooooooooo 00m00m00m0mmm AAUGACAACGCCU 321 13322 CTGF-1128-13324 Chl ooooooooooooo 00m0000mm0m00 GGCGAGGUCAUGA 322 13-13324CTGF-756-13- 13326 Chl ooooooooooooo 00m0m0mmm00mm GACACGUUUGGCC 32313326 CTGF-1234- 13328 Chl ooooooooooooo 0m00000m0m00m ACGGAGACAUGGC 32413-13328 CTGF-916-13- 13330 Chl ooooooooooooo mm000mmmm0m00UCAGGCCUUGCGA 325 13330 CTGF-925-13- 13332 Chl ooooooooooooo0m0000mm00mmm GCGAAGCUGACCU 326 13332 CTGF-1225- 13334 Chl ooooooooooooo000000m0m0m00 GGAAGAUGUACGG 327 13-13334 CTGF-445-13- 13336 Chlooooooooooooo 0m00mmmm00mmm GUGACUUCGGCUC 328 13336 CTGF-446-13- 13338Chl ooooooooooooo m00mmmm00mmmm UGACUUCGGCUCC 329 13338 CTGF-913-13-13340 Chl ooooooooooooo m00mm000mmmm0 UGGUCAGGCCUUG 330 13340CTGF-997-13- 13342 Chl ooooooooooooo mm000mmm000mm UCAAGUUUGAGCU 33113342 CTGF-277-13- 13344 Chl ooooooooooooo 0mm0000mm0m00 GCCAGAACUGCAG332 13344 CTGF-1052- 13346 Chl ooooooooooooo m0000m0m0m0mm UGGAGUAUGUACC333 13-13346 CTGF-887-13- 13348 Chl ooooooooooooo 0mm0000000m00GCUAGAGAAGCAG 334 13348 CTGF-914-13- 13350 Chl ooooooooooooo00mm000mmmm0m GGUCAGGCCUUGC 335 13350 CTGF-1039- 13352 Chl ooooooooooooo000mm000mmmm0 GAGCUAAAUUCUG 336 13-13352 CTGF-754-13- 13354 Chlooooooooooooo 0000m0m0mmm00 AAGACACGUUUGG 337 13354 CTGF-1130- 13356 Chlooooooooooooo m0000mm0m0000 CGAGGUCAUGAAG 338 13-13356 CTGF-919-13-13358 Chl ooooooooooooo 00mmmm0m0000m GGCCUUGCGAAGC 339 13358CTGF-922-13- 13360 Chl ooooooooooooo mmm0m0000mm00 CUUGCGAAGCUGA 34013360 CTGF-746-13- 13362 Chl ooooooooooooo mm00mm000000m CCGACUGGAAGAC341 13362 CTGF-993-13- 13364 Chl ooooooooooooo mmm0mm000mmm0CCUAUCAAGUUUG 342 13364 CTGF-825-13- 13366 Chl ooooooooooooom0mmmm0000mmm UGUUCCAAGACCU 343 13366 CTGF-926-13- 13368 Chlooooooooooooo m0000mm00mmm0 CGAAGCUGACCUG 344 13368 CTGF-923-13- 13370Chl ooooooooooooo mm0m0000mm00m UUGCGAAGCUGAC 345 13370 CTGF-866-13-13372 Chl ooooooooooooo m00m00m00m0mm CAAUGACAACGCC 346 13372CTGF-563-13- 13374 Chl ooooooooooooo 0m0mm00m0m0m0 GUACCAGUGCACG 34713374 CTGF-823-13- 13376 Chl ooooooooooooo mmm0mmmm0000m CCUGUUCCAAGAC348 13376 CTGF-1233- 13378 Chl ooooooooooooo m0m00000m0m00 UACGGAGACAUGG349 13-13378 CTGF-924-13- 13380 Chl ooooooooooooo m0m0000mm00mmUGCGAAGCUGACC 350 13380 CTGF-921-13- 13382 Chl ooooooooooooommmm0m0000mm0 CCUUGCGAAGCUG 351 13382 CTGF-443-13- 13384 Chlooooooooooooo mm0m00mmmm00m CUGUGACUUCGGC 352 13384 CTGF-1041- 13386 Chlooooooooooooo 0mm000mmmm0m0 GCUAAAUUCUGUG 353 13-13386 CTGF-1042- 13388Chl ooooooooooooo mm000mmmm0m00 CUAAAUUCUGUGG 354 13-13388 CTGF-755-13-13390 Chl ooooooooooooo 000m0m0mmm00m AGACACGUUUGGC 355 13390CTGF-467-13- 13392 Chl ooooooooooooo mm0m0000mm00m CCGCAAGAUCGGC 35613392 CTGF-995-13- 13394 Chl ooooooooooooo m0mm000mmm000 UAUCAAGUUUGAG357 13394 CTGF-927-13- 13396 Chl ooooooooooooo 0000mm00mmm00GAAGCUGACCUGG 358 13396 SPP1-1025- 13398 Chl ooooooooooooo mmm0m000mm000CUCAUGAAUUAGA 359 13-13398 SPP1-1049- 13400 Chl ooooooooooooomm0000mm00mm0 CUGAGGUCAAUUA 360 13-13400 SPP1-1051- 13402 Chlooooooooooooo 0000mm00mm000 GAGGUCAAUUAAA 361 13-13402 SPP1-1048- 13404Chl ooooooooooooo mmm0000mm00mm UCUGAGGUCAAUU 362 13-13404 SPP1-1050-13406 Chl ooooooooooooo m0000mm00mm00 UGAGGUCAAUUAA 363 13-13406SPP1-1047- 13408 Chl ooooooooooooo mmmm0000mm00m UUCUGAGGUCAAU 36413-13408 SPP1-800-13- 13410 Chl ooooooooooooo 0mm00mm000m00GUCAGCUGGAUGA 365 13410 SPP1-492-13- 13412 Chl ooooooooooooommmm00m000mmm UUCUGAUGAAUCU 366 13412 SPP1-612-13- 13414 Chlooooooooooooo m000mm0000mm0 UGGACUGAGGUCA 367 13414 SPP1-481-13- 13416Chl ooooooooooooo 000mmmm0mm0mm GAGUCUCACCAUU 368 13416 SPP1-614-13-13418 Chl ooooooooooooo 00mm0000mm000 GACUGAGGUCAAA 369 13418SPP1-951-13- 13420 Chl ooooooooooooo mm0m00mm0m000 UCACAGCCAUGAA 37013420 SPP1-482-13- 13422 Chl ooooooooooooo 00mmmm0mm0mmm AGUCUCACCAUUC371 13422 SPP1-856-13- 13424 Chl ooooooooooooo 000m000000mm0AAGCGGAAAGCCA 372 13424 SPP1-857-13- 13426 Chl ooooooooooooo00m000000mm00 AGCGGAAAGCCAA 373 13426 SPP1-365-13- 13428 Chlooooooooooooo 0mm0m0m000m00 ACCACAUGGAUGA 374 13428 SPP1-359-13- 13430Chl ooooooooooooo 0mm0m00mm0m0m GCCAUGACCACAU 375 13430 SPP1-357-13-13432 Chl ooooooooooooo 000mm0m00mm0m AAGCCAUGACCAC 376 13432SPP1-858-13- 13434 Chl ooooooooooooo 0m000000mm00m GCGGAAAGCCAAU 37713434 SPP1-1012- 13436 Chl ooooooooooooo 000mmmm0m0mmm AAAUUUCGUAUUU 37813-13436 SPP1-1014- 13438 Chl ooooooooooooo 0mmmm0m0mmmmm AUUUCGUAUUUCU379 13-13438 SPP1-356-13- 13440 Chl ooooooooooooo 0000mm0m00mm0AAAGCCAUGACCA 380 13440 SPP1-368-13- 13442 Chl ooooooooooooo0m0m000m00m0m ACAUGGAUGAUAU 381 13442 SPP1-1011- 13444 Chl ooooooooooooo0000mmmm0m0mm GAAAUUUCGUAUU 382 13-13444 SPP1-754-13- 13446 Chlooooooooooooo 0m0mmmmmm00mm GCGCCUUCUGAUU 383 13446 SPP1-1021- 13448 Chlooooooooooooo 0mmmmmm0m000m AUUUCUCAUGAAU 384 13-13448 SPP1-1330- 13450Chl ooooooooooooo mmmmm0m000m00 CUCUCAUGAAUAG 385 13-13450 SPP1-346-13-13452 Chl ooooooooooooo 000mmm00m0000 AAGUCCAACGAAA 386 13452SPP1-869-13- 13454 Chl ooooooooooooo 0m00m00000m00 AUGAUGAGAGCAA 38713454 SPP1-701-13- 13456 Chl ooooooooooooo 0m000000mm000 GCGAGGAGUUGAA388 13456 SPP1-896-13- 13458 Chl ooooooooooooo m00mm00m00mm0UGAUUGAUAGUCA 389 13458 SPP1-1035- 13460 Chl ooooooooooooo 000m00m0m0mmmAGAUAGUGCAUCU 390 13-13460 SPP1-1170- 13462 Chl ooooooooooooo0m0m0m0mmm0mm AUGUGUAUCUAUU 391 13-13462 SPP1-1282- 13464 Chlooooooooooooo mmmm0m0000000 UUCUAUAGAAGAA 392 13-13464 SPP1-1537- 13466Chl ooooooooooooo mm0mmm00m00mm UUGUCCAGCAAUU 393 13-13466 SPP1-692-13-13468 Chl ooooooooooooo 0m0m000000m00 ACAUGGAAAGCGA 394 13468SPP1-840-13- 13470 Chl ooooooooooooo 0m00mmm000mm0 GCAGUCCAGAUUA 39513470 SPP1-1163- 13472 Chl ooooooooooooo m00mm000m0m0m UGGUUGAAUGUGU 39613-13472 SPP1-789-13- 13474 Chl ooooooooooooo mm0m0000m000mUUAUGAAACGAGU 397 13474 SPP1-841-13- 13476 Chl ooooooooooooom00mmm000mm0m CAGUCCAGAUUAU 398 13476 SPP1-852-13- 13478 Chlooooooooooooo 0m0m000m00000 AUAUAAGCGGAAA 399 13478 SPP1-209-13- 13480Chl ooooooooooooo m0mm00mm000m0 UACCAGUUAAACA 400 13480 SPP1-1276- 13482Chl ooooooooooooo m0mmm0mmmm0m0 UGUUCAUUCUAUA 401 13-13482 SPP1-137-13-13484 Chl ooooooooooooo mm00mm0000000 CCGACCAAGGAAA 402 13484SPP1-711-13- 13486 Chl ooooooooooooo 000m00m0m0m0m GAAUGGUGCAUAC 40313486 SPP1-582-13- 13488 Chl ooooooooooooo 0m0m00m00mm00 AUAUGAUGGCCGA404 13488 SPP1-839-13- 13490 Chl ooooooooooooo 00m00mmm000mmAGCAGUCCAGAUU 405 13490 SPP1-1091- 13492 Chl ooooooooooooo 0m0mmm00mm000GCAUUUAGUCAAA 406 13-13492 SPP1-884-13- 13494 Chl ooooooooooooo00m0mmmm00m0m AGCAUUCCGAUGU 407 13494 SPP1-903-13- 13496 Chlooooooooooooo m00mm00000mmm UAGUCAGGAACUU 408 13496 SPP1-1090- 13498 Chlooooooooooooo m0m0mmm00mm00 UGCAUUUAGUCAA 409 13-13498 SPP1-474-13-13500 Chl ooooooooooooo 0mmm00m000mmm GUCUGAUGAGUCU 410 13500SPP1-575-13- 13502 Chl ooooooooooooo m000m0m0m0m00 UAGACACAUAUGA 41113502 SPP1-671-13- 13504 Chl ooooooooooooo m000m00000m0m CAGACGAGGACAU412 13504 SPP1-924-13- 13506 Chl ooooooooooooo m00mm0m000mmmCAGCCGUGAAUUC 413 13506 SPP1-1185- 13508 Chl ooooooooooooo 00mmm00000m00AGUCUGGAAAUAA 414 13-13508 SPP1-1221- 13510 Chl ooooooooooooo00mmm0m00mmmm AGUUUGUGGCUUC 415 13-13510 SPP1-347-13- 13512 Chlooooooooooooo 00mmm00m00000 AGUCCAACGAAAG 416 13512 SPP1-634-13- 13514Chl ooooooooooooo 000mmmm0m000m AAGUUUCGCAGAC 417 13514 SPP1-877-13-13516 Chl ooooooooooooo 00m00m000m0mm AGCAAUGAGCAUU 418 13516 SPP1-1033-13518 Chl ooooooooooooo mm000m00m0m0m UUAGAUAGUGCAU 419 13-13518SPP1-714-13- 13520 Chl ooooooooooooo m00m0m0m0m000 UGGUGCAUACAAG 42013520 SPP1-791-13- 13522 Chl ooooooooooooo 0m0000m000mm0 AUGAAACGAGUCA421 13522 SPP1-813-13- 13524 Chl ooooooooooooo mm0000m0mm000CCAGAGUGCUGAA 422 13524 SPP1-939-13- 13526 Chl ooooooooooooom00mm0m000mmm CAGCCAUGAAUUU 423 13526 SPP1-1161- 13528 Chl ooooooooooooo0mm00mm000m0m AUUGGUUGAAUGU 424 13-13528 SPP1-1164- 13530 Chlooooooooooooo 00mm000m0m0m0 GGUUGAAUGUGUA 425 13-13530 SPP1-1190- 13532Chl ooooooooooooo 00000m00mm00m GGAAAUAACUAAU 426 13-13532 SPP1-1333-13534 Chl ooooooooooooo mm0m000m00000 UCAUGAAUAGAAA 427 13-13534SPP1-537-13- 13536 Chl ooooooooooooo 0mm00m00mm000 GCCAGCAACCGAA 42813536 SPP1-684-13- 13538 Chl ooooooooooooo m0mmmm0m0m0m0 CACCUCACACAUG429 13538 SPP1-707-13- 13540 Chl ooooooooooooo 00mm000m00m0mAGUUGAAUGGUGC 430 13540 SPP1-799-13- 13542 Chl ooooooooooooo00mm00mm000m0 AGUCAGCUGGAUG 431 13542 SPP1-853-13- 13544 Chlooooooooooooo m0m000m000000 UAUAAGCGGAAAG 432 13544 SPP1-888-13- 13546Chl ooooooooooooo mmmm00m0m00mm UUCCGAUGUGAUU 433 13546 SPP1-1194- 13548Chl ooooooooooooo 0m00mm00m0m0m AUAACUAAUGUGU 434 13-13548 SPP1-1279-13550 Chl ooooooooooooo mm0mmmm0m0000 UCAUUCUAUAGAA 435 13-13550SPP1-1300- 13552 Chl ooooooooooooo 00mm0mm0mm0m0 AACUAUCACUGUA 43613-13552 SPP1-1510- 13554 Chl ooooooooooooo 0mm00mm0mmm0m GUCAAUUGCUUAU437 13-13554 SPP1-1543- 13556 Chl ooooooooooooo 00m00mm00m000AGCAAUUAAUAAA 438 13-13556 SPP1-434-13- 13558 Chl ooooooooooooo0m00mmmm00m00 ACGACUCUGAUGA 439 13558 SPP1-600-13- 13560 Chlooooooooooooo m00m0m00mmm0m UAGUGUGGUUUAU 440 13560 SPP1-863-13- 13562Chl ooooooooooooo 000mm00m00m00 AAGCCAAUGAUGA 441 13562 SPP1-902-13-13564 Chl ooooooooooooo 0m00mm00000mm AUAGUCAGGAACU 442 13564SPP1-921-13- 13566 Chl ooooooooooooo 00mm00mm0m000 AGUCAGCCGUGAA 44313566 SPP1-154-13- 13568 Chl ooooooooooooo 0mm0mm0m00000 ACUACCAUGAGAA444 13568 SPP1-217-13- 13570 Chl ooooooooooooo 000m000mm00mmAAACAGGCUGAUU 445 13570 SPP1-816-13- 13572 Chl ooooooooooooo000m0mm0000mm GAGUGCUGAAACC 446 13572 SPP1-882-13- 13574 Chlooooooooooooo m000m0mmmm00m UGAGCAUUCCGAU 447 13574 SPP1-932-13- 13576Chl ooooooooooooo 00mmmm0m00mm0 AAUUCCACAGCCA 448 13576 SPP1-1509- 13578Chl ooooooooooooo m0mm00mm0mmm0 UGUCAAUUGCUUA 449 13-13578 SPP1-157-13-13580 Chl ooooooooooooo 0mm0m00000mm0 ACCAUGAGAAUUG 450 13580SPP1-350-13- 13582 Chl ooooooooooooo mm00m00000mm0 CCAACGAAAGCCA 45113582 SPP1-511-13- 13584 Chl ooooooooooooo mm00mm0mm00mm CUGGUCACUGAUU452 13584 SPP1-605-13- 13586 Chl ooooooooooooo m00mmm0m000mmUGGUUUAUGGACU 453 13586 SPP1-811-13- 13588 Chl ooooooooooooo00mm0000m0mm0 GACCAGAGUGCUG 454 13588 SPP1-892-13- 13590 Chlooooooooooooo 00m0m00mm00m0 GAUGUGAUUGAUA 455 13590 SPP1-922-13- 13592Chl ooooooooooooo 0mm00mm0m000m GUCAGCCGUGAAU 456 13592 SPP1-1169- 13594Chl ooooooooooooo 00m0m0m0mmm0m AAUGUGUAUCUAU 457 13-13594 SPP1-1182-13596 Chl ooooooooooooo mm000mmm00000 UUGAGUCUGGAAA 458 13-13596SPP1-1539- 13598 Chl ooooooooooooo 0mmm00m00mm00 GUCCAGCAAUUAA 45913-13598 SPP1-1541- 13600 Chl ooooooooooooo mm00m00mm00m0 CCAGCAAUUAAUA460 13-13600 SPP1-427-13- 13602 Chl ooooooooooooo 00mmm000m00mmGACUCGAACGACU 461 13602 SPP1-533-13- 13604 Chl ooooooooooooo0mmm0mm00m00m ACCUGCCAGCAAC 462 13604 APOB--13- 13763 Chl ooooooooooooo0m+00+m0+m0+m ACtGAaUAcCAaU 463 13763 TEG APOB--13- 13764 Chlooooooooooooo 0mm000m0mm00m ACUGAAUACCAAU 464 13764 TEG MAP4K4--16-13766 Chl ooooooooooooo DY547mm0m00000mmm0 CUGUGGAAGUCUA 465 13766PPIB--13- 13767 Chl ooooooooooooo mmmmmmmmmmmmm GGCUACAAAAACA 466 13767PPIB--15- 13768 Chl ooooooooooooo mm00mm0m00000m0 UUGGCUACAAAAACA 46713768 oo PPIB--17- 13769 Chl ooooooooooooo 0mmm00mm0m00000m0AUUUGGCUACAAAA 468 13769 oooo ACA MAP4K4--16- 13939 Chl ooooooooooooom0m0000m0mmm0 UGUAGGAUGUCUA 469 13939 APOB-4314- 13940 Chl ooooooooooooo0mmm0000000m0 AUCUGGAGAAACA 470 16-13940 APOB-4314- 13941 Chlooooooooooooo 000mmm0000000m0 AGAUCUGGAGAAACA 471 17-13941 oo APOB--16-13942 Chl ooooooooooooo 00mmm0mmm0mm0 GACUCAUCUGCUA 472 13942 APOB--18-13943 Chl ooooooooooooo 00mmm0mmm0mm0 GACUCAUCUGCUA 473 13943 APOB--17-13944 Chl ooooooooooooo m000mmm0mmm0mm0 UGGACUCAUCUGCUA 474 13944 ooAPOB--19- 13945 Chl ooooooooooooo m000mmm0mmm0mm0 UGGACUCAUCUGCUA 47513945 oo APOB-4314- 13946 Chl ooooooooooooo 0000000m00m0m GGAGAAACAACAU476 16-13946 APOB-4314- 13947 Chl ooooooooooooo mm0000000m00m0mCUGGAGAAACAACAU 477 17-13947 oo APOB--16- 13948 Chl ooooooooooooo00mmmmmm000m0 AGUCCCUCAAACA 478 13948 APOB--17- 13949 Chl ooooooooooooo0000mmmmmm000m0 AGAGUCCCUCAAACA 479 13949 oo APOB--16- 13950 Chlooooooooooooo 0mm000m0mm00m ACUGAAUACCAAU 480 13950 APOB--18- 13951 Chlooooooooooooo 0mm000m0mm00m ACUGAAUACCAAU 481 13951 APOB--17- 13952 Chlooooooooooooo 0m0mm000m0mm00m ACACUGAAUACCAAU 482 13952 oo APOB--19-13953 Chl ooooooooooooo 0m0mm000m0mm00m ACACUGAAUACCAAU 483 13953 ooMAP4K4--16- 13766.2 Chl ooooooooooooo DY547mm0m00000mmm0 CUGUGGAAGUCUA484 13766.2 CTGF-1222- 13980 Chl ooooooooooooo 0m0000000m0m0ACAGGAAGAUGUA 485 16-13980 CTGF-813-16- 13981 Chl ooooooooooooo000m0000mmmm GAGUGGAGCGCCU 486 13981 CTGF-747-16- 13982 Chlooooooooooooo m0mm000000m0 CGACUGGAAGACA 487 13982 CTGF-817-16- 13983Chl ooooooooooooo 0000mmmm0mmm GGAGCGCCUGUUC 488 13983 CTGF-1174- 13984Chl ooooooooooooo 0mm0mm0m00mm0 GCCAUUACAACUG 489 16-13984 CTGF-1005-13985 Chl ooooooooooooo 000mmmmmm00mm GAGCUUUCUGGCU 490 16-13985CTGF-814-16- 13986 Chl ooooooooooooo 00m0000mmmm0 AGUGGAGCGCCUG 49113986 CTGF-816-16- 13987 Chl ooooooooooooo m0000mmmm0mm UGGAGCGCCUGUU492 13987 CTGF-1001- 13988 Chl ooooooooooooo 0mmm000mmmmmm GUUUGAGCUUUCU493 16-13988 CTGF-1173- 13989 Chl ooooooooooooo m0mm0mm0m00mmUGCCAUUACAACU 494 16-13989 CTGF-749-16- 13990 Chl ooooooooooooo0mm000000m0m ACUGGAAGACACG 495 13990 CTGF-792-16- 13991 Chlooooooooooooo 00mm0mmm00mmm AACUGCCUGGUCC 496 13991 CTGF-1162- 13992 Chlooooooooooooo 000mmm0m0mmm0 AGACCUGUGCCUG 497 16-13992 CTGF-811-16-13993 Chl ooooooooooooo m0000m0000mm CAGAGUGGAGCGC 498 13993CTGF-797-16- 13994 Chl ooooooooooooo mmm00mmm000mm CCUGGUCCAGACC 49913994 CTGF-1175- 13995 Chl ooooooooooooo mm0mm0m00mm0m CCAUUACAACUGU 50016-13995 CTGF-1172- 13996 Chl ooooooooooooo mm0mm0mm0m00m CUGCCAUUACAAC501 16-13996 CTGF-1177- 13997 Chl ooooooooooooo 0mm0m00mm0mmmAUUACAACUGUCC 502 16-13997 CTGF-1176- 13998 Chl ooooooooooooom0mm0m00mm0mm CAUUACAACUGUC 503 16-13998 CTGF-812-16- 13999 Chlooooooooooooo 0000m0000mmm AGAGUGGAGCGCC 504 13999 CTGF-745-16- 14000Chl ooooooooooooo 0mm0mm000000 ACCGACUGGAAGA 505 14000 CTGF-1230- 14001Chl ooooooooooooo 0m0m0m0000m0 AUGUACGGAGACA 506 16-14001 CTGF-920-16-14002 Chl ooooooooooooo 0mmmm0m000mm GCCUUGCGAAGCU 507 14002CTGF-679-16- 14003 Chl ooooooooooooo 0mm0m00000m0 GCUGCGAGGAGUG 50814003 CTGF-992-16- 14004 Chl ooooooooooooo 0mmm0mm000mmm GCCUAUCAAGUUU509 14004 CTGF-1045- 14005 Chl ooooooooooooo 00mmmm0m0000m AAUUCUGUGGAGU510 16-14005 CTGF-1231- 14006 Chl ooooooooooooo m0m0m0000m0mUGUACGGAGACAU 511 16-14006 CTGF-991-16- 14007 Chl ooooooooooooo00mmm0mm000mm AGCCUAUCAAGUU 512 14007 CTGF-998-16- 14008 Chlooooooooooooo m000mmm000mmm CAAGUUUGAGCUU 513 14008 CTGF-1049- 14009 Chlooooooooooooo mm0m0000m0m0m CUGUGGAGUAUGU 514 16-14009 CTGF-1044- 14010Chl ooooooooooooo 000mmmm0m0000 AAAUUCUGUGGAG 515 16-14010 CTGF-1327-14011 Chl ooooooooooooo mmmm00m00m0m0 UUUCAGUAGCACA 516 16-14011CTGF-1196- 14012 Chl ooooooooooooo m00m00m0mmmmm CAAUGACAUCUUU 51716-14012 CTGF-562-16- 14013 Chl ooooooooooooo 00m0mm00m0m0mAGUACCAGUGCAC 518 14013 CTGF-752-16- 14014 Chl ooooooooooooo000000m0mmmm GGAAGACACGUUU 519 14014 CTGF-994-16- 14015 Chlooooooooooooo mm0mm000mmm00 CUAUCAAGUUUGA 520 14015 CTGF-1040- 14016 Chlooooooooooooo 00mm000mmmm0m AGCUAAAUUCUGU 521 16-14016 CTGF-1984- 14017Chl ooooooooooooo 000m0000m0m00 AGGUAGAAUGUAA 522 16-14017 CTGF-2195-14018 Chl ooooooooooooo 00mm00mm00mmm AGCUGAUCAGUUU 523 16-14018CTGF-2043- 14019 Chl ooooooooooooo mmmm0mmm000m0 UUCUGCUCAGAUA 52416-14019 CTGF-1892- 14020 Chl ooooooooooooo mm0mmm000mm00 UUAUCUAAGUUAA525 16-14020 CTGF-1567- 14021 Chl ooooooooooooo m0m0m00m00m0UAUACGAGUAAUA 526 16-14021 CTGF-1780- 14022 Chl ooooooooooooo00mm000m00mmm GACUGGACAGCUU 527 16-14022 CTGF-2162- 14023 Chlooooooooooooo 0m00mmmmm0mm0 AUGGCCUUUAUUA 528 16-14023 CTGF-1034- 14024Chl ooooooooooooo 0m0mm00mm000 AUACCGAGCUAAA 529 16-14024 CTGF-2264-14025 Chl ooooooooooooo mm0mm00000m0m UUGUUGAGAGUGU 530 16-14025CTGF-1032- 14026 Chl ooooooooooooo 0m0m0mm00mm0 ACAUACCGAGCUA 53116-14026 CTGF-1535- 14027 Chl ooooooooooooo 00m0000000mm0 AGCAGAAAGGUUA532 16-14027 CTGF-1694- 14028 Chl ooooooooooooo 00mm0mmmmmm00AGUUGUUCCUUAA 533 16-14028 CTGF-1588- 14029 Chl ooooooooooooo0mmm0000m0m00 AUUUGAAGUGUAA 534 16-14029 CTGF-928-16- 14030 Chlooooooooooooo 000mm00mmm000 AAGCUGACCUGGA 535 14030 CTGF-1133- 14031 Chlooooooooooooo 00mm0m0000000 GGUCAUGAAGAAG 536 16-14031 CTGF-912-16-14032 Chl ooooooooooooo 0m00mm000mmmm AUGGUCAGGCCUU 537 14032CTGF-753-16- 14033 Chl ooooooooooooo 00000m0mmmm0 GAAGACACGUUUG 53814033 CTGF-918-16- 14034 Chl ooooooooooooo 000mmmm0m000 AGGCCUUGCGAAG539 14034 CTGF-744-16- 14035 Chl ooooooooooooo m0mm0mm00000UACCGACUGGAAG 540 14035 CTGF-466-16- 14036 Chl ooooooooooooo 0mmm0000mm0ACCGCAAGAUCGG 541 14036 CTGF-917-16- 14037 Chl ooooooooooooom000mmmm0m00 CAGGCCUUGCGAA 542 14037 CTGF-1038- 14038 Chl ooooooooooooom00mm000mmmm CGAGCUAAAUUCU 543 16-14038 CTGF-1048- 14039 Chlooooooooooooo mmm0m0000m0m0 UCUGUGGAGUAUG 544 16-14039 CTGF-1235- 14040Chl ooooooooooooo m0000m0m00m0 CGGAGACAUGGCA 545 16-14040 CTGF-868-16-14041 Chl ooooooooooooo 0m00m00mmmmm AUGACAACGCCUC 546 14041 CTGF-1131-14042 Chl ooooooooooooo 0000mm0m00000 GAGGUCAUGAAGA 547 16-14042CTGF-1043- 14043 Chl ooooooooooooo m000mmmm0m000 UAAAUUCUGUGGA 54816-14043 CTGF-751-16- 14044 Chl ooooooooooooo m000000m0mmm UGGAAGACACGUU549 14044 CTGF-1227- 14045 Chl ooooooooooooo 0000m0m0m000 AAGAUGUACGGAG550 16-14045 CTGF-867-16- 14046 Chl ooooooooooooo 00m00m00mmmmAAUGACAACGCCU 551 14046 CTGF-1128- 14047 Chl ooooooooooooo 00m000mm0m00GGCGAGGUCAUGA 552 16-14047 CTGF-756-16- 14048 Chl ooooooooooooo00m0m0mmm00mm GACACGUUUGGCC 553 14048 CTGF-1234- 14049 Chl ooooooooooooo0m00000m0m00m ACGGAGACAUGGC 554 16-14049 CTGF-916-16- 14050 Chlooooooooooooo mm000mmmm0m00 UCAGGCCUUGCGA 555 14050 CTGF-925-16- 14051Chl ooooooooooooo 0m0000mm00mmm GCGAAGCUGACCU 556 14051 CTGF-1225- 14052Chl ooooooooooooo 000000m0m0m00 GGAAGAUGUACGG 557 16-14052 CTGF-445-16-14053 Chl ooooooooooooo 0m00mmmm00mmm GUGACUUCGGCUC 558 14053CTGF-446-16- 14054 Chl ooooooooooooo m00mmmm00mmmm UGACUUCGGCUCC 55914054 CTGF-913-16- 14055 Chl ooooooooooooo m00mm000mmmm0 UGGUCAGGCCUUG560 14055 CTGF-997-16- 14056 Chl ooooooooooooo mm000mmm000mmUCAAGUUUGAGCU 561 14056 CTGF-277-16- 14057 Chl ooooooooooooo0mm0000mm0m00 GCCAGAACUGCAG 562 14057 CTGF-1052- 14058 Chl ooooooooooooom0000m0m0m0mm UGGAGUAUGUACC 563 16-14058 CTGF-887-16- 14059 Chlooooooooooooo 0mm0000000m00 GCUAGAGAAGCAG 564 14059 CTGF-914-16- 14060Chl ooooooooooooo 00mm000mmmm0m GGUCAGGCCUUGC 565 14060 CTGF-1039- 14061Chl ooooooooooooo 000mm000mmmm0 GAGCUAAAUUCUG 566 16-14061 CTGF-754-16-14062 Chl ooooooooooooo 0000m0m0mmm00 AAGACACGUUUGG 567 14062 CTGF-1130-14063 Chl ooooooooooooo m0000mm0m0000 CGAGGUCAUGAAG 568 16-14063CTGF-919-16- 14064 Chl ooooooooooooo 00mmmm0m0000m GGCCUUGCGAAGC 56914064 CTGF-922-16- 14065 Chl ooooooooooooo mmm0m0000mm00 CUUGCGAAGCUGA570 14065 CTGF-746-16- 14066 Chl ooooooooooooo mm00mm000000mCCGACUGGAAGAC 571 14066 CTGF-993-16- 14067 Chl ooooooooooooommm0mm000mmm0 CCUAUCAAGUUUG 572 14067 CTGF-825-16- 14068 Chlooooooooooooo m0mmmm0000mmm UGUUCCAAGACCU 573 14068 CTGF-926-16- 14069Chl ooooooooooooo m0000mm00mmm0 CGAAGCUGACCUG 574 14069 CTGF-923-16-14070 Chl ooooooooooooo mm0m0000mm00m UUGCGAAGCUGAC 575 14070CTGF-866-16- 14071 Chl ooooooooooooo m00m00m00m0mm CAAUGACAACGCC 57614071 CTGF-563-16- 14072 Chl ooooooooooooo 0m0mm00m0m0m0 GUACCAGUGCACG577 14072 CTGF-823-16- 14073 Chl ooooooooooooo mmm0mmmm0000mCCUGUUCCAAGAC 578 14073 CTGF-1233- 14074 Chl ooooooooooooo m0m00000m0m00UACGGAGACAUGG 579 16-14074 CTGF-924-16- 14075 Chl ooooooooooooom0m0000mm00mm UGCGAAGCUGACC 580 14075 CTGF-921-16- 14076 Chlooooooooooooo mmmm0m0000mm0 CCUUGCGAAGCUG 581 14076 CTGF-443-16- 14077Chl ooooooooooooo mm0m00mmmm00m CUGUGACUUCGGC 582 14077 CTGF-1041- 14078Chl ooooooooooooo 0mm000mmmm0m0 GCUAAAUUCUGUG 583 16-14078 CTGF-1042-14079 Chl ooooooooooooo mm000mmmm0m00 CUAAAUUCUGUGG 584 16-14079CTGF-755-16- 14080 Chl ooooooooooooo 000m0m0mmm00m AGACACGUUUGGC 58514080 CTGF-467-16- 14081 Chl ooooooooooooo mm0m0000mm00m CCGCAAGAUCGGC586 14081 CTGF-995-16- 14082 Chl ooooooooooooo m0mm000mmm000UAUCAAGUUUGAG 587 14082 CTGF-927-16- 14083 Chl ooooooooooooo0000mm00mmm00 GAAGCUGACCUGG 588 14083 SPP1-1091- 14131 Chl ooooooooooooo0m0mmm00mm000 GCAUUUAGUCAAA 589 16-14131 PPIB--16- 14188 Chlooooooooooooo mmmmmmmmmmmmm GGCUACAAAAACA 590 14188 PPIB--17- 14189 Chlooooooooooooo mm00mm0m00000m0 UUGGCUACAAAAACA 591 14189 oo PPIB--18-14190 Chl ooooooooooooo 0mmm00mm0m00000m0 AUUUGGCUACAAAA 592 14190 ooooACA pGL3-1172- 14386 Chl ooooooooooooo 0m000m0m00mmm ACAAAUACGAUUU 59316-14386 pGL3-1172- 14387 Chl ooooooooooooo DY5470m000m0m00mmmACAAAUACGAUUU 594 16-14387 MAP4K4-2931- 14390 Chl oooooooooooooPmmmmmmmmmmmm000m CUUUGAAGAGUUCU 595 25-14390 oooooooooooo mmmmmmmmmGUGGAAGUCUA miR-122--23- 14391 Chl ssooooooooooo mmmmmmmmmmmmmmmmmACAAACACCAUUGU 596 14391 oooooossss mmmmmm CACACUCCA 14084 Chlooooooooooooo mmm0m000mm000 CUCAUGAAUUAGA 719 14085 Chl ooooooooooooomm0000mm00mm0 CUGAGGUCAAUUA 720 14086 Chl ooooooooooooo 0000mm00mm000GAGGUCAAUUAAA 721 14087 Chl ooooooooooooo mmm0000mm00mm UCUGAGGUCAAUU722 14088 Chl ooooooooooooo m0000mm00mm00 UGAGGUCAAUUAA 723 14089 Chlooooooooooooo mmmm0000mm00m UUCUGAGGUCAAU 724 14090 Chl ooooooooooooo0mm00mm000m00 GUCAGCUGGAUGA 725 14091 Chl ooooooooooooo mmmm00m000mmmUUCUGAUGAAUCU 726 14092 Chl ooooooooooooo m000mm0000mm0 UGGACUGAGGUCA727 14093 Chl ooooooooooooo 000mmmm0mm0mm GAGUCUCACCAUU 728 14094 Chlooooooooooooo 00mm0000mm000 GACUGAGGUCAAA 729 14095 Chl ooooooooooooomm0m00mm0m000 UCACAGCCAUGAA 730 14096 Chl ooooooooooooo 00mmmm0mm0mmmAGUCUCACCAUUC 731 14097 Chl ooooooooooooo 000m00000mm0 AAGCGGAAAGCCA 73214098 Chl ooooooooooooo 00m00000mm00 AGCGGAAAGCCAA 733 14099 Chlooooooooooooo 0mm0m0m000m00 ACCACAUGGAUGA 734 14100 Chl ooooooooooooo0mm0m00mm0m0m GCCAUGACCACAU 735 14101 Chl ooooooooooooo 000mm0m00mm0mAAGCCAUGACCAC 736 14102 Chl ooooooooooooo 0m00000mm00m GCGGAAAGCCAAU 73714103 Chl ooooooooooooo 000mmmmm0mmm AAAUUUCGUAUUU 738 14104 Chlooooooooooooo 0mmmmm0mmmmm AUUUCGUAUUUCU 739 14105 Chl ooooooooooooo0000mm0m00mm0 AAAGCCAUGACCA 740 14106 Chl ooooooooooooo 0m0m000m00m0mACAUGGAUGAUAU 741 14107 Chl ooooooooooooo 0000mmmmm0mm GAAAUUUCGUAUU 74214108 Chl ooooooooooooo 0mmmmmmm00mm GCGCCUUCUGAUU 743 14109 Chlooooooooooooo 0mmmmmm0m000m AUUUCUCAUGAAU 744 14110 Chl ooooooooooooommmmm0m000m00 CUCUCAUGAAUAG 745 14111 Chl ooooooooooooo 000mmm00m000AAGUCCAACGAAA 746 14112 Chl ooooooooooooo 0m00m00000m00 AUGAUGAGAGCAA747 14113 Chl ooooooooooooo 0m00000mm000 GCGAGGAGUUGAA 748 14114 Chlooooooooooooo m00mm00m00mm0 UGAUUGAUAGUCA 749 14115 Chl ooooooooooooo000m00m0m0mmm AGAUAGUGCAUCU 750 14116 Chl ooooooooooooo 0m0m0m0mmm0mmAUGUGUAUCUAUU 751 14117 Chl ooooooooooooo mmmm0m0000000 UUCUAUAGAAGAA752 14118 Chl ooooooooooooo mm0mmm00m00mm UUGUCCAGCAAUU 753 14119 Chlooooooooooooo 0m0m000000m0 ACAUGGAAAGCGA 754 14120 Chl ooooooooooooo0m00mmm000mm0 GCAGUCCAGAUUA 755 14121 Chl ooooooooooooo m00mm000m0m0mUGGUUGAAUGUGU 756 14122 Chl ooooooooooooo mm0m0000m00m UUAUGAAACGAGU 75714123 Chl ooooooooooooo m00mmm000mm0m CAGUCCAGAUUAU 758 14124 Chlooooooooooooo 0m0m000m0000 AUAUAAGCGGAAA 759 14125 Chl ooooooooooooom0mm00mm000m0 UACCAGUUAAACA 760 14126 Chl ooooooooooooo m0mmm0mmmm0m0UGUUCAUUCUAUA 761 14127 Chl ooooooooooooo mm0mm0000000 CCGACCAAGGAAA 76214128 Chl ooooooooooooo 000m00m0m0m0m GAAUGGUGCAUAC 763 14129 Chlooooooooooooo 0m0m00m00mm0 AUAUGAUGGCCGA 764 14130 Chl ooooooooooooo00m00mmm000mm AGCAGUCCAGAUU 765 14132 Chl ooooooooooooo 00m0mmmm0m0mAGCAUUCCGAUGU 766 14133 Chl ooooooooooooo m00mm00000mmm UAGUCAGGAACUU767 14134 Chl ooooooooooooo m0m0mmm00mm00 UGCAUUUAGUCAA 768 14135 Chlooooooooooooo 0mmm00m000mmm GUCUGAUGAGUCU 769 14136 Chl ooooooooooooom000m0m0m0m00 UAGACACAUAUGA 770 14137 Chl ooooooooooooo m000m0000m0mCAGACGAGGACAU 771 14138 Chl ooooooooooooo m00mmm000mmm CAGCCGUGAAUUC 77214139 Chl ooooooooooooo 00mmm00000m00 AGUCUGGAAAUAA 773 14140 Chlooooooooooooo 00mmm0m00mmmm AGUUUGUGGCUUC 774 14141 Chl ooooooooooooo00mmm00m0000 AGUCCAACGAAAG 775 14142 Chl ooooooooooooo 000mmmmm000mAAGUUUCGCAGAC 776 14143 Chl ooooooooooooo 00m00m000m0mm AGCAAUGAGCAUU777 14144 Chl ooooooooooooo mm000m00m0m0m UUAGAUAGUGCAU 778 14145 Chlooooooooooooo m00m0m0m0m000 UGGUGCAUACAAG 779 14146 Chl ooooooooooooo0m0000m00mm0 AUGAAACGAGUCA 780 14147 Chl ooooooooooooo mm0000m0mm000CCAGAGUGCUGAA 781 14148 Chl ooooooooooooo m00mm0m000mmm CAGCCAUGAAUUU782 14149 Chl ooooooooooooo 0mm00mm000m0m AUUGGUUGAAUGU 783 14150 Chlooooooooooooo 00mm000m0m0m0 GGUUGAAUGUGUA 784 14151 Chl ooooooooooooo00000m00mm00m GGAAAUAACUAAU 785 14152 Chl ooooooooooooo mm0m000m00000UCAUGAAUAGAAA 786 14153 Chl ooooooooooooo 0mm00m00mm00 GCCAGCAACCGAA 78714154 Chl ooooooooooooo m0mmmm0m0m0m0 CACCUCACACAUG 788 14155 Chlooooooooooooo 00mm000m00m0m AGUUGAAUGGUGC 789 14156 Chl ooooooooooooo00mm00mm000m0 AGUCAGCUGGAUG 790 14157 Chl ooooooooooooo m0m000m00000UAUAAGCGGAAAG 791 14158 Chl ooooooooooooo mmmm0m0m00mm UUCCGAUGUGAUU 79214159 Chl ooooooooooooo 0m00mm00m0m0m AUAACUAAUGUGU 793 14160 Chlooooooooooooo mm0mmmm0m0000 UCAUUCUAUAGAA 794 14161 Chl ooooooooooooo00mm0mm0mm0m0 AACUAUCACUGUA 795 14162 Chl ooooooooooooo 0mm00mm0mmm0mGUCAAUUGCUUAU 796 14163 Chl ooooooooooooo 00m00mm00m000 AGCAAUUAAUAAA797 14164 Chl ooooooooooooo 0m0mmmm00m00 ACGACUCUGAUGA 798 14165 Chlooooooooooooo m00m0m00mmm0m UAGUGUGGUUUAU 799 14166 Chl ooooooooooooo000mm00m00m00 AAGCCAAUGAUGA 800 14167 Chl ooooooooooooo 0m00mm00000mmAUAGUCAGGAACU 801 14168 Chl ooooooooooooo 00mm00mmm000 AGUCAGCCGUGAA 80214169 Chl ooooooooooooo 0mm0mm0m00000 ACUACCAUGAGAA 803 14170 Chlooooooooooooo 000m000mm00mm AAACAGGCUGAUU 804 14171 Chl ooooooooooooo000m0mm0000mm GAGUGCUGAAACC 805 14172 Chl ooooooooooooo m000m0mmmm0mUGAGCAUUCCGAU 806 14173 Chl ooooooooooooo 00mmmm0m00mm0 AAUUCCACAGCCA807 14174 Chl ooooooooooooo m0mm00mm0mmm0 UGUCAAUUGCUUA 808 14175 Chlooooooooooooo 0mm0m00000mm0 ACCAUGAGAAUUG 809 14176 Chl ooooooooooooomm00m0000mm0 CCAACGAAAGCCA 810 14177 Chl ooooooooooooo mm00mm0mm00mmCUGGUCACUGAUU 811 14178 Chl ooooooooooooo m00mmm0m000mm UGGUUUAUGGACU812 14179 Chl ooooooooooooo 00mm0000m0mm0 GACCAGAGUGCUG 813 14180 Chlooooooooooooo 00m0m00mm00m0 GAUGUGAUUGAUA 814 14181 Chl ooooooooooooo0mm00mmm000m GUCAGCCGUGAAU 815 14182 Chl ooooooooooooo 00m0m0m0mmm0mAAUGUGUAUCUAU 816 14183 Chl ooooooooooooo mm000mmm00000 UUGAGUCUGGAAA817 14184 Chl ooooooooooooo 0mmm00m00mm00 GUCCAGCAAUUAA 818 14185 Chlooooooooooooo mm00m00mm00m0 CCAGCAAUUAAUA 819 14186 Chl ooooooooooooo00mmm00m0mm GACUCGAACGACU 820 14187 Chl ooooooooooooo 0mmm0mm00m00mACCUGCCAGCAAC 821 o: phosphodiester; s: phosphorothioate; P:5′ phosphorylation; 0: 2′-OH; F: 2′-fluoro; m: 2′ O-methyl; +: LNAmodification. Capital letters in the sequence signify ribonucleotides,lower case letters signify deoxyribonucleotides.

TABLE 4 sd-rxRNA miRNA designs SEQ miRNA Sequence SEQ ID sd-rxRNA SEQsd-rxRNA miRNA Name ID NO mature NO Antisense ID NO Sense hsa-let-7a 822UGAGGUAGUAGGUUGUA 823 UGAGGUAGUAGG 824 AACCUACUACC MIMAT0000062 UAGUUUUGUAUAG UCA hsa-let-7a* 825 CUAUACAAUCUACUGUC 826 CUAUACAAUCUA 827AGUAGAUUGUA MIMAT0004481 UUUC CUGUCUUU UAG hsa-let-7a-2* 828CUGUACAGCCUCCUAGC 829 CUGUACAGCCUC 830 AGGAGGCUGUA MIMAT0010195 UUUCCCUAGCUUU CAG hsa-let-7b 831 UGAGGUAGUAGGUUGUG 832 UGAGGUAGUAGG 833AACCUACUACC MIMAT0000063 UGGUU UUGUGUGG UCA hsa-let-7b* 834CUAUACAACCUACUGCC 835 CUAUACAACCUA 836 AGUAGGUUGUA MIMAT0004482 UUCCCCUGCCUUC UAG hsa-let-7c 837 UGAGGUAGUAGGUUGUA 838 UGAGGUAGUAGG 839AACCUACUACC MIMAT0000064 UGGUU UUGUAUGG UCA hsa-let-7c* 840UAGAGUUACACCCUGGG 841 UAGAGUUACACC 842 AGGGUGUAACU MIMAT0004483 AGUUACUGGGAGU CUA hsa-let-7d 843 AGAGGUAGUAGGUUGCA 844 AGAGGUAGUAGG 845AACCUACUACC MIMAT0000065 UAGUU UUGCAUAG UCU hsa-let-7d* 846CUAUACGACCUGCUGCC 847 CUAUACGACCUG 848 AGCAGGUCGUA MIMAT0004484 UUUCUCUGCCUUU UAG hsa-let-7e 849 UGAGGUAGGAGGUUGUA 850 UGAGGUAGGAGG 851AACCUCCUACC MIMAT0000066 UAGUU UUGUAUAG UCA hsa-let-7e* 852CUAUACGGCCUCCUAGC 853 CUAUACGGCCUC 854 AGGAGGCCGUA MIMAT0004485 UUUCCCUAGCUUU UAG hsa-let-7f 855 UGAGGUAGUAGAUUGUA 856 UGAGGUAGUAGA 857AAUCUACUACC MIMAT0000067 UAGUU UUGUAUAG UCA hsa-let-7f-1* 858CUAUACAAUCUAUUGCC 859 CUAUACAAUCUA 860 AAUAGAUUGUA MIMAT0004486 UUCCCUUGCCUUC UAG hsa-let-7f-2* 861 CUAUACAGUCUACUGUC 862 CUAUACAGUCUA 863AGUAGACUGUA MIMAT0004487 UUUCC CUGUCUUU UAG hsa-let-7g 864UGAGGUAGUAGUUUGUA 865 UGAGGUAGUAGU 866 AAACUACUACC MIMAT0000414 CAGUUUUGUACAG UCA hsa-let-7g* 867 CUGUACAGGCCACUGCC 868 CUGUACAGGCCA 869AGUGGCCUGUA MIMAT0004584 UUGC CUGCCUUG CAG hsa-let-7i 870UGAGGUAGUAGUUUGUG 871 UGAGGUAGUAGU 872 AAACUACUACC MIMAT0000415 CUGUUUUGUGCUG UCA hsa-let-7i* 873 CUGCGCAAGCUACUGCC 874 CUGCGCAAGCUA 875AGUAGCUUGCG MIMAT0004585 UUGCU CUGCCUUG CAG hsa-miR-1 876UGGAAUGUAAAGAAGUA 877 UGGAAUGUAAAG 878 UUCUUUACAUU MIMAT0000416 UGUAUAAGUAUGU CCA hsa-miR-100 879 AACCCGUAGAUCCGAAC 880 AACCCGUAGAUC 881CGGAUCUACGG MIMAT0000098 UUGUG CGAACUUG GUU hsa-miR-100* 882CAAGCUUGUAUCUAUAG 883 CAAGCUUGUAUC 884 UAGAUACAAGC MIMAT0004512 GUAUGUAUAGGUA UUG hsa-miR-101 885 UACAGUACUGUGAUAAC 886 UACAGUACUGUG 887AUCACAGUACU MIMAT0000099 UGAA AUAACUGA GUA hsa-miR-101* 888CAGUUAUCACAGUGCUG 889 CAGUUAUCACAG 890 CACUGUGAUAA MIMAT0004513 AUGCUUGCUGAUG CUG hsa-miR-103 891 AGCAGCAUUGUACAGGG 892 AGCAGCAUUGUA 893UGUACAAUGCU MIMAT0000101 CUAUGA CAGGGCUA GCU hsa-miR-103-2* 894AGCUUCUUUACAGUGCU 895 AGCUUCUUUACA 896 ACUGUAAAGAA MIMAT0009196 GCCUUGGUGCUGCC GCU hsa-miR-103-as 897 UCAUAGCCCUGUACAAU 898 UCAUAGCCCUGU 899GUACAGGGCUA MIMAT0007402 GCUGCU ACAAUGCU UGA hsa-miR-105 900UCAAAUGCUCAGACUCC 901 UCAAAUGCUCAG 902 GUCUGAGCAUU MIMAT0000102 UGUGGUACUCCUGU UGA hsa-miR-105* 903 ACGGAUGUUUGAGCAUG 904 ACGGAUGUUUGA 905GCUCAAACAUC MIMAT0004516 UGCUA GCAUGUGC CGU hsa-miR-106a 906AAAGUGCUUACAGUGC 907 AAAAGUGCUUAC 908 CUGUAAGCACU MIMAT0000103 AGGUAGAGUGCAGG UUU hsa-miR-106a* 909 CUGCAAUGUAAGCACUU 910 CUGCAAUGUAAG 911UGCUUACAUUG MIMAT0004517 CUUAC CACUUCUU CAG hsa-miR-106b 912UAAAGUGCUGACAGUGC 913 UAAAGUGCUGAC 914 CUGUCAGCACU MIMAT0000680 AGAUAGUGCAGA UUA hsa-miR-106b* 915 CCGCACUGUGGGUACUU 916 CCGCACUGUGGG 917UACCCACAGUG MIMAT0004672 GCUGC UACUUGCU CGG hsa-miR-107 918AGCAGCAUUGUACAGGG 919 AGCAGCAUUGUA 920 UGUACAAUGCU MIMAT0000104 CUAUCACAGGGCUA GCU hsa-miR-10a 921 UACCCUGUAGAUCCGAA 922 UACCCUGUAGAU 923GGAUCUACAGG MIMAT0000253 UUUGUG CCGAAUUU GUA hsa-miR-10a* 924CAAAUUCGUAUCUAGGG 925 CAAAUUCGUAUC 926 UAGAUACGAAU MIMAT0004555 GAAUAUAGGGGAA UUG hsa-miR-10b 927 UACCCUGUAGAACCGAA 928 UACCCUGUAGAA 929GGUUCUACAGG MIMAT0000254 UUUGUG CCGAAUUU GUA hsa-miR-10b* 930ACAGAUUCGAUUCUAGG 931 ACAGAUUCGAUU 932 AGAAUCGAAUC MIMAT0004556 GGAAUCUAGGGGA UGU hsa-miR-1178 933 UUGCUCACUGUUCUUCC 934 UUGCUCACUGUU 935AGAACAGUGAG MIMAT0005823 CUAG CUUCCCUA CAA hsa-miR-1179 936AAGCAUUCUUUCAUUGG 937 AAGCAUUCUUUC 938 AUGAAAGAAUG MIMAT0005824 UUGGAUUGGUUG CUU hsa-miR-1180 939 UUUCCGGCUCGCGUGGG 940 UUUCCGGCUCGC 941ACGCGAGCCGG MIMAT0005825 UGUGU GUGGGUGU AAA hsa-miR-1181 942CCGUCGCCGCCACCCGA 943 CCGUCGCCGCCA 944 GGUGGCGGCGA MIMAT0005826 GCCGCCCGAGCC CGG hsa-miR-1182 945 GAGGGUCUUGGGAGGGA 946 GAGGGUCUUGGG 947CUCCCAAGACC MIMAT0005827 UGUGAC AGGGAUGU CUC hsa-miR-1183 948CACUGUAGGUGAUGGUG 949 CACUGUAGGUGA 950 CAUCACCUACA MIMAT0005828AGAGUGGGCA UGGUGAGA GUG hsa-miR-1184 951 CCUGCAGCGACUUGAUG 952CCUGCAGCGACU 953 CAAGUCGCUGC MIMAT0005829 GCUUCC UGAUGGCU AGGhsa-miR-1185 954 AGAGGAUACCCUUUGUA 955 AGAGGAUACCCU 956 AAAGGGUAUCCMIMAT0005798 UGUU UUGUAUGU UCU hsa-miR-1193 957 GGGAUGGUAGACCGGUG 958GGGAUGGUAGAC 959 CGGUCUACCAU MIMAT0015049 ACGUGC CGGUGACG CCChsa-miR-1197 960 UAGGACACAUGGUCUAC 961 UAGGACACAUGG 962 GACCAUGUGUCMIMAT0005955 UUCU UCUACUUC CUA hsa-miR-1200 963 CUCCUGAGCCAUUCUGA 964CUCCUGAGCCAU 965 GAAUGGCUCAG MIMAT0005863 GCCUC UCUGAGCC GAGhsa-miR-1202 966 GUGCCAGCUGCAGUGGG 967 GUGCCAGCUGCA 968 ACUGCAGCUGGMIMAT0005865 GGAG GUGGGGGA CAC hsa-miR-1203 969 CCCGGAGCCAGGAUGCA 970CCCGGAGCCAGG 971 AUCCUGGCUCC MIMAT0005866 GCUC AUGCAGCU GGG hsa-miR-1204972 UCGUGGCCUGGUCUCCA 973 UCGUGGCCUGGU 974 AGACCAGGCCA MIMAT0005868 UUAUCUCCAUUA CGA hsa-miR-1205 975 UCUGCAGGGUUUGCUUU 976 UCUGCAGGGUUU 977GCAAACCCUGC MIMAT0005869 GAG GCUUUGAG AGA hsa-miR-1206 978UGUUCAUGUAGAUGUUU 979 UGUUCAUGUAGA 980 CAUCUACAUGA MIMAT0005870 AAGCUGUUUAAG ACA hsa-miR-1207- 981 UCAGCUGGCCCUCAUUUC 982 UCAGCUGGCCCU 983UGAGGGCCAGC 3p CAUUUC UGA MIMAT0005872 hsa-miR-1207- 984UGGCAGGGAGGCUGGGA 985 UGGCAGGGAGGC 986 CAGCCUCCCUG 5p GGGG UGGGAGGG CCAMIMAT0005871 hsa-miR-1208 987 UCACUGUUCAGACAGGC 988 UCACUGUUCAGA 989UGUCUGAACAG MIMAT0005873 GGA CAGGCGGA UGA hsa-miR-122 990UGGAGUGUGACAAUGGU 991 UGGAGUGUGACA 992 AUUGUCACACU MIMAT0000421 GUUUGAUGGUGUU CCA hsa-miR-122* 993 AACGCCAUUAUCACACU 994 AACGCCAUUAUC 995GUGAUAAUGGC MIMAT0004590 AAAUA ACACUAAA GUU hsa-miR-1224- 996CCCCACCUCCUCUCUCC 997 CCCCACCUCCUC 998 GAGAGGAGGUG 3p UCAG UCUCCUCA GGGMIMAT0005459 hsa-miR-1224- 999 GUGAGGACUCGGGAGGU 1000 GUGAGGACUCGG 1001UCCCGAGUCCU 5p GG GAGGUGG CAC MIMAT0005458 hsa-miR-1225- 1002UGAGCCCCUGUGCCGCC 1003 UGAGCCCCUGUG 1004 GGCACAGGGGC 3p CCCAG CCGCCCCCUCA MIMAT0005573 hsa-miR-1225- 1005 GUGGGUACGGCCCAGUG 1006 GUGGGUACGGCC1007 UGGGCCGUACC 5p GGGGG CAGUGGGG CAC MIMAT0005572 hsa-miR-1226 1008UCACCAGCCCUGUGUUC 1009 UCACCAGCCCUG 1010 CACAGGGCUGG MIMAT0005577 CCUAGUGUUCCCU UGA hsa-miR-1226* 1011 GUGAGGGCAUGCAGGCC 1012 GUGAGGGCAUGC 1013CUGCAUGCCCU MIMAT0005576 UGGAUGGGG AGGCCUGG CAC hsa-miR-1227 1014CGUGCCACCCUUUUCCC 1015 CGUGCCACCCUU 1016 AAAAGGGUGGC MIMAT0005580 CAGUUCCCCAG ACG hsa-miR-1228 1017 UCACACCUGCCUCGCCC 1018 UCACACCUGCCU 1019CGAGGCAGGUG MIMAT0005583 CCC CGCCCCCC UGA hsa-miR-1228* 1020GUGGGCGGGGGCAGGUG 1021 GUGGGCGGGGGC 1022 CUGCCCCCGCC MIMAT0005582 UGUGAGGUGUGU CAC hsa-miR-1229 1023 CUCUCACCACUGCCCUC 1024 CUCUCACCACUG 1025GGCAGUGGUGA MIMAT0005584 CCACAG CCCUCCCA GAG hsa-miR-1231 1026GUGUCUGGGCGGACAGC 1027 GUGUCUGGGCGG 1028 GUCCGCCCAGA MIMAT0005586 UGCACAGCUGC CAC hsa-miR-1233 1029 UGAGCCCUGUCCUCCCG 1030 UGAGCCCUGUCC 1031GAGGACAGGGC MIMAT0005588 CAG UCCCGCAG UCA hsa-miR-1234 1032UCGGCCUGACCACCCAC 1033 UCGGCCUGACCA 1034 GGUGGUCAGGC MIMAT0005589 CCCACCCCACCCC CGA hsa-miR-1236 1035 CCUCUUCCCCUUGUCUC 1036 CCUCUUCCCCUU 1037ACAAGGGGAAG MIMAT0005591 UCCAG GUCUCUCC AGG hsa-miR-1237 1038UCCUUCUGCUCCGUCCC 1039 UCCUUCUGCUCC 1040 ACGGAGCAGAA MIMAT0005592 CCAGGUCCCCCA GGA hsa-miR-1238 1041 CUUCCUCGUCUGUCUGC 1042 CUUCCUCGUCUG 1043GACAGACGAGG MIMAT0005593 CCC UCUGCCCC AAG hsa-miR-124 1044UAAGGCACGCGGUGAAU 1045 UAAGGCACGCGG 1046 CACCGCGUGCC MIMAT0000422 GCCUGAAUGCC UUA hsa-miR-124* 1047 CGUGUUCACAGCGGACC 1048 CGUGUUCACAGC 1049CCGCUGUGAAC MIMAT0004591 UUGAU GGACCUUG ACG hsa-miR-1243 1050AACUGGAUCAAUUAUAG 1051 AACUGGAUCAAU 1052 UAAUUGAUCCA MIMAT0005894 GAGUGUAUAGGAG GUU hsa-miR-1244 1053 AAGUAGUUGGUUUGUAU 1054 AAGUAGUUGGUU 1055CAAACCAACUA MIMAT0005896 GAGAUGGUU UGUAUGAG CUU hsa-miR-1245 1056AAGUGAUCUAAAGGCCU 1057 AAGUGAUCUAAA 1058 CCUUUAGAUCA MIMAT0005897 ACAUGGCCUACA CUU hsa-miR-1246 1059 AAUGGAUUUUUGGAGCA 1060 AAUGGAUUUUUG 1061UCCAAAAAUCC MIMAT0005898 GG GAGCAGG AUU hsa-miR-1247 1062ACCCGUCCCGUUCGUCC 1063 ACCCGUCCCGUU 1064 CGAACGGGACG MIMAT0005899 CCGGACGUCCCCG GGU hsa-miR-1248 1065 ACCUUCUUGUAUAAGCA 1066 ACCUUCUUGUAU 1067UUAUACAAGAA MIMAT0005900 CUGUGCUAAA AAGCACUG GGU hsa-miR-1249 1068ACGCCCUUCCCCCCCUU 1069 ACGCCCUUCCCC 1070 GGGGGGAAGGG MIMAT0005901 CUUCACCCUUCUU CGU hsa-miR-1250 1071 ACGGUGCUGGAUGUGGC 1072 ACGGUGCUGGAU 1073ACAUCCAGCAC MIMAT0005902 CUUU GUGGCCUU CGU hsa-miR-1251 1074ACUCUAGCUGCCAAAGG 1075 ACUCUAGCUGCC 1076 UUGGCAGCUAG MIMAT0005903 CGCUAAAGGCGC AGU hsa-miR-1252 1077 AGAAGGAAAUUGAAUUC 1078 AGAAGGAAAUUG 1079UUCAAUUUCCU MIMAT0005944 AUUUA AAUUCAUU UCU hsa-miR-1253 1080AGAGAAGAAGAUCAGCC 1081 AGAGAAGAAGAU 1082 UGAUCUUCUUC MIMAT0005904 UGCACAGCCUGC UCU hsa-miR-1254 1083 AGCCUGGAAGCUGGAGC 1084 AGCCUGGAAGCU 1085CCAGCUUCCAG MIMAT0005905 CUGCAGU GGAGCCUG GCU hsa-miR-1255a 1086AGGAUGAGCAAAGAAAG 1087 AGGAUGAGCAAA 1088 UCUUUGCUCAU MIMAT0005906 UAGAUUGAAAGUAG CCU hsa-miR-1255b 1089 CGGAUGAGCAAAGAAAG 1090 CGGAUGAGCAAA 1091UCUUUGCUCAU MIMAT0005945 UGGUU GAAAGUGG CCG hsa-miR-1256 1092AGGCAUUGACUUCUCAC 1093 AGGCAUUGACUU 1094 AGAAGUCAAUG MIMAT0005907 UAGCUCUCACUAG CCU hsa-miR-1257 1095 AGUGAAUGAUGGGUUCU 1096 AGUGAAUGAUGG 1097ACCCAUCAUUC MIMAT0005908 GACC GUUCUGAC ACU hsa-miR-1258 1098AGUUAGGAUUAGGUCGU 1099 AGUUAGGAUUAG 1100 ACCUAAUCCUA MIMAT0005909 GGAAGUCGUGGA ACU hsa-miR-125a- 1101 ACAGGUGAGGUUCUUGG 1102 ACAGGUGAGGUU 1103AGAACCUCACC 3p GAGCC CUUGGGAG UGU MIMAT0004602 hsa-miR-125a- 1104UCCCUGAGACCCUUUAA 1105 UCCCUGAGACCC 1106 AAGGGUCUCAG 5p CCUGUGA UUUAACCUGGA MIMAT0000443 hsa-miR-125b 1107 UCCCUGAGACCCUAACU 1108 UCCCUGAGACCC1109 UAGGGUCUCAG MIMAT0000423 UGUGA UAACUUGU GGA hsa-miR-125b- 1110ACGGGUUAGGCUCUUGG 1111 ACGGGUUAGGCU 1112 AGAGCCUAACC 1* GAGCU CUUGGGAGCGU MIMAT0004592 hsa-miR-125b- 1113 UCACAAGUCAGGCUCUU 1114 UCACAAGUCAGG1115 AGCCUGACUUG 2* GGGAC CUCUUGGG UGA MIMAT0004603 hsa-miR-126 1116UCGUACCGUGAGUAAUA 1117 UCGUACCGUGAG 1118 UACUCACGGUA MIMAT0000445 AUGCGUAAUAAUG CGA hsa-miR-126* 1119 CAUUAUUACUUUUGGUA 1120 CAUUAUUACUUU 1121CAAAAGUAAUA MIMAT0000444 CGCG UGGUACGC AUG hsa-miR-1260 1122AUCCCACCUCUGCCACCA 1123 AUCCCACCUCUG 1124 GGCAGAGGUGG MIMAT0005911CCACCA GAU hsa-miR-1260b 1125 AUCCCACCACUGCCACC 1126 AUCCCACCACUG 1127GGCAGUGGUGG MIMAT0015041 AU CCACCAU GAU hsa-miR-1261 1128AUGGAUAAGGCUUUGGC 1129 AUGGAUAAGGCU 1130 AAAGCCUUAUC MIMAT0005913 UUUUGGCUU CAU hsa-miR-1262 1131 AUGGGUGAAUUUGUAGA 1132 AUGGGUGAAUUU 1133ACAAAUUCACC MIMAT0005914 AGGAU GUAGAAGG CAU hsa-miR-1263 1134AUGGUACCCUGGCAUAC 1135 AUGGUACCCUGG 1136 UGCCAGGGUAC MIMAT0005915 UGAGUCAUACUGA CAU hsa-miR-1264 1137 CAAGUCUUAUUUGAGCA 1138 CAAGUCUUAUUU 1139UCAAAUAAGAC MIMAT0005791 CCUGUU GAGCACCU UUG hsa-miR-1265 1140CAGGAUGUGGUCAAGUG 1141 CAGGAUGUGGUC 1142 UUGACCACAUC MIMAT0005918 UUGUUAAGUGUUG CUG hsa-miR-1266 1143 CCUCAGGGCUGUAGAAC 1144 CCUCAGGGCUGU 1145CUACAGCCCUG MIMAT0005920 AGGGCU AGAACAGG AGG hsa-miR-1267 1146CCUGUUGAAGUGUAAUC 1147 CCUGUUGAAGUG 1148 UACACUUCAAC MIMAT0005921 CCCAUAAUCCCC AGG hsa-miR-1268 1149 CGGGCGUGGUGGUGGGGG 1150 CGGGCGUGGUGG 1151CACCACCACGC MIMAT0005922 UGGGGG CCG hsa-miR-1269 1152 CUGGACUGAGCCGUGCU1153 CUGGACUGAGCC 1154 ACGGCUCAGUC MIMAT0005923 ACUGG GUGCUACU CAGhsa-miR-1270 1155 CUGGAGAUAUGGAAGAG 1156 CUGGAGAUAUGG 1157 UUCCAUAUCUCMIMAT0005924 CUGUGU AAGAGCUG CAG hsa-miR-1271 1158 CUUGGCACCUAGCAAGC1159 CUUGGCACCUAG 1160 UGCUAGGUGCC MIMAT0005796 ACUCA CAAGCACU AAGhsa-miR-1272 1161 GAUGAUGAUGGCAGCAA 1162 GAUGAUGAUGGC 1163 CUGCCAUCAUCMIMAT0005925 AUUCUGAAA AGCAAAUU AUC hsa-miR-1273 1164 GGGCGACAAAGCAAGAC1165 GGGCGACAAAGC 1166 UUGCUUUGUCG MIMAT0005926 UCUUUCUU AAGACUCU CCChsa-miR-1273c 1167 GGCGACAAAACGAGACC 1168 GGCGACAAAACG 1169 CUCGUUUUGUCMIMAT0015017 CUGUC AGACCCUG GCC hsa-miR-1273d 1170 GAACCCAUGAGGUUGAG1171 GAACCCAUGAGG 1172 AACCUCAUGGG MIMAT0015090 GCUGCAGU UUGAGGCU UUChsa-miR-1273e 1173 UUGCUUGAACCCAGGAA 1174 UUGCUUGAACCC 1175 CUGGGUUCAAGMIMAT0018079 GUGGA AGGAAGUG CAA hsa-miR-127-3p 1176 UCGGAUCCGUCUGAGCU1177 UCGGAUCCGUCU 1178 UCAGACGGAUC MIMAT0000446 UGGCU GAGCUUGG CGAhsa-miR-1274a 1179 GUCCCUGUUCAGGCGCCA 1180 GUCCCUGUUCAG 1181 GCCUGAACAGGMIMAT0005927 GCGCCA GAC hsa-miR-1274b 1182 UCCCUGUUCGGGCGCCA 1183UCCCUGUUCGGG 1184 CGCCCGAACAG MIMAT0005938 CGCCA GGA hsa-miR-1275 1185GUGGGGGAGAGGCUGUC 1186 GUGGGGGAGAGG 1187 AGCCUCUCCCC MIMAT0005929 CUGUCCAC hsa-miR-127-5p 1188 CUGAAGCUCAGAGGGCU 1189 CUGAAGCUCAGA 1190CCUCUGAGCUU MIMAT0004604 CUGAU GGGCUCUG CAG hsa-miR-1276 1191UAAAGAGCCCUGUGGAG 1192 UAAAGAGCCCUG 1193 CACAGGGCUCU MIMAT0005930 ACAUGGAGACA UUA hsa-miR-1277 1194 UACGUAGAUAUAUAUGU 1195 UACGUAGAUAUA 1196UAUAUAUCUAC MIMAT0005933 AUUUU UAUGUAUU GUA hsa-miR-1278 1197UAGUACUGUGCAUAUCA 1198 UAGUACUGUGCA 1199 UAUGCACAGUA MIMAT0005936 UCUAUUAUCAUCU CUA hsa-miR-1279 1200 UCAUAUUGCUUCUUUCU 1201 UCAUAUUGCUUC 1202AAGAAGCAAUA MIMAT0005937 UUUCU UGA hsa-miR-128 1203 UCACAGUGAACCGGUCU1204 UCACAGUGAACC 1205 CCGGUUCACUG MIMAT0000424 CUUU GGUCUCUU UGAhsa-miR-1280 1206 UCCCACCGCUGCCACCC 1207 UCCCACCGCUGC 1208 UGGCAGCGGUGMIMAT0005946 CACCC GGA hsa-miR-1281 1209 UCGCCUCCUCCUCUCCC 1210UCGCCUCCUCCU 1211 AGAGGAGGAGG MIMAT0005939 CUCCC CGA hsa-miR-1282 1212UCGUUUGCCUUUUUCUG 1213 UCGUUUGCCUUU 1214 AAAAAGGCAAA MIMAT0005940 CUUUUCUGCUU CGA hsa-miR-1283 1215 UCUACAAAGGAAAGCGC 1216 UCUACAAAGGAA 1217CUUUCCUUUGU MIMAT0005799 UUUCU AGCGCUUU AGA hsa-miR-1284 1218UCUAUACAGACCCUGGC 1219 UCUAUACAGACC 1220 AGGGUCUGUAU MIMAT0005941 UUUUCCUGGCUUU AGA hsa-miR-1285 1221 UCUGGGCAACAAAGUGA 1222 UCUGGGCAACAA 1223CUUUGUUGCCC MIMAT0005876 GACCU AGUGAGAC AGA hsa-miR-1286 1224UGCAGGACCAAGAUGAG 1225 UGCAGGACCAAG 1226 AUCUUGGUCCU MIMAT0005877 CCCUAUGAGCCC GCA hsa-miR-1287 1227 UGCUGGAUCAGUGGUUC 1228 UGCUGGAUCAGU 1229CCACUGAUCCA MIMAT0005878 GAGUC GGUUCGAG GCA hsa-miR-1288 1230UGGACUGCCCUGAUCUG 1231 UGGACUGCCCUG 1232 AUCAGGGCAGU MIMAT0005942 GAGAAUCUGGAG CCA hsa-miR-1289 1233 UGGAGUCCAGGAAUCUG 1234 UGGAGUCCAGGA 1235AUUCCUGGACU MIMAT0005879 CAUUUU AUCUGCAU CCA hsa-miR-129* 1236AAGCCCUUACCCCAAAA 1237 AAGCCCUUACCC 1238 UGGGGUAAGGG MIMAT0004548 AGUAUCAAAAAGU CUU hsa-miR-1290 1239 UGGAUUUUUGGAUCAGG 1240 UGGAUUUUUGGA 1241GAUCCAAAAAU MIMAT0005880 GA UCAGGGA CCA hsa-miR-1291 1242UGGCCCUGACUGAAGAC 1243 UGGCCCUGACUG 1244 UUCAGUCAGGG MIMAT0005881CAGCAGU AAGACCAG CCA hsa-miR-1292 1245 UGGGAACGGGUUCCGGC 1246UGGGAACGGGUU 1247 GGAACCCGUUC MIMAT0005943 AGACGCUG CCGGCAGA CCAhsa-miR-1293 1248 UGGGUGGUCUGGAGAUU 1249 UGGGUGGUCUGG 1250 CUCCAGACCACMIMAT0005883 UGUGC AGAUUUGU CCA hsa-miR-129-3p 1251 AAGCCCUUACCCCAAAA1252 AAGCCCUUACCC 1253 UGGGGUAAGGG MIMAT0004605 AGCAU CAAAAAGC CUUhsa-miR-1294 1254 UGUGAGGUUGGCAUUGU 1255 UGUGAGGUUGGC 1256 AUGCCAACCUCMIMAT0005884 UGUCU AUUGUUGU ACA hsa-miR-1295 1257 UUAGGCCGCAGAUCUGG 1258UUAGGCCGCAGA 1259 GAUCUGCGGCC MIMAT0005885 GUGA UCUGGGUG UAAhsa-miR-129-5p 1260 CUUUUUGCGGUCUGGGC 1261 CUUUUUGCGGUC 1262 CAGACCGCAAAMIMAT0000242 UUGC UGGGCUUG AAG hsa-miR-1296 1263 UUAGGGCCCUGGCUCCA 1264UUAGGGCCCUGG 1265 AGCCAGGGCCC MIMAT0005794 UCUCC CUCCAUCU UAAhsa-miR-1297 1266 UUCAAGUAAUUCAGGUG 1267 UUCAAGUAAUUC 1268 CUGAAUUACUUMIMAT0005886 AGGUG GAA hsa-miR-1298 1269 UUCAUUCGGCUGUCCAG 1270UUCAUUCGGCUG 1271 GACAGCCGAAU MIMAT0005800 AUGUA UCCAGAUG GAAhsa-miR-1299 1272 UUCUGGAAUUCUGUGUG 1273 UUCUGGAAUUCU 1274 ACAGAAUUCCAMIMAT0005887 AGGGA GUGUGAGG GAA hsa-miR-1301 1275 UUGCAGCUGCCUGGGAG 1276UUGCAGCUGCCU 1277 CCAGGCAGCUG MIMAT0005797 UGACUUC GGGAGUGA CAAhsa-miR-1302 1278 UUGGGACAUACUUAUGC 1279 UUGGGACAUACU 1280 UAAGUAUGUCCMIMAT0005890 UAAA UAUGCUAA CAA hsa-miR-1303 1281 UUUAGAGACGGGGUCUU 1282UUUAGAGACGGG 1283 ACCCCGUCUCU MIMAT0005891 GCUCU GUCUUGCU AAAhsa-miR-1304 1284 UUUGAGGCUACAGUGAG 1285 UUUGAGGCUACA 1286 ACUGUAGCCUCMIMAT0005892 AUGUG GUGAGAUG AAA hsa-miR-1305 1287 UUUUCAACUCUAAUGGG 1288UUUUCAACUCUA 1289 AUUAGAGUUGA MIMAT0005893 AGAGA AUGGGAGA AAAhsa-miR-1306 1290 ACGUUGGCUCUGGUGGUG 1291 ACGUUGGCUCUG 1292 ACCAGAGCCAAMIMAT0005950 GUGGUG CGU hsa-miR-1307 1293 ACUCGGCGUGGCGUCGG 1294ACUCGGCGUGGC 1295 ACGCCACGCCG MIMAT0005951 UCGUG GUCGGUCG AGUhsa-miR-130a 1296 CAGUGCAAUGUUAAAAG 1297 CAGUGCAAUGUU 1298 UUAACAUUGCAMIMAT0000425 GGCAU AAAAGGGC CUG hsa-miR-130a* 1299 UUCACAUUGUGCUACUG1300 UUCACAUUGUGC 1301 UAGCACAAUGU MIMAT0004593 UCUGC UACUGUCU GAAhsa-miR-130b 1302 CAGUGCAAUGAUGAAAG 1303 CAGUGCAAUGAU 1304 UCAUCAUUGCAMIMAT0000691 GGCAU GAAAGGGC CUG hsa-miR-130b* 1305 ACUCUUUCCCUGUUGCA1306 ACUCUUUCCCUG 1307 AACAGGGAAAG MIMAT0004680 CUAC UUGCACUA AGUhsa-miR-132 1308 UAACAGUCUACAGCCAU 1309 UAACAGUCUACA 1310 GCUGUAGACUGMIMAT0000426 GGUCG GCCAUGGU UUA hsa-miR-132* 1311 ACCGUGGCUUUCGAUUG 1312ACCGUGGCUUUC 1313 UCGAAAGCCAC MIMAT0004594 UUACU GAUUGUUA GGUhsa-miR-1321 1314 CAGGGAGGUGAAUGUGAU 1315 CAGGGAGGUGAA 1316 CAUUCACCUCCMIMAT0005952 UGUGAU CUG hsa-miR-1322 1317 GAUGAUGCUGCUGAUGC 1318GAUGAUGCUGCU 1319 UCAGCAGCAUC MIMAT0005953 UG GAUGCUG AUC hsa-miR-13231320 UCAAAACUGAGGGGCAU 1321 UCAAAACUGAGG 1322 CCCCUCAGUUU MIMAT0005795UUUCU GGCAUUUU UGA hsa-miR-1324 1323 CCAGACAGAAUUCUAUG 1324 CCAGACAGAAUU1325 AGAAUUCUGUC MIMAT0005956 CACUUUC CUAUGCAC UGG hsa-miR-133a 1326UUUGGUCCCCUUCAACC 1327 UUUGGUCCCCUU 1328 UGAAGGGGACC MIMAT0000427 AGCUGCAACCAGC AAA hsa-miR-133b 1329 UUUGGUCCCCUUCAACC 1330 UUUGGUCCCCUU 1331UGAAGGGGACC MIMAT0000770 AGCUA CAACCAGC AAA hsa-miR-134 1332UGUGACUGGUUGACCAG 1333 UGUGACUGGUUG 1334 GUCAACCAGUC MIMAT0000447 AGGGGACCAGAGG ACA hsa-miR-135a 1335 UAUGGCUUUUUAUUCCU 1336 UAUGGCUUUUUA 1337AAUAAAAAGCC MIMAT0000428 AUGUGA UUCCUAUG AUA hsa-miR-135a* 1338UAUAGGGAUUGGAGCCG 1339 UAUAGGGAUUGG 1340 CUCCAAUCCCU MIMAT0004595 UGGCGAGCCGUGG AUA hsa-miR-135b 1341 UAUGGCUUUUCAUUCCU 1342 UAUGGCUUUUCA 1343AAUGAAAAGCC MIMAT0000758 AUGUGA UUCCUAUG AUA hsa-miR-135b* 1344AUGUAGGGCUAAAAGCC 1345 AUGUAGGGCUAA 1346 UUUUAGCCCUA MIMAT0004698 AUGGGAAGCCAUG CAU hsa-miR-136 1347 ACUCCAUUUGUUUUGAU 1348 ACUCCAUUUGUU 1349AAAACAAAUGG MIMAT0000448 GAUGGA UUGAUGAU AGU hsa-miR-136* 1350CAUCAUCGUCUCAAAUG 1351 CAUCAUCGUCUC 1352 UUGAGACGAUG MIMAT0004606 AGUCUAAAUGAGU AUG hsa-miR-137 1353 UUAUUGCUUAAGAAUAC 1354 UUAUUGCUUAAG 1355UUCUUAAGCAA MIMAT0000429 GCGUAG AAUACGCG UAA hsa-miR-138 1356AGCUGGUGUUGUGAAUC 1357 AGCUGGUGUUGU 1358 UCACAACACCA MIMAT0000430 AGGCCGGAAUCAGG GCU hsa-miR-138-1* 1359 GCUACUUCACAACACCA 1360 GCUACUUCACAA1361 UGUUGUGAAGU MIMAT0004607 GGGCC CACCAGGG AGC hsa-miR-138-2* 1362GCUAUUUCACGACACCA 1363 GCUAUUUCACGA 1364 UGUCGUGAAAU MIMAT0004596 GGGUUCACCAGGG AGC hsa-miR-139-3p 1365 GGAGACGCGGCCCUGUU 1366 GGAGACGCGGCC1367 AGGGCCGCGUC MIMAT0004552 GGAGU CUGUUGGA UCC hsa-miR-139-5p 1368UCUACAGUGCACGUGUC 1369 UCUACAGUGCAC 1370 ACGUGCACUGU MIMAT0000250 UCCAGGUGUCUCC AGA hsa-miR-140-3p 1371 UACCACAGGGUAGAACC 1372 UACCACAGGGUA1373 UCUACCCUGUG MIMAT0004597 ACGG GAACCACG GUA hsa-miR-140-5p 1374CAGUGGUUUUACCCUAU 1375 CAGUGGUUUUAC 1376 GGGUAAAACCA MIMAT0000431 GGUAGCCUAUGGU CUG hsa-miR-141 1377 UAACACUGUCUGGUAAA 1378 UAACACUGUCUG 1379ACCAGACAGUG MIMAT0000432 GAUGG GUAAAGAU UUA hsa-miR-141* 1380CAUCUUCCAGUACAGUG 1381 CAUCUUCCAGUA 1382 UGUACUGGAAG MIMAT0004598 UUGGACAGUGUUG AUG hsa-miR-142-3p 1383 UGUAGUGUUUCCUACUU 1384 UGUAGUGUUUCC1385 UAGGAAACACU MIMAT0000434 UAUGGA UACUUUAU ACA hsa-miR-142-5p 1386CAUAAAGUAGAAAGCAC 1387 CAUAAAGUAGAA 1388 CUUUCUACUUU MIMAT0000433 UACUAGCACUAC AUG hsa-miR-143 1389 UGAGAUGAAGCACUGUA 1390 UGAGAUGAAGCA 1391AGUGCUUCAUC MIMAT0000435 GCUC CUGUAGCU UCA hsa-miR-143* 1392GGUGCAGUGCUGCAUCU 1393 GGUGCAGUGCUG 1394 UGCAGCACUGC MIMAT0004599 CUGGUCAUCUCUG ACC hsa-miR-144 1395 UACAGUAUAGAUGAUGU 1396 UACAGUAUAGAU 1397UCAUCUAUACU MIMAT0000436 ACU GAUGUACU GUA hsa-miR-144* 1398GGAUAUCAUCAUAUACU 1399 GGAUAUCAUCAU 1400 AUAUGAUGAUA MIMAT0004600 GUAAGAUACUGUA UCC hsa-miR-145 1401 GUCCAGUUUUCCCAGGA 1402 GUCCAGUUUUCC 1403UGGGAAAACUG MIMAT0000437 AUCCCU CAGGAAUC GAC hsa-miR-145* 1404GGAUUCCUGGAAAUACU 1405 GGAUUCCUGGAA 1406 AUUUCCAGGAA MIMAT0004601 GUUCUAUACUGUU UCC hsa-miR-1468 1407 CUCCGUUUGCCUGUUUC 1408 CUCCGUUUGCCU 1409ACAGGCAAACG MIMAT0006789 GCUG GUUUCGCU GAG hsa-miR-1469 1410CUCGGCGCGGGGCGCGG 1411 CUCGGCGCGGGG 1412 CGCCCCGCGCC MIMAT0007347 GCUCCCGCGGGCU GAG hsa-miR-146a 1413 UGAGAACUGAAUUCCAU 1414 UGAGAACUGAAU 1415GAAUUCAGUUC MIMAT0000449 GGGUU UCCAUGGG UCA hsa-miR-146a* 1416CCUCUGAAAUUCAGUUC 1417 CCUCUGAAAUUC 1418 CUGAAUUUCAG MIMAT0004608 UUCAGAGUUCUUC AGG hsa-miR-146b- 1419 UGCCCUGUGGACUCAGU 1420 UGCCCUGUGGAC 1421GAGUCCACAGG 3p UCUGG UCAGUUCU GCA MIMAT0004766 hsa-miR-146b- 1422UGAGAACUGAAUUCCAU 1423 UGAGAACUGAAU 1424 GAAUUCAGUUC 5p AGGCU UCCAUAGGUCA MIMAT0002809 hsa-miR-147 1425 GUGUGUGGAAAUGCUUC 1426 GUGUGUGGAAAU1427 GCAUUUCCACA MIMAT0000251 UGC GCUUCUGC CAC hsa-miR-1470 1428GCCCUCCGCCCGUGCAC 1429 GCCCUCCGCCCG 1430 CACGGGCGGAG MIMAT0007348 CCCGUGCACCCC GGC hsa-miR-1471 1431 GCCCGCGUGUGGAGCCA 1432 GCCCGCGUGUGG 1433CUCCACACGCG MIMAT0007349 GGUGU AGCCAGGU GGC hsa-miR-147b 1434GUGUGCGGAAAUGCUUC 1435 GUGUGCGGAAAU 1436 GCAUUUCCGCA MIMAT0004928 UGCUAGCUUCUGC CAC hsa-miR-148a 1437 UCAGUGCACUACAGAAC 1438 UCAGUGCACUAC 1439CUGUAGUGCAC MIMAT0000243 UUUGU AGAACUUU UGA hsa-miR-148a* 1440AAAGUUCUGAGACACUC 1441 AAAGUUCUGAGA 1442 UGUCUCAGAAC MIMAT0004549 CGACUCACUCCGA UUU hsa-miR-148b 1443 UCAGUGCAUCACAGAAC 1444 UCAGUGCAUCAC 1445CUGUGAUGCAC MIMAT0000759 UUUGU AGAACUUU UGA hsa-miR-148b* 1446AAGUUCUGUUAUACACU 1447 AAGUUCUGUUAU 1448 GUAUAACAGAA MIMAT0004699 CAGGCACACUCAG CUU hsa-miR-149 1449 UCUGGCUCCGUGUCUUC 1450 UCUGGCUCCGUG 1451GACACGGAGCC MIMAT0000450 ACUCCC UCUUCACU AGA hsa-miR-149* 1452AGGGAGGGACGGGGGCU 1453 AGGGAGGGACGG 1454 CCCCGUCCCUC MIMAT0004609 GUGCGGGCUGUG CCU hsa-miR-150 1455 UCUCCCAACCCUUGUAC 1456 UCUCCCAACCCU 1457CAAGGGUUGGG MIMAT0000451 CAGUG UGUACCAG AGA hsa-miR-150* 1458CUGGUACAGGCCUGGGG 1459 CUGGUACAGGCC 1460 CAGGCCUGUAC MIMAT0004610 GACAGUGGGGGAC CAG hsa-miR-151-3p 1461 CUAGACUGAAGCUCCUU 1462 CUAGACUGAAGC1463 GAGCUUCAGUC MIMAT0000757 GAGG UCCUUGAG UAG hsa-miR-151-5p 1464UCGAGGAGCUCACAGUC 1465 UCGAGGAGCUCA 1466 UGUGAGCUCCU MIMAT0004697 UAGUCAGUCUAG CGA hsa-miR-152 1467 UCAGUGCAUGACAGAAC 1468 UCAGUGCAUGAC 1469CUGUCAUGCAC MIMAT0000438 UUGG AGAACUUG UGA hsa-miR-153 1470UUGCAUAGUCACAAAAG 1471 UUGCAUAGUCAC 1472 UUGUGACUAUG MIMAT0000439 UGAUCAAAAGUGA CAA hsa-miR-1537 1473 AAAACCGUCUAGUUACA 1474 AAAACCGUCUAG 1475AACUAGACGGU MIMAT0007399 GUUGU UUACAGUU UUU hsa-miR-1538 1476CGGCCCGGGCUGCUGCU 1477 CGGCCCGGGCUG 1478 AGCAGCCCGGG MIMAT0007400 GUUCCUCUGCUGUU CCG hsa-miR-1539 1479 UCCUGCGCGUCCCAGAU 1480 UCCUGCGCGUCC 1481UGGGACGCGCA MIMAT0007401 GCCC CAGAUGCC GGA hsa-miR-154 1482UAGGUUAUCCGUGUUGC 1483 UAGGUUAUCCGU 1484 ACACGGAUAAC MIMAT0000452 CUUCGGUUGCCUU CUA hsa-miR-154* 1485 AAUCAUACACGGUUGAC 1486 AAUCAUACACGG 1487AACCGUGUAUG MIMAT0000453 CUAUU UUGACCUA AUU hsa-miR-155 1488UUAAUGCUAAUCGUGAU 1489 UUAAUGCUAAUC 1490 ACGAUUAGCAU MIMAT0000646 AGGGGUGUGAUAGG UAA hsa-miR-155* 1491 CUCCUACAUAUUAGCAU 1492 CUCCUACAUAUU 1493CUAAUAUGUAG MIMAT0004658 UAACA AGCAUUAA GAG hsa-miR-15a 1494UAGCAGCACAUAAUGGU 1495 UAGCAGCACAUA 1496 AUUAUGUGCUG MIMAT0000068 UUGUGAUGGUUUG CUA hsa-miR-15a* 1497 CAGGCCAUAUUGUGCUG 1498 CAGGCCAUAUUG 1499CACAAUAUGGC MIMAT0004488 CCUCA UGCUGCCU CUG hsa-miR-15b 1500UAGCAGCACAUCAUGGU 1501 UAGCAGCACAUC 1502 AUGAUGUGCUG MIMAT0000417 UUACAAUGGUUUA CUA hsa-miR-15b* 1503 CGAAUCAUUAUUUGCUG 1504 CGAAUCAUUAUU 1505CAAAUAAUGAU MIMAT0004586 CUCUA UGCUGCUC UCG hsa-miR-16 1506UAGCAGCACGUAAAUAU 1507 UAGCAGCACGUA 1508 UUUACGUGCUG MIMAT0000069 UGGCGAAUAUUGG CUA hsa-miR-16-1* 1509 CCAGUAUUAACUGUGCU 1510 CCAGUAUUAACU 1511ACAGUUAAUAC MIMAT0004489 GCUGA GUGCUGCU UGG hsa-miR-16-2* 1512CCAAUAUUACUGUGCUG 1513 CCAAUAUUACUG 1514 CACAGUAAUAU MIMAT0004518 CUUUAUGCUGCUU UGG hsa-miR-17 1515 CAAAGUGCUUACAGUGC 1516 CAAAGUGCUUAC 1517CUGUAAGCACU MIMAT0000070 AGGUAG AGUGCAGG UUG hsa-miR-17* 1518ACUGCAGUGAAGGCACU 1519 ACUGCAGUGAAG 1520 GCCUUCACUGC MIMAT0000071 UGUAGGCACUUGU AGU hsa-miR-181a 1521 AACAUUCAACGCUGUCG 1522 AACAUUCAACGC 1523CAGCGUUGAAU MIMAT0000256 GUGAGU UGUCGGUG GUU hsa-miR-181a* 1524ACCAUCGACCGUUGAUU 1525 ACCAUCGACCGU 1526 CAACGGUCGAU MIMAT0000270 GUACCUGAUUGUA GGU hsa-miR-181a- 1527 ACCACUGACCGUUGACU 1528 ACCACUGACCGU 1529CAACGGUCAGU 2* GUACC UGACUGUA GGU MIMAT0004558 hsa-miR-181b 1530AACAUUCAUUGCUGUCG 1531 AACAUUCAUUGC 1532 CAGCAAUGAAU MIMAT0000257 GUGGGUUGUCGGUG GUU hsa-miR-181c 1533 AACAUUCAACCUGUCGG 1534 AACAUUCAACCU 1535ACAGGUUGAAU MIMAT0000258 UGAGU GUCGGUGA GUU hsa-miR-181c* 1536AACCAUCGACCGUUGAG 1537 AACCAUCGACCG 1538 AACGGUCGAUG MIMAT0004559 UGGACUUGAGUGG GUU hsa-miR-181d 1539 AACAUUCAUUGUUGUCG 1540 AACAUUCAUUGU 1541CAACAAUGAAU MIMAT0002821 GUGGGU UGUCGGUG GUU hsa-miR-182 1542UUUGGCAAUGGUAGAAC 1543 UUUGGCAAUGGU 1544 CUACCAUUGCC MIMAT0000259UCACACU AGAACUCA AAA hsa-miR-182* 1545 UGGUUCUAGACUUGCCA 1546UGGUUCUAGACU 1547 CAAGUCUAGAA MIMAT0000260 ACUA UGCCAACU CCAhsa-miR-1825 1548 UCCAGUGCCCUCCUCUCC 1549 UCCAGUGCCCUC 1550 AGGAGGGCACUMIMAT0006765 CUCUCC GGA hsa-miR-1827 1551 UGAGGCAGUAGAUUGAAU 1552UGAGGCAGUAGA 1553 AAUCUACUGCC MIMAT0006767 UUGAAU UCA hsa-miR-183 1554UAUGGCACUGGUAGAAU 1555 UAUGGCACUGGU 1556 CUACCAGUGCC MIMAT0000261 UCACUAGAAUUCA AUA hsa-miR-183* 1557 GUGAAUUACCGAAGGGC 1558 GUGAAUUACCGA 1559CUUCGGUAAUU MIMAT0004560 CAUAA AGGGCCAU CAC hsa-miR-184 1560UGGACGGAGAACUGAUA 1561 UGGACGGAGAAC 1562 CAGUUCUCCGU MIMAT0000454 AGGGUUGAUAAGG CCA hsa-miR-185 1563 UGGAGAGAAAGGCAGUU 1564 UGGAGAGAAAGG 1565UGCCUUUCUCU MIMAT0000455 CCUGA CAGUUCCU CCA hsa-miR-185* 1566AGGGGCUGGCUUUCCUC 1567 AGGGGCUGGCUU 1568 GAAAGCCAGCC MIMAT0004611 UGGUCUCCUCUGG CCU hsa-miR-186 1569 CAAAGAAUUCUCCUUUU 1570 CAAAGAAUUCUC 1571AGGAGAAUUCU MIMAT0000456 GGGCU CUUUUGGG UUG hsa-miR-186* 1572GCCCAAAGGUGAAUUUU 1573 GCCCAAAGGUGA 1574 AUUCACCUUUG MIMAT0004612 UUGGGAUUUUUUG GGC hsa-miR-187 1575 UCGUGUCUUGUGUUGCA 1576 UCGUGUCUUGUG 1577AACACAAGACA MIMAT0000262 GCCGG UUGCAGCC CGA hsa-miR-187* 1578GGCUACAACACAGGACC 1579 GGCUACAACACA 1580 CCUGUGUUGUA MIMAT0004561 CGGGCGGACCCGG GCC hsa-miR-188-3p 1581 CUCCCACAUGCAGGGUU 1582 CUCCCACAUGCA1583 CCUGCAUGUGG MIMAT0004613 UGCA GGGUUUGC GAG hsa-miR-188-5p 1584CAUCCCUUGCAUGGUGG 1585 CAUCCCUUGCAU 1586 CCAUGCAAGGG MIMAT0000457 AGGGGGUGGAGG AUG hsa-miR-18a 1587 UAAGGUGCAUCUAGUGC 1588 UAAGGUGCAUCU 1589CUAGAUGCACC MIMAT0000072 AGAUAG AGUGCAGA UUA hsa-miR-18a* 1590ACUGCCCUAAGUGCUCC 1591 ACUGCCCUAAGU 1592 GCACUUAGGGC MIMAT0002891 UUCUGGGCUCCUUC AGU hsa-miR-18b 1593 UAAGGUGCAUCUAGUGC 1594 UAAGGUGCAUCU 1595CUAGAUGCACC MIMAT0001412 AGUUAG AGUGCAGU UUA hsa-miR-18b* 1596UGCCCUAAAUGCCCCUU 1597 UGCCCUAAAUGC 1598 GGGCAUUUAGG MIMAT0004751 CUGGCCCCUUCUG GCA hsa-miR-190 1599 UGAUAUGUUUGAUAUAU 1600 UGAUAUGUUUGA 1601UAUCAAACAUA MIMAT0000458 UAGGU UAUAUUAG UCA hsa-miR-1908 1602CGGCGGGGACGGCGAUU 1603 CGGCGGGGACGG 1604 CGCCGUCCCCG MIMAT0007881 GGUCCGAUUGGU CCG hsa-miR-1909 1605 CGCAGGGGCCGGGUGCU 1606 CGCAGGGGCCGG 1607ACCCGGCCCCU MIMAT0007883 CACCG GUGCUCAC GCG hsa-miR-1909* 1608UGAGUGCCGGUGCCUGC 1609 UGAGUGCCGGUG 1610 GGCACCGGCAC MIMAT0007882 CCUGCCUGCCCU UCA hsa-miR-190b 1611 UGAUAUGUUUGAUAUUG 1612 UGAUAUGUUUGA 1613UAUCAAACAUA MIMAT0004929 GGUU UAUUGGGU UCA hsa-miR-191 1614CAACGGAAUCCCAAAAG 1615 CAACGGAAUCCC 1616 UUGGGAUUCCG MIMAT0000440 CAGCUGAAAAGCAG UUG hsa-miR-191* 1617 GCUGCGCUUGGAUUUCG 1618 GCUGCGCUUGGA 1619AAUCCAAGCGC MIMAT0001618 UCCCC UUUCGUCC AGC hsa-miR-1910 1620CCAGUCCUGUGCCUGCC 1621 CCAGUCCUGUGC 1622 AGGCACAGGAC MIMAT0007884 GCCUCUGCCGCC UGG hsa-miR-1911 1623 UGAGUACCGCCAUGUCU 1624 UGAGUACCGCCA 1625CAUGGCGGUAC MIMAT0007885 GUUGGG UGUCUGUU UCA hsa-miR-1911* 1626CACCAGGCAUUGUGGUC 1627 CACCAGGCAUUG 1628 CACAAUGCCUG MIMAT0007886 UCCUGGUCUCC GUG hsa-miR-1912 1629 UACCCAGAGCAUGCAGU 1630 UACCCAGAGCAU 1631GCAUGCUCUGG MIMAT0007887 GUGAA GCAGUGUG GUA hsa-miR-1913 1632UCUGCCCCCUCCGCUGC 1633 UCUGCCCCCUCC 1634 GCGGAGGGGGC MIMAT0007888 UGCCAGCUGCUGC AGA hsa-miR-1914 1635 CCCUGUGCCCGGCCCAC 1636 CCCUGUGCCCGG 1637GGCCGGGCACA MIMAT0007889 UUCUG CCCACUUC GGG hsa-miR-1914* 1638GGAGGGGUCCCGCACUG 1639 GGAGGGGUCCCG 1640 UGCGGGACCCC MIMAT0007890 GGAGGCACUGGGA UCC hsa-miR-1915 1641 CCCCAGGGCGACGCGGC 1642 CCCCAGGGCGAC 1643GCGUCGCCCUG MIMAT0007892 GGG GCGGCGGG GGG hsa-miR-1915* 1644ACCUUGCCUUGCUGCCC 1645 ACCUUGCCUUGC 1646 CAGCAAGGCAA MIMAT0007891 GGGCCUGCCCGGG GGU hsa-miR-192 1647 CUGACCUAUGAAUUGAC 1648 CUGACCUAUGAA 1649AAUUCAUAGGU MIMAT0000222 AGCC UUGACAGC CAG hsa-miR-192* 1650CUGCCAAUUCCAUAGGU 1651 CUGCCAAUUCCA 1652 UAUGGAAUUGG MIMAT0004543 CACAGUAGGUCAC CAG hsa-miR-193a- 1653 AACUGGCCUACAAAGUC 1654 AACUGGCCUACA 1655UUUGUAGGCCA 3p CCAGU AAGUCCCA GUU MIMAT0000459 hsa-miR-193a- 1656UGGGUCUUUGCGGGCGA 1657 UGGGUCUUUGCG 1658 CCCGCAAAGAC 5p GAUGA GGCGAGAUCCA MIMAT0004614 hsa-miR-193b 1659 AACUGGCCCUCAAAGUC 1660 AACUGGCCCUCA1661 UUUGAGGGCCA MIMAT0002819 CCGCU AAGUCCCG GUU hsa-miR-193b* 1662CGGGGUUUUGAGGGCGA 1663 CGGGGUUUUGAG 1664 CCCUCAAAACC MIMAT0004767 GAUGAGGCGAGAU CCG hsa-miR-194 1665 UGUAACAGCAACUCCAU 1666 UGUAACAGCAAC 1667GAGUUGCUGUU MIMAT0000460 GUGGA UCCAUGUG ACA hsa-miR-194* 1668CCAGUGGGGCUGCUGUU 1669 CCAGUGGGGCUG 1670 AGCAGCCCCAC MIMAT0004671 AUCUGCUGUUAUC UGG hsa-miR-195 1671 UAGCAGCACAGAAAUAU 1672 UAGCAGCACAGA 1673UUUCUGUGCUG MIMAT0000461 UGGC AAUAUUGG CUA hsa-miR-195* 1674CCAAUAUUGGCUGUGCU 1675 CCAAUAUUGGCU 1676 ACAGCCAAUAU MIMAT0004615 GCUCCGUGCUGCU UGG hsa-miR-196a 1677 UAGGUAGUUUCAUGUUG 1678 UAGGUAGUUUCA 1679CAUGAAACUAC MIMAT0000226 UUGGG UGUUGUUG CUA hsa-miR-196a* 1680CGGCAACAAGAAACUGC 1681 CGGCAACAAGAA 1682 GUUUCUUGUUG MIMAT0004562 CUGAGACUGCCUG CCG hsa-miR-196b 1683 UAGGUAGUUUCCUGUUG 1684 UAGGUAGUUUCC 1685CAGGAAACUAC MIMAT0001080 UUGGG UGUUGUUG CUA hsa-miR-196b* 1686UCGACAGCACGACACUG 1687 UCGACAGCACGA 1688 UGUCGUGCUGU MIMAT0009201 CCUUCCACUGCCU CGA hsa-miR-197 1689 UUCACCACCUUCUCCAC 1690 UUCACCACCUUC 1691GAGAAGGUGGU MIMAT0000227 CCAGC UCCACCCA GAA hsa-miR-1972 1692UCAGGCCAGGCACAGUG 1693 UCAGGCCAGGCA 1694 UGUGCCUGGCC MIMAT0009447 GCUCACAGUGGCU UGA hsa-miR-1973 1695 ACCGUGCAAAGGUAGCA 1696 ACCGUGCAAAGG 1697UACCUUUGCAC MIMAT0009448 UA UAGCAUA GGU hsa-miR-1976 1698CCUCCUGCCCUCCUUGC 1699 CCUCCUGCCCUC 1700 AGGAGGGCAGG MIMAT0009451 UGUCUUGCUGU AGG hsa-miR-198 1701 GGUCCAGAGGGGAGAUA 1702 GGUCCAGAGGGG 1703CUCCCCUCUGG MIMAT0000228 GGUUC AGAUAGGU ACC hsa-miR-199a- 1704ACAGUAGUCUGCACAUU 1705 ACAGUAGUCUGC 1706 GUGCAGACUAC 3p GGUUA ACAUUGGUUGU MIMAT0000232 hsa-miR-199a- 1707 CCCAGUGUUCAGACUAC 1708 CCCAGUGUUCAG1709 GUCUGAACACU 5p CUGUUC ACUACCUG GGG MIMAT0000231 hsa-miR-199b- 1710ACAGUAGUCUGCACAUU 1711 ACAGUAGUCUGC 1712 GUGCAGACUAC 3p GGUUA ACAUUGGUUGU MIMAT0004563 hsa-miR-199b- 1713 CCCAGUGUUUAGACUAU 1714 CCCAGUGUUUAG1715 GUCUAAACACU 5p CUGUUC ACUAUCUG GGG MIMAT0000263 hsa-miR-19a 1716UGUGCAAAUCUAUGCAA 1717 UGUGCAAAUCUA 1718 CAUAGAUUUGC MIMAT0000073 AACUGAUGCAAAAC ACA hsa-miR-19a* 1719 AGUUUUGCAUAGUUGCA 1720 AGUUUUGCAUAG 1721AACUAUGCAAA MIMAT0004490 CUACA UUGCACUA ACU hsa-miR-19b 1722UGUGCAAAUCCAUGCAA 1723 UGUGCAAAUCCA 1724 CAUGGAUUUGC MIMAT0000074 AACUGAUGCAAAAC ACA hsa-miR-19b-1* 1725 AGUUUUGCAGGUUUGCA 1726 AGUUUUGCAGGU1727 AAACCUGCAAA MIMAT0004491 UCCAGC UUGCAUCC ACU hsa-miR-19b-2* 1728AGUUUUGCAGGUUUGCA 1729 AGUUUUGCAGGU 1730 AAACCUGCAAA MIMAT0004492 UUUCAUUGCAUUU ACU hsa-miR-200a 1731 UAACACUGUCUGGUAAC 1732 UAACACUGUCUG 1733ACCAGACAGUG MIMAT0000682 GAUGU GUAACGAU UUA hsa-miR-200a* 1734CAUCUUACCGGACAGUG 1735 CAUCUUACCGGA 1736 UGUCCGGUAAG MIMAT0001620 CUGGACAGUGCUG AUG hsa-miR-200b 1737 UAAUACUGCCUGGUAAU 1738 UAAUACUGCCUG 1739ACCAGGCAGUA MIMAT0000318 GAUGA GUAAUGAU UUA hsa-miR-200b* 1740CAUCUUACUGGGCAGCA 1741 CAUCUUACUGGG 1742 UGCCCAGUAAG MIMAT0004571 UUGGACAGCAUUG AUG hsa-miR-200c 1743 UAAUACUGCCGGGUAAU 1744 UAAUACUGCCGG 1745ACCCGGCAGUA MIMAT0000617 GAUGGA GUAAUGAU UUA hsa-miR-200c* 1746CGUCUUACCCAGCAGUG 1747 CGUCUUACCCAG 1748 UGCUGGGUAAG MIMAT0004657 UUUGGCAGUGUUU ACG hsa-miR-202 1749 AGAGGUAUAGGGCAUGG 1750 AGAGGUAUAGGG 1751UGCCCUAUACC MIMAT0002811 GAA CAUGGGAA UCU hsa-miR-202* 1752UUCCUAUGCAUAUACUU 1753 UUCCUAUGCAUA 1754 UAUAUGCAUAG MIMAT0002810 CUUUGUACUUCUU GAA hsa-miR-203 1755 GUGAAAUGUUUAGGACC 1756 GUGAAAUGUUUA 1757CCUAAACAUUU MIMAT0000264 ACUAG GGACCACU CAC hsa-miR-204 1758UUCCCUUUGUCAUCCUA 1759 UUCCCUUUGUCA 1760 GAUGACAAAGG MIMAT0000265 UGCCUUCCUAUGC GAA hsa-miR-205 1761 UCCUUCAUUCCACCGGA 1762 UCCUUCAUUCCA 1763GGUGGAAUGAA MIMAT0000266 GUCUG CCGGAGUC GGA hsa-miR-205* 1764GAUUUCAGUGGAGUGAA 1765 GAUUUCAGUGGA 1766 ACUCCACUGAA MIMAT0009197 GUUCGUGAAGUU AUC hsa-miR-2052 1767 UGUUUUGAUAACAGUAA 1768 UGUUUUGAUAAC 1769CUGUUAUCAAA MIMAT0009977 UGU AGUAAUGU ACA hsa-miR-2053 1770GUGUUAAUUAAACCUCU 1771 GUGUUAAUUAAA 1772 GGUUUAAUUAA MIMAT0009978 AUUUACCCUCUAUU CAC hsa-miR-2054 1773 CUGUAAUAUAAAUUUAA 1774 CUGUAAUAUAAA 1775AAUUUAUAUUA MIMAT0009979 UUUAUU UUUAAUUU CAG hsa-miR-206 1776UGGAAUGUAAGGAAGUG 1777 UGGAAUGUAAGG 1778 UUCCUUACAUU MIMAT0000462 UGUGGAAGUGUGU CCA hsa-miR-208a 1779 AUAAGACGAGCAAAAAG 1780 AUAAGACGAGCA 1781UUUGCUCGUCU MIMAT0000241 CUUGU AAAAGCUU UAU hsa-miR-208b 1782AUAAGACGAACAAAAGG 1783 AUAAGACGAACA 1784 UUUGUUCGUCU MIMAT0004960 UUUGUAAAGGUUU UAU hsa-miR-20a 1785 UAAAGUGCUUAUAGUGC 1786 UAAAGUGCUUAU 1787CUAUAAGCACU MIMAT0000075 AGGUAG AGUGCAGG UUA hsa-miR-20a* 1788ACUGCAUUAUGAGCACU 1789 ACUGCAUUAUGA 1790 GCUCAUAAUGC MIMAT0004493 UAAAGGCACUUAA AGU hsa-miR-20b 1791 CAAAGUGCUCAUAGUGC 1792 CAAAGUGCUCAU 1793CUAUGAGCACU MIMAT0001413 AGGUAG AGUGCAGG UUG hsa-miR-20b* 1794ACUGUAGUAUGGGCACU 1795 ACUGUAGUAUGG 1796 GCCCAUACUAC MIMAT0004752 UCCAGGCACUUCC AGU hsa-miR-21 1797 UAGCUUAUCAGACUGAU 1798 UAGCUUAUCAGA 1799AGUCUGAUAAG MIMAT0000076 GUUGA CUGAUGUU CUA hsa-miR-21* 1800CAACACCAGUCGAUGGG 1801 CAACACCAGUCG 1802 AUCGACUGGUG MIMAT0004494 CUGUAUGGGCUG UUG hsa-miR-210 1803 CUGUGCGUGUGACAGCG 1804 CUGUGCGUGUGA 1805UGUCACACGCA MIMAT0000267 GCUGA CAGCGGCU CAG hsa-miR-211 1806UUCCCUUUGUCAUCCUU 1807 UUCCCUUUGUCA 1808 GAUGACAAAGG MIMAT0000268 CGCCUUCCUUCGC GAA hsa-miR-2110 1809 UUGGGGAAACGGCCGCU 1810 UUGGGGAAACGG 1811GGCCGUUUCCC MIMAT0010133 GAGUG CCGCUGAG CAA hsa-miR-2113 1812AUUUGUGCUUGGCUCUG 1813 AUUUGUGCUUGG 1814 AGCCAAGCACA MIMAT0009206 UCACCUCUGUCA AAU hsa-miR-2114 1815 UAGUCCCUUCCUUGAAG 1816 UAGUCCCUUCCU 1817CAAGGAAGGGA MIMAT0011156 CGGUC UGAAGCGG CUA hsa-miR-2114* 1818CGAGCCUCAAGCAAGGG 1819 CGAGCCUCAAGC 1820 UUGCUUGAGGC MIMAT0011157 ACUUAAGGGACU UCG hsa-miR-2115 1821 AGCUUCCAUGACUCCUG 1822 AGCUUCCAUGAC 1823GAGUCAUGGAA MIMAT0011158 AUGGA UCCUGAUG GCU hsa-miR-2115* 1824CAUCAGAAUUCAUGGAG 1825 CAUCAGAAUUCA 1826 CAUGAAUUCUG MIMAT0011159 GCUAGUGGAGGCU AUG hsa-miR-2116 1827 GGUUCUUAGCAUAGGAG 1828 GGUUCUUAGCAU 1829CUAUGCUAAGA MIMAT0011160 GUCU AGGAGGUC ACC hsa-miR-2116* 1830CCUCCCAUGCCAAGAAC 1831 CCUCCCAUGCCA 1832 CUUGGCAUGGG MIMAT0011161 UCCCAGAACUCC AGG hsa-miR-2117 1833 UGUUCUCUUUGCCAAGG 1834 UGUUCUCUUUGC 1835UGGCAAAGAGA MIMAT0011162 ACAG CAAGGACA ACA hsa-miR-212 1836UAACAGUCUCCAGUCAC 1837 UAACAGUCUCCA 1838 ACUGGAGACUG MIMAT0000269 GGCCGUCACGGC UUA hsa-miR-214 1839 ACAGCAGGCACAGACAG 1840 ACAGCAGGCACA 1841UCUGUGCCUGC MIMAT0000271 GCAGU GACAGGCA UGU hsa-miR-214* 1842UGCCUGUCUACACUUGC 1843 UGCCUGUCUACA 1844 AGUGUAGACAG MIMAT0004564 UGUGCCUUGCUGU GCA hsa-miR-215 1845 AUGACCUAUGAAUUGAC 1846 AUGACCUAUGAA 1847AAUUCAUAGGU MIMAT0000272 AGAC UUGACAGA CAU hsa-miR-216a 1848UAAUCUCAGCUGGCAAC 1849 UAAUCUCAGCUG 1850 GCCAGCUGAGA MIMAT0000273 UGUGAGCAACUGU UUA hsa-miR-216b 1851 AAAUCUCUGCAGGCAAA 1852 AAAUCUCUGCAG 1853GCCUGCAGAGA MIMAT0004959 UGUGA GCAAAUGU UUU hsa-miR-217 1854UACUGCAUCAGGAACUG 1855 UACUGCAUCAGG 1856 UUCCUGAUGCA MIMAT0000274 AUUGGAAACUGAUU GUA hsa-miR-218 1857 UUGUGCUUGAUCUAACC 1858 UUGUGCUUGAUC 1859UAGAUCAAGCA MIMAT0000275 AUGU UAACCAUG CAA hsa-miR-218-1* 1860AUGGUUCCGUCAAGCAC 1861 AUGGUUCCGUCA 1862 CUUGACGGAAC MIMAT0004565 CAUGGAGCACCAU CAU hsa-miR-218-2* 1863 CAUGGUUCUGUCAAGCA 1864 CAUGGUUCUGUC1865 UUGACAGAACC MIMAT0004566 CCGCG AAGCACCG AUG hsa-miR-219-1- 1866AGAGUUGAGUCUGGACG 1867 AGAGUUGAGUCU 1868 CCAGACUCAAC 3p UCCCG GGACGUCCUCU MIMAT0004567 hsa-miR-219-2- 1869 AGAAUUGUGGCUGGACA 1870 AGAAUUGUGGCU1871 CCAGCCACAAU 3p UCUGU GGACAUCU UCU MIMAT0004675 hsa-miR-219-5p 1872UGAUUGUCCAAACGCAA 1873 UGAUUGUCCAAA 1874 CGUUUGGACAA MIMAT0000276 UUCUCGCAAUUC UCA hsa-miR-22 1875 AAGCUGCCAGUUGAAGA 1876 AAGCUGCCAGUU 1877UCAACUGGCAG MIMAT0000077 ACUGU GAAGAACU CUU hsa-miR-22* 1878AGUUCUUCAGUGGCAAG 1879 AGUUCUUCAGUG 1880 GCCACUGAAGA MIMAT0004495 CUUUAGCAAGCUU ACU hsa-miR-221 1881 AGCUACAUUGUCUGCUG 1882 AGCUACAUUGUC 1883CAGACAAUGUA MIMAT0000278 GGUUUC UGCUGGGU GCU hsa-miR-221* 1884ACCUGGCAUACAAUGUA 1885 ACCUGGCAUACA 1886 AUUGUAUGCCA MIMAT0004568 GAUUUAUGUAGAU GGU hsa-miR-222 1887 AGCUACAUCUGGCUACU 1888 AGCUACAUCUGG 1889AGCCAGAUGUA MIMAT0000279 GGGU CUACUGGG GCU hsa-miR-222* 1890CUCAGUAGCCAGUGUAG 1891 CUCAGUAGCCAG 1892 CACUGGCUACU MIMAT0004569 AUCCUUGUAGAUC GAG hsa-miR-223 1893 UGUCAGUUUGUCAAAUA 1894 UGUCAGUUUGUC 1895UUGACAAACUG MIMAT0000280 CCCCA AAAUACCC ACA hsa-miR-223* 1896CGUGUAUUUGACAAGCU 1897 CGUGUAUUUGAC 1898 UUGUCAAAUAC MIMAT0004570 GAGUUAAGCUGAG ACG hsa-miR-224 1899 CAAGUCACUAGUGGUUC 1900 CAAGUCACUAGU 1901CCACUAGUGAC MIMAT0000281 CGUU GGUUCCGU UUG hsa-miR-224* 1902AAAAUGGUGCCCUAGUG 1903 AAAAUGGUGCCC 1904 UAGGGCACCAU MIMAT0009198 ACUACAUAGUGACU UUU hsa-miR-2276 1905 UCUGCAAGUGUCAGAGG 1906 UCUGCAAGUGUC 1907CUGACACUUGC MIMAT0011775 CGAGG AGAGGCGA AGA hsa-miR-2277- 1908UGACAGCGCCCUGCCUG 1909 UGACAGCGCCCU 1910 GCAGGGCGCUG 3p GCUC GCCUGGCUUCA MIMAT0011777 hsa-miR-2277- 1911 AGCGCGGGCUGAGCGCU 1912 AGCGCGGGCUGA1913 GCUCAGCCCGC 5p GCCAGUC GCGCUGCC GCU MIMAT0017352 hsa-miR-2278 1914GAGAGCAGUGUGUGUUG 1915 GAGAGCAGUGUG 1916 CACACACUGCU MIMAT0011778 CCUGGUGUUGCCU CUC hsa-miR-2355- 1917 AUUGUCCUUGCUGUUUG 1918 AUUGUCCUUGCU 1919ACAGCAAGGAC 3p GAGAU GUUUGGAG AAU MIMAT0017950 hsa-miR-2355- 1920AUCCCCAGAUACAAUGG 1921 AUCCCCAGAUAC 1922 UUGUAUCUGGG 5p ACAA AAUGGACAGAU MIMAT0016895 hsa-miR-23a 1923 AUCACAUUGCCAGGGAU 1924 AUCACAUUGCCA1925 CCUGGCAAUGU MIMAT0000078 UUCC GGGAUUUC GAU hsa-miR-23a* 1926GGGGUUCCUGGGGAUGG 1927 GGGGUUCCUGGG 1928 UCCCCAGGAAC MIMAT0004496 GAUUUGAUGGGAU CCC hsa-miR-23b 1929 AUCACAUUGCCAGGGAU 1930 AUCACAUUGCCA 1931CCUGGCAAUGU MIMAT0000418 UACC GGGAUUAC GAU hsa-miR-23b* 1932UGGGUUCCUGGCAUGCU 1933 UGGGUUCCUGGC 1934 AUGCCAGGAAC MIMAT0004587 GAUUUAUGCUGAU CCA hsa-miR-23c 1935 AUCACAUUGCCAGUGAU 1936 AUCACAUUGCCA 1937ACUGGCAAUGU MIMAT0018000 UACCC GUGAUUAC GAU hsa-miR-24 1938UGGCUCAGUUCAGCAGG 1939 UGGCUCAGUUCA 1940 GCUGAACUGAG MIMAT0000080 AACAGGCAGGAAC CCA hsa-miR-24-1* 1941 UGCCUACUGAGCUGAUA 1942 UGCCUACUGAGC 1943CAGCUCAGUAG MIMAT0000079 UCAGU UGAUAUCA GCA hsa-miR-24-2* 1944UGCCUACUGAGCUGAAA 1945 UGCCUACUGAGC 1946 CAGCUCAGUAG MIMAT0004497 CACAGUGAAACAC GCA hsa-miR-25 1947 CAUUGCACUUGUCUCGG 1948 CAUUGCACUUGU 1949AGACAAGUGCA MIMAT0000081 UCUGA CUCGGUCU AUG hsa-miR-25* 1950AGGCGGAGACUUGGGCA 1951 AGGCGGAGACUU 1952 CCAAGUCUCCG MIMAT0004498 AUUGGGGCAAUU CCU hsa-miR-26a 1953 UUCAAGUAAUCCAGGAU 1954 UUCAAGUAAUCC 1955CUGGAUUACUU MIMAT0000082 AGGCU AGGAUAGG GAA hsa-miR-26a-1* 1956CCUAUUCUUGGUUACUU 1957 CCUAUUCUUGGU 1958 UAACCAAGAAU MIMAT0004499 GCACGUACUUGCA AGG hsa-miR-26a-2* 1959 CCUAUUCUUGAUUACUU 1960 CCUAUUCUUGAU1961 UAAUCAAGAAU MIMAT0004681 GUUUC UACUUGUU AGG hsa-miR-26b 1962UUCAAGUAAUUCAGGAU 1963 UUCAAGUAAUUC 1964 CUGAAUUACUU MIMAT0000083 AGGUAGGAUAGG GAA hsa-miR-26b* 1965 CCUGUUCUCCAUUACUU 1966 CCUGUUCUCCAU 1967UAAUGGAGAAC MIMAT0004500 GGCUC UACUUGGC AGG hsa-miR-27a 1968UUCACAGUGGCUAAGUU 1969 UUCACAGUGGCU 1970 UUAGCCACUGU MIMAT0000084 CCGCAAGUUCCG GAA hsa-miR-27a* 1971 AGGGCUUAGCUGCUUGU 1972 AGGGCUUAGCUG 1973AGCAGCUAAGC MIMAT0004501 GAGCA CUUGUGAG CCU hsa-miR-27b 1974UUCACAGUGGCUAAGUU 1975 UUCACAGUGGCU 1976 UUAGCCACUGU MIMAT0000419 CUGCAAGUUCUG GAA hsa-miR-27b* 1977 AGAGCUUAGCUGAUUGG 1978 AGAGCUUAGCUG 1979AUCAGCUAAGC MIMAT0004588 UGAAC AUUGGUGA UCU hsa-miR-28-3p 1980CACUAGAUUGUGAGCUC 1981 CACUAGAUUGUG 1982 CUCACAAUCUA MIMAT0004502 CUGGAAGCUCCUG GUG hsa-miR-28-5p 1983 AAGGAGCUCACAGUCUA 1984 AAGGAGCUCACA 1985ACUGUGAGCUC MIMAT0000085 UUGAG GUCUAUUG CUU hsa-miR-2861 1986GGGGCCUGGCGGUGGGC 1987 GGGGCCUGGCGG 1988 CACCGCCAGGC MIMAT0013802 GGUGGGCGG CCC hsa-miR-2909 1989 GUUAGGGCCAACAUCUC 1990 GUUAGGGCCAAC 1991AUGUUGGCCCU MIMAT0013863 UUGG AUCUCUUG AAC hsa-miR-296-3p 1992GAGGGUUGGGUGGAGGC 1993 GAGGGUUGGGUG 1994 UCCACCCAACC MIMAT0004679 UCUCCGAGGCUCU CUC hsa-miR-296-5p 1995 AGGGCCCCCCCUCAAUC 1996 AGGGCCCCCCCU1997 UGAGGGGGGGC MIMAT0000690 CUGU CAAUCCUG CCU hsa-miR-297 1998AUGUAUGUGUGCAUGUG 1999 AUGUAUGUGUGC 2000 AUGCACACAUA MIMAT0004450 CAUGAUGUGCAU CAU hsa-miR-298 2001 AGCAGAAGCAGGGAGGU 2002 AGCAGAAGCAGG 2003UCCCUGCUUCU MIMAT0004901 UCUCCCA GAGGUUCU GCU hsa-miR-299-3p 2004UAUGUGGGAUGGUAAAC 2005 UAUGUGGGAUGG 2006 UACCAUCCCAC MIMAT0000687 CGCUUUAAACCGC AUA hsa-miR-299-5p 2007 UGGUUUACCGUCCCACA 2008 UGGUUUACCGUC2009 GGGACGGUAAA MIMAT0002890 UACAU CCACAUAC CCA hsa-miR-29a 2010UAGCACCAUCUGAAAUC 2011 UAGCACCAUCUG 2012 UUCAGAUGGUG MIMAT0000086 GGUUAAAAUCGGU CUA hsa-miR-29a* 2013 ACUGAUUUCUUUUGGUG 2014 ACUGAUUUCUUU 2015CAAAAGAAAUC MIMAT0004503 UUCAG UGGUGUUC AGU hsa-miR-29b 2016UAGCACCAUUUGAAAUC 2017 UAGCACCAUUUG 2018 UUCAAAUGGUG MIMAT0000100 AGUGUUAAAUCAGU CUA hsa-miR-29b-1* 2019 GCUGGUUUCAUAUGGUG 2020 GCUGGUUUCAUA2021 CAUAUGAAACC MIMAT0004514 GUUUAGA UGGUGGUU AGC hsa-miR-29b-2* 2022CUGGUUUCACAUGGUGG 2023 CUGGUUUCACAU 2024 CCAUGUGAAAC MIMAT0004515 CUUAGGGUGGCUU CAG hsa-miR-29c 2025 UAGCACCAUUUGAAAUC 2026 UAGCACCAUUUG 2027UUCAAAUGGUG MIMAT0000681 GGUUA AAAUCGGU CUA hsa-miR-29c* 2028UGACCGAUUUCUCCUGG 2029 UGACCGAUUUCU 2030 GGAGAAAUCGG MIMAT0004673 UGUUCCCUGGUGU UCA hsa-miR-300 2031 UAUACAAGGGCAGACUC 2032 UAUACAAGGGCA 2033UCUGCCCUUGU MIMAT0004903 UCUCU GACUCUCU AUA hsa-miR-301a 2034CAGUGCAAUAGUAUUGU 2035 CAGUGCAAUAGU 2036 AUACUAUUGCA MIMAT0000688 CAAAGCAUUGUCAA CUG hsa-miR-301b 2037 CAGUGCAAUGAUAUUGU 2038 CAGUGCAAUGAU 2039AUAUCAUUGCA MIMAT0004958 CAAAGC AUUGUCAA CUG hsa-miR-302a 2040UAAGUGCUUCCAUGUUU 2041 UAAGUGCUUCCA 2042 CAUGGAAGCAC MIMAT0000684 UGGUGAUGUUUUGG UUA hsa-miR-302a* 2043 ACUUAAACGUGGAUGUA 2044 ACUUAAACGUGG 2045AUCCACGUUUA MIMAT0000683 CUUGCU AUGUACUU AGU hsa-miR-302b 2046UAAGUGCUUCCAUGUUU 2047 UAAGUGCUUCCA 2048 CAUGGAAGCAC MIMAT0000715 UAGUAGUGUUUUAG UUA hsa-miR-302b* 2049 ACUUUAACAUGGAAGUG 2050 ACUUUAACAUGG 2051UUCCAUGUUAA MIMAT0000714 CUUUC AAGUGCUU AGU hsa-miR-302c 2052UAAGUGCUUCCAUGUUU 2053 UAAGUGCUUCCA 2054 CAUGGAAGCAC MIMAT0000717 CAGUGGUGUUUCAG UUA hsa-miR-302c* 2055 UUUAACAUGGGGGUACC 2056 UUUAACAUGGGG 2057ACCCCCAUGUU MIMAT0000716 UGCUG GUACCUGC AAA hsa-miR-302d 2058UAAGUGCUUCCAUGUUU 2059 UAAGUGCUUCCA 2060 CAUGGAAGCAC MIMAT0000718 GAGUGUUGUUUGAG UUA hsa-miR-302d* 2061 ACUUUAACAUGGAGGCA 2062 ACUUUAACAUGG 2063CUCCAUGUUAA MIMAT0004685 CUUGC AGGCACUU AGU hsa-miR-302e 2064UAAGUGCUUCCAUGCUU 2065 UAAGUGCUUCCA 2066 CAUGGAAGCAC MIMAT0005931 UGCUUUUA hsa-miR-302f 2067 UAAUUGCUUCCAUGUUU 2068 UAAUUGCUUCCA 2069CAUGGAAGCAA MIMAT0005932 UGUUU UUA hsa-miR-3065- 2070 UCAGCACCAGGAUAUUG2071 UCAGCACCAGGA 2072 UAUCCUGGUGC 3p UUGGAG UAUUGUUG UGA MIMAT0015378hsa-miR-3065- 2073 UCAACAAAAUCACUGAU 2074 UCAACAAAAUCA 2075 AGUGAUUUUGU5p GCUGGA CUGAUGCU UGA MIMAT0015066 hsa-miR-3074 2076 GAUAUCAGCUCAGUAGG2077 GAUAUCAGCUCA 2078 ACUGAGCUGAU MIMAT0015027 CACCG GUAGGCAC AUChsa-miR-30a 2079 UGUAAACAUCCUCGACU 2080 UGUAAACAUCCU 2081 CGAGGAUGUUUMIMAT0000087 GGAAG CGACUGGA ACA hsa-miR-30a* 2082 CUUUCAGUCGGAUGUUU 2083CUUUCAGUCGGA 2084 CAUCCGACUGA MIMAT0000088 GCAGC UGUUUGCA AAGhsa-miR-30b 2085 UGUAAACAUCCUACACU 2086 UGUAAACAUCCU 2087 GUAGGAUGUUUMIMAT0000420 CAGCU ACACUCAG ACA hsa-miR-30b* 2088 CUGGGAGGUGGAUGUUU 2089CUGGGAGGUGGA 2090 CAUCCACCUCC MIMAT0004589 ACUUC UGUUUACU CAGhsa-miR-30c 2091 UGUAAACAUCCUACACU 2092 UGUAAACAUCCU 2093 GUAGGAUGUUUMIMAT0000244 CUCAGC ACACUCUC ACA hsa-miR-30c-1* 2094 CUGGGAGAGGGUUGUUU2095 CUGGGAGAGGGU 2096 CAACCCUCUCC MIMAT0004674 ACUCC UGUUUACU CAGhsa-miR-30c-2* 2097 CUGGGAGAAGGCUGUUU 2098 CUGGGAGAAGGC 2099 CAGCCUUCUCCMIMAT0004550 ACUCU UGUUUACU CAG hsa-miR-30d 2100 UGUAAACAUCCCCGACU 2101UGUAAACAUCCC 2102 CGGGGAUGUUU MIMAT0000245 GGAAG CGACUGGA ACAhsa-miR-30d* 2103 CUUUCAGUCAGAUGUUU 2104 CUUUCAGUCAGA 2105 CAUCUGACUGAMIMAT0004551 GCUGC UGUUUGCU AAG hsa-miR-30e 2106 UGUAAACAUCCUUGACU 2107UGUAAACAUCCU 2108 CAAGGAUGUUU MIMAT0000692 GGAAG UGACUGGA ACAhsa-miR-30e* 2109 CUUUCAGUCGGAUGUUU 2110 CUUUCAGUCGGA 2111 CAUCCGACUGAMIMAT0000693 ACAGC UGUUUACA AAG hsa-miR-31 2112 AGGCAAGAUGCUGGCAU 2113AGGCAAGAUGCU 2114 CCAGCAUCUUG MIMAT0000089 AGCU GGCAUAGC CCU hsa-miR-31*2115 UGCUAUGCCAACAUAUU 2116 UGCUAUGCCAAC 2117 AUGUUGGCAUA MIMAT0004504GCCAU AUAUUGCC GCA hsa-miR-3115 2118 AUAUGGGUUUACUAGUU 2119 AUAUGGGUUUAC2120 UAGUAAACCCA MIMAT0014977 GGU UAGUUGGU UAU hsa-miR-3116 2121UGCCUGGAACAUAGUAG 2122 UGCCUGGAACAU 2123 CUAUGUUCCAG MIMAT0014978 GGACUAGUAGGGA GCA hsa-miR-3117 2124 AUAGGACUCAUAUAGUG 2125 AUAGGACUCAUA 2126UAUAUGAGUCC MIMAT0014979 CCAG UAGUGCCA UAU hsa-miR-3118 2127UGUGACUGCAUUAUGAA 2128 UGUGACUGCAUU 2129 AUAAUGCAGUC MIMAT0014980 AAUUCUAUGAAAAU ACA hsa-miR-3119 2130 UGGCUUUUAACUUUGAU 2131 UGGCUUUUAACU 2132AAAGUUAAAAG MIMAT0014981 GGC UUGAUGGC CCA hsa-miR-3120 2133CACAGCAAGUGUAGACA 2134 CACAGCAAGUGU 2135 CUACACUUGCU MIMAT0014982 GGCAAGACAGGC GUG hsa-miR-3121 2136 UAAAUAGAGUAGGCAAA 2137 UAAAUAGAGUAG 2138GCCUACUCUAU MIMAT0014983 GGACA GCAAAGGA UUA hsa-miR-3122 2139GUUGGGACAAGAGGACG 2140 GUUGGGACAAGA 2141 CCUCUUGUCCC MIMAT0014984 GUCUUGGACGGUC AAC hsa-miR-3123 2142 CAGAGAAUUGUUUAAUC 2143 CAGAGAAUUGUU 2144UAAACAAUUCU MIMAT0014985 UAAUC CUG hsa-miR-3124 2145 UUCGCGGGCGAAGGCAA2146 UUCGCGGGCGAA 2147 CCUUCGCCCGC MIMAT0014986 AGUC GGCAAAGU GAAhsa-miR-3125 2148 UAGAGGAAGCUGUGGAG 2149 UAGAGGAAGCUG 2150 CACAGCUUCCUMIMAT0014988 AGA UGGAGAGA CUA hsa-miR-3126- 2151 CAUCUGGCAUCCGUCAC 2152CAUCUGGCAUCC 2153 ACGGAUGCCAG 3p ACAGA GUCACACA AUG MIMAT0015377hsa-miR-3126- 2154 UGAGGGACAGAUGCCAG 2155 UGAGGGACAGAU 2156 GCAUCUGUCCC5p AAGCA GCCAGAAG UCA MIMAT0014989 hsa-miR-3127 2157 AUCAGGGCUUGUGGAAU2158 AUCAGGGCUUGU 2159 CCACAAGCCCU MIMAT0014990 GGGAAG GGAAUGGG GAUhsa-miR-3128 2160 UCUGGCAAGUAAAAAAC 2161 UCUGGCAAGUAA 2162 UUUUACUUGCCMIMAT0014991 UCUCAU AAAACUCU AGA hsa-miR-3129 2163 GCAGUAGUGUAGAGAUU2164 GCAGUAGUGUAG 2165 CUCUACACUAC MIMAT0014992 GGUUU AGAUUGGU UGChsa-miR-3130- 2166 GCUGCACCGGAGACUGG 2167 GCUGCACCGGAG 2168 GUCUCCGGUGC3p GUAA ACUGGGUA AGC MIMAT0014994 hsa-miR-3130- 2169 UACCCAGUCUCCGGUGC2170 UACCCAGUCUCC 2171 CCGGAGACUGG 5p AGCC GGUGCAGC GUA MIMAT0014995hsa-miR-3131 2172 UCGAGGACUGGUGGAAG 2173 UCGAGGACUGGU 2174 CCACCAGUCCUMIMAT0014996 GGCCUU GGAAGGGC CGA hsa-miR-3132 2175 UGGGUAGAGAAGGAGCU2176 UGGGUAGAGAAG 2177 UCCUUCUCUAC MIMAT0014997 CAGAGGA GAGCUCAG CCAhsa-miR-3133 2178 UAAAGAACUCUUAAAAC 2179 UAAAGAACUCUU 2180 UUAAGAGUUCUMIMAT0014998 CCAAU AAAACCCA UUA hsa-miR-3134 2181 UGAUGGAUAAAAGACUA 2182UGAUGGAUAAAA 2183 UCUUUUAUCCA MIMAT0015000 CAUAUU GACUACAU UCAhsa-miR-3135 2184 UGCCUAGGCUGAGACUG 2185 UGCCUAGGCUGA 2186 UCUCAGCCUAGMIMAT0015001 CAGUG GACUGCAG GCA hsa-miR-3136 2187 CUGACUGAAUAGGUAGG 2188CUGACUGAAUAG 2189 ACCUAUUCAGU MIMAT0015003 GUCAUU GUAGGGUC CAGhsa-miR-3137 2190 UCUGUAGCCUGGGAGCA 2191 UCUGUAGCCUGG 2192 UCCCAGGCUACMIMAT0015005 AUGGGGU GAGCAAUG AGA hsa-miR-3138 2193 UGUGGACAGUGAGGUAG2194 UGUGGACAGUGA 2195 CCUCACUGUCC MIMAT0015006 AGGGAGU GGUAGAGG ACAhsa-miR-3139 2196 UAGGAGCUCAACAGAUG 2197 UAGGAGCUCAAC 2198 CUGUUGAGCUCMIMAT0015007 CCUGUU AGAUGCCU CUA hsa-miR-3140 2199 AGCUUUUGGGAAUUCAG2200 AGCUUUUGGGAA 2201 AAUUCCCAAAA MIMAT0015008 GUAGU UUCAGGUA GCUhsa-miR-3141 2202 GAGGGCGGGUGGAGGAG 2203 GAGGGCGGGUGG 2204 CUCCACCCGCCMIMAT0015010 GA AGGAGGA CUC hsa-miR-3142 2205 AAGGCCUUUCUGAACCU 2206AAGGCCUUUCUG 2207 UUCAGAAAGGC MIMAT0015011 UCAGA AACCUUCA CUUhsa-miR-3143 2208 AUAACAUUGUAAAGCGC 2209 AUAACAUUGUAA 2210 CUUUACAAUGUMIMAT0015012 UUCUUUCG AGCGCUUC UAU hsa-miR-3144- 2211 AUAUACCUGUUCGGUCU2212 AUAUACCUGUUC 2213 CCGAACAGGUA 3p CUUUA GGUCUCUU UAU MIMAT0015015hsa-miR-3144- 2214 AGGGGACCAAAGAGAUA 2215 AGGGGACCAAAG 2216 CUCUUUGGUCC5p UAUAG AGAUAUAU CCU MIMAT0015014 hsa-miR-3145 2217 AGAUAUUUUGAGUGUUU2218 AGAUAUUUUGAG 2219 CACUCAAAAUA MIMAT0015016 GGAAUUG UGUUUGGA UCUhsa-miR-3146 2220 CAUGCUAGGAUAGAAAG 2221 CAUGCUAGGAUA 2222 UCUAUCCUAGCMIMAT0015018 AAUGG GAAAGAAU AUG hsa-miR-3147 2223 GGUUGGGCAGUGAGGAG 2224GGUUGGGCAGUG 2225 CUCACUGCCCA MIMAT0015019 GGUGUGA AGGAGGGU ACChsa-miR-3148 2226 UGGAAAAAACUGGUGUG 2227 UGGAAAAAACUG 2228 ACCAGUUUUUUMIMAT0015021 UGCUU GUGUGUGC CCA hsa-miR-3149 2229 UUUGUAUGGAUAUGUGU 2230UUUGUAUGGAUA 2231 CAUAUCCAUAC MIMAT0015022 GUGUAU UGUGUGUG AAAhsa-miR-3150 2232 CUGGGGAGAUCCUCGAG 2233 CUGGGGAGAUCC 2234 GAGGAUCUCCCMIMAT0015023 GUUGG UCGAGGUU CAG hsa-miR-3150b 2235 UGAGGAGAUCGUCGAGG2236 UGAGGAGAUCGU 2237 CGACGAUCUCC MIMAT0018194 UUGG CGAGGUUG UCAhsa-miR-3151 2238 GGUGGGGCAAUGGGAUC 2239 GGUGGGGCAAUG 2240 CCCAUUGCCCCMIMAT0015024 AGGU GGAUCAGG ACC hsa-miR-3152 2241 UGUGUUAGAAUAGGGGC 2242UGUGUUAGAAUA 2243 CCUAUUCUAAC MIMAT0015025 AAUAA GGGGCAAU ACAhsa-miR-3153 2244 GGGGAAAGCGAGUAGGG 2245 GGGGAAAGCGAG 2246 UACUCGCUUUCMIMAT0015026 ACAUUU UAGGGACA CCC hsa-miR-3154 2247 CAGAAGGGGAGUUGGGA2248 CAGAAGGGGAGU 2249 CAACUCCCCUU MIMAT0015028 GCAGA UGGGAGCA CUGhsa-miR-3155 2250 CCAGGCUCUGCAGUGGG 2251 CCAGGCUCUGCA 2252 ACUGCAGAGCCMIMAT0015029 AACU GUGGGAAC UGG hsa-miR-3156 2253 AAAGAUCUGGAAGUGGG 2254AAAGAUCUGGAA 2255 ACUUCCAGAUC MIMAT0015030 AGACA GUGGGAGA UUUhsa-miR-3157 2256 UUCAGCCAGGCUAGUGC 2257 UUCAGCCAGGCU 2258 CUAGCCUGGCUMIMAT0015031 AGUCU AGUGCAGU GAA hsa-miR-3158 2259 AAGGGCUUCCUCUCUGC 2260AAGGGCUUCCUC 2261 GAGAGGAAGCC MIMAT0015032 AGGAC UCUGCAGG CUUhsa-miR-3159 2262 UAGGAUUACAAGUGUCG 2263 UAGGAUUACAAG 2264 CACUUGUAAUCMIMAT0015033 GCCAC UGUCGGCC CUA hsa-miR-3160 2265 AGAGCUGAGACUAGAAA 2266AGAGCUGAGACU 2267 CUAGUCUCAGC MIMAT0015034 GCCCA AGAAAGCC UCUhsa-miR-3161 2268 CUGAUAAGAACAGAGGC 2269 CUGAUAAGAACA 2270 UCUGUUCUUAUMIMAT0015035 CCAGAU GAGGCCCA CAG hsa-miR-3162 2271 UUAGGGAGUAGAAGGGU2272 UUAGGGAGUAGA 2273 CUUCUACUCCC MIMAT0015036 GGGGAG AGGGUGGG UAAhsa-miR-3163 2274 UAUAAAAUGAGGGCAGU 2275 UAUAAAAUGAGG 2276 GCCCUCAUUUUMIMAT0015037 AAGAC GCAGUAAG AUA hsa-miR-3164 2277 UGUGACUUUAAGGGAAA 2278UGUGACUUUAAG 2279 CCCUUAAAGUC MIMAT0015038 UGGCG GGAAAUGG ACAhsa-miR-3165 2280 AGGUGGAUGCAAUGUGA 2281 AGGUGGAUGCAA 2282 CAUUGCAUCCAMIMAT0015039 CCUCA UGUGACCU CCU hsa-miR-3166 2283 CGCAGACAAUGCCUACU 2284CGCAGACAAUGC 2285 AGGCAUUGUCU MIMAT0015040 GGCCUA CUACUGGC GCGhsa-miR-3167 2286 AGGAUUUCAGAAAUACU 2287 AGGAUUUCAGAA 2288 AUUUCUGAAAUMIMAT0015042 GGUGU AUACUGGU CCU hsa-miR-3168 2289 GAGUUCUACAGUCAGAC 2290GAGUUCUACAGU 2291 UGACUGUAGAA MIMAT0015043 CAGAC CUC hsa-miR-3169 2292UAGGACUGUGCUUGGCA 2293 UAGGACUGUGCU 2294 CAAGCACAGUC MIMAT0015044 CAUAGUGGCACAU CUA hsa-miR-3170 2295 CUGGGGUUCUGAGACAG 2296 CUGGGGUUCUGA 2297UCUCAGAACCC MIMAT0015045 ACAGU GACAGACA CAG hsa-miR-3171 2298AGAUGUAUGGAAUCUGU 2299 AGAUGUAUGGAA 2300 GAUUCCAUACA MIMAT0015046AUAUAUC UCUGUAUA UCU hsa-miR-3173 2301 AAAGGAGGAAAUAGGCA 2302AAAGGAGGAAAU 2303 CUAUUUCCUCC MIMAT0015048 GGCCA AGGCAGGC UUUhsa-miR-3174 2304 UAGUGAGUUAGAGAUGC 2305 UAGUGAGUUAGA 2306 UCUCUAACUCAMIMAT0015051 AGAGCC GAUGCAGA CUA hsa-miR-3175 2307 CGGGGAGAGAACGCAGU2308 CGGGGAGAGAAC 2309 GCGUUCUCUCC MIMAT0015052 GACGU GCAGUGAC CCGhsa-miR-3176 2310 ACUGGCCUGGGACUACC 2311 ACUGGCCUGGGA 2312 AGUCCCAGGCCMIMAT0015053 GG CUACCGG AGU hsa-miR-3177 2313 UGCACGGCACUGGGGAC 2314UGCACGGCACUG 2315 CCCAGUGCCGU MIMAT0015054 ACGU GGGACACG GCAhsa-miR-3178 2316 GGGGCGCGGCCGGAUCG 2317 GGGGCGCGGCCG 2318 UCCGGCCGCGCMIMAT0015055 GAUCG CCC hsa-miR-3179 2319 AGAAGGGGUGAAAUUUA 2320AGAAGGGGUGAA 2321 AUUUCACCCCU MIMAT0015056 AACGU AUUUAAAC UCUhsa-miR-3180 2322 UGGGGCGGAGCUUCCGG 2323 UGGGGCGGAGCU 2324 GAAGCUCCGCCMIMAT0018178 AG UCCGGAG CCA hsa-miR-3180- 2325 UGGGGCGGAGCUUCCGG 2326UGGGGCGGAGCU 2327 GAAGCUCCGCC 3p AGGCC UCCGGAGG CCA MIMAT0015058hsa-miR-3180- 2328 CUUCCAGACGCUCCGCC 2329 CUUCCAGACGCU 2330 GGAGCGUCUGG5p CCACGUCG CCGCCCCA AAG MIMAT0015057 hsa-miR-3181 2331AUCGGGCCCUCGGCGCC 2332 AUCGGGCCCUCG 2333 GCCGAGGGCCC MIMAT0015061 GGGCGCCGG GAU hsa-miR-3182 2334 GCUUCUGUAGUGUAGUC 2335 GCUUCUGUAGUG 2336UACACUACAGA MIMAT0015062 UAGUC AGC hsa-miR-3183 2337 GCCUCUCUCGGAGUCGC2338 GCCUCUCUCGGA 2339 ACUCCGAGAGA MIMAT0015063 UCGGA GUCGCUCG GGChsa-miR-3184 2340 UGAGGGGCCUCAGACCG 2341 UGAGGGGCCUCA 2342 UCUGAGGCCCCMIMAT0015064 AGCUUUU GACCGAGC UCA hsa-miR-3185 2343 AGAAGAAGGCGGUCGGU2344 AGAAGAAGGCGG 2345 GACCGCCUUCU MIMAT0015065 CUGCGG UCGGUCUG UCUhsa-miR-3186- 2346 UCACGCGGAGAGAUGGC 2347 UCACGCGGAGAG 2348 AUCUCUCCGCG3p UUUG AUGGCUUU UGA MIMAT0015068 hsa-miR-3186- 2349 CAGGCGUCUGUCUACGU2350 CAGGCGUCUGUC 2351 UAGACAGACGC 5p GGCUU UACGUGGC CUG MIMAT0015067hsa-miR-3187 2352 UUGGCCAUGGGGCUGCG 2353 UUGGCCAUGGGG 2354 AGCCCCAUGGCMIMAT0015069 CGG CUGCGCGG CAA hsa-miR-3188 2355 AGAGGCUUUGUGCGGAU 2356AGAGGCUUUGUG 2357 CGCACAAAGCC MIMAT0015070 ACGGGG CGGAUACG UCUhsa-miR-3189 2358 CCCUUGGGUCUGAUGGG 2359 CCCUUGGGUCUG 2360 AUCAGACCCAAMIMAT0015071 GUAG AUGGGGUA GGG hsa-miR-3190 2361 UGUGGAAGGUAGACGGC 2362UGUGGAAGGUAG 2363 GUCUACCUUCC MIMAT0015073 CAGAGA ACGGCCAG ACAhsa-miR-3191 2364 UGGGGACGUAGCUGGCC 2365 UGGGGACGUAGC 2366 CAGCUACGUCCMIMAT0015075 AGACAG UGGCCAGA CCA hsa-miR-3192 2367 UCUGGGAGGUUGUAGCA2368 UCUGGGAGGUUG 2369 UACAACCUCCC MIMAT0015076 GUGGAA UAGCAGUG AGAhsa-miR-3193 2370 UCCUGCGUAGGAUCUGA 2371 UCCUGCGUAGGA 2372 GAUCCUACGCAMIMAT0015077 GGAGU UCUGAGGA GGA hsa-miR-3194 2373 GGCCAGCCACCAGGAGG 2374GGCCAGCCACCA 2375 CCUGGUGGCUG MIMAT0015078 GCUG GGAGGGCU GCChsa-miR-3195 2376 CGCGCCGGGCCCGGGUU 2377 CGCGCCGGGCCC 2378 CCGGGCCCGGCMIMAT0015079 GGGUU GCG hsa-miR-3196 2379 CGGGGCGGCAGGGGCCUC 2380CGGGGCGGCAGG 2381 CCCCUGCCGCC MIMAT0015080 GGCCUC CCG hsa-miR-3197 2382GGAGGCGCAGGCUCGGA 2383 GGAGGCGCAGGC 2384 GAGCCUGCGCC MIMAT0015082 AAGGCGUCGGAAAG UCC hsa-miR-3198 2385 GUGGAGUCCUGGGGAAU 2386 GUGGAGUCCUGG 2387CCCCAGGACUC MIMAT0015083 GGAGA GGAAUGGA CAC hsa-miR-3199 2388AGGGACUGCCUUAGGAG 2389 AGGGACUGCCUU 2390 CUAAGGCAGUC MIMAT0015084 AAAGUUAGGAGAAA CCU hsa-miR-32 2391 UAUUGCACAUUACUAAG 2392 UAUUGCACAUUA 2393AGUAAUGUGCA MIMAT0000090 UUGCA CUAAGUUG AUA hsa-miR-32* 2394CAAUUUAGUGUGUGUGA 2395 CAAUUUAGUGUG 2396 CACACACUAAA MIMAT0004505 UAUUUUGUGAUAU UUG hsa-miR-3200- 2397 CACCUUGCGCUACUCAG 2398 CACCUUGCGCUA 2399AGUAGCGCAAG 3p GUCUG CUCAGGUC GUG MIMAT0015085 hsa-miR-3200- 2400AAUCUGAGAAGGCGCAC 2401 AAUCUGAGAAGG 2402 CGCCUUCUCAG 5p AAGGU CGCACAAGAUU MIMAT0017392 hsa-miR-3201 2403 GGGAUAUGAAGAAAAAU 2404 GGGAUAUGAAGA2405 UUUCUUCAUAU MIMAT0015086 AAAAU CCC hsa-miR-3202 2406UGGAAGGGAGAAGAGCU 2407 UGGAAGGGAGAA 2408 UCUUCUCCCUU MIMAT0015089 UUAAUGAGCUUUA CCA hsa-miR-320a 2409 AAAAGCUGGGUUGAGAG 2410 AAAAGCUGGGUU 2411UCAACCCAGCU MIMAT0000510 GGCGA GAGAGGGC UUU hsa-miR-320b 2412AAAAGCUGGGUUGAGAG 2413 AAAAGCUGGGUU 2414 UCAACCCAGCU MIMAT0005792 GGCAAGAGAGGGC UUU hsa-miR-320c 2415 AAAAGCUGGGUUGAGAG 2416 AAAAGCUGGGUU 2417UCAACCCAGCU MIMAT0005793 GGU GAGAGGGU UUU hsa-miR-320d 2418AAAAGCUGGGUUGAGAG 2419 AAAAGCUGGGUU 2420 UCAACCCAGCU MIMAT0006764 GAGAGAGGA UUU hsa-miR-320e 2421 AAAGCUGGGUUGAGAAGG 2422 AAAGCUGGGUUG 2423CUCAACCCAGC MIMAT0015072 AGAAGG UUU hsa-miR-323-3p 2424CACAUUACACGGUCGAC 2425 CACAUUACACGG 2426 GACCGUGUAAU MIMAT0000755 CUCUUCGACCUC GUG hsa-miR-323-5p 2427 AGGUGGUCCGUGGCGCG 2428 AGGUGGUCCGUG2429 GCCACGGACCA MIMAT0004696 UUCGC GCGCGUUC CCU hsa-miR-323b- 2430CCCAAUACACGGUCGAC 2431 CCCAAUACACGG 2432 GACCGUGUAUU 3p CUCUU UCGACCUCGGG MIMAT0015050 hsa-miR-323b- 2433 AGGUUGUCCGUGGUGAG 2434 AGGUUGUCCGUG2435 ACCACGGACAA 5p UUCGCA GUGAGUUC CCU MIMAT0001630 hsa-miR-324-3p 2436ACUGCCCCAGGUGCUGC 2437 ACUGCCCCAGGU 2438 GCACCUGGGGC MIMAT0000762 UGGGCUGCUGG AGU hsa-miR-324-5p 2439 CGCAUCCCCUAGGGCAU 2440 CGCAUCCCCUAG2441 CCCUAGGGGAU MIMAT0000761 UGGUGU GGCAUUGG GCG hsa-miR-325 2442CCUAGUAGGUGUCCAGU 2443 CCUAGUAGGUGU 2444 GGACACCUACU MIMAT0000771 AAGUGUCCAGUAAG AGG hsa-miR-326 2445 CCUCUGGGCCCUUCCUC 2446 CCUCUGGGCCCU 2447GAAGGGCCCAG MIMAT0000756 CAG UCCUCCAG AGG hsa-miR-328 2448CUGGCCCUCUCUGCCCU 2449 CUGGCCCUCUCU 2450 GCAGAGAGGGC MIMAT0000752 UCCGUGCCCUUCC CAG hsa-miR-329 2451 AACACACCUGGUUAACC 2452 AACACACCUGGU 2453UAACCAGGUGU MIMAT0001629 UCUUU UAACCUCU GUU hsa-miR-330-3p 2454GCAAAGCACACGGCCUG 2455 GCAAAGCACACG 2456 GCCGUGUGCUU MIMAT0000751 CAGAGAGCCUGCAG UGC hsa-miR-330-5p 2457 UCUCUGGGCCUGUGUCU 2458 UCUCUGGGCCUG2459 CACAGGCCCAG MIMAT0004693 UAGGC UGUCUUAG AGA hsa-miR-331-3p 2460GCCCCUGGGCCUAUCCU 2461 GCCCCUGGGCCU 2462 AUAGGCCCAGG MIMAT0000760 AGAAAUCCUAGA GGC hsa-miR-331-5p 2463 CUAGGUAUGGUCCCAGG 2464 CUAGGUAUGGUC2465 GGGACCAUACC MIMAT0004700 GAUCC CCAGGGAU UAG hsa-miR-335 2466UCAAGAGCAAUAACGAA 2467 UCAAGAGCAAUA 2468 GUUAUUGCUCU MIMAT0000765 AAAUGUACGAAAAA UGA hsa-miR-335* 2469 UUUUUCAUUAUUGCUCC 2470 UUUUUCAUUAUU 2471GCAAUAAUGAA MIMAT0004703 UGACC GCUCCUGA AAA hsa-miR-337-3p 2472CUCCUAUAUGAUGCCUU 2473 CUCCUAUAUGAU 2474 GCAUCAUAUAG MIMAT0000754 UCUUCGCCUUUCU GAG hsa-miR-337-5p 2475 GAACGGCUUCAUACAGG 2476 GAACGGCUUCAU2477 GUAUGAAGCCG MIMAT0004695 AGUU ACAGGAGU UUC hsa-miR-338-3p 2478UCCAGCAUCAGUGAUUU 2479 UCCAGCAUCAGU 2480 UCACUGAUGCU MIMAT0000763 UGUUGGAUUUUGU GGA hsa-miR-338-5p 2481 AACAAUAUCCUGGUGCU 2482 AACAAUAUCCUG2483 ACCAGGAUAUU MIMAT0004701 GAGUG GUGCUGAG GUU hsa-miR-339-3p 2484UGAGCGCCUCGACGACA 2485 UGAGCGCCUCGA 2486 CGUCGAGGCGC MIMAT0004702 GAGCCGCGACAGAG UCA hsa-miR-339-5p 2487 UCCCUGUCCUCCAGGAG 2488 UCCCUGUCCUCC2489 CUGGAGGACAG MIMAT0000764 CUCACG AGGAGCUC GGA hsa-miR-33a 2490GUGCAUUGUAGUUGCAU 2491 GUGCAUUGUAGU 2492 CAACUACAAUG MIMAT0000091 UGCAUGCAUUGC CAC hsa-miR-33a* 2493 CAAUGUUUCCACAGUGC 2494 CAAUGUUUCCAC 2495CUGUGGAAACA MIMAT0004506 AUCAC AGUGCAUC UUG hsa-miR-33b 2496GUGCAUUGCUGUUGCAU 2497 GUGCAUUGCUGU 2498 CAACAGCAAUG MIMAT0003301 UGCUGCAUUGC CAC hsa-miR-33b* 2499 CAGUGCCUCGGCAGUGC 2500 CAGUGCCUCGGC 2501CUGCCGAGGCA MIMAT0004811 AGCCC AGUGCAGC CUG hsa-miR-340 2502UUAUAAAGCAAUGAGAC 2503 UUAUAAAGCAAU 2504 UCAUUGCUUUA MIMAT0004692 UGAUUGAGACUGA UAA hsa-miR-340* 2505 UCCGUCUCAGUUACUUU 2506 UCCGUCUCAGUU 2507GUAACUGAGAC MIMAT0000750 AUAGC ACUUUAUA GGA hsa-miR-342-3p 2508UCUCACACAGAAAUCGC 2509 UCUCACACAGAA 2510 AUUUCUGUGUG MIMAT0000753 ACCCGUAUCGCACC AGA hsa-miR-342-5p 2511 AGGGGUGCUAUCUGUGA 2512 AGGGGUGCUAUC2513 CAGAUAGCACC MIMAT0004694 UUGA UGUGAUUG CCU hsa-miR-345 2514GCUGACUCCUAGUCCAG 2515 GCUGACUCCUAG 2516 GACUAGGAGUC MIMAT0000772 GGCUCUCCAGGGC AGC hsa-miR-346 2517 UGUCUGCCCGCAUGCCU 2518 UGUCUGCCCGCA 2519CAUGCGGGCAG MIMAT0000773 GCCUCU UGCCUGCC ACA hsa-miR-34a 2520UGGCAGUGUCUUAGCUG 2521 UGGCAGUGUCUU 2522 CUAAGACACUG MIMAT0000255 GUUGUAGCUGGUU CCA hsa-miR-34a* 2523 CAAUCAGCAAGUAUACU 2524 CAAUCAGCAAGU 2525AUACUUGCUGA MIMAT0004557 GCCCU AUACUGCC UUG hsa-miR-34b 2526CAAUCACUAACUCCACU 2527 CAAUCACUAACU 2528 GGAGUUAGUGA MIMAT0004676 GCCAUCCACUGCC UUG hsa-miR-34b* 2529 UAGGCAGUGUCAUUAGC 2530 UAGGCAGUGUCA 2531AAUGACACUGC MIMAT0000685 UGAUUG UUAGCUGA CUA hsa-miR-34c-3p 2532AAUCACUAACCACACGG 2533 AAUCACUAACCA 2534 UGUGGUUAGUG MIMAT0004677 CCAGGCACGGCCA AUU hsa-miR-34c-5p 2535 AGGCAGUGUAGUUAGCU 2536 AGGCAGUGUAGU2537 UAACUACACUG MIMAT0000686 GAUUGC UAGCUGAU CCU hsa-miR-3605- 2538CCUCCGUGUUACCUGUC 2539 CCUCCGUGUUAC 2540 AGGUAACACGG 3p CUCUAG CUGUCCUCAGG MIMAT0017982 hsa-miR-3605- 2541 UGAGGAUGGAUAGCAAG 2542 UGAGGAUGGAUA2543 GCUAUCCAUCC 5p GAAGCC GCAAGGAA UCA MIMAT0017981 hsa-miR-3606 2544UUAGUGAAGGCUAUUUU 2545 UUAGUGAAGGCU 2546 AUAGCCUUCAC MIMAT0017983 AAUUAUUUUAAU UAA hsa-miR-3607- 2547 ACUGUAAACGCUUUCUG 2548 ACUGUAAACGCU 2549AAAGCGUUUAC 3p AUG UUCUGAUG AGU MIMAT0017985 hsa-miR-3607- 2550GCAUGUGAUGAAGCAAA 2551 GCAUGUGAUGAA 2552 GCUUCAUCACA 5p UCAGU GCAAAUCAUGC MIMAT0017984 hsa-miR-3609 2553 CAAAGUGAUGAGUAAUA 2554 CAAAGUGAUGAG2555 UACUCAUCACU MIMAT0017986 CUGGCUG UAAUACUG UUG hsa-miR-3610 2556GAAUCGGAAAGGAGGCG 2557 GAAUCGGAAAGG 2558 CUCCUUUCCGA MIMAT0017987 CCGAGGCGCCG UUC hsa-miR-3611 2559 UUGUGAAGAAAGAAAUU 2560 UUGUGAAGAAAG 2561UUCUUUCUUCA MIMAT0017988 CUUA AAAUUCUU CAA hsa-miR-3612 2562AGGAGGCAUCUUGAGAA 2563 AGGAGGCAUCUU 2564 UCAAGAUGCCU MIMAT0017989 AUGGAGAGAAAUG CCU hsa-miR-3613- 2565 ACAAAAAAAAAAGCCCA 2566 ACAAAAAAAAAA 2567GCUUUUUUUUU 3p ACCCUUC GCCCAACC UGU MIMAT0017991 hsa-miR-3613- 2568UGUUGUACUUUUUUUUU 2569 UGUUGUACUUUU 2570 AAAAAAGUACA 5p UGUUC UUUUUUGUACA MIMAT0017990 hsa-miR-361-3p 2571 UCCCCCAGGUGUGAUUC 2572 UCCCCCAGGUGU2573 UCACACCUGGG MIMAT0004682 UGAUUU GAUUCUGA GGA hsa-miR-3614- 2574UAGCCUUCAGAUCUUGG 2575 UAGCCUUCAGAU 2576 AGAUCUGAAGG 3p UGUUUU CUUGGUGUCUA MIMAT0017993 hsa-miR-3614- 2577 CCACUUGGAUCUGAAGG 2578 CCACUUGGAUCU2579 UCAGAUCCAAG 5p CUGCCC GAAGGCUG UGG MIMAT0017992 hsa-miR-3615 2580UCUCUCGGCUCCUCGCG 2581 UCUCUCGGCUCC 2582 GAGGAGCCGAG MIMAT0017994 GCUCUCGCGGCU AGA hsa-miR-361-5p 2583 UUAUCAGAAUCUCCAGG 2584 UUAUCAGAAUCU2585 GGAGAUUCUGA MIMAT0000703 GGUAC CCAGGGGU UAA hsa-miR-3616- 2586CGAGGGCAUUUCAUGAU 2587 CGAGGGCAUUUC 2588 AUGAAAUGCCC 3p GCAGGC AUGAUGCAUCG MIMAT0017996 hsa-miR-3616- 2589 AUGAAGUGCACUCAUGA 2590 AUGAAGUGCACU2591 UGAGUGCACUU 5p UAUGU CAUGAUAU CAU MIMAT0017995 hsa-miR-3617 2592AAAGACAUAGUUGCAAG 2593 AAAGACAUAGUU 2594 GCAACUAUGUC MIMAT0017997 AUGGGGCAAGAUG UUU hsa-miR-3618 2595 UGUCUACAUUAAUGAAA 2596 UGUCUACAUUAA 2597CAUUAAUGUAG MIMAT0017998 AGAGC UGAAAAGA ACA hsa-miR-3619 2598UCAGCAGGCAGGCUGGU 2599 UCAGCAGGCAGG 2600 AGCCUGCCUGC MIMAT0017999 GCAGCCUGGUGCA UGA hsa-miR-3620 2601 UCACCCUGCAUCCCGCA 2602 UCACCCUGCAUC 2603GGGAUGCAGGG MIMAT0018001 CCCAG CCGCACCC UGA hsa-miR-3621 2604CGCGGGUCGGGGUCUGC 2605 CGCGGGUCGGGG 2606 GACCCCGACCC MIMAT0018002 AGGUCUGCAGG GCG hsa-miR-3622a- 2607 UCACCUGACCUCCCAUG 2608 UCACCUGACCUC2609 GGGAGGUCAGG 3p CCUGU CCAUGCCU UGA MIMAT0018004 hsa-miR-3622a- 2610CAGGCACGGGAGCUCAG 2611 CAGGCACGGGAG 2612 AGCUCCCGUGC 5p GUGAG CUCAGGUGCUG MIMAT0018003 hsa-miR-3622b- 2613 UCACCUGAGCUCCCGUG 2614 UCACCUGAGCUC2615 GGGAGCUCAGG 3p CCUG CCGUGCCU UGA MIMAT0018006 hsa-miR-3622b- 2616AGGCAUGGGAGGUCAGG 2617 AGGCAUGGGAGG 2618 GACCUCCCAUG 5p UGA UCAGGUGA CCUMIMAT0018005 hsa-miR-362-3p 2619 AACACACCUAUUCAAGG 2620 AACACACCUAUU2621 UGAAUAGGUGU MIMAT0004683 AUUCA CAAGGAUU GUU hsa-miR-362-5p 2622AAUCCUUGGAACCUAGG 2623 AAUCCUUGGAAC 2624 AGGUUCCAAGG MIMAT0000705UGUGAGU CUAGGUGU AUU hsa-miR-363 2625 AAUUGCACGGUAUCCAU 2626AAUUGCACGGUA 2627 GAUACCGUGCA MIMAT0000707 CUGUA UCCAUCUG AUUhsa-miR-363* 2628 CGGGUGGAUCACGAUGC 2629 CGGGUGGAUCAC 2630 UCGUGAUCCACMIMAT0003385 AAUUU GAUGCAAU CCG hsa-miR-3646 2631 AAAAUGAAAUGAGCCCA 2632AAAAUGAAAUGA 2633 GCUCAUUUCAU MIMAT0018065 GCCCA GCCCAGCC UUUhsa-miR-3647- 2634 AGAAAAUUUUUGUGUGU 2635 AGAAAAUUUUUG 2636 CACAAAAAUUU3p CUGAUC UGUGUCUG UCU MIMAT0018067 hsa-miR-3647- 2637 CUGAAGUGAUGAUUCAC2638 CUGAAGUGAUGA 2639 AAUCAUCACUU 5p AUUCAU UUCACAUU CAG MIMAT0018066hsa-miR-3648 2640 AGCCGCGGGGAUCGCCG 2641 AGCCGCGGGGAU 2642 CGAUCCCCGCGMIMAT0018068 AGGG CGCCGAGG GCU hsa-miR-3649 2643 AGGGACCUGAGUGUCUA 2644AGGGACCUGAGU 2645 ACACUCAGGUC MIMAT0018069 AG GUCUAAG CCU hsa-miR-3652646 UAAUGCCCCUAAAAAUC 2647 UAAUGCCCCUAA 2648 UUUUAGGGGCA MIMAT0000710CUUAU AAAUCCUU UUA hsa-miR-365* 2649 AGGGACUUUCAGGGGCA 2650 AGGGACUUUCAG2651 CCCUGAAAGUC MIMAT0009199 GCUGU GGGCAGCU CCU hsa-miR-3650 2652AGGUGUGUCUGUAGAGU 2653 AGGUGUGUCUGU 2654 CUACAGACACA MIMAT0018070 CCAGAGUCC CCU hsa-miR-3651 2655 CAUAGCCCGGUCGCUGG 2656 CAUAGCCCGGUC 2657GCGACCGGGCU MIMAT0018071 UACAUGA GCUGGUAC AUG hsa-miR-3652 2658CGGCUGGAGGUGUGAGGA 2659 CGGCUGGAGGUG 2660 CACACCUCCAG MIMAT0018072UGAGGA CCG hsa-miR-3653 2661 CUAAGAAGUUGACUGAAG 2662 CUAAGAAGUUGA 2663AGUCAACUUCU MIMAT0018073 CUGAAG UAG hsa-miR-3654 2664 GACUGGACAAGCUGAGG2665 GACUGGACAAGC 2666 CAGCUUGUCCA MIMAT0018074 AA UGAGGAA GUChsa-miR-3655 2667 GCUUGUCGCUGCGGUGU 2668 GCUUGUCGCUGC 2669 CCGCAGCGACAMIMAT0018075 UGCU GGUGUUGC AGC hsa-miR-3656 2670 GGCGGGUGCGGGGGUGG 2671GGCGGGUGCGGG 2672 CCCCCGCACCC MIMAT0018076 GGUGG GCC hsa-miR-3657 2673UGUGUCCCAUUAUUGGU 2674 UGUGUCCCAUUA 2675 AAUAAUGGGAC MIMAT0018077 GAUUUUGGUGAU ACA hsa-miR-3658 2676 UUUAAGAAAACACCAUG 2677 UUUAAGAAAACA 2678GGUGUUUUCUU MIMAT0018078 GAGAU CCAUGGAG AAA hsa-miR-3659 2679UGAGUGUUGUCUACGAG 2680 UGAGUGUUGUCU 2681 GUAGACAACAC MIMAT0018080 GGCAACGAGGGC UCA hsa-miR-3660 2682 ACUGACAGGAGAGCAUU 2683 ACUGACAGGAGA 2684GCUCUCCUGUC MIMAT0018081 UUGA GCAUUUUG AGU hsa-miR-3661 2685UGACCUGGGACUCGGAC 2686 UGACCUGGGACU 2687 CGAGUCCCAGG MIMAT0018082 AGCUGCGGACAGC UCA hsa-miR-3662 2688 GAAAAUGAUGAGUAGUG 2689 GAAAAUGAUGAG 2690UACUCAUCAUU MIMAT0018083 ACUGAUG UAGUGACU UUC hsa-miR-3663- 2691UGAGCACCACACAGGCC 2692 UGAGCACCACAC 2693 CUGUGUGGUGC 3p GGGCGC AGGCCGGGUCA MIMAT0018085 hsa-miR-3663- 2694 GCUGGUCUGCGUGGUGC 2695 GCUGGUCUGCGU2696 CCACGCAGACC 5p UCGG GGUGCUCG AGC MIMAT0018084 hsa-miR-3664 2697AACUCUGUCUUCACUCA 2698 AACUCUGUCUUC 2699 GUGAAGACAGA MIMAT0018086 UGAGUACUCAUGA GUU hsa-miR-3665 2700 AGCAGGUGCGGGGCGGCG 2701 AGCAGGUGCGGG 2702GCCCCGCACCU MIMAT0018087 GCGGCG GCU hsa-miR-3666 2703 CAGUGCAAGUGUAGAUG2704 CAGUGCAAGUGU 2705 CUACACUUGCA MIMAT0018088 CCGA AGAUGCCG CUGhsa-miR-3667- 2706 ACCUUCCUCUCCAUGGG 2707 ACCUUCCUCUCC 2708 AUGGAGAGGAA3p UCUUU AUGGGUCU GGU MIMAT0018090 hsa-miR-3667- 2709 AAAGACCCAUUGAGGAG2710 AAAGACCCAUUG 2711 CUCAAUGGGUC 5p AAGGU AGGAGAAG UUU MIMAT0018089hsa-miR-3668 2712 AAUGUAGAGAUUGAUCA 2713 AAUGUAGAGAUU 2714 UCAAUCUCUACMIMAT0018091 AAAU GAUCAAAA AUU hsa-miR-3669 2715 ACGGAAUAUGUAUACGG 2716ACGGAAUAUGUA 2717 UAUACAUAUUC MIMAT0018092 AAUAUA UACGGAAU CGUhsa-miR-367 2718 AAUUGCACUUUAGCAAU 2719 AAUUGCACUUUA 2720 GCUAAAGUGCAMIMAT0000719 GGUGA GCAAUGGU AUU hsa-miR-367* 2721 ACUGUUGCUAAUAUGCA 2722ACUGUUGCUAAU 2723 AUAUUAGCAAC MIMAT0004686 ACUCU AUGCAACU AGUhsa-miR-3670 2724 AGAGCUCACAGCUGUCC 2725 AGAGCUCACAGC 2726 CAGCUGUGAGCMIMAT0018093 UUCUCUA UGUCCUUC UCU hsa-miR-3671 2727 AUCAAAUAAGGACUAGU2728 AUCAAAUAAGGA 2729 AGUCCUUAUUU MIMAT0018094 CUGCA CUAGUCUG GAUhsa-miR-3672 2730 AUGAGACUCAUGUAAAA 2731 AUGAGACUCAUG 2732 UACAUGAGUCUMIMAT0018095 CAUCUU UAAAACAU CAU hsa-miR-3673 2733 AUGGAAUGUAUAUACGG2734 AUGGAAUGUAUA 2735 UAUAUACAUUC MIMAT0018096 AAUA UACGGAAU CAUhsa-miR-3674 2736 AUUGUAGAACCUAAGAU 2737 AUUGUAGAACCU 2738 UUAGGUUCUACMIMAT0018097 UGGCC AAGAUUGG AAU hsa-miR-3675- 2739 CAUCUCUAAGGAACUCC2740 CAUCUCUAAGGA 2741 GUUCCUUAGAG 3p CCCAA ACUCCCCC AUG MIMAT0018099hsa-miR-3675- 2742 UAUGGGGCUUCUGUAGA 2743 UAUGGGGCUUCU 2744 ACAGAAGCCCC5p GAUUUC GUAGAGAU AUA MIMAT0018098 hsa-miR-3676 2745 CCGUGUUUCCCCCACGC2746 CCGUGUUUCCCC 2747 UGGGGGAAACA MIMAT0018100 UUU CACGCUUU CGGhsa-miR-3677 2748 CUCGUGGGCUCUGGCCA 2749 CUCGUGGGCUCU 2750 CCAGAGCCCACMIMAT0018101 CGGCC GGCCACGG GAG hsa-miR-3678- 2751 CUGCAGAGUUUGUACGG2752 CUGCAGAGUUUG 2753 UACAAACUCUG 3p ACCGG UACGGACC CAG MIMAT0018103hsa-miR-3678- 2754 UCCGUACAAACUCUGCU 2755 UCCGUACAAACU 2756 AGAGUUUGUAC5p GUG CUGCUGUG GGA MIMAT0018102 hsa-miR-3679- 2757 CUUCCCCCCAGUAAUCU2758 CUUCCCCCCAGU 2759 UUACUGGGGGG 3p UCAUC AAUCUUCA AAG MIMAT0018105hsa-miR-3679- 2760 UGAGGAUAUGGCAGGGA 2761 UGAGGAUAUGGC 2762 CUGCCAUAUCC5p AGGGGA AGGGAAGG UCA MIMAT0018104 hsa-miR-3680 2763 GACUCACUCACAGGAUU2764 GACUCACUCACA 2765 CCUGUGAGUGA MIMAT0018106 GUGCA GGAUUGUG GUChsa-miR-3680* 2766 UUUUGCAUGACCCUGGG 2767 UUUUGCAUGACC 2768 AGGGUCAUGCAMIMAT0018107 AGUAGG CUGGGAGU AAA hsa-miR-3681 2769 UAGUGGAUGAUGCACUC2770 UAGUGGAUGAUG 2771 UGCAUCAUCCA MIMAT0018108 UGUGC CACUCUGU CUAhsa-miR-3681* 2772 ACACAGUGCUUCAUCCA 2773 ACACAGUGCUUC 2774 AUGAAGCACUGMIMAT0018109 CUACU AUCCACUA UGU hsa-miR-3682 2775 UGAUGAUACAGGUGGAG 2776UGAUGAUACAGG 2777 CACCUGUAUCA MIMAT0018110 GUAG UGGAGGUA UCAhsa-miR-3683 2778 UGCGACAUUGGAAGUAG 2779 UGCGACAUUGGA 2780 CUUCCAAUGUCMIMAT0018111 UAUCA AGUAGUAU GCA hsa-miR-3684 2781 UUAGACCUAGUACACGU 2782UUAGACCUAGUA 2783 UGUACUAGGUC MIMAT0018112 CCUU CACGUCCU UAAhsa-miR-3685 2784 UUUCCUACCCUACCUGA 2785 UUUCCUACCCUA 2786 GGUAGGGUAGGMIMAT0018113 AGACU CCUGAAGA AAA hsa-miR-3686 2787 AUCUGUAAGAGAAAGUA 2788AUCUGUAAGAGA 2789 UUUCUCUUACA MIMAT0018114 AAUGA AAGUAAAU GAUhsa-miR-3687 2790 CCCGGACAGGCGUUCGU 2791 CCCGGACAGGCG 2792 AACGCCUGUCCMIMAT0018115 GCGACGU UUCGUGCG GGG hsa-miR-3688 2793 UAUGGAAAGACUUUGCC2794 UAUGGAAAGACU 2795 AAAGUCUUUCC MIMAT0018116 ACUCU UUGCCACU AUAhsa-miR-3689a- 2796 CUGGGAGGUGUGAUAUC 2797 CUGGGAGGUGUG 2798 AUCACACCUCC3p GUGGU AUAUCGUG CAG MIMAT0018118 hsa-miR-3689a- 2799 UGUGAUAUCAUGGUUCC2800 UGUGAUAUCAUG 2801 ACCAUGAUAUC 5p UGGGA GUUCCUGG ACA MIMAT0018117hsa-miR-3689b 2802 UGUGAUAUCAUGGUUCC 2803 UGUGAUAUCAUG 2804 ACCAUGAUAUCMIMAT0018180 UGGGA GUUCCUGG ACA hsa-miR-3689b* 2805 CUGGGAGGUGUGAUAUU2806 CUGGGAGGUGUG 2807 AUCACACCUCC MIMAT0018181 GUGGU AUAUUGUG CAGhsa-miR-3690 2808 ACCUGGACCCAGCGUAG 2809 ACCUGGACCCAG 2810 CGCUGGGUCCAMIMAT0018119 ACAAAG CGUAGACA GGU hsa-miR-3691 2811 AGUGGAUGAUGGAGACU2812 AGUGGAUGAUGG 2813 CUCCAUCAUCC MIMAT0018120 CGGUAC AGACUCGG ACUhsa-miR-3692 2814 GUUCCACACUGACACUG 2815 GUUCCACACUGA 2816 UGUCAGUGUGGMIMAT0018122 CAGAAGU CACUGCAG AAC hsa-miR-3692* 2817 CCUGCUGGUCAGGAGUG2818 CCUGCUGGUCAG 2819 UCCUGACCAGC MIMAT0018121 GAUACUG GAGUGGAU AGGhsa-miR-369-3p 2820 AAUAAUACAUGGUUGAU 2821 AAUAAUACAUGG 2822 AACCAUGUAUUMIMAT0000721 CUUU UUGAUCUU AUU hsa-miR-369-5p 2823 AGAUCGACCGUGUUAUA2824 AGAUCGACCGUG 2825 AACACGGUCGA MIMAT0001621 UUCGC UUAUAUUC UCUhsa-miR-370 2826 GCCUGCUGGGGUGGAAC 2827 GCCUGCUGGGGU 2828 CCACCCCAGCAMIMAT0000722 CUGGU GGAACCUG GGC hsa-miR-3713 2829 GGUAUCCGUUUGGGGAU 2830GGUAUCCGUUUG 2831 CCCAAACGGAU MIMAT0018164 GGU GGGAUGGU ACChsa-miR-371-3p 2832 AAGUGCCGCCAUCUUUU 2833 AAGUGCCGCCAU 2834 AGAUGGCGGCAMIMAT0000723 GAGUGU CUUUUGAG CUU hsa-miR-3714 2835 GAAGGCAGCAGUGCUCC2836 GAAGGCAGCAGU 2837 GCACUGCUGCC MIMAT0018165 CCUGU GCUCCCCU UUChsa-miR-371-5p 2838 ACUCAAACUGUGGGGGC 2839 ACUCAAACUGUG 2840 CCCACAGUUUGMIMAT0004687 ACU GGGGCACU AGU hsa-miR-372 2841 AAAGUGCUGCGACAUUU 2842AAAGUGCUGCGA 2843 UGUCGCAGCAC MIMAT0000724 GAGCGU CAUUUGAG UUUhsa-miR-373 2844 GAAGUGCUUCGAUUUUG 2845 GAAGUGCUUCGA 2846 AAUCGAAGCACMIMAT0000726 GGGUGU UUUUGGGG UUC hsa-miR-373* 2847 ACUCAAAAUGGGGGCGC2848 ACUCAAAAUGGG 2849 CCCCCAUUUUG MIMAT0000725 UUUCC GGCGCUUU AGUhsa-miR-374a 2850 UUAUAAUACAACCUGAU 2851 UUAUAAUACAAC 2852 AGGUUGUAUUAMIMAT0000727 AAGUG CUGAUAAG UAA hsa-miR-374a* 2853 CUUAUCAGAUUGUAUUG2854 CUUAUCAGAUUG 2855 UACAAUCUGAU MIMAT0004688 UAAUU UAUUGUAA AAGhsa-miR-374b 2856 AUAUAAUACAACCUGCU 2857 AUAUAAUACAAC 2858 AGGUUGUAUUAMIMAT0004955 AAGUG CUGCUAAG UAU hsa-miR-374b* 2859 CUUAGCAGGUUGUAUUA2860 CUUAGCAGGUUG 2861 UACAACCUGCU MIMAT0004956 UCAUU UAUUAUCA AAGhsa-miR-374c 2862 AUAAUACAACCUGCUAA 2863 AUAAUACAACCU 2864 GCAGGUUGUAUMIMAT0018443 GUGCU GCUAAGUG UAU hsa-miR-375 2865 UUUGUUCGUUCGGCUCG 2866UUUGUUCGUUCG 2867 GCCGAACGAAC MIMAT0000728 CGUGA GCUCGCGU AAAhsa-miR-376a 2868 AUCAUAGAGGAAAAUCC 2869 AUCAUAGAGGAA 2870 UUUUCCUCUAUMIMAT0000729 ACGU AAUCCACG GAU hsa-miR-376a* 2871 GUAGAUUCUCCUUCUAU 2872GUAGAUUCUCCU 2873 GAAGGAGAAUC MIMAT0003386 GAGUA UCUAUGAG UAChsa-miR-376b 2874 AUCAUAGAGGAAAAUCC 2875 AUCAUAGAGGAA 2876 UUUUCCUCUAUMIMAT0002172 AUGUU AAUCCAUG GAU hsa-miR-376c 2877 AACAUAGAGGAAAUUCC 2878AACAUAGAGGAA 2879 AUUUCCUCUAU MIMAT0000720 ACGU AUUCCACG GUU hsa-miR-3772880 AUCACACAAAGGCAACU 2881 AUCACACAAAGG 2882 UGCCUUUGUGU MIMAT0000730UUUGU CAACUUUU GAU hsa-miR-377* 2883 AGAGGUUGCCCUUGGUG 2884 AGAGGUUGCCCU2885 CAAGGGCAACC MIMAT0004689 AAUUC UGGUGAAU UCU hsa-miR-378 2886ACUGGACUUGGAGUCAG 2887 ACUGGACUUGGA 2888 ACUCCAAGUCC MIMAT0000732 AAGGGUCAGAAG AGU hsa-miR-378* 2889 CUCCUGACUCCAGGUCC 2890 CUCCUGACUCCA 2891CCUGGAGUCAG MIMAT0000731 UGUGU GGUCCUGU GAG hsa-miR-378b 2892ACUGGACUUGGAGGCAG 2893 ACUGGACUUGGA 2894 CCUCCAAGUCC MIMAT0014999 AAGGCAGAA AGU hsa-miR-378c 2895 ACUGGACUUGGAGUCAG 2896 ACUGGACUUGGA 2897ACUCCAAGUCC MIMAT0016847 AAGAGUGG GUCAGAAG AGU hsa-miR-379 2898UGGUAGACUAUGGAACG 2899 UGGUAGACUAUG 2900 UCCAUAGUCUA MIMAT0000733 UAGGGAACGUAG CCA hsa-miR-379* 2901 UAUGUAACAUGGUCCAC 2902 UAUGUAACAUGG 2903GACCAUGUUAC MIMAT0004690 UAACU UCCACUAA AUA hsa-miR-380 2904UAUGUAAUAUGGUCCAC 2905 UAUGUAAUAUGG 2906 GACCAUAUUAC MIMAT0000735 AUCUUUCCACAUC AUA hsa-miR-380* 2907 UGGUUGACCAUAGAACA 2908 UGGUUGACCAUA 2909UCUAUGGUCAA MIMAT0000734 UGCGC GAACAUGC CCA hsa-miR-381 2910UAUACAAGGGCAAGCUC 2911 UAUACAAGGGCA 2912 CUUGCCCUUGU MIMAT0000736 UCUGUAGCUCUCU AUA hsa-miR-382 2913 GAAGUUGUUCGUGGUGG 2914 GAAGUUGUUCGU 2915CCACGAACAAC MIMAT0000737 AUUCG GGUGGAUU UUC hsa-miR-383 2916AGAUCAGAAGGUGAUUG 2917 AGAUCAGAAGGU 2918 UCACCUUCUGA MIMAT0000738 UGGCUGAUUGUGG UCU hsa-miR-384 2919 AUUCCUAGAAAUUGUUC 2920 AUUCCUAGAAAU 2921CAAUUUCUAGG MIMAT0001075 AUA UGUUCAUA AAU hsa-miR-3907 2922AGGUGCUCCAGGCUGGC 2923 AGGUGCUCCAGG 2924 AGCCUGGAGCA MIMAT0018179 UCACACUGGCUCA CCU hsa-miR-3908 2925 GAGCAAUGUAGGUAGAC 2926 GAGCAAUGUAGG 2927UACCUACAUUG MIMAT0018182 UGUUU UAGACUGU CUC hsa-miR-3909 2928UGUCCUCUAGGGCCUGC 2929 UGUCCUCUAGGG 2930 GGCCCUAGAGG MIMAT0018183 AGUCUCCUGCAGU ACA hsa-miR-3910 2931 AAAGGCAUAAAACCAAG 2932 AAAGGCAUAAAA 2933GGUUUUAUGCC MIMAT0018184 ACA CCAAGACA UUU hsa-miR-3911 2934UGUGUGGAUCCUGGAGG 2935 UGUGUGGAUCCU 2936 CCAGGAUCCAC MIMAT0018185 AGGCAGGAGGAGG ACA hsa-miR-3912 2937 UAACGCAUAAUAUGGAC 2938 UAACGCAUAAUA 2939CAUAUUAUGCG MIMAT0018186 AUGU UGGACAUG UUA hsa-miR-3913 2940UUUGGGACUGAUCUUGA 2941 UUUGGGACUGAU 2942 AGAUCAGUCCC MIMAT0018187 UGUCUCUUGAUGU AAA hsa-miR-3914 2943 AAGGAACCAGAAAAUGA 2944 AAGGAACCAGAA 2945UUUUCUGGUUC MIMAT0018188 GAAGU AAUGAGAA CUU hsa-miR-3915 2946UUGAGGAAAAGAUGGUC 2947 UUGAGGAAAAGA 2948 CAUCUUUUCCU MIMAT0018189 UUAUUUGGUCUUA CAA hsa-miR-3916 2949 AAGAGGAAGAAAUGGCU 2950 AAGAGGAAGAAA 2951CAUUUCUUCCU MIMAT0018190 GGUUCUCAG UGGCUGGU CUU hsa-miR-3917 2952GCUCGGACUGAGCAGGU 2953 GCUCGGACUGAG 2954 UGCUCAGUCCG MIMAT0018191 GGGCAGGUGGG AGC hsa-miR-3918 2955 ACAGGGCCGCAGAUGGA 2956 ACAGGGCCGCAG 2957AUCUGCGGCCC MIMAT0018192 GACU AUGGAGAC UGU hsa-miR-3919 2958GCAGAGAACAAAGGACU 2959 GCAGAGAACAAA 2960 CCUUUGUUCUC MIMAT0018193 CAGUGGACUCAG UGC hsa-miR-3920 2961 ACUGAUUAUCUUAACUC 2962 ACUGAUUAUCUU 2963UUAAGAUAAUC MIMAT0018195 UCUGA AACUCUCU AGU hsa-miR-3921 2964UCUCUGAGUACCAUAUG 2965 UCUCUGAGUACC 2966 AUGGUACUCAG MIMAT0018196 CCUUGUAUAUGCCU AGA hsa-miR-3922 2967 UCUGGCCUUGACUUGAC 2968 UCUGGCCUUGAC 2969AAGUCAAGGCC MIMAT0018197 UCUUU UUGACUCU AGA hsa-miR-3923 2970AACUAGUAAUGUUGGAU 2971 AACUAGUAAUGU 2972 CAACAUUACUA MIMAT0018198 UAGGGUGGAUUAG GUU hsa-miR-3924 2973 AUAUGUAUAUGUGACUG 2974 AUAUGUAUAUGU 2975UCACAUAUACA MIMAT0018199 CUACU GACUGCUA UAU hsa-miR-3925 2976AAGAGAACUGAAAGUGG 2977 AAGAGAACUGAA 2978 CUUUCAGUUCU MIMAT0018200 AGCCUAGUGGAGC CUU hsa-miR-3926 2979 UGGCCAAAAAGCAGGCA 2980 UGGCCAAAAAGC 2981CUGCUUUUUGG MIMAT0018201 GAGA AGGCAGAG CCA hsa-miR-3927 2982CAGGUAGAUAUUUGAUA 2983 CAGGUAGAUAUU 2984 CAAAUAUCUAC MIMAT0018202 GGCAUUGAUAGGC CUG hsa-miR-3928 2985 GGAGGAACCUUGGAGCU 2986 GGAGGAACCUUG 2987UCCAAGGUUCC MIMAT0018205 UCGGC GAGCUUCG UCC hsa-miR-3929 2988GAGGCUGAUGUGAGUAG 2989 GAGGCUGAUGUG 2990 CUCACAUCAGC MIMAT0018206 ACCACUAGUAGACC CUC hsa-miR-3934 2991 UCAGGUGUGGAAACUGA 2992 UCAGGUGUGGAA 2993GUUUCCACACC MIMAT0018349 GGCAG ACUGAGGC UGA hsa-miR-3935 2994UGUAGAUACGAGCACCA 2995 UGUAGAUACGAG 2996 UGCUCGUAUCU MIMAT0018350 GCCACCACCAGCC ACA hsa-miR-3936 2997 UAAGGGGUGUAUGGCAG 2998 UAAGGGGUGUAU 2999CCAUACACCCC MIMAT0018351 AUGCA GGCAGAUG UUA hsa-miR-3937 3000ACAGGCGGCUGUAGCAA 3001 ACAGGCGGCUGU 3002 CUACAGCCGCC MIMAT0018352 UGGGGGAGCAAUGG UGU hsa-miR-3938 3003 AAUUCCCUUGUAGAUAA 3004 AAUUCCCUUGUA 3005UCUACAAGGGA MIMAT0018353 CCCGG GAUAACCC AUU hsa-miR-3939 3006UACGCGCAGACCACAGG 3007 UACGCGCAGACC 3008 GUGGUCUGCGC MIMAT0018355 AUGUCACAGGAUG GUA hsa-miR-3940 3009 CAGCCCGGAUCCCAGCC 3010 CAGCCCGGAUCC 3011UGGGAUCCGGG MIMAT0018356 CACUU CAGCCCAC CUG hsa-miR-3941 3012UUACACACAACUGAGGA 3013 UUACACACAACU 3014 UCAGUUGUGUG MIMAT0018357 UCAUAGAGGAUCA UAA hsa-miR-3942 3015 AAGCAAUACUGUUACCU 3016 AAGCAAUACUGU 3017UAACAGUAUUG MIMAT0018358 GAAAU UACCUGAA CUU hsa-miR-3943 3018UAGCCCCCAGGCUUCAC 3019 UAGCCCCCAGGC 3020 AAGCCUGGGGG MIMAT0018359 UUGGCGUUCACUUG CUA hsa-miR-3944 3021 UUCGGGCUGGCCUGCUG 3022 UUCGGGCUGGCC 3023CAGGCCAGCCC MIMAT0018360 CUCCGG UGCUGCUC GAA hsa-miR-3945 3024AGGGCAUAGGAGAGGGU 3025 AGGGCAUAGGAG 3026 CUCUCCUAUGC MIMAT0018361 UGAUAUAGGGUUGA CCU hsa-miR-409-3p 3027 GAAUGUUGCUCGGUGAA 3028 GAAUGUUGCUCG3029 ACCGAGCAACA MIMAT0001639 CCCCU GUGAACCC UUC hsa-miR-409-5p 3030AGGUUACCCGAGCAACU 3031 AGGUUACCCGAG 3032 UGCUCGGGUAA MIMAT0001638 UUGCAUCAACUUUG CCU hsa-miR-410 3033 AAUAUAACACAGAUGGC 3034 AAUAUAACACAG 3035AUCUGUGUUAU MIMAT0002171 CUGU AUGGCCUG AUU hsa-miR-411 3036UAGUAGACCGUAUAGCG 3037 UAGUAGACCGUA 3038 UAUACGGUCUA MIMAT0003329 UACGUAGCGUAC CUA hsa-miR-411* 3039 UAUGUAACACGGUCCAC 3040 UAUGUAACACGG 3041GACCGUGUUAC MIMAT0004813 UAACC UCCACUAA AUA hsa-miR-412 3042ACUUCACCUGGUCCACU 3043 ACUUCACCUGGU 3044 GGACCAGGUGA MIMAT0002170 AGCCGUCCACUAGC AGU hsa-miR-421 3045 AUCAACAGACAUUAAUU 3046 AUCAACAGACAU 3047UAAUGUCUGUU MIMAT0003339 GGGCGC UAAUUGGG GAU hsa-miR-422a 3048ACUGGACUUAGGGUCAG 3049 ACUGGACUUAGG 3050 ACCCUAAGUCC MIMAT0001339 AAGGCGUCAGAAG AGU hsa-miR-423-3p 3051 AGCUCGGUCUGAGGCCC 3052 AGCUCGGUCUGA3053 CCUCAGACCGA MIMAT0001340 CUCAGU GGCCCCUC GCU hsa-miR-423-5p 3054UGAGGGGCAGAGAGCGA 3055 UGAGGGGCAGAG 3056 CUCUCUGCCCC MIMAT0004748 GACUUUAGCGAGAC UCA hsa-miR-424 3057 CAGCAGCAAUUCAUGUU 3058 CAGCAGCAAUUC 3059AUGAAUUGCUG MIMAT0001341 UUGAA AUGUUUUG CUG hsa-miR-424* 3060CAAAACGUGAGGCGCUG 3061 CAAAACGUGAGG 3062 CGCCUCACGUU MIMAT0004749 CUAUCGCUGCUA UUG hsa-miR-425 3063 AAUGACACGAUCACUCC 3064 AAUGACACGAUC 3065GUGAUCGUGUC MIMAT0003393 CGUUGA ACUCCCGU AUU hsa-miR-425* 3066AUCGGGAAUGUCGUGUC 3067 AUCGGGAAUGUC 3068 ACGACAUUCCC MIMAT0001343 CGCCCGUGUCCGC GAU hsa-miR-4251 3069 CCUGAGAAAAGGGCCAA 3070 CCUGAGAAAAGG 3071GCCCUUUUCUC MIMAT0016883 GCCAA AGG hsa-miR-4252 3072 GGCCACUGAGUCAGCAC3073 GGCCACUGAGUC 3074 CUGACUCAGUG MIMAT0016886 CA AGCACCA GCChsa-miR-4253 3075 AGGGCAUGUCCAGGGGGU 3076 AGGGCAUGUCCA 3077 CCUGGACAUGCMIMAT0016882 GGGGGU CCU hsa-miR-4254 3078 GCCUGGAGCUACUCCAC 3079GCCUGGAGCUAC 3080 GAGUAGCUCCA MIMAT0016884 CAUCUC UCCACCAU GGChsa-miR-4255 3081 CAGUGUUCAGAGAUGGA 3082 CAGUGUUCAGAG 3083 AUCUCUGAACAMIMAT0016885 AUGGA CUG hsa-miR-4256 3084 AUCUGACCUGAUGAAGGU 3085AUCUGACCUGAU 3086 UCAUCAGGUCA MIMAT0016877 GAAGGU GAU hsa-miR-4257 3087CCAGAGGUGGGGACUGAG 3088 CCAGAGGUGGGG 3089 GUCCCCACCUC MIMAT0016878ACUGAG UGG hsa-miR-4258 3090 CCCCGCCACCGCCUUGG 3091 CCCCGCCACCGC 3092AGGCGGUGGCG MIMAT0016879 CUUGG GGG hsa-miR-4259 3093 CAGUUGGGUCUAGGGGU3094 CAGUUGGGUCUA 3095 CCUAGACCCAA MIMAT0016880 CAGGA GGGGUCAG CUGhsa-miR-4260 3096 CUUGGGGCAUGGAGUCC 3097 CUUGGGGCAUGG 3098 CUCCAUGCCCCMIMAT0016881 CA AGUCCCA AAG hsa-miR-4261 3099 AGGAAACAGGGACCCA 3100AGGAAACAGGGA 3101 GGUCCCUGUUU MIMAT0016890 CCCA CCU hsa-miR-4262 3102GACAUUCAGACUACCUG 3103 GACAUUCAGACU 3104 GUAGUCUGAAU MIMAT0016894 ACCUGGUC hsa-miR-4263 3105 AUUCUAAGUGCCUUGGCC 3106 AUUCUAAGUGCC 3107AAGGCACUUAG MIMAT0016898 UUGGCC AAU hsa-miR-4264 3108 ACUCAGUCAUGGUCAUU3109 ACUCAGUCAUGG 3110 GACCAUGACUG MIMAT0016899 UCAUU AGU hsa-miR-42653111 CUGUGGGCUCAGCUCUG 3112 CUGUGGGCUCAG 3113 AGCUGAGCCCA MIMAT0016891GG CUCUGGG CAG hsa-miR-4266 3114 CUAGGAGGCCUUGGCC 3115 CUAGGAGGCCUU 3116CCAAGGCCUCC MIMAT0016892 GGCC UAG hsa-miR-4267 3117 UCCAGCUCGGUGGCAC3118 UCCAGCUCGGUG 3119 GCCACCGAGCU MIMAT0016893 GCAC GGA hsa-miR-42683120 GGCUCCUCCUCUCAGGA 3121 GGCUCCUCCUCU 3122 UGAGAGGAGGA MIMAT0016896UGUG CAGGAUGU GCC hsa-miR-4269 3123 GCAGGCACAGACAGCCC 3124 GCAGGCACAGAC3125 CUGUCUGUGCC MIMAT0016897 UGGC AGCCCUGG UGC hsa-miR-4270 3126UCAGGGAGUCAGGGGAG 3127 UCAGGGAGUCAG 3128 CCCUGACUCCC MIMAT0016900 GGCGGGAGGGC UGA hsa-miR-4271 3129 GGGGGAAGAAAAGGUGG 3130 GGGGGAAGAAAA 3131CCUUUUCUUCC MIMAT0016901 GG GGUGGGG CCC hsa-miR-4272 3132CAUUCAACUAGUGAUUGU 3133 CAUUCAACUAGU 3134 UCACUAGUUGA MIMAT0016902GAUUGU AUG hsa-miR-4273 3135 GUGUUCUCUGAUGGACAG 3136 GUGUUCUCUGAU 3137CCAUCAGAGAA MIMAT0016903 GGACAG CAC hsa-miR-4274 3138 CAGCAGUCCCUCCCCCUG3139 CAGCAGUCCCUC 3140 GGGAGGGACUG MIMAT0016906 CCCCUG CUG hsa-miR-42753141 CCAAUUACCACUUCUUU 3142 CCAAUUACCACU 3143 GAAGUGGUAAU MIMAT0016905UCUUU UGG hsa-miR-4276 3144 CUCAGUGACUCAUGUGC 3145 CUCAGUGACUCA 3146CAUGAGUCACU MIMAT0016904 UGUGC GAG hsa-miR-4277 3147 GCAGUUCUGAGCACAGU3148 GCAGUUCUGAGC 3149 GUGCUCAGAAC MIMAT0016908 ACAC ACAGUACA UGChsa-miR-4278 3150 CUAGGGGGUUUGCCCUUG 3151 CUAGGGGGUUUG 3152 GGCAAACCCCCMIMAT0016910 CCCUUG UAG hsa-miR-4279 3153 CUCUCCUCCCGGCUUC 3154CUCUCCUCCCGG 3155 AGCCGGGAGGA MIMAT0016909 CUUC GAG hsa-miR-4280 3156GAGUGUAGUUCUGAGCA 3157 GAGUGUAGUUCU 3158 UCAGAACUACA MIMAT0016911 GAGCGAGCAGAG CUC hsa-miR-4281 3159 GGGUCCCGGGGAGGGGGG 3160 GGGUCCCGGGGA 3161CCUCCCCGGGA MIMAT0016907 GGGGGG CCC hsa-miR-4282 3162 UAAAAUUUGCAUCCAGGA3163 UAAAAUUUGCAU 3164 GGAUGCAAAUU MIMAT0016912 CCAGGA UUA hsa-miR-42833165 UGGGGCUCAGCGAGUUU 3166 UGGGGCUCAGCG 3167 CUCGCUGAGCC MIMAT0016914AGUUU CCA hsa-miR-4284 3168 GGGCUCACAUCACCCCAU 3169 GGGCUCACAUCA 3170GGUGAUGUGAG MIMAT0016915 CCCCAU CCC hsa-miR-4285 3171 GCGGCGAGUCCGACUCAU3172 GCGGCGAGUCCG 3173 GUCGGACUCGC MIMAT0016913 ACUCAU CGC hsa-miR-42863174 ACCCCACUCCUGGUACC 3175 ACCCCACUCCUG 3176 ACCAGGAGUGG MIMAT0016916GUACC GGU hsa-miR-4287 3177 UCUCCCUUGAGGGCACU 3178 UCUCCCUUGAGG 3179GCCCUCAAGGG MIMAT0016917 UU GCACUUU AGA hsa-miR-4288 3180UUGUCUGCUGAGUUUCC 3181 UUGUCUGCUGAG 3182 AACUCAGCAGA MIMAT0016918 UUUCCCAA hsa-miR-4289 3183 GCAUUGUGCAGGGCUAU 3184 GCAUUGUGCAGG 3185GCCCUGCACAA MIMAT0016920 CA GCUAUCA UGC hsa-miR-429 3186UAAUACUGUCUGGUAAA 3187 UAAUACUGUCUG 3188 ACCAGACAGUA MIMAT0001536 ACCGUGUAAAACC UUA hsa-miR-4290 3189 UGCCCUCCUUUCUUCCC 3190 UGCCCUCCUUUC 3191AAGAAAGGAGG MIMAT0016921 UC UUCCCUC GCA hsa-miR-4291 3192UUCAGCAGGAACAGCU 3193 UUCAGCAGGAAC 3194 CUGUUCCUGCU MIMAT0016922 AGCUGAA hsa-miR-4292 3195 CCCCUGGGCCGGCCUUGG 3196 CCCCUGGGCCGG 3197GGCCGGCCCAG MIMAT0016919 CCUUGG GGG hsa-miR-4293 3198 CAGCCUGACAGGAACAG3199 CAGCCUGACAGG 3200 UUCCUGUCAGG MIMAT0016848 AACAG CUG hsa-miR-42943201 GGGAGUCUACAGCAGGG 3202 GGGAGUCUACAG 3203 UGCUGUAGACU MIMAT0016849CAGGG CCC hsa-miR-4295 3204 CAGUGCAAUGUUUUCCUU 3205 CAGUGCAAUGUU 3206AAAACAUUGCA MIMAT0016844 UUCCUU CUG hsa-miR-4296 3207 AUGUGGGCUCAGGCUCA3208 AUGUGGGCUCAG 3209 GCCUGAGCCCA MIMAT0016845 GCUCA CAU hsa-miR-42973210 UGCCUUCCUGUCUGUG 3211 UGCCUUCCUGUC 3212 CAGACAGGAAG MIMAT0016846UGUG GCA hsa-miR-4298 3213 CUGGGACAGGAGGAGGA 3214 CUGGGACAGGAG 3215UCCUCCUGUCC MIMAT0016852 GGCAG GAGGAGGC CAG hsa-miR-4299 3216GCUGGUGACAUGAGAGGC 3217 GCUGGUGACAUG 3218 CUCAUGUCACC MIMAT0016851AGAGGC AGC hsa-miR-4300 3219 UGGGAGCUGGACUACUUC 3220 UGGGAGCUGGAC 3221UAGUCCAGCUC MIMAT0016853 UACUUC CCA hsa-miR-4301 3222 UCCCACUACUUCACUUG3223 UCCCACUACUUC 3224 GUGAAGUAGUG MIMAT0016850 UGA ACUUGUGA GGAhsa-miR-4302 3225 CCAGUGUGGCUCAGCGAG 3226 CCAGUGUGGCUC 3227 CUGAGCCACACMIMAT0016855 AGCGAG UGG hsa-miR-4303 3228 UUCUGAGCUGAGGACAG 3229UUCUGAGCUGAG 3230 UCCUCAGCUCA MIMAT0016856 GACAG GAA hsa-miR-4304 3231CCGGCAUGUCCAGGGCA 3232 CCGGCAUGUCCA 3233 CCUGGACAUGC MIMAT0016854 GGGCACGG hsa-miR-4305 3234 CCUAGACACCUCCAGUUC 3235 CCUAGACACCUC 3236UGGAGGUGUCU MIMAT0016857 CAGUUC AGG hsa-miR-4306 3237 UGGAGAGAAAGGCAGUA3238 UGGAGAGAAAGG 3239 UGCCUUUCUCU MIMAT0016858 CAGUA CCA hsa-miR-43073240 AAUGUUUUUUCCUGUUU 3241 AAUGUUUUUUCC 3242 CAGGAAAAAAC MIMAT0016860CC UGUUUCC AUU hsa-miR-4308 3243 UCCCUGGAGUUUCUUCUU 3244 UCCCUGGAGUUU3245 AGAAACUCCAG MIMAT0016861 CUUCUU GGA hsa-miR-4309 3246CUGGAGUCUAGGAUUCCA 3247 CUGGAGUCUAGG 3248 AUCCUAGACUC MIMAT0016859AUUCCA CAG hsa-miR-431 3249 UGUCUUGCAGGCCGUCA 3250 UGUCUUGCAGGC 3251CGGCCUGCAAG MIMAT0001625 UGCA CGUCAUGC ACA hsa-miR-431* 3252CAGGUCGUCUUGCAGGG 3253 CAGGUCGUCUUG 3254 UGCAAGACGAC MIMAT0004757 CUUCUCAGGGCUU CUG hsa-miR-4310 3255 GCAGCAUUCAUGUCCC 3256 GCAGCAUUCAUG 3257GACAUGAAUGC MIMAT0016862 UCCC UGC hsa-miR-4311 3258 GAAAGAGAGCUGAGUGUG3259 GAAAGAGAGCUG 3260 CUCAGCUCUCU MIMAT0016863 AGUGUG UUC hsa-miR-43123261 GGCCUUGUUCCUGUCCC 3262 GGCCUUGUUCCU 3263 ACAGGAACAAG MIMAT0016864CA GUCCCCA GCC hsa-miR-4313 3264 AGCCCCCUGGCCCCAAA 3265 AGCCCCCUGGCC3266 GGGGCCAGGGG MIMAT0016865 CCC CCAAACCC GCU hsa-miR-4314 3267CUCUGGGAAAUGGGACAG 3268 CUCUGGGAAAUG 3269 CCCAUUUCCCA MIMAT0016868GGACAG GAG hsa-miR-4315 3270 CCGCUUUCUGAGCUGGAC 3271 CCGCUUUCUGAG 3272AGCUCAGAAAG MIMAT0016866 CUGGAC CGG hsa-miR-4316 3273 GGUGAGGCUAGCUGGUG3274 GGUGAGGCUAGC 3275 CAGCUAGCCUC MIMAT0016867 UGGUG ACC hsa-miR-43173276 ACAUUGCCAGGGAGUUU 3277 ACAUUGCCAGGG 3278 CUCCCUGGCAA MIMAT0016872AGUUU UGU hsa-miR-4318 3279 CACUGUGGGUACAUGCU 3280 CACUGUGGGUAC 3281AUGUACCCACA MIMAT0016869 AUGCU GUG hsa-miR-4319 3282 UCCCUGAGCAAAGCCAC3283 UCCCUGAGCAAA 3284 GCUUUGCUCAG MIMAT0016870 GCCAC GGA hsa-miR-4323285 UCUUGGAGUAGGUCAUU 3286 UCUUGGAGUAGG 3287 GACCUACUCCA MIMAT0002814GGGUGG UCAUUGGG AGA hsa-miR-432* 3288 CUGGAUGGCUCCUCCAU 3289CUGGAUGGCUCC 3290 GAGGAGCCAUC MIMAT0002815 GUCU UCCAUGUC CAGhsa-miR-4320 3291 GGGAUUCUGUAGCUUCCU 3292 GGGAUUCUGUAG 3293 AGCUACAGAAUMIMAT0016871 CUUCCU CCC hsa-miR-4321 3294 UUAGCGGUGGACCGCCC 3295UUAGCGGUGGAC 3296 CGGUCCACCGC MIMAT0016874 UGCG CGCCCUGC UAAhsa-miR-4322 3297 CUGUGGGCUCAGCGCGU 3298 CUGUGGGCUCAG 3299 CGCUGAGCCCAMIMAT0016873 GGGG CGCGUGGG CAG hsa-miR-4323 3300 CAGCCCCACAGCCUCAGA 3301CAGCCCCACAGC 3302 AGGCUGUGGGG MIMAT0016875 CUCAGA CUG hsa-miR-4324 3303CCCUGAGACCCUAACCU 3304 CCCUGAGACCCU 3305 UUAGGGUCUCA MIMAT0016876 UAAAACCUUAA GGG hsa-miR-4325 3306 UUGCACUUGUCUCAGUGA 3307 UUGCACUUGUCU 3308UGAGACAAGUG MIMAT0016887 CAGUGA CAA hsa-miR-4326 3309 UGUUCCUCUGUCUCCCA3310 UGUUCCUCUGUC 3311 GAGACAGAGGA MIMAT0016888 GAC UCCCAGAC ACAhsa-miR-4327 3312 GGCUUGCAUGGGGGACU 3313 GGCUUGCAUGGG 3314 CCCCCAUGCAAMIMAT0016889 GG GGACUGG GCC hsa-miR-4328 3315 CCAGUUUUCCCAGGAUU 3316CCAGUUUUCCCA 3317 CCUGGGAAAAC MIMAT0016926 GGAUU UGG hsa-miR-4329 3318CCUGAGACCCUAGUUCC 3319 CCUGAGACCCUA 3320 ACUAGGGUCUC MIMAT0016923 ACGUUCCAC AGG hsa-miR-433 3321 AUCAUGAUGGGCUCCUC 3322 AUCAUGAUGGGC 3323GAGCCCAUCAU MIMAT0001627 GGUGU UCCUCGGU GAU hsa-miR-4330 3324CCUCAGAUCAGAGCCUU 3325 CCUCAGAUCAGA 3326 GCUCUGAUCUG MIMAT0016924 GCGCCUUGC AGG hsa-miR-448 3327 UUGCAUAUGUAGGAUGU 3328 UUGCAUAUGUAG 3329UCCUACAUAUG MIMAT0001532 CCCAU GAUGUCCC CAA hsa-miR-449a 3330UGGCAGUGUAUUGUUAG 3331 UGGCAGUGUAUU 3332 ACAAUACACUG MIMAT0001541 CUGGUGUUAGCUG CCA hsa-miR-449b 3333 AGGCAGUGUAUUGUUAG 3334 AGGCAGUGUAUU 3335ACAAUACACUG MIMAT0003327 CUGGC GUUAGCUG CCU hsa-miR-449b* 3336CAGCCACAACUACCCUG 3337 CAGCCACAACUA 3338 GGUAGUUGUGG MIMAT0009203 CCACUCCCUGCCA CUG hsa-miR-449c 3339 UAGGCAGUGUAUUGCUA 3340 UAGGCAGUGUAU 3341CAAUACACUGC MIMAT0010251 GCGGCUGU UGCUAGCG CUA hsa-miR-449c* 3342UUGCUAGUUGCACUCCU 3343 UUGCUAGUUGCA 3344 AGUGCAACUAG MIMAT0013771 CUCUGUCUCCUCUC CAA hsa-miR-450a 3345 UUUUGCGAUGUGUUCCU 3346 UUUUGCGAUGUG 3347AACACAUCGCA MIMAT0001545 AAUAU UUCCUAAU AAA hsa-miR-450b- 3348UUGGGAUCAUUUUGCAU 3349 UUGGGAUCAUUU 3350 CAAAAUGAUCC 3p CCAUA UGCAUCCACAA MIMAT0004910 hsa-miR-450b- 3351 UUUUGCAAUAUGUUCCU 3352 UUUUGCAAUAUG3353 AACAUAUUGCA 5p GAAUA UUCCUGAA AAA MIMAT0004909 hsa-miR-451 3354AAACCGUUACCAUUACU 3355 AAACCGUUACCA 3356 AAUGGUAACGG MIMAT0001631 GAGUUUUACUGAG UUU hsa-miR-452 3357 AACUGUUUGCAGAGGAA 3358 AACUGUUUGCAG 3359CUCUGCAAACA MIMAT0001635 ACUGA AGGAAACU GUU hsa-miR-452* 3360CUCAUCUGCAAAGAAGU 3361 CUCAUCUGCAAA 3362 UCUUUGCAGAU MIMAT0001636 AAGUGGAAGUAAG GAG hsa-miR-454 3363 UAGUGCAAUAUUGCUUA 3364 UAGUGCAAUAUU 3365GCAAUAUUGCA MIMAT0003885 UAGGGU GCUUAUAG CUA hsa-miR-454* 3366ACCCUAUCAAUAUUGUC 3367 ACCCUAUCAAUA 3368 AAUAUUGAUAG MIMAT0003884 UCUGCUUGUCUCU GGU hsa-miR-455-3p 3369 GCAGUCCAUGGGCAUAU 3370 GCAGUCCAUGGG3371 UGCCCAUGGAC MIMAT0004784 ACAC CAUAUACA UGC hsa-miR-455-5p 3372UAUGUGCCUUUGGACUA 3373 UAUGUGCCUUUG 3374 UCCAAAGGCAC MIMAT0003150 CAUCGGACUACAU AUA hsa-miR-466 3375 AUACACAUACACGCAAC 3376 AUACACAUACAC 3377GCGUGUAUGUG MIMAT0015002 ACACAU GCAACACA UAU hsa-miR-483-3p 3378UCACUCCUCUCCUCCCG 3379 UCACUCCUCUCC 3380 GAGGAGAGGAG MIMAT0002173 UCUUUCCCGUCU UGA hsa-miR-483-5p 3381 AAGACGGGAGGAAAGAA 3382 AAGACGGGAGGA3383 UUUCCUCCCGU MIMAT0004761 GGGAG AAGAAGGG CUU hsa-miR-484 3384UCAGGCUCAGUCCCCUC 3385 UCAGGCUCAGUC 3386 GGGACUGAGCC MIMAT0002174 CCGAUCCCUCCCG UGA hsa-miR-485-3p 3387 GUCAUACACGGCUCUCC 3388 GUCAUACACGGC3389 GAGCCGUGUAU MIMAT0002176 UCUCU UCUCCUCU GAC hsa-miR-485-5p 3390AGAGGCUGGCCGUGAUG 3391 AGAGGCUGGCCG 3392 CACGGCCAGCC MIMAT0002175 AAUUCUGAUGAAU UCU hsa-miR-486-3p 3393 CGGGGCAGCUCAGUACA 3394 CGGGGCAGCUCA3395 ACUGAGCUGCC MIMAT0004762 GGAU GUACAGGA CCG hsa-miR-486-5p 3396UCCUGUACUGAGCUGCC 3397 UCCUGUACUGAG 3398 AGCUCAGUACA MIMAT0002177 CCGAGCUGCCCCG GGA hsa-miR-487a 3399 AAUCAUACAGGGACAUC 3400 AAUCAUACAGGG 3401GUCCCUGUAUG MIMAT0002178 CAGUU ACAUCCAG AUU hsa-miR-487b 3402AAUCGUACAGGGUCAUC 3403 AAUCGUACAGGG 3404 GACCCUGUACG MIMAT0003180 CACUUUCAUCCAC AUU hsa-miR-488 3405 UUGAAAGGCUAUUUCUU 3406 UUGAAAGGCUAU 3407AAAUAGCCUUU MIMAT0004763 GGUC UUCUUGGU CAA hsa-miR-488* 3408CCCAGAUAAUGGCACUC 3409 CCCAGAUAAUGG 3410 UGCCAUUAUCU MIMAT0002804 UCAACACUCUCA GGG hsa-miR-489 3411 GUGACAUCACAUAUACG 3412 GUGACAUCACAU 3413AUAUGUGAUGU MIMAT0002805 GCAGC AUACGGCA CAC hsa-miR-490-3p 3414CAACCUGGAGGACUCCA 3415 CAACCUGGAGGA 3416 AGUCCUCCAGG MIMAT0002806 UGCUGCUCCAUGC UUG hsa-miR-490-5p 3417 CCAUGGAUCUCCAGGUG 3418 CCAUGGAUCUCC3419 CUGGAGAUCCA MIMAT0004764 GGU AGGUGGGU UGG hsa-miR-491-3p 3420CUUAUGCAAGAUUCCCU 3421 CUUAUGCAAGAU 3422 GAAUCUUGCAU MIMAT0004765 UCUACUCCCUUCU AAG hsa-miR-491-5p 3423 AGUGGGGAACCCUUCCA 3424 AGUGGGGAACCC3425 AAGGGUUCCCC MIMAT0002807 UGAGG UUCCAUGA ACU hsa-miR-492 3426AGGACCUGCGGGACAAG 3427 AGGACCUGCGGG 3428 GUCCCGCAGGU MIMAT0002812 AUUCUUACAAGAUU CCU hsa-miR-493 3429 UGAAGGUCUACUGUGUG 3430 UGAAGGUCUACU 3431ACAGUAGACCU MIMAT0003161 CCAGG GUGUGCCA UCA hsa-miR-493* 3432UUGUACAUGGUAGGCUU 3433 UUGUACAUGGUA 3434 CCUACCAUGUA MIMAT0002813 UCAUUGGCUUUCA CAA hsa-miR-494 3435 UGAAACAUACACGGGAA 3436 UGAAACAUACAC 3437CCGUGUAUGUU MIMAT0002816 ACCUC GGGAAACC UCA hsa-miR-495 3438AAACAAACAUGGUGCAC 3439 AAACAAACAUGG 3440 CACCAUGUUUG MIMAT0002817 UUCUUUGCACUUC UUU hsa-miR-496 3441 UGAGUAUUACAUGGCCA 3442 UGAGUAUUACAU 3443CCAUGUAAUAC MIMAT0002818 AUCUC GGCCAAUC UCA hsa-miR-497 3444CAGCAGCACACUGUGGU 3445 CAGCAGCACACU 3446 ACAGUGUGCUG MIMAT0002820 UUGUGUGGUUUG CUG hsa-miR-497* 3447 CAAACCACACUGUGGUG 3448 CAAACCACACUG 3449CACAGUGUGGU MIMAT0004768 UUAGA UGGUGUUA UUG hsa-miR-498 3450UUUCAAGCCAGGGGGCG 3451 UUUCAAGCCAGG 3452 CCCCUGGCUUG MIMAT0002824 UUUUUCGGGCGUUU AAA hsa-miR-499-3p 3453 AACAUCACAGCAAGUCU 3454 AACAUCACAGCA3455 CUUGCUGUGAU MIMAT0004772 GUGCU AGUCUGUG GUU hsa-miR-499-5p 3456UUAAGACUUGCAGUGAU 3457 UUAAGACUUGCA 3458 ACUGCAAGUCU MIMAT0002870 GUUUGUGAUGUU UAA hsa-miR-500a 3459 UAAUCCUUGCUACCUGG 3460 UAAUCCUUGCUA 3461GGUAGCAAGGA MIMAT0004773 GUGAGA CCUGGGUG UUA hsa-miR-500a* 3462AUGCACCUGGGCAAGGA 3463 AUGCACCUGGGC 3464 UUGCCCAGGUG MIMAT0002871 UUCUGAAGGAUUC CAU hsa-miR-500b 3465 AAUCCUUGCUACCUGGGU 3466 AAUCCUUGCUAC 3467AGGUAGCAAGG MIMAT0016925 CUGGGU AUU hsa-miR-501-3p 3468AAUGCACCCGGGCAAGG 3469 AAUGCACCCGGG 3470 UGCCCGGGUGC MIMAT0004774 AUUCUCAAGGAUU AUU hsa-miR-501-5p 3471 AAUCCUUUGUCCCUGGG 3472 AAUCCUUUGUCC3473 AGGGACAAAGG MIMAT0002872 UGAGA CUGGGUGA AUU hsa-miR-502-3p 3474AAUGCACCUGGGCAAGG 3475 AAUGCACCUGGG 3476 UGCCCAGGUGC MIMAT0004775 AUUCACAAGGAUU AUU hsa-miR-502-5p 3477 AUCCUUGCUAUCUGGGU 3478 AUCCUUGCUAUC3479 CAGAUAGCAAG MIMAT0002873 GCUA UGGGUGCU GAU hsa-miR-503 3480UAGCAGCGGGAACAGUU 3481 UAGCAGCGGGAA 3482 UGUUCCCGCUG MIMAT0002874 CUGCAGCAGUUCUG CUA hsa-miR-504 3483 AGACCCUGGUCUGCACU 3484 AGACCCUGGUCU 3485GCAGACCAGGG MIMAT0002875 CUAUC GCACUCUA UCU hsa-miR-505 3486CGUCAACACUUGCUGGU 3487 CGUCAACACUUG 3488 AGCAAGUGUUG MIMAT0002876 UUCCUCUGGUUUC ACG hsa-miR-505* 3489 GGGAGCCAGGAAGUAUU 3490 GGGAGCCAGGAA 3491ACUUCCUGGCU MIMAT0004776 GAUGU GUAUUGAU CCC hsa-miR-506 3492UAAGGCACCCUUCUGAG 3493 UAAGGCACCCUU 3494 AGAAGGGUGCC MIMAT0002878 UAGACUGAGUAG UUA hsa-miR-507 3495 UUUUGCACCUUUUGGAG 3496 UUUUGCACCUUU 3497CAAAAGGUGCA MIMAT0002879 UGAA UGGAGUGA AAA hsa-miR-508-3p 3498UGAUUGUAGCCUUUUGG 3499 UGAUUGUAGCCU 3500 AAAGGCUACAA MIMAT0002880 AGUAGAUUUGGAGU UCA hsa-miR-508-5p 3501 UACUCCAGAGGGCGUCA 3502 UACUCCAGAGGG3503 CGCCCUCUGGA MIMAT0004778 CUCAUG CGUCACUC GUA hsa-miR-509-3- 3504UACUGCAGACGUGGCAA 3505 UACUGCAGACGU 3506 CCACGUCUGCA 5p UCAUG GGCAAUCAGUA MIMAT0004975 hsa-miR-509-3p 3507 UGAUUGGUACGUCUGUG 3508 UGAUUGGUACGU3509 AGACGUACCAA MIMAT0002881 GGUAG CUGUGGGU UCA hsa-miR-509-5p 3510UACUGCAGACAGUGGCA 3511 UACUGCAGACAG 3512 CACUGUCUGCA MIMAT0004779 AUCAUGGCAAUC GUA hsa-miR-510 3513 UACUCAGGAGAGUGGCA 3514 UACUCAGGAGAG 3515CACUCUCCUGA MIMAT0002882 AUCAC UGGCAAUC GUA hsa-miR-511 3516GUGUCUUUUGCUCUGCA 3517 GUGUCUUUUGCU 3518 AGAGCAAAAGA MIMAT0002808 GUCACUGCAGUC CAC hsa-miR-512-3p 3519 AAGUGCUGUCAUAGCUG 3520 AAGUGCUGUCAU3521 CUAUGACAGCA MIMAT0002823 AGGUC AGCUGAGG CUU hsa-miR-512-5p 3522CACUCAGCCUUGAGGGC 3523 CACUCAGCCUUG 3524 CUCAAGGCUGA MIMAT0002822 ACUUUCAGGGCACU GUG hsa-miR-513a- 3525 UAAAUUUCACCUUUCUG 3526 UAAAUUUCACCU 3527AAAGGUGAAAU 3p AGAAGG UUCUGAGA UUA MIMAT0004777 hsa-miR-513a- 3528UUCACAGGGAGGUGUCAU 3529 UUCACAGGGAGG 3530 CACCUCCCUGU 5p UGUCAU GAAMIMAT0002877 hsa-miR-513b 3531 UUCACAAGGAGGUGUCA 3532 UUCACAAGGAGG 3533CACCUCCUUGU MIMAT0005788 UUUAU UGUCAUUU GAA hsa-miR-513c 3534UUCUCAAGGAGGUGUCG 3535 UUCUCAAGGAGG 3536 CACCUCCUUGA MIMAT0005789 UUUAUUGUCGUUU GAA hsa-miR-514 3537 AUUGACACUUCUGUGAG 3538 AUUGACACUUCU 3539ACAGAAGUGUC MIMAT0002883 UAGA GUGAGUAG AAU hsa-miR-514b- 3540AUUGACACUUCUGUGAG 3541 AUUGACACCUCU 3542 ACAGAGGUGUC 3p UGGA GUGAGUGGAAU MIMAT0015088 hsa-miR-514b- 3543 UUCUCAAGAGGGAGGCA 3544 UUCUCAAGAGGG3545 CUCCCUCUUGA 5p AUCAU AGGCAAUC GAA MIMAT0015087 hsa-miR-515-3p 3546GAGUGCCUUCUUUUGGA 3547 GAGUGCCUUCUU 3548 AAAAGAAGGCA MIMAT0002827 GCGUUUUGGAGCG CUC hsa-miR-515-5p 3549 UUCUCCAAAAGAAAGCA 3550 UUCUCCAAAAGA3551 UUUCUUUUGGA MIMAT0002826 CUUUCUG AAGCACUU GAA hsa-miR-516a- 3552UGCUUCCUUUCAGAGGGU 3553 UGCUUCCUUUCA 3554 UCUGAAAGGAA 3p GAGGGU GCAMIMAT0006778 hsa-miR-516a- 3555 UUCUCGAGGAAAGAAGC 3556 UUCUCGAGGAAA 3557UCUUUCCUCGA 5p ACUUUC GAAGCACU GAA MIMAT0004770 hsa-miR-516b 3558AUCUGGAGGUAAGAAGC 3559 AUCUGGAGGUAA 3560 UCUUACCUCCA MIMAT0002859 ACUUUGAAGCACU GAU hsa-miR-516b* 3561 UGCUUCCUUUCAGAGGGU 3562 UGCUUCCUUUCA3563 UCUGAAAGGAA MIMAT0002860 GAGGGU GCA hsa-miR-517* 3564CCUCUAGAUGGAAGCAC 3565 CCUCUAGAUGGA 3566 CUUCCAUCUAG MIMAT0002851 UGUCUAGCACUGU AGG hsa-miR-517a 3567 AUCGUGCAUCCCUUUAG 3568 AUCGUGCAUCCC 3569AAGGGAUGCAC MIMAT0002852 AGUGU UUUAGAGU GAU hsa-miR-517b 3570UCGUGCAUCCCUUUAGA 3571 UCGUGCAUCCCU 3572 AAAGGGAUGCA MIMAT0002857 GUGUUUUAGAGUG CGA hsa-miR-517c 3573 AUCGUGCAUCCUUUUAG 3574 AUCGUGCAUCCU 3575AAAGGAUGCAC MIMAT0002866 AGUGU UUUAGAGU GAU hsa-miR-518a- 3576GAAAGCGCUUCCCUUUG 3577 GAAAGCGCUUCC 3578 AGGGAAGCGCU 3p CUGGA CUUUGCUGUUC MIMAT0002863 hsa-miR-518a- 3579 CUGCAAAGGGAAGCCCU 3580 CUGCAAAGGGAA3581 GCUUCCCUUUG 5p UUC GCCCUUUC CAG MIMAT0005457 hsa-miR-518b 3582CAAAGCGCUCCCCUUUA 3583 CAAAGCGCUCCC 3584 AGGGGAGCGCU MIMAT0002844 GAGGUCUUUAGAG UUG hsa-miR-518c 3585 CAAAGCGCUUCUCUUUA 3586 CAAAGCGCUUCU 3587AGAGAAGCGCU MIMAT0002848 GAGUGU CUUUAGAG UUG hsa-miR-518c* 3588UCUCUGGAGGGAAGCAC 3589 UCUCUGGAGGGA 3590 CUUCCCUCCAG MIMAT0002847 UUUCUGAGCACUUU AGA hsa-miR-518d- 3591 CAAAGCGCUUCCCUUUG 3592 CAAAGCGCUUCC 3593AGGGAAGCGCU 3p GAGC CUUUGGAG UUG MIMAT0002864 hsa-miR-518d- 3594CUCUAGAGGGAAGCACU 3595 CUCUAGAGGGAA 3596 GCUUCCCUCUA 5p UUCUG GCACUUUCGAG MIMAT0005456 hsa-miR-518e 3597 AAAGCGCUUCCCUUCAG 3598 AAAGCGCUUCCC3599 AAGGGAAGCGC MIMAT0002861 AGUG UUCAGAGU UUU hsa-miR-518e* 3600CUCUAGAGGGAAGCGCU 3601 CUCUAGAGGGAA 3602 GCUUCCCUCUA MIMAT0005450 UUCUGGCGCUUUC GAG hsa-miR-518f 3603 GAAAGCGCUUCUCUUUA 3604 GAAAGCGCUUCU 3605AGAGAAGCGCU MIMAT0002842 GAGG CUUUAGAG UUC hsa-miR-518f* 3606CUCUAGAGGGAAGCACU 3607 CUCUAGAGGGAA 3608 GCUUCCCUCUA MIMAT0002841 UUCUCGCACUUUC GAG hsa-miR-519a 3609 AAAGUGCAUCCUUUUAG 3610 AAAGUGCAUCCU 3611AAAGGAUGCAC MIMAT0002869 AGUGU UUUAGAGU UUU hsa-miR-519a* 3612CUCUAGAGGGAAGCGCU 3613 CUCUAGAGGGAA 3614 GCUUCCCUCUA MIMAT0005452 UUCUGGCGCUUUC GAG hsa-miR-519b- 3615 AAAGUGCAUCCUUUUAG 3616 AAAGUGCAUCCU 3617AAAGGAUGCAC 3p AGGUU UUUAGAGG UUU MIMAT0002837 hsa-miR-519b- 3618CUCUAGAGGGAAGCGCU 3619 CUCUAGAGGGAA 3620 GCUUCCCUCUA 5p UUCUG GCGCUUUCGAG MIMAT0005454 hsa-miR-519c- 3621 AAAGUGCAUCUUUUUAG 3622 AAAGUGCAUCUU3623 AAAAGAUGCAC 3p AGGAU UUUAGAGG UUU MIMAT0002832 hsa-miR-519c- 3624CUCUAGAGGGAAGCGCU 3625 CUCUAGAGGGAA 3626 GCUUCCCUCUA 5p UUCUG GCGCUUUCGAG MIMAT0002831 hsa-miR-519d 3627 CAAAGUGCCUCCCUUUA 3628 CAAAGUGCCUCC3629 AGGGAGGCACU MIMAT0002853 GAGUG CUUUAGAG UUG hsa-miR-519e 3630AAGUGCCUCCUUUUAGA 3631 AAGUGCCUCCUU 3632 AAAAGGAGGCA MIMAT0002829 GUGUUUUAGAGUG CUU hsa-miR-519e* 3633 UUCUCCAAAAGGGAGCA 3634 UUCUCCAAAAGG 3635UCCCUUUUGGA MIMAT0002828 CUUUC GAGCACUU GAA hsa-miR-520a- 3636AAAGUGCUUCCCUUUGG 3637 AAAGUGCUUCCC 3638 AAGGGAAGCAC 3p ACUGU UUUGGACUUUU MIMAT0002834 hsa-miR-520a- 3639 CUCCAGAGGGAAGUACU 3640 CUCCAGAGGGAA3641 ACUUCCCUCUG 5p UUCU GUACUUUC GAG MIMAT0002833 hsa-miR-520b 3642AAAGUGCUUCCUUUUAG 3643 AAAGUGCUUCCU 3644 AAAGGAAGCAC MIMAT0002843 AGGGUUUAGAGG UUU hsa-miR-520c- 3645 AAAGUGCUUCCUUUUAG 3646 AAAGUGCUUCCU 3647AAAGGAAGCAC 3p AGGGU UUUAGAGG UUU MIMAT0002846 hsa-miR-520c- 3648CUCUAGAGGGAAGCACU 3649 CUCUAGAGGGAA 3650 GCUUCCCUCUA 5p UUCUG GCACUUUCGAG MIMAT0005455 hsa-miR-520d- 3651 AAAGUGCUUCUCUUUGG 3652 AAAGUGCUUCUC3653 AAGAGAAGCAC 3p UGGGU UUUGGUGG UUU MIMAT0002856 hsa-miR-520d- 3654CUACAAAGGGAAGCCCU 3655 CUACAAAGGGAA 3656 GCUUCCCUUUG 5p UUC GCCCUUUC UAGMIMAT0002855 hsa-miR-520e 3657 AAAGUGCUUCCUUUUUG 3658 AAAGUGCUUCCU 3659AAAGGAAGCAC MIMAT0002825 AGGG UUUUGAGG UUU hsa-miR-520f 3660AAGUGCUUCCUUUUAGA 3661 AAGUGCUUCCUU 3662 AAAAGGAAGCA MIMAT0002830 GGGUUUUAGAGGG CUU hsa-miR-520g 3663 ACAAAGUGCUUCCCUUU 3664 ACAAAGUGCUUC 3665GGGAAGCACUU MIMAT0002858 AGAGUGU CCUUUAGA UGU hsa-miR-520h 3666ACAAAGUGCUUCCCUUU 3667 ACAAAGUGCUUC 3668 GGGAAGCACUU MIMAT0002867 AGAGUCCUUUAGA UGU hsa-miR-521 3669 AACGCACUUCCCUUUAG 3670 AACGCACUUCCC 3671AAGGGAAGUGC MIMAT0002854 AGUGU UUUAGAGU GUU hsa-miR-522 3672AAAAUGGUUCCCUUUAG 3673 AAAAUGGUUCCC 3674 AAGGGAACCAU MIMAT0002868 AGUGUUUUAGAGU UUU hsa-miR-522* 3675 CUCUAGAGGGAAGCGCU 3676 CUCUAGAGGGAA 3677GCUUCCCUCUA MIMAT0005451 UUCUG GCGCUUUC GAG hsa-miR-523 3678GAACGCGCUUCCCUAUA 3679 GAACGCGCUUCC 3680 AGGGAAGCGCG MIMAT0002840 GAGGGUCUAUAGAG UUC hsa-miR-523* 3681 CUCUAGAGGGAAGCGCU 3682 CUCUAGAGGGAA 3683GCUUCCCUCUA MIMAT0005449 UUCUG GCGCUUUC GAG hsa-miR-524-3p 3684GAAGGCGCUUCCCUUUG 3685 GAAGGCGCUUCC 3686 AGGGAAGCGCC MIMAT0002850 GAGUCUUUGGAG UUC hsa-miR-524-5p 3687 CUACAAAGGGAAGCACU 3688 CUACAAAGGGAA3689 GCUUCCCUUUG MIMAT0002849 UUCUC GCACUUUC UAG hsa-miR-525-3p 3690GAAGGCGCUUCCCUUUA 3691 GAAGGCGCUUCC 3692 AGGGAAGCGCC MIMAT0002839 GAGCGCUUUAGAG UUC hsa-miR-525-5p 3693 CUCCAGAGGGAUGCACU 3694 CUCCAGAGGGAU3695 GCAUCCCUCUG MIMAT0002838 UUCU GCACUUUC GAG hsa-miR-526a 3696CUCUAGAGGGAAGCACU 3697 CUCUAGAGGGAA 3698 GCUUCCCUCUA MIMAT0002845 UUCUGGCACUUUC GAG hsa-miR-526b 3699 CUCUUGAGGGAAGCACU 3700 CUCUUGAGGGAA 3701GCUUCCCUCAA MIMAT0002835 UUCUGU GCACUUUC GAG hsa-miR-526b* 3702GAAAGUGCUUCCUUUUA 3703 GAAAGUGCUUCC 3704 AAGGAAGCACU MIMAT0002836 GAGGCUUUUAGAG UUC hsa-miR-527 3705 CUGCAAAGGGAAGCCCU 3706 CUGCAAAGGGAA 3707GCUUCCCUUUG MIMAT0002862 UUC GCCCUUUC CAG hsa-miR-532-3p 3708CCUCCCACACCCAAGGC 3709 CCUCCCACACCC 3710 UUGGGUGUGGG MIMAT0004780 UUGCAAAGGCUUG AGG hsa-miR-532-5p 3711 CAUGCCUUGAGUGUAGG 3712 CAUGCCUUGAGU3713 ACACUCAAGGC MIMAT0002888 ACCGU GUAGGACC AUG hsa-miR-539 3714GGAGAAAUUAUCCUUGG 3715 GGAGAAAUUAUC 3716 AGGAUAAUUUC MIMAT0003163 UGUGUCUUGGUGU UCC hsa-miR-541 3717 UGGUGGGCACAGAAUCU 3718 UGGUGGGCACAG 3719UUCUGUGCCCA MIMAT0004920 GGACU AAUCUGGA CCA hsa-miR-541* 3720AAAGGAUUCUGCUGUCG 3721 AAAGGAUUCUGC 3722 CAGCAGAAUCC MIMAT0004919GUCCCACU UGUCGGUC UUU hsa-miR-542-3p 3723 UGUGACAGAUUGAUAAC 3724UGUGACAGAUUG 3725 AUCAAUCUGUC MIMAT0003389 UGAAA AUAACUGA ACAhsa-miR-542-5p 3726 UCGGGGAUCAUCAUGUC 3727 UCGGGGAUCAUC 3728 AUGAUGAUCCCMIMAT0003340 ACGAGA AUGUCACG CGA hsa-miR-543 3729 AAACAUUCGCGGUGCAC 3730AAACAUUCGCGG 3731 CACCGCGAAUG MIMAT0004954 UUCUU UGCACUUC UUUhsa-miR-544 3732 AUUCUGCAUUUUUAGCA 3733 AUUCUGCAUUUU 3734 UAAAAAUGCAGMIMAT0003164 AGUUC UAGCAAGU AAU hsa-miR-544b 3735 ACCUGAGGUUGUGCAUU 3736ACCUGAGGUUGU 3737 GCACAACCUCA MIMAT0015004 UCUAA GCAUUUCU GGUhsa-miR-545 3738 UCAGCAAACAUUUAUUG 3739 UCAGCAAACAUU 3740 UAAAUGUUUGCMIMAT0003165 UGUGC UAUUGUGU UGA hsa-miR-545* 3741 UCAGUAAAUGUUUAUUA 3742UCAGUAAAUGUU 3743 UAAACAUUUAC MIMAT0004785 GAUGA UAUUAGAU UGAhsa-miR-548a- 3744 CAAAACUGGCAAUUACU 3745 CAAAACUGGCAA 3746 AAUUGCCAGUU3p UUUGC UUACUUUU UUG MIMAT0003251 hsa-miR-548a- 3747 AAAAGUAAUUGCGAGUU3748 AAAAGUAAUUGC 3749 UCGCAAUUACU 5p UUACC GAGUUUUA UUU MIMAT0004803hsa-miR-548aa 3750 AAAAACCACAAUUACUU 3751 AAAAACCACAAU 3752 UAAUUGUGGUUMIMAT0018447 UUGCACCA UACUUUUG UUU hsa-miR-548b- 3753 CAAGAACCUCAGUUGCU3754 CAAGAACCUCAG 3755 AACUGAGGUUC 3p UUUGU UUGCUUUU UUG MIMAT0003254hsa-miR-548b- 3756 AAAAGUAAUUGUGGUUU 3757 AAAAGUAAUUGU 3758 CCACAAUUACU5p UGGCC GGUUUUGG UUU MIMAT0004798 hsa-miR-548c- 3759 CAAAAAUCUCAAUUACU3760 CAAAAAUCUCAA 3761 AAUUGAGAUUU 3p UUUGC UUACUUUU UUG MIMAT0003285hsa-miR-548c- 3762 AAAAGUAAUUGCGGUUU 3763 AAAAGUAAUUGC 3764 CCGCAAUUACU5p UUGCC GGUUUUUG UUU MIMAT0004806 hsa-miR-548d- 3765 CAAAAACCACAGUUUCU3766 CAAAAACCACAG 3767 AACUGUGGUUU 3p UUUGC UUUCUUUU UUG MIMAT0003323hsa-miR-548d- 3768 AAAAGUAAUUGUGGUUU 3769 AAAAGUAAUUGU 3770 CCACAAUUACU5p UUGCC GGUUUUUG UUU MIMAT0004812 hsa-miR-548e 3771 AAAAACUGAGACUACUU3772 AAAAACUGAGAC 3773 UAGUCUCAGUU MIMAT0005874 UUGCA UACUUUUG UUUhsa-miR-548f 3774 AAAAACUGUAAUUACUU 3775 AAAAACUGUAAU 3776 UAAUUACAGUUMIMAT0005895 UU UACUUUU UUU hsa-miR-548g 3777 AAAACUGUAAUUACUUU 3778AAAACUGUAAUU 3779 GUAAUUACAGU MIMAT0005912 UGUAC ACUUUUGU UUUhsa-miR-548h 3780 AAAAGUAAUCGCGGUUU 3781 AAAAGUAAUCGC 3782 CCGCGAUUACUMIMAT0005928 UUGUC GGUUUUUG UUU hsa-miR-548i 3783 AAAAGUAAUUGCGGAUU 3784AAAAGUAAUUGC 3785 CCGCAAUUACU MIMAT0005935 UUGCC GGAUUUUG UUUhsa-miR-548j 3786 AAAAGUAAUUGCGGUCU 3787 AAAAGUAAUUGC 3788 CCGCAAUUACUMIMAT0005875 UUGGU GGUCUUUG UUU hsa-miR-548k 3789 AAAAGUACUUGCGGAUU 3790AAAAGUACUUGC 3791 CCGCAAGUACU MIMAT0005882 UUGCU GGAUUUUG UUUhsa-miR-548l 3792 AAAAGUAUUUGCGGGUU 3793 AAAAGUAUUUGC 3794 CCGCAAAUACUMIMAT0005889 UUGUC GGGUUUUG UUU hsa-miR-548m 3795 CAAAGGUAUUUGUGGUU 3796CAAAGGUAUUUG 3797 CACAAAUACCU MIMAT0005917 UUUG UGGUUUUU UUGhsa-miR-548n 3798 CAAAAGUAAUUGUGGAU 3799 CAAAAGUAAUUG 3800 CACAAUUACUUMIMAT0005916 UUUGU UGGAUUUU UUG hsa-miR-548o 3801 CCAAAACUGCAGUUACU 3802CCAAAACUGCAG 3803 AACUGCAGUUU MIMAT0005919 UUUGC UUACUUUU UGGhsa-miR-548p 3804 UAGCAAAAACUGCAGUU 3805 UAGCAAAAACUG 3806 UGCAGUUUUUGMIMAT0005934 ACUUU CAGUUACU CUA hsa-miR-548q 3807 GCUGGUGCAAAAGUAAU 3808GCUGGUGCAAAA 3809 ACUUUUGCACC MIMAT0011163 GGCGG GUAAUGGC AGChsa-miR-548s 3810 AUGGCCAAAACUGCAGU 3811 AUGGCCAAAACU 3812 GCAGUUUUGGCMIMAT0014987 UAUUUU GCAGUUAU CAU hsa-miR-548t 3813 CAAAAGUGAUCGUGGUU3814 CAAAAGUGAUCG 3815 CACGAUCACUU MIMAT0015009 UUUG UGGUUUUU UUGhsa-miR-548u 3816 CAAAGACUGCAAUUACU 3817 CAAAGACUGCAA 3818 AAUUGCAGUCUMIMAT0015013 UUUGCG UUACUUUU UUG hsa-miR-548v 3819 AGCUACAGUUACUUUUG3820 AGCUACAGUUAC 3821 AAGUAACUGUA MIMAT0015020 CACCA UUUUGCAC GCUhsa-miR-548w 3822 AAAAGUAACUGCGGUUU 3823 AAAAGUAACUGC 3824 CCGCAGUUACUMIMAT0015060 UUGCCU GGUUUUUG UUU hsa-miR-548x 3825 UAAAAACUGCAAUUACU3826 UAAAAACUGCAA 3827 AAUUGCAGUUU MIMAT0015081 UUCA UUACUUUC UUAhsa-miR-548y 3828 AAAAGUAAUCACUGUUU 3829 AAAAGUAAUCAC 3830 CAGUGAUUACUMIMAT0018354 UUGCC UGUUUUUG UUU hsa-miR-548z 3831 CAAAAACCGCAAUUACU 3832CAAAAACCGCAA 3833 AAUUGCGGUUU MIMAT0018446 UUUGCA UUACUUUU UUGhsa-miR-549 3834 UGACAACUAUGGAUGAG 3835 UGACAACUAUGG 3836 AUCCAUAGUUGMIMAT0003333 CUCU AUGAGCUC UCA hsa-miR-550a 3837 AGUGCCUGAGGGAGUAA 3838AGUGCCUGAGGG 3839 CUCCCUCAGGC MIMAT0004800 GAGCCC AGUAAGAG ACUhsa-miR-550a* 3840 UGUCUUACUCCCUCAGG 3841 UGUCUUACUCCC 3842 GAGGGAGUAAGMIMAT0003257 CACAU UCAGGCAC ACA hsa-miR-550b 3843 UCUUACUCCCUCAGGCA 3844UCUUACUCCCUC 3845 CUGAGGGAGUA MIMAT0018445 CUG AGGCACUG AGA hsa-miR-551a3846 GCGACCCACUCUUGGUU 3847 GCGACCCACUCU 3848 CAAGAGUGGGU MIMAT0003214UCCA UGGUUUCC CGC hsa-miR-551b 3849 GCGACCCAUACUUGGUU 3850 GCGACCCAUACU3851 CAAGUAUGGGU MIMAT0003233 UCAG UGGUUUCA CGC hsa-miR-551b* 3852GAAAUCAAGCGUGGGUG 3853 GAAAUCAAGCGU 3854 CCACGCUUGAU MIMAT0004794 AGACCGGGUGAGA UUC hsa-miR-552 3855 AACAGGUGACUGGUUAG 3856 AACAGGUGACUG 3857ACCAGUCACCU MIMAT0003215 ACAA GUUAGACA GUU hsa-miR-553 3858AAAACGGUGAGAUUUUG 3859 AAAACGGUGAGA 3860 AAUCUCACCGU MIMAT0003216 UUUUUUUUGUUU UUU hsa-miR-554 3861 GCUAGUCCUGACUCAGC 3862 GCUAGUCCUGAC 3863GAGUCAGGACU MIMAT0003217 CAGU UCAGCCAG AGC hsa-miR-555 3864AGGGUAAGCUGAACCUC 3865 AGGGUAAGCUGA 3866 GUUCAGCUUAC MIMAT0003219 UGAUACCUCUGA CCU hsa-miR-556-3p 3867 AUAUUACCAUUAGCUCA 3868 AUAUUACCAUUA3869 GCUAAUGGUAA MIMAT0004793 UCUUU GCUCAUCU UAU hsa-miR-556-5p 3870GAUGAGCUCAUUGUAAU 3871 GAUGAGCUCAUU 3872 ACAAUGAGCUC MIMAT0003220 AUGAGGUAAUAUG AUC hsa-miR-557 3873 GUUUGCACGGGUGGGCC 3874 GUUUGCACGGGU 3875CCACCCGUGCA MIMAT0003221 UUGUCU GGGCCUUG AAC hsa-miR-558 3876UGAGCUGCUGUACCAAA 3877 UGAGCUGCUGUA 3878 GGUACAGCAGC MIMAT0003222 AUCCAAAAU UCA hsa-miR-559 3879 UAAAGUAAAUAUGCACC 3880 UAAAGUAAAUAU 3881GCAUAUUUACU MIMAT0003223 AAAA GCACCAAA UUA hsa-miR-561 3882CAAAGUUUAAGAUCCUU 3883 CAAAGUUUAAGA 3884 GAUCUUAAACU MIMAT0003225 GAAGUUCCUUGAA UUG hsa-miR-562 3885 AAAGUAGCUGUACCAUU 3886 AAAGUAGCUGUA 3887GGUACAGCUAC MIMAT0003226 UGC CCAUUUGC UUU hsa-miR-563 3888AGGUUGACAUACGUUUC 3889 AGGUUGACAUAC 3890 ACGUAUGUCAA MIMAT0003227 CCGUUUCCC CCU hsa-miR-564 3891 AGGCACGGUGUCAGCAG 3892 AGGCACGGUGUC 3893CUGACACCGUG MIMAT0003228 GC AGCAGGC CCU hsa-miR-566 3894GGGCGCCUGUGAUCCCA 3895 GGGCGCCUGUGA 3896 GAUCACAGGCG MIMAT0003230 ACUCCCAAC CCC hsa-miR-567 3897 AGUAUGUUCUUCCAGGA 3898 AGUAUGUUCUUC 3899UGGAAGAACAU MIMAT0003231 CAGAAC CAGGACAG ACU hsa-miR-568 3900AUGUAUAAAUGUAUACA 3901 AUGUAUAAAUGU 3902 AUACAUUUAUA MIMAT0003232 CACAUACACAC CAU hsa-miR-569 3903 AGUUAAUGAAUCCUGGA 3904 AGUUAAUGAAUC 3905AGGAUUCAUUA MIMAT0003234 AAGU CUGGAAAG ACU hsa-miR-570 3906CGAAAACAGCAAUUACC 3907 CGAAAACAGCAA 3908 AAUUGCUGUUU MIMAT0003235 UUUGCUUACCUUU UCG hsa-miR-571 3909 UGAGUUGGCCAUCUGAG 3910 UGAGUUGGCCAU 3911AGAUGGCCAAC MIMAT0003236 UGAG CUGAGUGA UCA hsa-miR-572 3912GUCCGCUCGGCGGUGGC 3913 GUCCGCUCGGCG 3914 ACCGCCGAGCG MIMAT0003237 CCAGUGGCCCA GAC hsa-miR-573 3915 CUGAAGUGAUGUGUAAC 3916 CUGAAGUGAUGU 3917ACACAUCACUU MIMAT0003238 UGAUCAG GUAACUGA CAG hsa-miR-574-3p 3918CACGCUCAUGCACACAC 3919 CACGCUCAUGCA 3920 UGUGCAUGAGC MIMAT0003239 CCACACACACCCA GUG hsa-miR-574-5p 3921 UGAGUGUGUGUGUGUGA 3922 UGAGUGUGUGUG3923 CACACACACAC MIMAT0004795 GUGUGU UGUGAGUG UCA hsa-miR-575 3924GAGCCAGUUGGACAGGA 3925 GAGCCAGUUGGA 3926 UGUCCAACUGG MIMAT0003240 GCCAGGAGC CUC hsa-miR-576-3p 3927 AAGAUGUGGAAAAAUUG 3928 AAGAUGUGGAAA 3929UUUUUCCACAU MIMAT0004796 GAAUC AAUUGGAA CUU hsa-miR-576-5p 3930AUUCUAAUUUCUCCACG 3931 AUUCUAAUUUCU 3932 GGAGAAAUUAG MIMAT0003241 UCUUUCCACGUCU AAU hsa-miR-577 3933 UAGAUAAAAUAUUGGUA 3934 UAGAUAAAAUAU 3935CAAUAUUUUAU MIMAT0003242 CCUG UGGUACCU CUA hsa-miR-578 3936CUUCUUGUGCUCUAGGA 3937 CUUCUUGUGCUC 3938 UAGAGCACAAG MIMAT0003243 UUGUUAGGAUUG AAG hsa-miR-579 3939 UUCAUUUGGUAUAAACC 3940 UUCAUUUGGUAU 3941UUAUACCAAAU MIMAT0003244 GCGAUU AAACCGCG GAA hsa-miR-580 3942UUGAGAAUGAUGAAUCA 3943 UUGAGAAUGAUG 3944 UUCAUCAUUCU MIMAT0003245 UUAGGAAUCAUUA CAA hsa-miR-581 3945 UCUUGUGUUCUCUAGAU 3946 UCUUGUGUUCUC 3947UAGAGAACACA MIMAT0003246 CAGU UAGAUCAG AGA hsa-miR-582-3p 3948UAACUGGUUGAACAACU 3949 UAACUGGUUGAA 3950 UGUUCAACCAG MIMAT0004797 GAACCCAACUGAA UUA hsa-miR-582-5p 3951 UUACAGUUGUUCAACCA 3952 UUACAGUUGUUC3953 UUGAACAACUG MIMAT0003247 GUUACU AACCAGUU UAA hsa-miR-583 3954CAAAGAGGAAGGUCCCA 3955 CAAAGAGGAAGG 3956 GACCUUCCUCU MIMAT0003248 UUACUCCCAUUA UUG hsa-miR-584 3957 UUAUGGUUUGCCUGGGA 3958 UUAUGGUUUGCC 3959CAGGCAAACCA MIMAT0003249 CUGAG UGGGACUG UAA hsa-miR-585 3960UGGGCGUAUCUGUAUGC 3961 UGGGCGUAUCUG 3962 UACAGAUACGC MIMAT0003250 UAUAUGCUA CCA hsa-miR-586 3963 UAUGCAUUGUAUUUUUA 3964 UAUGCAUUGUAU 3965AAAUACAAUGC MIMAT0003252 GGUCC UUUUAGGU AUA hsa-miR-587 3966UUUCCAUAGGUGAUGAG 3967 UUUCCAUAGGUG 3968 AUCACCUAUGG MIMAT0003253 UCACAUGAGUCA AAA hsa-miR-588 3969 UUGGCCACAAUGGGUUA 3970 UUGGCCACAAUG 3971CCCAUUGUGGC MIMAT0003255 GAAC GGUUAGAA CAA hsa-miR-589 3972UGAGAACCACGUCUGCU 3973 UGAGAACCACGU 3974 AGACGUGGUUC MIMAT0004799 CUGAGCUGCUCUG UCA hsa-miR-589* 3975 UCAGAACAAAUGCCGGU 3976 UCAGAACAAAUG 3977GGCAUUUGUUC MIMAT0003256 UCCCAGA CCGGUUCC UGA hsa-miR-590-3p 3978UAAUUUUAUGUAUAAGC 3979 UAAUUUUAUGUA 3980 UAUACAUAAAA MIMAT0004801 UAGUUAAGCUAG UUA hsa-miR-590-5p 3981 GAGCUUAUUCAUAAAAG 3982 GAGCUUAUUCAU3983 UUAUGAAUAAG MIMAT0003258 UGCAG AAAAGUGC CUC hsa-miR-591 3984AGACCAUGGGUUCUCAU 3985 AGACCAUGGGUU 3986 AGAACCCAUGG MIMAT0003259 UGUCUCAUUGU UCU hsa-miR-592 3987 UUGUGUCAAUAUGCGAU 3988 UUGUGUCAAUAU 3989GCAUAUUGACA MIMAT0003260 GAUGU GCGAUGAU CAA hsa-miR-593 3990UGUCUCUGCUGGGGUUU 3991 UGUCUCUGCUGG 3992 CCCCAGCAGAG MIMAT0004802 CUGGUUUCU ACA hsa-miR-593* 3993 AGGCACCAGCCAGGCAU 3994 AGGCACCAGCCA 3995CCUGGCUGGUG MIMAT0003261 UGCUCAGC GGCAUUGC CCU hsa-miR-595 3996GAAGUGUGCCGUGGUGU 3997 GAAGUGUGCCGU 3998 CCACGGCACAC MIMAT0003263 GUCUGGUGUGUC UUC hsa-miR-596 3999 AAGCCUGCCCGGCUCCU 4000 AAGCCUGCCCGG 4001AGCCGGGCAGG MIMAT0003264 CGGG CUCCUCGG CUU hsa-miR-597 4002UGUGUCACUCGAUGACC 4003 UGUGUCACUCGA 4004 CAUCGAGUGAC MIMAT0003265 ACUGUUGACCACU ACA hsa-miR-598 4005 UACGUCAUCGUUGUCAU 4006 UACGUCAUCGUU 4007ACAACGAUGAC MIMAT0003266 CGUCA GUCAUCGU GUA hsa-miR-599 4008GUUGUGUCAGUUUAUCA 4009 GUUGUGUCAGUU 4010 UAAACUGACAC MIMAT0003267 AACUAUCAAAC AAC hsa-miR-600 4011 ACUUACAGACAAGAGCC 4012 ACUUACAGACAA 4013UCUUGUCUGUA MIMAT0003268 UUGCUC GAGCCUUG AGU hsa-miR-601 4014UGGUCUAGGAUUGUUGG 4015 UGGUCUAGGAUU 4016 ACAAUCCUAGA MIMAT0003269 AGGAGGUUGGAGG CCA hsa-miR-602 4017 GACACGGGCGACAGCUG 4018 GACACGGGCGAC 4019CUGUCGCCCGU MIMAT0003270 CGGCCC AGCUGCGG GUC hsa-miR-603 4020CACACACUGCAAUUACU 4021 CACACACUGCAA 4022 AAUUGCAGUGU MIMAT0003271 UUUGCUUACUUUU GUG hsa-miR-604 4023 AGGCUGCGGAAUUCAGG 4024 AGGCUGCGGAAU 4025GAAUUCCGCAG MIMAT0003272 AC UCAGGAC CCU hsa-miR-605 4026UAAAUCCCAUGGUGCCU 4027 UAAAUCCCAUGG 4028 CACCAUGGGAU MIMAT0003273 UCUCCUUGCCUUCU UUA hsa-miR-606 4029 AAACUACUGAAAAUCAA 4030 AAACUACUGAAA 4031AUUUUCAGUAG MIMAT0003274 AGAU AUCAAAGA UUU hsa-miR-607 4032GUUCAAAUCCAGAUCUA 4033 GUUCAAAUCCAG 4034 AUCUGGAUUUG MIMAT0003275 UAACAUCUAUAA AAC hsa-miR-608 4035 AGGGGUGGUGUUGGGAC 4036 AGGGGUGGUGUU 4037CCAACACCACC MIMAT0003276 AGCUCCGU GGGACAGC CCU hsa-miR-609 4038AGGGUGUUUCUCUCAUC 4039 AGGGUGUUUCUC 4040 GAGAGAAACAC MIMAT0003277 UCUUCAUCUCU CCU hsa-miR-610 4041 UGAGCUAAAUGUGUGCU 4042 UGAGCUAAAUGU 4043ACACAUUUAGC MIMAT0003278 GGGA GUGCUGGG UCA hsa-miR-611 4044GCGAGGACCCCUCGGGG 4045 GCGAGGACCCCU 4046 CGAGGGGUCCU MIMAT0003279 UCUGACCGGGGUCU CGC hsa-miR-612 4047 GCUGGGCAGGGCUUCUG 4048 GCUGGGCAGGGC 4049AAGCCCUGCCC MIMAT0003280 AGCUCCUU UUCUGAGC AGC hsa-miR-613 4050AGGAAUGUUCCUUCUUU 4051 AGGAAUGUUCCU 4052 GAAGGAACAUU MIMAT0003281 GCCUCUUUGCC CCU hsa-miR-614 4053 GAACGCCUGUUCUUGCC 4054 GAACGCCUGUUC 4055AAGAACAGGCG MIMAT0003282 AGGUGG UUGCCAGG UUC hsa-miR-615-3p 4056UCCGAGCCUGGGUCUCC 4057 UCCGAGCCUGGG 4058 GACCCAGGCUC MIMAT0003283 CUCUUUCUCCCUC GGA hsa-miR-615-5p 4059 GGGGGUCCCCGGUGCUC 4060 GGGGGUCCCCGG4061 CACCGGGGACC MIMAT0004804 GGAUC UGCUCGGA CCC hsa-miR-616 4062AGUCAUUGGAGGGUUUG 4063 AGUCAUUGGAGG 4064 ACCCUCCAAUG MIMAT0004805 AGCAGGUUUGAGC ACU hsa-miR-616* 4065 ACUCAAAACCCUUCAGU 4066 ACUCAAAACCCU 4067GAAGGGUUUUG MIMAT0003284 GACUU UCAGUGAC AGU hsa-miR-617 4068AGACUUCCCAUUUGAAG 4069 AGACUUCCCAUU 4070 CAAAUGGGAAG MIMAT0003286 GUGGCUGAAGGUG UCU hsa-miR-618 4071 AAACUCUACUUGUCCUU 4072 AAACUCUACUUG 4073GACAAGUAGAG MIMAT0003287 CUGAGU UCCUUCUG UUU hsa-miR-619 4074GACCUGGACAUGUUUGU 4075 GACCUGGACAUG 4076 AACAUGUCCAG MIMAT0003288GCCCAGU UUUGUGCC GUC hsa-miR-620 4077 AUGGAGAUAGAUAUAGA 4078AUGGAGAUAGAU 4079 AUAUCUAUCUC MIMAT0003289 AAU AUAGAAAU CAU hsa-miR-6214080 GGCUAGCAACAGCGCUU 4081 GGCUAGCAACAG 4082 CGCUGUUGCUA MIMAT0003290ACCU CGCUUACC GCC hsa-miR-622 4083 ACAGUCUGCUGAGGUUG 4084 ACAGUCUGCUGA4085 CCUCAGCAGAC MIMAT0003291 GAGC GGUUGGAG UGU hsa-miR-623 4086AUCCCUUGCAGGGGCUG 4087 AUCCCUUGCAGG 4088 CCCCUGCAAGG MIMAT0003292 UUGGGUGGCUGUUG GAU hsa-miR-624 4089 CACAAGGUAUUGGUAUU 4090 CACAAGGUAUUG 4091ACCAAUACCUU MIMAT0004807 ACCU GUAUUACC GUG hsa-miR-624* 4092UAGUACCAGUACCUUGU 4093 UAGUACCAGUAC 4094 AGGUACUGGUA MIMAT0003293 GUUCACUUGUGUU CUA hsa-miR-625 4095 AGGGGGAAAGUUCUAUA 4096 AGGGGGAAAGUU 4097AGAACUUUCCC MIMAT0003294 GUCC CUAUAGUC CCU hsa-miR-625* 4098GACUAUAGAACUUUCCC 4099 GACUAUAGAACU 4100 AAAGUUCUAUA MIMAT0004808 CCUCAUUCCCCCU GUC hsa-miR-626 4101 AGCUGUCUGAAAAUGUC 4102 AGCUGUCUGAAA 4103AUUUUCAGACA MIMAT0003295 UU AUGUCUU GCU hsa-miR-627 4104GUGAGUCUCUAAGAAAA 4105 GUGAGUCUCUAA 4106 UCUUAGAGACU MIMAT0003296 GAGGAGAAAAGAG CAC hsa-miR-628-3p 4107 UCUAGUAAGAGUGGCAG 4108 UCUAGUAAGAGU4109 CCACUCUUACU MIMAT0003297 UCGA GGCAGUCG AGA hsa-miR-628-5p 4110AUGCUGACAUAUUUACU 4111 AUGCUGACAUAU 4112 AAAUAUGUCAG MIMAT0004809 AGAGGUUACUAGA CAU hsa-miR-629 4113 UGGGUUUACGUUGGGAG 4114 UGGGUUUACGUU 4115CCAACGUAAAC MIMAT0004810 AACU GGGAGAAC CCA hsa-miR-629* 4116GUUCUCCCAACGUAAGC 4117 GUUCUCCCAACG 4118 UACGUUGGGAG MIMAT0003298 CCAGCUAAGCCCA AAC hsa-miR-630 4119 AGUAUUCUGUACCAGGG 4120 AGUAUUCUGUAC 4121UGGUACAGAAU MIMAT0003299 AAGGU CAGGGAAG ACU hsa-miR-631 4122AGACCUGGCCCAGACCU 4123 AGACCUGGCCCA 4124 UCUGGGCCAGG MIMAT0003300 CAGCGACCUCAG UCU hsa-miR-632 4125 GUGUCUGCUUCCUGUGG 4126 GUGUCUGCUUCC 4127CAGGAAGCAGA MIMAT0003302 GA UGUGGGA CAC hsa-miR-633 4128CUAAUAGUAUCUACCAC 4129 CUAAUAGUAUCU 4130 GUAGAUACUAU MIMAT0003303 AAUAAAACCACAAU UAG hsa-miR-634 4131 AACCAGCACCCCAACUU 4132 AACCAGCACCCC 4133UUGGGGUGCUG MIMAT0003304 UGGAC AACUUUGG GUU hsa-miR-635 4134ACUUGGGCACUGAAACA 4135 ACUUGGGCACUG 4136 UUCAGUGCCCA MIMAT0003305 AUGUCCAAACAAUG AGU hsa-miR-636 4137 UGUGCUUGCUCGUCCCG 4138 UGUGCUUGCUCG 4139GACGAGCAAGC MIMAT0003306 CCCGCA UCCCGCCC ACA hsa-miR-637 4140ACUGGGGGCUUUCGGGC 4141 ACUGGGGGCUUU 4142 CGAAAGCCCCC MIMAT0003307UCUGCGU CGGGCUCU AGU hsa-miR-638 4143 AGGGAUCGCGGGCGGGU 4144AGGGAUCGCGGG 4145 CGCCCGCGAUC MIMAT0003308 GGCGGCCU CGGGUGGC CCUhsa-miR-639 4146 AUCGCUGCGGUUGCGAG 4147 AUCGCUGCGGUU 4148 GCAACCGCAGCMIMAT0003309 CGCUGU GCGAGCGC GAU hsa-miR-640 4149 AUGAUCCAGGAACCUGC 4150AUGAUCCAGGAA 4151 GGUUCCUGGAU MIMAT0003310 CUCU CCUGCCUC CAU hsa-miR-6414152 AAAGACAUAGGAUAGAG 4153 AAAGACAUAGGA 4154 UAUCCUAUGUC MIMAT0003311UCACCUC UAGAGUCA UUU hsa-miR-642a 4155 GUCCCUCUCCAAAUGUG 4156GUCCCUCUCCAA 4157 AUUUGGAGAGG MIMAT0003312 UCUUG AUGUGUCU GAChsa-miR-642b 4158 AGACACAUUUGGAGAGG 4159 AGACACAUUUGG 4160 CUCCAAAUGUGMIMAT0018444 GACCC AGAGGGAC UCU hsa-miR-643 4161 ACUUGUAUGCUAGCUCA 4162ACUUGUAUGCUA 4163 GCUAGCAUACA MIMAT0003313 GGUAG GCUCAGGU AGUhsa-miR-644 4164 AGUGUGGCUUUCUUAGA 4165 AGUGUGGCUUUC 4166 AAGAAAGCCACMIMAT0003314 GC UUAGAGC ACU hsa-miR-645 4167 UCUAGGCUGGUACUGCU 4168UCUAGGCUGGUA 4169 AGUACCAGCCU MIMAT0003315 GA CUGCUGA AGA hsa-miR-6464170 AAGCAGCUGCCUCUGAG 4171 AAGCAGCUGCCU 4172 AGAGGCAGCUG MIMAT0003316GC CUGAGGC CUU hsa-miR-647 4173 GUGGCUGCACUCACUUC 4174 GUGGCUGCACUC 4175GUGAGUGCAGC MIMAT0003317 CUUC ACUUCCUU CAC hsa-miR-648 4176AAGUGUGCAGGGCACUG 4177 AAGUGUGCAGGG 4178 UGCCCUGCACA MIMAT0003318 GUCACUGGU CUU hsa-miR-649 4179 AAACCUGUGUUGUUCAA 4180 AAACCUGUGUUG 4181AACAACACAGG MIMAT0003319 GAGUC UUCAAGAG UUU hsa-miR-650 4182AGGAGGCAGCGCUCUCA 4183 AGGAGGCAGCGC 4184 GAGCGCUGCCU MIMAT0003320 GGACUCUCAGGA CCU hsa-miR-651 4185 UUUAGGAUAAGCUUGAC 4186 UUUAGGAUAAGC 4187AAGCUUAUCCU MIMAT0003321 UUUUG UUGACUUU AAA hsa-miR-652 4188AAUGGCGCCACUAGGGU 4189 AAUGGCGCCACU 4190 CUAGUGGCGCC MIMAT0003322 UGUGAGGGUUGU AUU hsa-miR-653 4191 GUGUUGAAACAAUCUCU 4192 GUGUUGAAACAA 4193GAUUGUUUCAA MIMAT0003328 ACUG UCUCUACU CAC hsa-miR-654-3p 4194UAUGUCUGCUGACCAUC 4195 UAUGUCUGCUGA 4196 GGUCAGCAGAC MIMAT0004814 ACCUUCCAUCACC AUA hsa-miR-654-5p 4197 UGGUGGGCCGCAGAACA 4198 UGGUGGGCCGCA4199 UCUGCGGCCCA MIMAT0003330 UGUGC GAACAUGU CCA hsa-miR-655 4200AUAAUACAUGGUUAACC 4201 AUAAUACAUGGU 4202 UAACCAUGUAU MIMAT0003331 UCUUUUAACCUCU UAU hsa-miR-656 4203 AAUAUUAUACAGUCAAC 4204 AAUAUUAUACAG 4205GACUGUAUAAU MIMAT0003332 CUCU UCAACCUC AUU hsa-miR-657 4206GGCAGGUUCUCACCCUC 4207 GGCAGGUUCUCA 4208 GGUGAGAACCU MIMAT0003335 UCUAGGCCCUCUCU GCC hsa-miR-658 4209 GGCGGAGGGAAGUAGGU 4210 GGCGGAGGGAAG 4211UACUUCCCUCC MIMAT0003336 CCGUUGGU UAGGUCCG GCC hsa-miR-659 4212CUUGGUUCAGGGAGGGU 4213 CUUGGUUCAGGG 4214 CUCCCUGAACC MIMAT0003337 CCCCAAGGGUCCC AAG hsa-miR-660 4215 UACCCAUUGCAUAUCGG 4216 UACCCAUUGCAU 4217AUAUGCAAUGG MIMAT0003338 AGUUG AUCGGAGU GUA hsa-miR-661 4218UGCCUGGGUCUCUGGCC 4219 UGCCUGGGUCUC 4220 CAGAGACCCAG MIMAT0003324UGCGCGU UGGCCUGC GCA hsa-miR-662 4221 UCCCACGUUGUGGCCCA 4222UCCCACGUUGUG 4223 GCCACAACGUG MIMAT0003325 GCAG GCCCAGCA GGA hsa-miR-6634224 AGGCGGGGCGCCGCGGG 4225 AGGCGGGGCGCC 4226 GCGGCGCCCCG MIMAT0003326ACCGC GCGGGACC CCU hsa-miR-663b 4227 GGUGGCCCGGCCGUGCC 4228 GGUGGCCCGGCC4229 ACGGCCGGGCC MIMAT0005867 UGAGG GUGCCUGA ACC hsa-miR-664 4230UAUUCAUUUAUCCCCAG 4231 UAUUCAUUUAUC 4232 GGGAUAAAUGA MIMAT0005949 CCUACACCCAGCCU AUA hsa-miR-664* 4233 ACUGGCUAGGGAAAAUG 4234 ACUGGCUAGGGA 4235UUUCCCUAGCC MIMAT0005948 AUUGGAU AAAUGAUU AGU hsa-miR-665 4236ACCAGGAGGCUGAGGCC 4237 ACCAGGAGGCUG 4238 CUCAGCCUCCU MIMAT0004952 CCUAGGCCCCU GGU hsa-miR-668 4239 UGUCACUCGGCUCGGCC 4240 UGUCACUCGGCU 4241CGAGCCGAGUG MIMAT0003881 CACUAC CGGCCCAC ACA hsa-miR-670 4242GUCCCUGAGUGUAUGUG 4243 GUCCCUGAGUGU 4244 AUACACUCAGG MIMAT0010357 GUGAUGUGGUG GAC hsa-miR-671-3p 4245 UCCGGUUCUCAGGGCUC 4246 UCCGGUUCUCAG4247 CCCUGAGAACC MIMAT0004819 CACC GGCUCCAC GGA hsa-miR-671-5p 4248AGGAAGCCCUGGAGGGG 4249 AGGAAGCCCUGG 4250 CUCCAGGGCUU MIMAT0003880 CUGGAGAGGGGCUG CCU hsa-miR-675 4251 UGGUGCGGAGAGGGCCC 4252 UGGUGCGGAGAG 4253CCCUCUCCGCA MIMAT0004284 ACAGUG GGCCCACA CCA hsa-miR-675* 4254CUGUAUGCCCUCACCGC 4255 CUGUAUGCCCUC 4256 GUGAGGGCAUA MIMAT0006790 UCAACCGCUCA CAG hsa-miR-676 4257 CUGUCCUAAGGUUGUUG 4258 CUGUCCUAAGGU 4259CAACCUUAGGA MIMAT0018204 AGUU UGUUGAGU CAG hsa-miR-676* 4260UCUUCAACCUCAGGACU 4261 UCUUCAACCUCA 4262 CCUGAGGUUGA MIMAT0018203 UGCAGGACUUGC AGA hsa-miR-7 4263 UGGAAGACUAGUGAUUU 4264 UGGAAGACUAGU 4265UCACUAGUCUU MIMAT0000252 UGUUGU GAUUUUGU CCA hsa-miR-708 4266AAGGAGCUUACAAUCUA 4267 AAGGAGCUUACA 4268 AUUGUAAGCUC MIMAT0004926 GCUGGGAUCUAGCU CUU hsa-miR-708* 4269 CAACUAGACUGUGAGCU 4270 CAACUAGACUGU 4271UCACAGUCUAG MIMAT0004927 UCUAG GAGCUUCU UUG hsa-miR-7-1* 4272CAACAAAUCACAGUCUG 4273 CAACAAAUCACA 4274 ACUGUGAUUUG MIMAT0004553 CCAUAGUCUGCCA UUG hsa-miR-711 4275 GGGACCCAGGGAGAGAC 4276 GGGACCCAGGGA 4277UCUCCCUGGGU MIMAT0012734 GUAAG GAGACGUA CCC hsa-miR-718 4278CUUCCGCCCCGCCGGGC 4279 CUUCCGCCCCGC 4280 CGGCGGGGCGG MIMAT0012735 GUCGCGGGCGUC AAG hsa-miR-7-2* 4281 CAACAAAUCCCAGUCUA 4282 CAACAAAUCCCA 4283ACUGGGAUUUG MIMAT0004554 CCUAA GUCUACCU UUG hsa-miR-720 4284UCUCGCUGGGGCCUCCA 4285 UCUCGCUGGGGC 4286 AGGCCCCAGCG MIMAT0005954 CUCCAAGA hsa-miR-744 4287 UGCGGGGCUAGGGCUAA 4288 UGCGGGGCUAGG 4289GCCCUAGCCCC MIMAT0004945 CAGCA GCUAACAG GCA hsa-miR-744* 4290CUGUUGCCACUAACCUC 4291 CUGUUGCCACUA 4292 GUUAGUGGCAA MIMAT0004946 AACCUACCUCAAC CAG hsa-miR-758 4293 UUUGUGACCUGGUCCAC 4294 UUUGUGACCUGG 4295GACCAGGUCAC MIMAT0003879 UAACC UCCACUAA AAA hsa-miR-759 4296GCAGAGUGCAAACAAUU 4297 GCAGAGUGCAAA 4298 UGUUUGCACUC MIMAT0010497 UUGACCAAUUUUG UGC hsa-miR-760 4299 CGGCUCUGGGUCUGUGG 4300 CGGCUCUGGGUC 4301CAGACCCAGAG MIMAT0004957 GGA UGUGGGGA CCG hsa-miR-761 4302GCAGCAGGGUGAAACUG 4303 GCAGCAGGGUGA 4304 UUUCACCCUGC MIMAT0010364 ACACAAACUGACA UGC hsa-miR-762 4305 GGGGCUGGGGCCGGGGC 4306 GGGGCUGGGGCC 4307CCGGCCCCAGC MIMAT0010313 CGAGC GGGGCCGA CCC hsa-miR-764 4308GCAGGUGCUCACUUGUC 4309 GCAGGUGCUCAC 4310 AAGUGAGCACC MIMAT0010367 CUCCUUUGUCCUC UGC hsa-miR-765 4311 UGGAGGAGAAGGAAGGU 4312 UGGAGGAGAAGG 4313UUCCUUCUCCU MIMAT0003945 GAUG AAGGUGAU CCA hsa-miR-766 4314ACUCCAGCCCCACAGCC 4315 ACUCCAGCCCCA 4316 UGUGGGGCUGG MIMAT0003888 UCAGCCAGCCUCA AGU hsa-miR-767-3p 4317 UCUGCUCAUACCCCAUG 4318 UCUGCUCAUACC4319 GGGGUAUGAGC MIMAT0003883 GUUUCU CCAUGGUU AGA hsa-miR-767-5p 4320UGCACCAUGGUUGUCUG 4321 UGCACCAUGGUU 4322 ACAACCAUGGU MIMAT0003882 AGCAUGGUCUGAGC GCA hsa-miR-769-3p 4323 CUGGGAUCUCCGGGGUC 4324 CUGGGAUCUCCG4325 CCCGGAGAUCC MIMAT0003887 UUGGUU GGGUCUUG CAG hsa-miR-769-5p 4326UGAGACCUCUGGGUUCU 4327 UGAGACCUCUGG 4328 ACCCAGAGGUC MIMAT0003886 GAGCUGUUCUGAG UCA hsa-miR-770-5p 4329 UCCAGUACCACGUGUCA 4330 UCCAGUACCACG4331 CACGUGGUACU MIMAT0003948 GGGCCA UGUCAGGG GGA hsa-miR-802 4332CAGUAACAAAGAUUCAU 4333 CAGUAACAAAGA 4334 AAUCUUUGUUA MIMAT0004185 CCUUGUUUCAUCCU CUG hsa-miR-873 4335 GCAGGAACUUGUGAGUC 4336 GCAGGAACUUGU 4337UCACAAGUUCC MIMAT0004953 UCCU GAGUCUCC UGC hsa-miR-874 4338CUGCCCUGGCCCGAGGG 4339 CUGCCCUGGCCC 4340 UCGGGCCAGGG MIMAT0004911 ACCGAGAGGGACC CAG hsa-miR-875-3p 4341 CCUGGAAACACUGAGGU 4342 CCUGGAAACACU4343 UCAGUGUUUCC MIMAT0004923 UGUG GAGGUUGU AGG hsa-miR-875-5p 4344UAUACCUCAGUUUUAUC 4345 UAUACCUCAGUU 4346 AAAACUGAGGU MIMAT0004922 AGGUGUUAUCAGG AUA hsa-miR-876-3p 4347 UGGUGGUUUACAAAGUA 4348 UGGUGGUUUACA4349 UUUGUAAACCA MIMAT0004925 AUUCA AAGUAAUU CCA hsa-miR-876-5p 4350UGGAUUUCUUUGUGAAU 4351 UGGAUUUCUUUG 4352 CACAAAGAAAU MIMAT0004924 CACCAUGAAUCAC CCA hsa-miR-877 4353 GUAGAGGAGAUGGCGCA 4354 GUAGAGGAGAUG 4355GCCAUCUCCUC MIMAT0004949 GGG GCGCAGGG UAC hsa-miR-877* 4356UCCUCUUCUCCCUCCUC 4357 UCCUCUUCUCCC 4358 GAGGGAGAAGA MIMAT0004950 CCAGUCCUCCCA GGA hsa-miR-885-3p 4359 AGGCAGCGGGGUGUAGU 4360 AGGCAGCGGGGU4361 ACACCCCGCUG MIMAT0004948 GGAUA GUAGUGGA CCU hsa-miR-885-5p 4362UCCAUUACACUACCCUG 4363 UCCAUUACACUA 4364 GGUAGUGUAAU MIMAT0004947 CCUCUCCCUGCCU GGA hsa-miR-887 4365 GUGAACGGGCGCCAUCC 4366 GUGAACGGGCGC 4367UGGCGCCCGUU MIMAT0004951 CGAGG CAUCCCGA CAC hsa-miR-888 4368UACUCAAAAAGCUGUCA 4369 UACUCAAAAAGC 4370 CAGCUUUUUGA MIMAT0004916 GUCAUGUCAGUC GUA hsa-miR-888* 4371 GACUGACACCUCUUUGG 4372 GACUGACACCUC 4373AAGAGGUGUCA MIMAT0004917 GUGAA UUUGGGUG GUC hsa-miR-889 4374UUAAUAUCGGACAACCA 4375 UUAAUAUCGGAC 4376 UUGUCCGAUAU MIMAT0004921 UUGUAACCAUUG UAA hsa-miR-890 4377 UACUUGGAAAGGCAUCA 4378 UACUUGGAAAGG 4379UGCCUUUCCAA MIMAT0004912 GUUG CAUCAGUU GUA hsa-miR-891a 4380UGCAACGAACCUGAGCC 4381 UGCAACGAACCU 4382 UCAGGUUCGUU MIMAT0004902 ACUGAGAGCCACU GCA hsa-miR-891b 4383 UGCAACUUACCUGAGUC 4384 UGCAACUUACCU 4385UCAGGUAAGUU MIMAT0004913 AUUGA GAGUCAUU GCA hsa-miR-892a 4386CACUGUGUCCUUUCUGC 4387 CACUGUGUCCUU 4388 GAAAGGACACA MIMAT0004907 GUAGUCUGCGUA GUG hsa-miR-892b 4389 CACUGGCUCCUUUCUGG 4390 CACUGGCUCCUU 4391GAAAGGAGCCA MIMAT0004918 GUAGA UCUGGGUA GUG hsa-miR-9 4392UCUUUGGUUAUCUAGCU 4393 UCUUUGGUUAUC 4394 UAGAUAACCAA MIMAT0000441 GUAUGAUAGCUGUA AGA hsa-miR-9* 4395 AUAAAGCUAGAUAACCG 4396 AUAAAGCUAGAU 4397UUAUCUAGCUU MIMAT0000442 AAAGU AACCGAAA UAU hsa-miR-920 4398GGGGAGCUGUGGAAGCA 4399 GGGGAGCUGUGG 4400 UUCCACAGCUC MIMAT0004970 GUAAAGCAGUA CCC hsa-miR-921 4401 CUAGUGAGGGACAGAAC 4402 CUAGUGAGGGAC 4403CUGUCCCUCAC MIMAT0004971 CAGGAUUC AGAACCAG UAG hsa-miR-922 4404GCAGCAGAGAAUAGGAC 4405 GCAGCAGAGAAU 4406 CUAUUCUCUGC MIMAT0004972 UACGUCAGGACUAC UGC hsa-miR-924 4407 AGAGUCUUGUGAUGUCU 4408 AGAGUCUUGUGA 4409CAUCACAAGAC MIMAT0004974 UGC UGUCUUGC UCU hsa-miR-92a 4410UAUUGCACUUGUCCCGG 4411 UAUUGCACUUGU 4412 GGACAAGUGCA MIMAT0000092 CCUGUCCCGGCCU AUA hsa-miR-92a-1* 4413 AGGUUGGGAUCGGUUGC 4414 AGGUUGGGAUCG4415 ACCGAUCCCAA MIMAT0004507 AAUGCU GUUGCAAU CCU hsa-miR-92a-2* 4416GGGUGGGGAUUUGUUGC 4417 GGGUGGGGAUUU 4418 ACAAAUCCCCA MIMAT0004508 AUUACGUUGCAUU CCC hsa-miR-92b 4419 UAUUGCACUCGUCCCGG 4420 UAUUGCACUCGU 4421GGACGAGUGCA MIMAT0003218 CCUCC CCCGGCCU AUA hsa-miR-92b* 4422AGGGACGGGACGCGGUG 4423 AGGGACGGGACG 4424 CGCGUCCCGUC MIMAT0004792 CAGUGCGGUGCAG CCU hsa-miR-93 4425 CAAAGUGCUGUUCGUGC 4426 CAAAGUGCUGUU 4427CGAACAGCACU MIMAT0000093 AGGUAG CGUGCAGG UUG hsa-miR-93* 4428ACUGCUGAGCUAGCACU 4429 ACUGCUGAGCUA 4430 GCUAGCUCAGC MIMAT0004509 UCCCGGCACUUCC AGU hsa-miR-933 4431 UGUGCGCAGGGAGACCU 4432 UGUGCGCAGGGA 4433UCUCCCUGCGC MIMAT0004976 CUCCC GACCUCUC ACA hsa-miR-934 4434UGUCUACUACUGGAGAC 4435 UGUCUACUACUG 4436 UCCAGUAGUAG MIMAT0004977 ACUGGGAGACACU ACA hsa-miR-935 4437 CCAGUUACCGCUUCCGC 4438 CCAGUUACCGCU 4439GAAGCGGUAAC MIMAT0004978 UACCGC UCCGCUAC UGG hsa-miR-936 4440ACAGUAGAGGGAGGAAU 4441 ACAGUAGAGGGA 4442 CCUCCCUCUAC MIMAT0004979 CGCAGGGAAUCGC UGU hsa-miR-937 4443 AUCCGCGCUCUGACUCU 4444 AUCCGCGCUCUG 4445GUCAGAGCGCG MIMAT0004980 CUGCC ACUCUCUG GAU hsa-miR-938 4446UGCCCUUAAAGGUGAAC 4447 UGCCCUUAAAGG 4448 CACCUUUAAGG MIMAT0004981 CCAGUUGAACCCA GCA hsa-miR-939 4449 UGGGGAGCUGAGGCUCU 4450 UGGGGAGCUGAG 4451GCCUCAGCUCC MIMAT0004982 GGGGGUG GCUCUGGG CCA hsa-miR-940 4452AAGGCAGGGCCCCCGCU 4453 AAGGCAGGGCCC 4454 GGGGGCCCUGC MIMAT0004983 CCCCCCGCUCCC CUU hsa-miR-941 4455 CACCCGGCUGUGUGCAC 4456 CACCCGGCUGUG 4457CACACAGCCGG MIMAT0004984 AUGUGC UGCACAUG GUG hsa-miR-942 4458UCUUCUCUGUUUUGGCC 4459 UCUUCUCUGUUU 4460 CAAAACAGAGA MIMAT0004985 AUGUGUGGCCAUG AGA hsa-miR-943 4461 CUGACUGUUGCCGUCCU 4462 CUGACUGUUGCC 4463ACGGCAACAGU MIMAT0004986 CCAG GUCCUCCA CAG hsa-miR-944 4464AAAUUAUUGUACAUCGG 4465 AAAUUAUUGUAC 4466 AUGUACAAUAA MIMAT0004987 AUGAGAUCGGAUG UUU hsa-miR-95 4467 UUCAACGGGUAUUUAUU 4468 UUCAACGGGUAU 4469AAAUACCCGUU MIMAT0000094 GAGCA UUAUUGAG GAA hsa-miR-96 4470UUUGGCACUAGCACAUU 4471 UUUGGCACUAGC 4472 GUGCUAGUGCC MIMAT0000095 UUUGCUACAUUUUU AAA hsa-miR-96* 4473 AAUCAUGUGCAGUGCCA 4474 AAUCAUGUGCAG 4475CACUGCACAUG MIMAT0004510 AUAUG UGCCAAUA AUU hsa-miR-98 4476UGAGGUAGUAAGUUGUA 4477 UGAGGUAGUAAG 4478 AACUUACUACC MIMAT0000096 UUGUUUUGUAUUG UCA hsa-miR-99a 4479 AACCCGUAGAUCCGAUC 4480 AACCCGUAGAUC 4481CGGAUCUACGG MIMAT0000097 UUGUG CGAUCUUG GUU hsa-miR-99a* 4482CAAGCUCGCUUCUAUGG 4483 CAAGCUCGCUUC 4484 UAGAAGCGAGC MIMAT0004511 GUCUGUAUGGGUC UUG hsa-miR-99b 4485 CACCCGUAGAACCGACC 4486 CACCCGUAGAAC 4487CGGUUCUACGG MIMAT0000689 UUGCG CGACCUUG GUG hsa-miR-99b* 4488CAAGCUCGUGUCUGUGG 4489 CAAGCUCGUGUC 4490 CAGACACGAGC MIMAT0004678 GUCCGUGUGGGUC UUG

TABLE 5 Examples of chemical modification patterns miRNA Name Example ofmodified AS strand Example of modified sense strand hsa-let-7a5′Pm0005f0f05f05f00f05f005f05f05m0*5m0* m0m00m00m0m000m00m0*m0*m0TEGCholMIMAT0000062 0*5m0*f0*5m0*0 hsa-let-7a*5′Pm0005f0f05f005f05f05f0005f00*5m0*0*5m0m0m0m00m00m00m00m0*m0*m0TEGChol MIMAT0004481 m0*5m0*0*0 hsa-let-7a-2*5′Pm05f05f05f05f005f05f05f00005f00*5m0* m0m0m0m0m0m000m0m000*0*m0TEGCholMIMAT0010195 5m0*0*** hsa-let-7b 5′Pm0000f0000f005f05f05f05m0*0*5m0*0*fm0m000m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0000063 0*5m0*0 hsa-let-7b*5′Pm0005f0f0000f05f0005f00*0*5m0*5m0*fm0m0m0m00m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004482 0*0*0 hsa-let-7c5′Pm005f05f0f05f000f005f05f05f05m0*5m0* m0m000m0m0m0m00m000*m0*m0TEGCholMIMAT0000064 5m0*5m0*5m0*5m0*0 hsa-let-7c*5′Pm0005f05f05f05f005f0005f05f00*0*0*5mm0m00m0m0m0m000m00m0*m0*m0TEGChol MIMAT0004483 0*** hsa-let-7d5′Pm005f05f0f05f05f05f0f0000f05m0*0*5m0 m0m0m0m0m0m0000m000*m0*m0TEGCholMIMAT0000065 *5m0*5m0*5m0* hsa-let-7d*5′Pm005f00f00005f05f000f05m0*0*5m0*5mm0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004484 0*5m0*0*0 hsa-let-7e5′Pm0005f0f005f05f05f005f00f00*0*5m0*0*m0m0m00m0m000m0m00m0*m0*m0TEGChol MIMAT0000066 f0*5m0*0 hsa-let-7e*5′Pm05f000f0000f00005f05m0*0*5m0*5m0m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004485 *** hsa-let-7f5′Pm05f000f05f05f05f05f05f000f00*0*0*0*fm0m0m0m00m0000m0m0m0*0*m0TEGChol MIMAT0000067 0*0*0 hsa-let-7f-1*5′Pm00005f005f05f0f005f005f05m0*5m0*0*m0m0m00m0m000m0m0m0m0*m0*m0TEGChol MIMAT0004486 5m0*5m0*5m0*0hsa-let-7f-2* 5′Pm0005f0f05f005f05f05f0005f00*5m0*5mm0m0m0m00m00m00m00m0*m0*m0TEGChol MIMAT0004487 0*0*f0*0*0 hsa-let-7g5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGCholMIMAT0000414 0*0*0*f0*0*0 hsa-let-7g*5′Pm0000f05f05f005f005f05f05f00*0*5m0*0m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004584 *5m0*0*0 hsa-let-7i5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0000415 m0*5m0*5m0*0 hsa-let-7i*5′Pm05f000f005f05f05f05f000f00*5m0*0*0*m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0004585 f0*5m0*0 hsa-miR-15′Pm00005f05f05f05f05f05f05f005f00*0*0*5m0m0m000m0000m0m0m0*m0*m0TEGChol MIMAT0000416 m0*5m0*0*0 hsa-miR-1005′Pm005f05f05f005f05f0f0005f05f00*0*0*0*m0m00m0m0m000m0m000*m0*m0TEGChol MIMAT0000098 5m0*0*0 hsa-miR-100*5′Pm005f05f0f05f005f05f05f005f05f05m0*5 m0m00m00m00m00m000*m0*m0TEGCholMIMAT0004512 m0*0*0*5m0*5m0*0 hsa-miR-1015′Pm0000f005f05f05f05f05f005f00*5m0*0*5m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0000099 m0*5m0*5m0*0 hsa-miR-101*5′Pm05f000f005f00f05f0005f05m0*5m0*0*5m0m0m0m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0004513 m0*f0*5m0*0 hsa-miR-1035′Pm005f05f0f05f000f0005f05f00*5m0*5m0 m0m00m0m0m0m0m00m000*m0*m0TEGCholMIMAT0000101 *0*f0*0*0 hsa-miR-103-2*5′Pm05f05f05f0f005f05f05f05f05f05f05f00*0 m0m0000m000m0m000*0*m0TEGCholMIMAT0009196 *0*0*f0*5m0*0 hsa-miR-103-as5′Pm0005f05f05f05f05f0f0000f05m0*0*5m0 m0m0m0m0m0m0000m00m0*m0*m0TEGCholMIMAT0007402 *5m0*f0*5m0*0 hsa-miR-1055′Pm0000f05f05f05f0f0005f0f05m0*5m0*5m m0m00m0m0m0000m0m0m0*m0*m0TEGCholMIMAT0000102 0*0*f0*0* hsa-miR-105*5′Pm0005f0f05f05f05f05f05f000f00*0*5m0* m0m0m0m00m0000m00m0*m0*m0TEGCholMIMAT0004516 5m0*5m0*5m0*0 hsa-miR-106a5′Pm05f000f05f0005f05f005f0f00*5m0*0*0*m0m00m00m0m0m00m0m0m0*0*m0TEGChol MIMAT0000103 5m0*0*0 hsa-miR-106a*5′Pm0005f0f005f005f005f05f0f05m0*5m0*0 m0m000m0m0m00m0m00m0*m0*m0TEGCholMIMAT0004517 *0*5m0*5m0*0 hsa-miR-106b5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0000680 *5m0*0*f0*0*0 hsa-miR-106b*5′Pm0000f05f05f05f05f05f000f00*0*5m0*0*m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0004672 f0*5m0*0 hsa-miR-1075′Pm0005f0f05f005f05f05f005f0f00*0*0*5m m0m00m00m00m00m00m0*m0*m0TEGCholMIMAT0000104 0*5m0*5m0* hsa-miR-10a5′Pm0005f0f00005f05f05f05f0f00*0*0*0*5mm0m0000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0000253 0*0*0 hsa-miR-10a*5′Pm0005f0f0000f05f05f05f0f00*0*5m0*0*fm0m0000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004555 0*5m0*0 hsa-miR-10b5′Pm0005f0f05f005f0f00005f05m0*5m0*0*5m0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0000254 m0*f0*5m0*0 hsa-miR-10b*5′Pm05f05f005f005f05f05f00005f05m0*5m0 m0m0m0m0m0m000m0m0m00*0*m0TEGCholMIMAT0004556 *5m0*0*5m0*5m0*0 hsa-miR-11785′Pm00005f05f05f05f05f005f005f05m0*0*5 m0m0m00m0m0000m0m0m0*m0*m0TEGCholMIMAT0005823 m0*5m0*5m0*5m0*0 hsa-miR-11795′Pm005f05f0f00005f05f000f05m0*5m0*0*5m0m0m0m00m0m0m0m0m000*m0*m0TEGChol MIMAT0005824 m0*f0*0*0 hsa-miR-11805′Pm05f000f05f000f005f05f05f05m0*5m0*0 m0m000m0m0m0m00m0m0m0*0*m0TEGCholMIMAT0005825 *0*f0*0*0 hsa-miR-11815′Pm05f000f005f05f05f0000f00*0*5m0*5m0m0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0005826 *5m0*5m0*0 hsa-miR-11825′Pm0000f005f00f05f0005f05m0*0*5m0*5mm0m0m0m00m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005827 0*5m0*5m0*0hsa-miR-1183 5′Pm0005f05f005f00f05f05f005f05m0*5m0*m0m0m000m0m00m0m00m0*m0*m0TEGChol MIMAT0005828 5m0*0*5m0*5m0*0hsa-miR-1184 5′Pm05f05f00f005f00f05f05f05f0f00*0*0*5mm0m0000m0m00m0m0m00*0*m0TEGChol MIMAT0005829 0*f0*0*0 hsa-miR-11855′Pm005f00f05f05f05f0f005f05f0f05m0*5m0 m0m000m0m0000m0m00*m0*m0TEGCholMIMAT0005798 *0*0*5m0*0*0 hsa-miR-11935′Pm00005f05f0005f05f005f05f05m0*0*0*0m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0015049 *5m0*0*0 hsa-miR-11975′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0005955 m0*5m0*5m0*0 hsa-miR-12005′Pm0000f0005f05f05f05f005f00*0*0*0*f0*m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0005863 5m0*0 hsa-miR-12025′Pm05f05f005f05f05f05f05f0005f05f00*5m0 m0m00m0m0m0000m0m00*0*m0TEGCholMIMAT0005865 *5m0*5m0*f0*5m0*0 hsa-miR-12035′Pm00005f0005f0f05f005f05f00*5m0*5m0*m0m00m00m00m0m0m0m0m0*m0*m0TEGChol MIMAT0005866 0*f0*5m0*0 hsa-miR-12045′Pm05f0005f05f05f05f0f05f005f05f05m0*0* m0m00m00m0000m0m0m0*0*m0TEGCholMIMAT0005868 5m0*5m0*f0*5m0*0 hsa-miR-12055′Pm05f05f005f05f05f05f05f0005f05f00*5m0 m0m00m0m0m0000m0m00*0*m0TEGCholMIMAT0005869 *5m0*5m0*f0*5m0*0 hsa-miR-12065′Pm0005f05f0000f005f005f00*0*0*0*f0**m0m0m00m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0005870 hsa-miR-1207-3p5′Pm00005f005f05f0f05f05f005f00*5m0*5m m0m0m000m000m0m0m0m0*m0*m0TEGCholMIMAT0005872 0*5m0*f0*5m0*0 hsa-miR-1207-5p5′Pm0005f0f05f000f0000f00*5m0*5m0*5m0m0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0005871 *f0*5m0*0 hsa-miR-12085′Pm05f05f00f005f00f05f05f05f0f00*0*0*5m m0m0000m0m00m0m0m00*0*m0TEGCholMIMAT0005873 0*f0*0*0 hsa-miR-1225′Pm05f05f05f0f05f05f05f0f005f00f05m0*0* m0m0m00m0m0000m000*0*m0TEGCholMIMAT0000421 0*5m0*5m0*5m0*0 hsa-miR-122*5′Pm05f05f05f0f05f05f05f0f05f05f05f0f05m0 m0m0000m0000m000*0*m0TEGCholMIMAT0004590 *5m0*5m0*5m0*f0*5m0*0 hsa-miR-1224-3p5′Pm0000f05f000f00005f05m0*0*5m0*0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005459 m0*0*0 hsa-miR-1224-5p5′Pm00005f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*m0*m0TEGCholMIMAT0005458 *0*0*f0*0*0 hsa-miR-1225-3p5′Pm05f05f005f05f05f05f05f05f005f05f00*5 m0m00m00m0000m0m00*0*m0TEGCholMIMAT0005573 m0*5m0*5m0*f0*0*0 hsa-miR-1225-5p5′Pm05f000f00005f05f0005f05m0*0*0*0*f0m0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0005572 ** hsa-miR-12265′Pm05f05f00f05f005f0f00005f00*5m0*0*0*m0m0m0m0m0m00m00m0m00*0*m0TEGChol MIMAT0005577 f0*5m0*0 hsa-miR-1226*5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0005576 m0*5m0*5m0*0 hsa-miR-12275′Pm005f005f00005f005f005f00*5m0*0*5mm0m0m00m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0005580 0*f0*5m0*0 hsa-miR-12285′Pm0005f0f05f05f005f005f005f00*5m0*5m m0m0m00m0m0m000m00m0*m0*m0TEGCholMIMAT0005583 0*0*5m0*5m0*0 hsa-miR-1228*5′Pm05f05f00f05f000f0005f0f00*5m0*0*0*5m0m00m0m0m0m0m00m0m00*0*m0TEGChol MIMAT0005582 m0*5m0*0 hsa-miR-12295′Pm05f000f05f005f0f005f05f05f00*0*5m0* m0m000m0m00m00m0m0m0*0*m0TEGCholMIMAT0005584 0*f0*0*0 hsa-miR-12315′Pm005f05f0f0005f0f0005f05f00*0*0*0*f0*m0m00m0m0m00m0m0m000*m0*m0TEGChol MIMAT0005586 0* hsa-miR-12335′Pm005f05f0f0005f0f05f05f005f00*0*5m0* m0m0m000m00m0m0m000*m0*m0TEGCholMIMAT0005588 5m0*5m0*5m0*0 hsa-miR-12345′Pm005f05f05f0000f05f005f0f05m0*0*0*5 m0m00m00m0m0m0m0m000*m0*m0TEGCholMIMAT0005589 m0*f0*5m0*0 hsa-miR-12365′Pm05f005f0f05f0005f05f05f05f05f05m0*0* m0m0000m0m0m00m00m0*0*m0TEGCholMIMAT0005591 0*5m0*5m0*5m0*0 hsa-miR-12375′Pm0000f05f005f05f05f005f0f00*5m0*0*5 m0m00m00m00m00m0m0m0*m0*m0TEGCholMIMAT0005592 m0*f0*0*0 hsa-miR-12385′Pm05f005f0f005f005f00005f00*5m0*5m0*m0m0m0m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0005593 5m0*5m0*5m0*0hsa-miR-124 5′Pm05f000f005f00f05f005f0f05m0*0*0*5mm0m00m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0000422 0*5m0*0*0 hsa-miR-124*5′Pm0000f0000f0005f0f00*0*5m0*0*f0*0*0m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004591 hsa-miR-12435′Pm005f05f05f05f05f05f05f005f00f00*5m0* m0m0m00m0m0000m000*m0*m0TEGCholMIMAT0005894 0*0*5m0*5m0*0 hsa-miR-12445′Pm005f005f005f00f005f05f0f05m0*0*0*0*m0m000m0m0m00m0m0m00*m0*m0TEGChol MIMAT0005896 f0*5m0*0 hsa-miR-12455′Pm00005f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*m0*m0TEGCholMIMAT0005897 *0*0*f0*0*0 hsa-miR-12465′Pm05f05f05f0f05f05f005f05f005f0f00*5m0 m0m00m00m0m000m000*0*m0TEGCholMIMAT0005898 *0*5m0*5m0*0*0 hsa-miR-12475′Pm05f005f05f0005f05f05f05f005f00*5m0* m0m0m000m00m0m0m00m0*0*m0TEGCholMIMAT0005899 5m0*5m0*5m0*5m0*0 hsa-miR-12485′Pm05f000f0005f0f05f005f0f00*0*5m0*5m m0m00m00m00m0m0m0m0m0*0*m0TEGCholMIMAT0005900 0*5m0*0*0 hsa-miR-12495′Pm0000f05f005f05f0005f0f00*5m0*0*5m0m0m00m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0005901 *f0*0*0 hsa-miR-12505′Pm005f00f005f005f0000f00*5m0*0*0***m0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0005902 hsa-miR-12515′Pm05f005f0f05f05f005f05f05f05f05f05m0* m0m0000m0m000m00m0*0*m0TEGCholMIMAT0005903 5m0*5m0*5m0*** hsa-miR-12525′Pm05f000f0000f005f00f05m0*0*5m0*0*f0m0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0005944 *0*0 hsa-miR-12535′Pm05f05f005f05f000f05f05f00f05m0*0*5m m0m0m000m0m0m00m0m00*0*m0TEGCholMIMAT0005904 0*5m0*5m0*5m0*0 hsa-miR-12545′Pm0005f05f05f000f05f05f05f05f00*0*5m0 m0m0000m0m0m00m00m0*m0*m0TEGCholMIMAT0005905 *5m0*5m0*0*0 hsa-miR-1255a5′Pm05f05f05f05f05f05f05f05f05f05f05f05f0 m0m0000m0000m000*0*m0TEGCholMIMAT0005906 5m0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-1255b5′Pm0005f0f005f00f0005f0f05m0*0*0*5m0*m0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0005945 f0*0*0 hsa-miR-12565′Pm05f05f005f05f05f05f05f05f05f05f0f05m m0m0000m0000m0m00*0*m0TEGCholMIMAT0005907 0*5m0*0*5m0*5m0*0*0 hsa-miR-12575′Pm005f005f05f05f005f005f005f00*5m0*0*m0m0m00m0m0m000m0m00*m0*m0TEGChol MIMAT0005908 5m0*5m0*5m0*0hsa-miR-1258 5′Pm05f005f05f0005f05f005f005f05m0*5m0m0m0m00m0m00m0m0m00m0*0*m0TEGChol MIMAT0005909 *5m0*5m0*5m0*5m0*0hsa-miR-125a-3p 5′Pm05f005f0f05f005f0f005f05f0f00*0*0*0*m0m000m0m00m00m00m0*0*m0TEGChol MIMAT0004602 5m0*5m0*0 hsa-miR-125a-5p5′Pm05f005f0f005f00f005f05f0f00*5m0*5m0 m0m000m0m0m00m0m00m0*0*m0TEGCholMIMAT0000443 *5m0*5m0*5m0*0 hsa-miR-125b5′Pm0000f005f05f0f0005f05f05m0*5m0*0*5m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0000423 m0*f0*0*0hsa-miR-125b-1* 5′Pm0005f0f0005f05f0000f00*5m0*0*5m0*fm0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0004592 0*0*0 hsa-miR-125b-2*5′Pm0005f0f005f005f05f005f05f00*5m0*5m m0m00m00m0m00m0m00m0*m0*m0TEGCholMIMAT0004603 0*5m0*f0*0*0 hsa-miR-1265′Pm005f005f05f05f05f0f05f05f005f05m0*0* m0m0m000m0000m0m00*m0*m0TEGCholMIMAT0000445 0*5m0*f0*0*0 hsa-miR-126*5′Pm05f05f05f05f0000f05f05f05f05f05m0*5 m0m0000m0m0m0m0m000*0*m0TEGCholMIMAT0000444 m0*0*0*5m0*5m0*0 hsa-miR-12605′Pm0000f05f0005f00005f05m0*0*5m0*0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005911 m0*0*0 hsa-miR-1260b5′Pm005f005f05f005f05f05f05f05f05f05m0*5 m0m0000m00m00m0m00*m0*m0TEGCholMIMAT0015041 m0*5m0*5m0*5m0*0*0 hsa-miR-12615′Pm0005f05f05f05f05f0f0005f05f05m0*5m0 m0m00m0m0m0000m00m0*m0*m0TEGCholMIMAT0005913 *0*5m0*5m0*5m0*0 hsa-miR-12625′Pm05f05f00f0000f005f005f05m0*0*5m0*0m0m0m00m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0005914 *f0*0*0 hsa-miR-12635′Pm05f05f005f0005f0f005f05f0f00*0*5m0* m0m000m0m00m0m0m0m00*0*m0TEGCholMIMAT0005915 5m0*5m0*5m0*0 hsa-miR-12645′Pm05f05f05f0f05f005f05f05f0005f05m0*5 m0m0m0m00m00m00m000*0*m0TEGCholMIMAT0005791 m0*0*5m0*5m0*5m0*0 hsa-miR-12655′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0005918 m0*5m0*5m0*0 hsa-miR-12665′Pm0000f0000f0005f0f05m0*0*0*5m0*f0*m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0005920 0*0 hsa-miR-12675′Pm00005f005f05f0f05f05f05f0f05m0*0*0* m0m0000m000m0m0m0m0*m0*m0TEGCholMIMAT0005921 0*f0*0*0 hsa-miR-12685′Pm00005f005f005f005f005f00*5m0*0*0*fm0m0m00m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005922 0*5m0*0 hsa-miR-12695′Pm05f05f00f05f000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m00m0m00*0*m0TEGCholMIMAT0005923 m0*5m0*5m0*0 hsa-miR-12705′Pm05f005f05f0005f0f05f005f05f05m0*0*5 m0m00m00m00m0m0m00m0*0*m0TEGCholMIMAT0005924 m0*5m0*f0*0*0 hsa-miR-12715′Pm00005f05f05f00f05f05f005f05m0*5m0* m0m0m000m0m000m0m0m0*m0*m0TEGCholMIMAT0005796 0*5m0*f0*0*0 hsa-miR-12725′Pm00005f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*m0*m0TEGCholMIMAT0005925 *0*0*f0*0*0 hsa-miR-12735′Pm00005f05f05f005f005f05f0f00*0*0*0*f0m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0005926 *0*0 hsa-miR-1273c5′Pm05f05f05f05f05f05f05f0f005f005f00*0* m0m0m00m0m0000m000*0*m0TEGCholMIMAT0015017 0*5m0*5m0*5m0*0 hsa-miR-1273d5′Pm05f05f00f005f05f0f005f05f05f00*5m0*5 m0m000m0m000m0m0m00*0*m0TEGCholMIMAT0015090 m0*0*5m0*5m0*0 hsa-miR-1273e5′Pm0000f0005f05f05f05f005f00*5m0*5m0*m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018079 0*f0*0*0 hsa-miR-127-3p5′Pm05f05f05f0f00005f0005f0f05m0*0*0*5 m0m00m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0000446 m0*f0*0*0 hsa-miR-1274a5′Pm05f05f05f05f0000f05f05f05f05f00*0*5m m0m0000m0m0m0m0m000*0*m0TEGCholMIMAT0005927 0*5m0*5m0*0*0 hsa-miR-1274b5′Pm05f05f05f05f0000f05f05f05f0f00*5m0*5 m0m0000m0m0m0m0m000*0*m0TEGCholMIMAT0005938 m0*5m0*5m0*5m0*0 hsa-miR-12755′Pm05f05f005f05f005f0f05f05f005f05m0*5 m0m0m000m00m00m0m00*0*m0TEGCholMIMAT0005929 m0*5m0*0*5m0*5m0*0 hsa-miR-127-5p5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0004604 m0*5m0*5m0*0 hsa-miR-12765′Pm05f05f05f0f05f0005f005f005f05m0*5m0 m0m0m00m0m0m0m00m000*0*m0TEGCholMIMAT0005930 *5m0*5m0*f0*0*0 hsa-miR-12775′Pm05f000f005f05f0f05f05f05f05f00*5m0*0 m0m0000m000m0m0m0m0*0*m0TEGCholMIMAT0005933 *5m0*5m0*5m0*0 hsa-miR-12785′Pm0005f05f05f000f005f05f05f00*0*0*5m0m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0005936 *f0*0*0 hsa-miR-12795′Pm05f005f0f05f05f05f0f05f05f05f05f00*5 m0m0000m0000m00m0*0*m0TEGCholMIMAT0005937 m0*5m0*5m0*5m0*5m0*0 hsa-miR-1285′Pm00005f005f00f0000f00*0*0*5m0*5m0*m0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0000424 0*0 hsa-miR-12805′Pm05f000f05f05f00f005f05f05f05m0*5m0* m0m000m0m0m000m0m0m0*0*m0TEGCholMIMAT0005946 0*0*f0*0*0 hsa-miR-12815′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGCholMIMAT0005939 m0*5m0*5m0*5m0*0 hsa-miR-12825′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGCholMIMAT0005940 m0*5m0*5m0*5m0*0 hsa-miR-12835′Pm005f005f05f05f05f0f05f005f05f00*0*0* m0m00m00m0000m0m00*m0*m0TEGCholMIMAT0005799 0*f0*0*0 hsa-miR-12845′Pm05f05f05f05f005f05f05f05f005f05f00*5 m0m00m00m000m0m000*0*m0TEGCholMIMAT0005941 m0*5m0*5m0*f0*0*0 hsa-miR-12855′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0005876 *5m0*0*f0*0*0 hsa-miR-12865′Pm0005f05f0005f05f00005f00*0*0*0*f0*5m0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0005877 m0* hsa-miR-12875′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0005878 0*5m0*5m0*0 hsa-miR-12885′Pm05f05f005f0005f0f005f05f0f00*0*5m0* m0m000m0m00m0m0m0m00*0*m0TEGCholMIMAT0005942 5m0*5m0*5m0*0 hsa-miR-12895′Pm05f05f05f05f0005f05f05f05f05f05f05m0 m0m0000m00m0m0m000*0*m0TEGCholMIMAT0005879 *0*5m0*0*5m0*5m0*0 hsa-miR-129*5′Pm05f005f0f0005f05f00005f05m0*5m0*5 m0m0m0m0m0m00m0m0m00m0*0*m0TEGCholMIMAT0004548 m0*5m0*f0*0*0 hsa-miR-12905′Pm05f05f00f05f05f05f0f00005f05m0*0*5m m0m0m0m0m0m0000m0m00*0*m0TEGCholMIMAT0005880 0*5m0*f0*0* hsa-miR-12915′Pm005f005f0005f0f05f05f00f00*0*0*5m0*m0m0m000m00m0m0m0m00*m0*m0TEGChol MIMAT0005881 f0*5m0*0 hsa-miR-12925′Pm0005f0f05f05f05f05f05f05f05f05f05m0* m0m0000m0000m00m0*m0*m0TEGCholMIMAT0005943 0*0*0*f0*5m0*0 hsa-miR-12935′Pm05f05f05f05f05f000f0000f00*0*5m0*0*m0m0m0m0m0m0m0m00m000*0*m0TEGChol MIMAT0005883 5m0*5m0*0 hsa-miR-129-3p5′Pm05f005f0f05f05f005f00005f00*0*5m0*0m0m0m0m0m0m0m000m00m0*0*m0TEGChol MIMAT0004605 *f0*5m0*0 hsa-miR-12945′Pm05f05f05f0f05f0005f005f005f05m0*5m0 m0m0m00m0m0m0m00m000*0*m0TEGCholMIMAT0005884 *5m0*5m0*f0*0*0 hsa-miR-12955′Pm0005f05f005f05f05f00005f00*0*5m0*5m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0005885 m0*5m0*5m0*0hsa-miR-129-5p 5′Pm005f05f0f05f05f005f05f05f05f05f00*0*m0m0000m0m000m000*m0*m0TEGChol MIMAT0000242 5m0*0*5m0*0*0 hsa-miR-12965′Pm00005f005f00f05f05f00f00*5m0*5m0*0m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0005794 *** hsa-miR-12975′Pm0000f00005f0000f05m0*5m0*5m0*0*f m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0005886 0*0*0 Chol hsa-miR-12985′Pm05f05f05f0f05f05f005f05f005f05f00*5m m0m00m00m0m000m000*0*m0TEGCholMIMAT0005800 0*5m0*5m0*** hsa-miR-12995′Pm005f05f05f05f005f0f0005f05f05m0*0*0 m0m00m0m0m00m00m000*m0*m0TEGCholMIMAT0005887 *5m0*5m0*5m0*0 hsa-miR-13015′Pm05f0005f05f05f005f00005f05m0*0*0*5m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0005797 m0*f0*0*0 hsa-miR-13025′Pm0000f05f0005f00005f00*0*5m0*0*f0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005890 m0*0 hsa-miR-13035′Pm00005f0000f05f005f05f00*0*5m0*0*5m0m00m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0005891 m0*5m0*0 hsa-miR-13045′Pm00005f005f05f0f05f005f0f00*0*5m0*5 m0m00m00m000m0m0m0m0*m0*m0TEGCholMIMAT0005892 m0*f0*0*0 hsa-miR-13055′Pm05f05f05f05f005f05f05f05f05f005f05m0 m0m0m000m000m0m000*0*m0TEGCholMIMAT0005893 *0*5m0*5m0*f0** hsa-miR-13065′Pm0000f005f05f0f0005f05f05m0*5m0*0*5m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0005950 m0*f0*0*0 hsa-miR-13075′Pm00005f05f05f00f05f05f00f05m0*5m0*0 m0m0m000m0m000m0m0m0*m0*m0TEGCholMIMAT0005951 *0*5m0*0*0 hsa-miR-130a5′Pm005f005f0005f0f05f000f05m0*0*0*5m0m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0000425 *5m0*5m0*0 hsa-miR-130a*5′Pm05f005f0f05f000f0005f0f05m0*5m0*5m m0m00m0m0m0m0m00m00m0*0*m0TEGCholMIMAT0004593 0*5m0*5m0*0*0 hsa-miR-130b5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGCholMIMAT0000691 0*0*0*f0*5m0*0 hsa-miR-130b*5′Pm05f005f0f05f0005f05f05f05f05f05m0*0* m0m0000m0m0m00m00m0*0*m0TEGCholMIMAT0004680 0*5m0*5m0*5m0*0 hsa-miR-1325′Pm05f05f00f05f05f05f0f05f005f0f00*5m0* m0m00m00m0000m0m00*0*m0TEGCholMIMAT0000426 0*5m0*5m0*5m0*0 hsa-miR-132*5′Pm05f005f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m00m0*0*m0TEGCholMIMAT0004594 m0*5m0*5m0*5m0*** hsa-miR-13215′Pm005f005f005f00f0000f00*5m0*5m0*5mm0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0005952 0*5m0*5m0*0hsa-miR-1322 5′Pm0000f05f000f005f05f05f05m0*5m0*0*0m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005953 *f0*0* hsa-miR-13235′Pm0005f05f05f0005f05f05f00f00*5m0*5m m0m0m000m0m0m00m00m0*m0*m0TEGCholMIMAT0005795 0*5m0*5m0*0*0 hsa-miR-13245′Pm0005f0f0005f05f005f005f00*0*5m0*0*m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0005956 5m0*0*0 hsa-miR-133a5′Pm05f005f0f05f05f005f00005f00*5m0*5m m0m0m0m0m0m0m000m00m0*0*m0TEGCholMIMAT0000427 0*5m0*f0*5m0*0 hsa-miR-133b5′Pm005f00f05f005f05f005f005f00*0*0*0*5m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0000770 m0*5m0*0 hsa-miR-1345′Pm005f05f05f05f005f05f05f05f05f0f05m0* m0m0000m00m00m000*m0*m0TEGCholMIMAT0000447 5m0*5m0*0*5m0*0*0 hsa-miR-135a5′Pm05f005f05f05f005f05f05f05f05f05f05m0 m0m0000m00m00m00m0*0*m0TEGCholMIMAT0000428 *5m0*5m0*0*5m0*5m0*0 hsa-miR-135a*5′Pm05f005f05f05f005f05f05f05f05f05f00*5 m0m0000m00m00m00m0*0*m0TEGCholMIMAT0004595 m0*0*0*f0*0* hsa-miR-135b5′Pm05f05f005f0000f0000f00*5m0*0*5m0*m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0000758 5m0*5m0*0 hsa-miR-135b*5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0004698 m0*5m0*5m0*0 hsa-miR-1365′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGCholMIMAT0000448 m0*5m0*5m0*5m0*0 hsa-miR-136*5′Pm05f05f005f005f00f005f05f05f05m0*0*0 m0m000m0m0m00m0m0m00*0*m0TEGCholMIMAT0004606 *5m0*5m0*5m0*0 hsa-miR-1375′Pm0000f05f000f005f05f05f05m0*5m0*0*0m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000429 *f0*0*0 hsa-miR-1385′Pm05f05f05f05f00005f005f05f05f05m0*0* m0m000m0m0m0m0m0m000*0*m0TEGCholMIMAT0000430 5m0*5m0*5m0*5m0*0 hsa-miR-138-1*5′Pm05f05f05f05f05f05f005f05f05f005f00*5 m0m0m000m0m000m000*0*m0TEGCholMIMAT0004607 m0*0*5m0*5m0*5m0*0 hsa-miR-138-2*5′Pm05f05f05f0f05f005f0f05f000f00*5m0*5 m0m0m0m00m00m00m000*0*m0TEGCholMIMAT0004596 m0*0*f0*0*0 hsa-miR-139-3p5′Pm005f005f0005f0f05f0005f05m0*5m0*0*m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0004552 5m0*5m0*0*0hsa-miR-139-5p 5′Pm005f05f0f0005f05f005f00f00*5m0*5m0m0m0m00m0m00m0m0m000*m0*m0TEGChol MIMAT0000250 *5m0*5m0*5m0*0hsa-miR-140-3p 5′Pm00005f005f05f05f05f05f05f05f05m0*5mm0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0004597 0*0*0*f0*0*0hsa-miR-140-5p 5′Pm05f005f05f0005f05f05f05f005f00*0*0*5m0m0m000m00m0m0m00m0*0*m0TEGChol MIMAT0000431 m0*5m0*0*0 hsa-miR-1415′Pm0000f005f05f05f005f00f05m0*5m0*5m m0m0m00m0m000m0m0m0m0*m0*m0TEGCholMIMAT0000432 0*0*5m0*5m0*0 hsa-miR-141*5′Pm05f005f0f05f000f0005f0f05m0*5m0*5m m0m00m0m0m0m0m00m00m0*0*m0TEGCholMIMAT0004598 0*5m0*5m0*0*0 hsa-miR-142-3p5′Pm05f0005f005f005f05f005f0f00*0*0*5m0m0m00m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0000434 *5m0*5m0*0 hsa-miR-142-5p5′Pm05f000f05f000f05f005f05f00*5m0*5m0 m0m00m00m0m0m00m0m0m0*0*m0TEGCholMIMAT0000433 *5m0*5m0*0*0 hsa-miR-1435′Pm05f0005f0005f0f05f05f05f0f05m0*5m0* m0m0000m00m0m0m0m0m0*0*m0TEGCholMIMAT0000435 0*5m0*f0*0*0 hsa-miR-143*5′Pm005f00f005f005f0000f05m0*0*0*5m0*fm0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0004599 0** hsa-miR-1445′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGCholMIMAT0000436 0*0*0*f0*0*0 hsa-miR-144*5′Pm00005f05f05f00f05f0005f00*0*0*5m0*fm0m0m0m00m0m000m0m0m0*m0*m0TEGChol MIMAT0004600 0*0* hsa-miR-1455′Pm005f05f05f05f005f0f0005f05f05m0*0*0 m0m00m0m0m00m00m000*m0*m0TEGCholMIMAT0000437 *0*5m0*5m0*0 hsa-miR-145*5′Pm0005f0f05f000f05f005f0f00*0*5m0*0*5m0m00m00m0m0m00m00m0*m0*m0TEGChol MIMAT0004601 m0*5m0*0 hsa-miR-14685′Pm00005f05f05f005f005f05f05f00*0*0*0*fm0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0006789 0*0*0 hsa-miR-14695′Pm0005f05f005f05f0f05f05f005f05m0*0*5 m0m0m000m000m0m00m0*m0*m0TEGCholMIMAT0007347 m0*5m0*f0*0*0 hsa-miR-146a5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0000449 m0*5m0*5m0*0 hsa-miR-146a*5′Pm005f05f0f005f05f05f005f00f00*0*5m0* m0m0m00m0m000m0m000*m0*m0TEGCholMIMAT0004608 5m0*5m0*5m0*0 hsa-miR-146b-3p5′Pm00005f05f05f05f05f005f00f00*5m0*0*0m0m0m00m0m0000m0m0m0*m0*m0TEGChol MIMAT0004766 *f0*0*0 hsa-miR-146b-5p5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGCholMIMAT0002809 0*0*0*5m0*0*0 hsa-miR-1475′Pm005f05f0f05f05f05f0f05f000f00*0*0*0*fm0m0m0m00m0000m000*m0*m0TEGChol MIMAT0000251 0*5m0*0 hsa-miR-14705′Pm005f05f05f05f005f0f00005f05m0*0*0*0m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0007348 *5m0*5m0*0 hsa-miR-14715′Pm05f05f00f005f05f05f05f05f00f05m0*0*5 m0m0m000m000m0m0m00*0*m0TEGCholMIMAT0007349 m0*5m0*f0*0* hsa-miR-147b5′Pm05f05f005f05f05f005f0000f00*0*0*5m0m0m0m0m0m0m0m000m0m00*0*m0TEGChol MIMAT0004928 *f0*0*0 hsa-miR-148a5′Pm05f05f05f05f05f005f0f005f005f00*0*5m m0m0m00m0m00m00m000*0*m0TEGCholMIMAT0000243 0*5m0*** hsa-miR-148a*5′Pm0005f0f05f0005f005f05f0f05m0*5m0*5 m0m000m0m0m0m00m00m0*m0*m0TEGCholMIMAT0004549 m0*0*5m0*0*0 hsa-miR-148b5′Pm05f05f05f05f05f05f05f05f0000f05m0*5 m0m0m0m0m0m0000m000*0*m0TEGCholMIMAT0000759 m0*0*5m0*5m0*5m0*0 hsa-miR-148b*5′Pm00005f05f05f05f0f00005f00*5m0*5m0*m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004699 5m0*5m0*0*0 hsa-miR-1495′Pm05f05f00f005f00f05f000f00*5m0*0*0*fm0m0m0m00m0m00m0m0m00*0*m0TEGChol MIMAT0000450 0*0*0 hsa-miR-149*5′Pm005f05f05f0005f05f005f005f00*5m0*0*m0m0m00m0m00m0m0m000*m0*m0TEGChol MIMAT0004609 5m0*f0*5m0*0 hsa-miR-1505′Pm05f000f05f05f05f0f005f05f05f05m0*0*0 m0m000m0m0000m0m0m0*0*m0TEGCholMIMAT0000451 *0*f0*0*0 hsa-miR-150*5′Pm05f05f05f05f05f05f05f05f05f05f05f0f05 m0m0000m0000m000*0*m0TEGCholMIMAT0004610 m0*0*0*0*5m0*5m0*0 hsa-miR-151-3p5′Pm05f05f05f05f005f05f05f0005f05f05m0*0 m0m00m0m0m000m0m000*0*m0TEGCholMIMAT0000757 *5m0*5m0*f0*0*0 hsa-miR-151-5p5′Pm05f05f05f05f005f05f0f005f005f05m0*0* m0m0m00m0m000m0m000*0*m0TEGCholMIMAT0004697 5m0*5m0*5m0*5m0*0 hsa-miR-1525′Pm05f05f00f05f000f05f005f05f00*0*5m0* m0m00m00m0m0m00m0m00*0*m0TEGCholMIMAT0000438 5m0*f0*0*0 hsa-miR-1535′Pm0000f0005f05f05f05f00f00*5m0*5m0*0m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0000439 *f0*0*0 hsa-miR-15375′Pm0000f0000f05f0005f05m0*0*0*5m0*5m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0007399 m0*5m0*0 hsa-miR-15385′Pm05f005f0f05f000f0000f05m0*0*0*5m0*m0m0m0m0m0m0m0m00m00m0*0*m0TEGChol MIMAT0007400 5m0*5m0*0 hsa-miR-15395′Pm05f05f05f05f005f05f0f05f05f005f05m0* m0m0m000m000m0m000*0*m0TEGCholMIMAT0007401 0*5m0*5m0*f0*5m0* hsa-miR-1545′Pm05f05f00f0005f05f0005f0f05m0*5m0*5 m0m00m0m0m00m0m0m0m00*0*m0TEGCholMIMAT0000452 m0*5m0*5m0*5m0*0 hsa-miR-154*5′Pm00005f005f05f05f005f05f05f00*5m0*0*m0m000m0m000m0m0m0m0*m0*m0TEGChol MIMAT0000453 5m0*f0*0*0 hsa-miR-1555′Pm0000f05f05f00f005f00f00*0*0*5m0*5mm0m0m00m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000646 0*5m0*0 hsa-miR-155*5′Pm005f00f0005f05f0000f05m0*0*0*0*5mm0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0004658 0*5m0*0 hsa-miR-15a5′Pm05f0005f05f05f005f00005f00*5m0*0*5m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0000068 m0*f0*5m0*0 hsa-miR-15a*5′Pm0000f05f05f05f0f05f05f00f00*0*0*0*f0m0m0m000m0000m0m0m0*m0*m0TEGChol MIMAT0004488 *0*0 hsa-miR-15b5′Pm005f005f0000f005f05f0f00*5m0*5m0*0m0m000m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000417 *f0*0*0 hsa-miR-15b*5′Pm00005f05f05f05f05f05f05f05f05f00*0*5 m0m0000m0000m0m0m0*m0*m0TEGCholMIMAT0004586 m0*5m0*5m0*5m0*0 hsa-miR-165′Pm05f005f0f0000f0000f05m0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0000069 m0*5m0*5m0*0hsa-miR-16-1* 5′Pm05f005f0f05f005f0f05f005f0f05m0*0*5m0m00m00m00m00m00m0*0*m0TEGChol MIMAT0004489 m0*0*5m0*0*0 hsa-miR-16-2*5′Pm005f00f00005f0000f00*0*0*5m0*5m0*m0m0m0m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004518 5m0*0 hsa-miR-175′Pm05f05f00f005f05f05f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGCholMIMAT0000070 *0*f0*0*0 hsa-miR-17*5′Pm005f005f005f05f05f05f05f00f00*5m0*5 m0m0m000m000m0m0m00*m0*m0TEGCholMIMAT0000071 m0*0*5m0*0*0 hsa-miR-181a5′Pm005f005f0000f05f0005f00*0*0*5m0*5m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000256 m0*0*0 hsa-miR-181a*5′Pm05f0005f005f005f05f005f0f00*0*0*5m0m0m00m00m0m00m0m0m0m0*0*m0TEGChol MIMAT0000270 *5m0*5m0*0hsa-miR-181a-2* 5′Pm0005f05f05f05f005f05f005f0f05m0*0*5m0m00m00m0m000m00m0*m0*m0TEGChol MIMAT0004558 m0*5m0*5m0*0*0hsa-miR-181b 5′Pm05f05f00f05f05f05f05f005f005f05m0*5m0m0m00m0m0000m0m00*0*m0TEGChol MIMAT0000257 m0*5m0*5m0*f0*5m0*0hsa-miR-181c 5′Pm0000f0000f05f000f00*0*5m0*5m0*f0*m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0000258 5m0*0 hsa-miR-181c*5′Pm005f05f0f005f05f05f05f05f00f00*0*5m0 m0m0m000m000m0m000*m0*m0TEGCholMIMAT0004559 *5m0*5m0*5m0*0 hsa-miR-181d5′Pm05f05f05f05f05f0005f05f05f05f05f00*5 m0m0000m0m0m00m000*0*m0TEGCholMIMAT0002821 m0*0*5m0*5m0*0*0 hsa-miR-1825′Pm005f05f05f0005f05f05f000f00*5m0*5m m0m0m0m00m00m0m0m000*m0*m0TEGCholMIMAT0000259 0*5m0*5m0*5m0*0 hsa-miR-182*5′Pm0005f05f05f005f05f005f05f05f05m0*0* m0m000m0m00m00m00m0*m0*m0TEGCholMIMAT0000260 5m0*0*5m0*0*0 hsa-miR-18255′Pm05f000f05f000f0005f0f00*0*5m0*0*5mm0m00m0m0m0m0m00m0m0m0*0*m0TEGChol MIMAT0006765 0*0*0 hsa-miR-18275′Pm005f05f0f005f005f05f05f05f0f00*5m0*5 m0m0000m0m00m0m000*m0*m0TEGCholMIMAT0006767 m0*5m0*5m0*0*0 hsa-miR-1835′Pm0000f0005f0f0000f00*5m0*0*0*f0*0*0m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0000261 hsa-miR-183*5′Pm0005f0f005f00f05f05f05f0f05m0*0*5m0 m0m0000m0m00m0m00m0*m0*m0TEGCholMIMAT0004560 *5m0*5m0*5m0*0 hsa-miR-1845′Pm05f005f0f05f005f05f05f05f05f0f05m0*5 m0m0000m00m00m00m0*0*m0TEGCholMIMAT0000454 m0*0*5m0*5m0*5m0*0 hsa-miR-1855′Pm005f05f0f05f005f0f05f0005f00*5m0*5m m0m0m0m00m00m00m000*m0*m0TEGCholMIMAT0000455 0*0*f0*5m0*0 hsa-miR-185*5′Pm05f0005f05f005f0f00005f05m0*0*5m0*m0m0m0m0m0m00m00m0m0m0*0*m0TEGChol MIMAT0004611 0*5m0*0*0 hsa-miR-1865′Pm0000f05f05f05f05f005f005f00*0*0*5m0m0m0m00m0m0000m0m0m0*m0*m0TEGChol MIMAT0000456 *f0*5m0*0 hsa-miR-186*5′Pm05f005f0f05f005f0f05f005f0f05m0*0*0* m0m00m00m00m00m00m0*0*m0TEGCholMIMAT0004612 5m0*f0*5m0*0 hsa-miR-1875′Pm005f05f0f0005f05f0005f0f00*5m0*5m0 m0m00m0m0m00m0m0m000*m0*m0TEGCholMIMAT0000262 *5m0*f0*0*0 hsa-miR-187*5′Pm0000f05f005f0f00005f00*5m0*5m0*0*m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004561 5m0*5m0*0hsa-miR-188-3p 5′Pm0000f05f05f05f05f0000f00*5m0*0*0*f0m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004613 *0*0 hsa-miR-188-5p5′Pm00005f05f005f05f05f05f00f05m0*5m0* m0m0m000m00m00m0m0m0*m0*m0TEGCholMIMAT0000457 5m0*0*f0*0*0 hsa-miR-18a5′Pm005f00f05f005f0f005f05f0f05m0*5m0*5 m0m000m0m00m00m0m00*m0*m0TEGCholMIMAT0000072 m0*5m0*5m0*0*0 hsa-miR-18a*5′Pm05f0005f005f00f005f05f05f00*0*0*0*f0m0m000m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0002891 *0*0 hsa-miR-18b5′Pm05f05f00f00005f005f05f0f05m0*0*5m0 m0m000m0m0m0m0m0m0m00*0*m0TEGCholMIMAT0001412 *5m0*5m0*0*0 hsa-miR-18b*5′Pm005f00f05f0005f0005f05f05m0*5m0*0*m0m00m0m0m0m0m00m0m00*m0*m0TEGChol MIMAT0004751 5m0*f0*5m0*0 hsa-miR-1905′Pm05f000f005f005f005f005f00*5m0*0*0*fm0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0000458 0*0*0 hsa-miR-19085′Pm05f005f05f05f05f00f0005f05f00*5m0*5 m0m00m0m0m0m000m00m0*0*m0TEGCholMIMAT0007881 m0*0*f0*0*0 hsa-miR-19095′Pm05f05f05f05f05f005f0f05f05f05f05f00*0 m0m0000m00m00m000*0*m0TEGCholMIMAT0007883 *0*0*5m0*5m0*0 hsa-miR-1909*5′Pm05f05f00f0000f0000f05m0*5m0*0*0***m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0007882 hsa-miR-190b5′Pm005f05f0f05f005f05f05f05f00f05m0*0*0 m0m0m000m00m00m000*m0*m0TEGCholMIMAT0004929 *5m0*f0*0*0 hsa-miR-1915′Pm005f05f0f05f05f00f005f05f0f00*5m0*0* m0m000m0m0m000m000*m0*m0TEGCholMIMAT0000440 5m0*5m0*0* hsa-miR-191*5′Pm05f0005f0000f05f05f005f05m0*0*5m0*m0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0001618 5m0*f0*5m0*0hsa-miR-1910 5′Pm0000f05f05f05f0f0000f05m0*5m0*5m0m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0007884 *0*5m0*0*0 hsa-miR-19115′Pm05f05f005f05f005f05f0005f0f05m0*0*5 m0m00m0m0m00m00m0m00*0*m0TEGCholMIMAT0007885 m0*0*f0*5m0*0 hsa-miR-1911*5′Pm00005f05f05f005f0005f05f00*5m0*5m0m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0007886 *5m0*5m0*5m0*0hsa-miR-1912 5′Pm05f05f00f005f00f00005f05m0*0*0*5m0m0m0m0m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0007887 *5m0*5m0*0 hsa-miR-19135′Pm0000f05f05f005f005f05f05f05m0*0*0*0m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0007888 *f0*0*0 hsa-miR-19145′Pm0005f05f05f05f05f0f05f05f05f05f00*0* m0m0000m0000m00m0*m0*m0TEGCholMIMAT0007889 0*0*f0*0*0 hsa-miR-1914*5′Pm05f005f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m00m0*0*m0TEGCholMIMAT0007890 m0*5m0*5m0*0*5m0*5m0*0 hsa-miR-19155′Pm05f000f005f05f05f005f005f00*0*0*0*5m0m0m00m0m000m0m0m0m0*0*m0TEGChol MIMAT0007892 m0*0*0 hsa-miR-1915*5′Pm05f005f05f05f005f05f005f05f05f05m0*5 m0m000m0m00m00m00m0*0*m0TEGCholMIMAT0007891 m0*5m0*5m0*5m0*5m0*0 hsa-miR-1925′Pm05f05f05f05f00005f05f05f00f05m0*0*0 m0m0m000m0m0m0m0m000*0*m0TEGCholMIMAT0000222 *0*f0*5m0*0 hsa-miR-192*5′Pm05f000f05f05f00f0005f05f05m0*5m0*5 m0m00m0m0m0m000m0m0m0*0*m0TEGCholMIMAT0004543 m0*5m0*f0*0*0 hsa-miR-193a-3p5′Pm005f00f0000f05f000f05m0*0*0*5m0*5m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000459 m0*0*0 hsa-miR-193a-5p5′Pm0000f005f005f0005f05f00*0*5m0*5m0m0m00m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004614 *f0*0*0 hsa-miR-193b5′Pm0005f0f005f005f0000f00*5m0*0*5m0*m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002819 5m0*0*0 hsa-miR-193b*5′Pm00005f005f05f05f05f05f05f05f05m0*5m m0m0000m000m0m0m0m0*m0*m0TEGCholMIMAT0004767 0*5m0*0*f0*0*0 hsa-miR-1945′Pm00005f005f005f05f05f00f00*0*0*0*5mm0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0000460 0** hsa-miR-194*5′Pm05f05f05f0f00005f05f005f05f05m0*5m0 m0m00m00m0m0m0m0m000*0*m0TEGCholMIMAT0004671 *0*5m0*5m0*0*0 hsa-miR-1955′Pm05f05f05f0f0005f0f05f05f00f00*0*5m0* m0m0m000m00m0m0m000*0*m0TEGCholMIMAT0000461 0*f0*5m0*0 hsa-miR-195*5′Pm0005f0f05f05f005f05f05f00f00*0*5m0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0004615 5m0*f0*0*0 hsa-miR-196a5′Pm05f000f005f005f005f005f00*5m0*0*0*fm0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0000226 0*0*0 hsa-miR-196a*5′Pm05f05f05f05f0005f05f05f05f00f00*0*5m m0m0m000m00m0m0m000*0*m0TEGCholMIMAT0004562 0*5m0*5m0*0*0 hsa-miR-196b5′Pm05f05f00f05f05f05f05f05f05f05f05f00*0 m0m0000m0000m0m00*0*m0TEGCholMIMAT0001080 *5m0*0*5m0*5m0*0 hsa-miR-196b*5′Pm00005f0000f0000f00*0*0*0*f0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0009201 Chol hsa-miR-197 5′Pm0000f05f0005f0005f05f05m0*0*5m0*0m0m00m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000227 *5m0*0*0 hsa-miR-19725′Pm05f000f05f05f05f0f005f05f05f05m0*5m m0m000m0m0000m0m0m0*0*m0TEGCholMIMAT0009447 0*5m0*5m0*5m0*5m0*0 hsa-miR-19735′Pm05f05f005f005f005f0005f05f05m0*5m0 m0m00m0m0m0m00m0m0m00*0*m0TEGCholMIMAT0009448 *5m0*5m0*5m0*5m0*0 hsa-miR-19765′Pm0000f05f0005f00005f05m0*0*5m0*0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0009451 m0*0*0 hsa-miR-1985′Pm005f005f05f05f005f05f05f005f05m0*5m m0m0m000m0m000m0m00*m0*m0TEGCholMIMAT0000228 0*5m0*0*5m0*5m0*0 hsa-miR-199a-3p5′Pm0005f0f05f05f005f05f05f00f00*0*5m0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0000232 5m0*f0*0*0 hsa-miR-199a-5p5′Pm05f05f00f05f05f05f05f005f005f00*0*5m m0m0m00m0m0000m0m00*0*m0TEGCholMIMAT0000231 0*0*f0*5m0*0 hsa-miR-199b-3p5′Pm05f0005f05f05f05f0f05f005f0f00*5m0*0 m0m00m00m0000m0m0m0*0*m0TEGCholMIMAT0004563 *0*5m0*5m0*0 hsa-miR-199b-5p5′Pm0005f0f05f05f005f05f05f00f00*0*5m0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0000263 5m0*f0*0*0 hsa-miR-19a5′Pm05f05f005f0000f05f05f05f0f00*0*0*5m m0m0000m0m0m0m0m0m00*0*m0TEGCholMIMAT0000073 0*5m0*0*0 hsa-miR-19a*5′Pm05f0005f005f05f0f005f05f0f05m0*0*5m m0m000m0m000m0m0m0m0*0*m0TEGCholMIMAT0004490 0*5m0*f0*5m0*0 hsa-miR-19b5′Pm005f05f05f05f05f00f0000f05m0*5m0*5 m0m0m0m0m0m0m000m000*m0*m0TEGCholMIMAT0000074 m0*5m0*5m0*5m0*0 hsa-miR-19b-1*5′Pm00005f0005f05f05f05f005f00*5m0*5m0m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004491 *0*5m0*5m0*0hsa-miR-19b-2* 5′Pm0005f0f005f00f0000f05m0*5m0*0*5m0m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0004492 *5m0*5m0*0 hsa-miR-200a5′Pm0005f05f0005f05f05f05f05f05f05m0*5m m0m0000m00m0m0m00m0*m0*m0TEGCholMIMAT0000682 0*0*0*5m0*0*0 hsa-miR-200a*5′Pm005f005f0000f005f00f00*5m0*5m0*5mm0m0m00m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0001620 0*5m0*5m0*0hsa-miR-200b 5′Pm0005f0f05f0005f0005f0f05m0*5m0*0*5m0m00m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0000318 m0*5m0*0*0 hsa-miR-200b*5′Pm0005f0f05f0005f0005f0f05m0*5m0*0*5m0m00m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0004571 m0*5m0*0*0 hsa-miR-200c5′Pm005f00f0005f05f05f05f05f0f05m0*0*0* m0m0000m00m0m0m0m00*m0*m0TEGCholMIMAT0000617 0*f0*0*0 hsa-miR-200c*5′Pm05f000f00005f05f05f005f00*0*5m0*5mm0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004657 0*5m0*0*0 hsa-miR-2025′Pm0000f0005f05f0005f0f00*5m0*5m0*5mm0m00m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0002811 0*5m0*0*0 hsa-miR-202*5′Pm05f0005f005f005f0005f0f00*0*0*5m0*m0m00m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0002810 5m0*5m0*0 hsa-miR-2035′Pm0005f0f05f05f05f0f0000f05m0*0*0*0***m0m0m0m0m0m0000m00m0*m0*m0TEGChol MIMAT0000264 hsa-miR-2045′Pm05f005f0f05f000f05f05f005f05m0*0*5m m0m0m000m0m0m00m00m0*0*m0TEGCholMIMAT0000265 0*5m0*5m0*5m0*0 hsa-miR-2055′Pm0000f05f0005f0005f05f05m0*0*5m0*0m0m00m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000266 *5m0*5m0*0 hsa-miR-205*5′Pm05f005f0f05f05f05f05f05f05f05f05f00*5 m0m0000m0000m00m0*0*m0TEGCholMIMAT0009197 m0*0*5m0*5m0*5m0*0 hsa-miR-20525′Pm05f05f00f0000f05f05f005f00*0*5m0*0*m0m0m000m0m0m0m0m0m00*0*m0TEGChol MIMAT0009977 f0*5m0*0 hsa-miR-20535′Pm05f05f05f0f05f005f0f00005f05m0*5m0* m0m0m0m0m0m00m00m000*0*m0TEGCholMIMAT0009978 0*0*f0*0*0 hsa-miR-20545′Pm05f05f05f0f005f05f05f0005f0f00*0*0*0 m0m00m0m0m000m0m000*0*m0TEGCholMIMAT0009979 *5m0** hsa-miR-206 5′Pm005f05f05f0000f0005f05f00*5m0*5m0*m0m00m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0000462 0*f0*5m0*0 hsa-miR-208a5′Pm05f05f00f00005f05f05f05f05f00*0*0*5 m0m0000m0m0m0m0m0m00*0*m0TEGCholMIMAT0000241 m0*5m0*5m0*0 hsa-miR-208b5′Pm0000f05f05f005f00005f00*0*0*5m0*f0m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004960 *0*0 hsa-miR-20a5′Pm05f000f0005f0f0000f05m0*5m0*0*0*f0m0m0m0m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0000075 ** hsa-miR-20a*5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGCholMIMAT0004493 m0*5m0*5m0*0*0 hsa-miR-20b5′Pm05f05f05f0f05f05f005f05f005f05f05m0* m0m00m00m0m000m000*0*m0TEGCholMIMAT0001413 5m0*0*0*** hsa-miR-20b*5′Pm05f05f005f00005f05f05f05f0f00*5m0*5 m0m0000m0m0m0m0m0m00*0*m0TEGCholMIMAT0004752 m0*0*5m0*0*0 hsa-miR-215′Pm005f05f0f005f05f0f05f05f00f00*0*0*0*fm0m0m000m000m0m000*m0*m0TEGChol MIMAT0000076 0*5m0*0 hsa-miR-21*5′Pm05f005f0f00005f05f05f005f00*5m0*0*0m0m0m000m0m0m0m0m00m0*0*m0TEGChol MIMAT0004494 *f0*5m0*0 hsa-miR-2105′Pm05f05f005f005f00f005f05f05f05m0*0*5 m0m000m0m0m00m0m0m00*0*m0TEGCholMIMAT0000267 m0*5m0*f0*5m0*0 hsa-miR-2115′Pm05f005f0f05f000f05f05f005f05m0*0*5m m0m0m000m0m0m00m00m0*0*m0TEGCholMIMAT0000268 0*5m0*5m0*5m0*0 hsa-miR-21105′Pm05f05f005f05f005f0f005f05f0f05m0*0*0 m0m000m0m00m00m0m00*0*m0TEGCholMIMAT0010133 *0*5m0*0*0 hsa-miR-21135′Pm00005f05f05f05f05f00005f05m0*0*0*0m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0009206 *f0*0* hsa-miR-21145′Pm0005f0f05f05f05f05f05f05f05f0f05m0*5 m0m0000m0000m00m0*m0*m0TEGCholMIMAT0011156 m0*0*0*5m0*5m0*0 hsa-miR-2114*5′Pm0005f05f00005f05f05f00f00*0*0*5m0*m0m0m000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0011157 5m0*0*0 hsa-miR-21155′Pm0005f05f05f05f00f05f05f00f00*0*0*5m m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0011158 0*5m0*0*0 hsa-miR-2115*5′Pm05f05f05f05f05f05f05f05f0005f0f00*5m m0m00m0m0m0000m000*0*m0TEGCholMIMAT0011159 0*5m0*5m0*5m0*5m0*0 hsa-miR-21165′Pm00005f0005f05f05f05f05f05f00*5m0*5 m0m0000m00m0m0m0m0m0*m0*m0TEGCholMIMAT0011160 m0*0*5m0*5m0*0 hsa-miR-2116*5′Pm0000f005f00f005f05f05f05m0*0*0*5m0m0m000m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0011161 *f0*0*0 hsa-miR-21175′Pm05f05f05f05f0005f05f05f005f0f05m0*0* m0m00m00m00m0m0m000*0*m0TEGCholMIMAT0011162 0*0*5m0*0*0 hsa-miR-2125′Pm05f05f05f0f0005f0f05f000f05m0*0*5m0 m0m0m0m00m00m0m0m000*0*m0TEGCholMIMAT0000269 *0*5m0*5m0*0 hsa-miR-2145′Pm0005f0f05f05f05f05f05f05f05f05f05m0* m0m0000m0000m00m0*m0*m0TEGCholMIMAT0000271 0*0*0*f0*0*0 hsa-miR-214*5′Pm00005f0005f05f05f000f00*0*5m0*5m0m0m0m0m00m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004564 *5m0*0*0 hsa-miR-2155′Pm005f005f05f000f05f05f05f0f00*0*5m0* m0m0000m0m0m00m0m00*m0*m0TEGCholMIMAT0000272 5m0*** hsa-miR-216a 5′Pm00005f005f05f05f05f05f005f00*5m0*5m0m0m000m000m0m0m0m0*m0*m0TEGChol MIMAT0000273 m0*5m0*5m0*0*0hsa-miR-216b 5′Pm05f05f05f05f0005f0f05f000f00*0*5m0*m0m0m0m00m00m0m0m000*0*m0TEGChol MIMAT0004959 0*5m0*5m0*0 hsa-miR-2175′Pm05f05f00f0005f0f05f000f00*5m0*5m0* m0m0m0m00m00m0m0m0m00*0*m0TEGCholMIMAT0000274 5m0*5m0*0* hsa-miR-2185′Pm05f005f0f05f0005f05f005f0f00*0*0*0*5m0m00m00m0m0m00m00m0*0*m0TEGChol MIMAT0000275 m0*0*0 hsa-miR-218-1*5′Pm05f0005f0005f0f05f0005f00*5m0*5m0*m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0004565 0*5m0*5m0*0hsa-miR-218-2* 5′Pm05f05f005f05f005f05f05f05f05f05f05m0m0m0000m00m00m0m00*0*m0TEGChol MIMAT0004566 *5m0*0*5m0*5m0*5m0*0hsa-miR-219-1-3p 5′Pm0000f005f00f00005f05m0*5m0*0****m0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004567 hsa-miR-219-2-3p5′Pm005f005f05f05f00f005f05f0f05m0*5m0* m0m000m0m0m000m0m00*m0*m0TEGCholMIMAT0004675 5m0*0*** hsa-miR-219-5p5′Pm0000f005f005f0005f0f00*0*0*0*f0*0*0m0m00m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0000276 hsa-miR-225′Pm0000f05f0005f0000f00*5m0*5m0*5m0m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000077 *5m0** hsa-miR-22*5′Pm00005f05f005f05f05f0005f05m0*0*5m0m0m0m0m00m00m00m0m0m0*m0*m0TEGChol MIMAT0004495 *0*f0*5m0*0 hsa-miR-2215′Pm0005f05f05f000f05f05f005f05m0*0*5m m0m0m000m0m0m00m00m0*m0*m0TEGCholMIMAT0000278 0*5m0*f0*5m0*0 hsa-miR-221*5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGCholMIMAT0004568 m0*5m0*5m0*0*0 hsa-miR-2225′Pm05f000f05f05f00f005f005f00*0*5m0*0*m0m0m00m0m0m000m0m0m0*0*m0TEGChol MIMAT0000279 f0*5m0*0 hsa-miR-222*5′Pm005f05f05f005f05f05f005f00f00*0*5m0 m0m0m00m0m000m0m000*m0*m0TEGCholMIMAT0004569 *5m0*f0*5m0*0 hsa-miR-2235′Pm05f05f005f005f00f00005f00*0*5m0*0*m0m0m0m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0000280 5m0*0* hsa-miR-223*5′Pm0000f05f005f0f0005f05f05m0*0*0*0*f0m0m00m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004570 *0*0 hsa-miR-2245′Pm05f05f05f05f00005f005f05f05f05m0*0* m0m000m0m0m0m0m0m000*0*m0TEGCholMIMAT0000281 0*5m0*5m0** hsa-miR-224*5′Pm05f05f05f0f05f005f0f005f05f05f05m0*0 m0m000m0m00m00m000*0*m0TEGCholMIMAT0009198 *0*0*f0*0*0 hsa-miR-22765′Pm05f000f005f05f05f05f000f00*0*0*5m0*m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0011775 f0*0*0 hsa-miR-2277-3p5′Pm05f05f00f05f005f0f0000f05m0*0*5m0* m0m0m0m0m0m00m00m0m00*0*m0TEGCholMIMAT0011777 5m0*5m0*0*0 hsa-miR-2277-5p5′Pm0000f05f05f00f05f05f005f00*0*5m0*0*m0m0m000m0m000m0m0m0*m0*m0TEGChol MIMAT0017352 f0*0*0 hsa-miR-22785′Pm05f05f005f05f05f00f05f005f0f00*0*5m0 m0m00m00m0m000m0m00*0*m0TEGCholMIMAT0011778 *5m0*f0*5m0*0 hsa-miR-2355-3p5′Pm05f005f05f005f05f0f05f05f005f05m0*5 m0m0m000m000m0m00m0*0*m0TEGCholMIMAT0017950 m0*0*0*f0*5m0*0 hsa-miR-2355-5p5′Pm05f05f05f05f05f005f05f05f05f05f05f05 m0m0000m00m00m000*0*m0TEGCholMIMAT0016895 m0*5m0*0*5m0*5m0*0*0 hsa-miR-23a5′Pm005f05f05f0000f0000f00*0*5m0*0*f0*m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0000078 0*0 hsa-miR-23a*5′Pm05f05f05f0f005f05f0f05f0005f05m0*0*5 m0m0m0m00m000m0m000*0*m0TEGCholMIMAT0004496 m0*5m0*** hsa-miR-23b5′Pm05f0005f0005f05f05f005f0f05m0*0*5m m0m00m00m00m0m0m0m0m0*0*m0TEGCholMIMAT0000418 0*5m0*f0*0*0 hsa-miR-23b*5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGCholMIMAT0004587 m0*5m0*f0*0*0 hsa-miR-23c5′Pm05f05f05f0f05f005f0f05f05f05f05f00*0* m0m0000m00m00m000*0*m0TEGCholMIMAT0018000 0*5m0*f0*5m0*0 hsa-miR-245′Pm05f05f05f05f0005f0f05f000f00*0*5m0* m0m0m0m00m00m0m0m000*0*m0TEGCholMIMAT0000080 0*5m0*5m0*0 hsa-miR-24-1*5′Pm00005f005f05f05f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*m0*m0TEGCholMIMAT0000079 m0*5m0*** hsa-miR-24-2*5′Pm0005f05f005f05f05f05f05f005f00*5m0* m0m0m000m000m0m00m0*m0*m0TEGCholMIMAT0004497 5m0*5m0*** hsa-miR-255′Pm0005f05f05f05f05f0f05f05f05f05f00*0* m0m0000m0000m00m0*m0*m0TEGCholMIMAT0000081 0*0*f0*0*0 hsa-miR-25*5′Pm05f000f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*0*m0TEGCholMIMAT0004498 *5m0*5m0*f0*0*0 hsa-miR-26a5′Pm0000f05f05f005f05f05f05f0f00*0*0*0*fm0m0000m0m000m0m0m0*m0*m0TEGChol MIMAT0000082 0*0*0 hsa-miR-26a-1*5′Pm05f000f05f000f005f05f05f05m0*0*0*5 m0m000m0m0m0m00m0m0m0*0*m0TEGCholMIMAT0004499 m0*5m0*5m0* hsa-miR-26a-2*5′Pm05f000f05f000f05f05f05f0f05m0*0*0*0 m0m0000m0m0m00m0m0m0*0*m0TEGCholMIMAT0004681 *f0*0*0 hsa-miR-26b5′Pm005f05f0f05f005f0f05f05f005f05m0*0*0 m0m0m000m00m00m000*m0*m0TEGCholMIMAT0000083 *0*5m0*5m0*0 hsa-miR-26b*5′Pm0000f05f05f05f05f0000f00*0*0*0*5m0m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004500 *0*0 hsa-miR-27a5′Pm0005f05f05f0005f005f005f00*5m0*0*0m0m0m00m0m0m0m00m00m0*m0*m0TEGChol MIMAT0000084 *5m0*0*0 hsa-miR-27a*5′Pm005f05f05f05f005f0f05f05f005f05m0*5 m0m0m000m00m00m000*m0*m0TEGCholMIMAT0004501 m0*0*0*f0*5m0*0 hsa-miR-27b5′Pm005f05f05f0000f00005f00*5m0*0*5m0m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0000419 *f0*0*0 hsa-miR-27b*5′Pm0005f0f0005f0f005f005f00*5m0*5m0*5m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0004588 m0*5m0*0*0 hsa-miR-28-3p5′Pm05f005f0f0005f05f05f0005f05m0*5m0* m0m0m0m00m00m0m0m00m0*0*m0TEGCholMIMAT0004502 5m0*0*f0*0* hsa-miR-28-5p5′Pm0000f05f0005f05f05f00f05m0*0*5m0*0m0m0m000m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000085 *f0*0*0 hsa-miR-28615′Pm05f05f05f0f05f005f05f00005f05m0*0*5 m0m0m0m0m0m00m00m000*0*m0TEGCholMIMAT0013802 m0*5m0*5m0*5m0*0 hsa-miR-29095′Pm05f005f0f005f005f05f05f05f0f05m0*5m m0m0000m0m00m0m00m0*0*m0TEGCholMIMAT0013863 0*5m0*0*5m0*5m0*0 hsa-miR-296-3p5′Pm05f0005f05f05f00f00005f05m0*5m0*0*m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0004679 5m0*5m0*5m0*0hsa-miR-296-5p 5′Pm05f0005f005f05f05f05f0005f00*5m0*0*m0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0000690 5m0*5m0*0*0 hsa-miR-2975′Pm05f0005f005f05f0f00005f00*5m0*5m0*m0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0004450 0*5m0*5m0*0 hsa-miR-2985′Pm005f05f0f005f005f05f05f05f05f05m0*5 m0m0000m0m00m0m000*m0*m0TEGCholMIMAT0004901 m0*0*0*f0*5m0*0 hsa-miR-299-3p5′Pm05f000f0005f0f005f00f00*5m0*5m0*0*m0m0m00m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0000687 5m0*5m0*0 hsa-miR-299-5p5′Pm005f00f0005f05f0005f0f05m0*5m0*0*5m0m00m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0002890 m0*5m0*0*0 hsa-miR-29a5′Pm00005f005f00f0000f00*0*0*5m0*** m0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGCholMIMAT0000086 hsa-miR-29a* 5′Pm005f05f0f05f000f05f0005f00*0*5m0*0*m0m0m0m00m0m0m00m000*m0*m0TEGChol MIMAT0004503 f0*0*0 hsa-miR-29b5′Pm0000f0000f0000f00*0*5m0*5m0*5m0* m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0000100 5m0*0 Chol hsa-miR-29b-1*5′Pm00005f05f005f05f05f005f0f05m0*5m0* m0m00m00m00m00m0m0m0*m0*m0TEGCholMIMAT0004514 0*5m0*5m0*5m0*0 hsa-miR-29b-2*5′Pm05f05f00f05f005f05f05f000f05m0*5m0* m0m0m0m00m00m00m0m00*0*m0TEGCholMIMAT0004515 0*5m0*5m0*5m0*0 hsa-miR-29c5′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000681 *0 hsa-miR-29c*5′Pm05f000f05f05f005f00005f05m0*5m0*0*m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0004673 0*f0*5m0*0 hsa-miR-3005′Pm0000f05f005f0f00005f00*0*0*0*5m0*5m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004903 m0*0 hsa-miR-301a5′Pm005f05f0f05f005f0f0000f05m0*0*5m0* m0m0m0m0m0m00m00m000*m0*m0TEGCholMIMAT0000688 5m0*5m0*0*0 hsa-miR-301b5′Pm005f05f0f05f005f0f00005f05m0*0*5m0 m0m0m0m0m0m00m00m000*m0*m0TEGCholMIMAT0004958 *5m0*5m0*0*0 hsa-miR-302a5′Pm05f0005f0000f05f05f005f05m0*0*0*5mm0m0m000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000684 0*f0*5m0*0 hsa-miR-302a*5′Pm0005f0f005f005f00005f00*0*0*0*f0*5m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0000683 m0*0 hsa-miR-302b5′Pm005f005f05f0005f05f05f00f05m0*0*0*0m0m0m000m0m0m00m0m00*m0*m0TEGChol MIMAT0000715 *5m0*0*0 hsa-miR-302b*5′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000714 *0 hsa-miR-302c5′Pm005f00f005f005f05f05f05f05f00*0*5m0 m0m0000m0m00m0m0m00*m0*m0TEGCholMIMAT0000717 *5m0*f0*0*0 hsa-miR-302c*5′Pm05f000f00005f05f005f05f05m0*5m0*5 m0m00m00m0m0m0m0m0m0m0*0*m0TEGCholMIMAT0000716 m0*5m0*f0*0*0 hsa-miR-302d5′Pm05f05f05f05f0005f05f00005f00*5m0*5 m0m0m0m0m0m00m0m0m000*0*m0TEGCholMIMAT0000718 m0*5m0*f0*5m0*0 hsa-miR-302d*5′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004685 *0 hsa-miR-302e5′Pm005f00f005f005f05f05f05f0f05m0*0*5m m0m0000m0m00m0m0m00*m0*m0TEGCholMIMAT0005931 0*5m0*5m0*0*0 hsa-miR-302f5′Pm005f05f0f05f005f0f05f0005f05m0*0*0* m0m0m0m00m00m00m000*m0*m0TEGCholMIMAT0005932 5m0*5m0*5m0*0 hsa-miR-3065-3p5′Pm05f05f00f005f00f05f0005f00*5m0*5m0 m0m0m0m00m0m00m0m0m00*0*m0TEGCholMIMAT0015378 *5m0*5m0*5m0*0 hsa-miR-3065-5p5′Pm05f000f00005f05f05f05f0f00*5m0*5m0 m0m0000m0m0m0m0m0m0m0*0*m0TEGCholMIMAT0015066 **** hsa-miR-3074 5′Pm05f000f00005f00005f00*5m0*5m0*5mm0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0015027 0*f0*5m0*0 hsa-miR-30a5′Pm005f00f005f005f05f05f05f0f05m0*0*5m m0m0000m0m00m0m0m00*m0*m0TEGCholMIMAT0000087 0*5m0*5m0*5m0*0 hsa-miR-30a*5′Pm05f000f0000f0005f05f00*5m0*5m0*5mm0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000088 0*f0*5m0*0 hsa-miR-30b5′Pm05f000f0000f0005f05f00*5m0*5m0*5mm0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000420 0*f0*5m0*0 hsa-miR-30b*5′Pm0000f005f05f05f005f00f05m0*5m0*5m m0m0m00m0m000m0m0m0m0*m0*m0TEGCholMIMAT0004589 0*0*f0*5m0*0 hsa-miR-30c5′Pm005f00f005f005f05f05f05f05f00*0*5m0 m0m0000m0m00m0m0m00*m0*m0TEGCholMIMAT0000244 *5m0*f0*0*0 hsa-miR-30c-1*5′Pm0005f05f00005f05f005f0f00*0*5m0*5mm0m00m00m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004674 0*5m0*5m0*0hsa-miR-30c-2* 5′Pm0005f0f0005f05f005f00f05m0*5m0*5mm0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0004550 0*0*5m0*5m0*0hsa-miR-30d 5′Pm05f05f05f05f0005f05f00005f00*5m0*5m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0000245 m0*5m0*f0*5m0*0hsa-miR-30d* 5′Pm005f00f005f005f05f05f05f05f00*0*5m0m0m0000m0m00m0m0m00*m0*m0TEGChol MIMAT0004551 *5m0*f0*0*0 hsa-miR-30e5′Pm05f05f05f05f0005f05f00005f00*5m0*5 m0m0m0m0m0m00m0m0m000*0*m0TEGCholMIMAT0000692 m0*5m0*f0*5m0*0 hsa-miR-30e*5′Pm0005f0f00005f005f05f0f00*5m0*0*5m0m0m000m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0000693 *f0*0*0 hsa-miR-315′Pm05f000f005f005f05f05f05f05f05m0*5m0 m0m0000m0m00m0m0m0m0*0*m0TEGCholMIMAT0000089 *5m0*5m0*f0*0*0 hsa-miR-31*5′Pm005f05f0f05f005f05f0005f0f05m0*0*5m m0m00m0m0m00m00m000*m0*m0TEGCholMIMAT0004504 0*5m0*f0*5m0*0 hsa-miR-31155′Pm05f005f0f0005f05f05f005f05f00*0*5m0 m0m00m00m00m0m0m00m0*0*m0TEGCholMIMAT0014977 *5m0*f0*0*0 hsa-miR-31165′Pm05f05f00f05f05f05f0f005f00f05m0*0*5 m0m0m00m0m0000m0m00*0*m0TEGCholMIMAT0014978 m0**** hsa-miR-3117 5′Pm005f00f05f005f05f0000f00*5m0*0*0*5m0m0m0m0m0m00m00m0m00*m0*m0TEGChol MIMAT0014979 m0*0*0 hsa-miR-31185′Pm005f05f05f0000f05f005f0f00*5m0*0*0*m0m00m00m0m0m0m0m000*m0*m0TEGChol MIMAT0014980 f0*0*0 hsa-miR-31195′Pm05f05f05f05f05f005f0f005f05f05f00*0* m0m000m0m00m00m000*0*m0TEGCholMIMAT0014981 0*5m0*5m0*5m0*0 hsa-miR-31205′Pm005f005f005f05f05f05f05f05f05f05m0*5 m0m0000m000m0m0m00*m0*m0TEGCholMIMAT0014982 m0*0*0*f0*0*0 hsa-miR-31215′Pm00005f05f05f00f0000f00*0*0*5m0*f0*m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0014983 5m0*0 hsa-miR-31225′Pm05f05f05f05f05f05f05f05f05f000f05m0* m0m0m0m00m0000m000*0*m0TEGCholMIMAT0014984 0*5m0*0*5m0*5m0*0 hsa-miR-31235′Pm05f0005f005f05f0f05f005f0f05m0*0*5m m0m00m00m000m0m0m0m0*0*m0TEGCholMIMAT0014985 0*0*f0*5m0*0 hsa-miR-31245′Pm00005f0005f05f05f05f05f05f05m0*5m0 m0m0000m00m0m0m0m0m0*m0*m0TEGCholMIMAT0014986 *0*0*f0*0*0 hsa-miR-31255′Pm05f05f05f05f005f05f05f05f005f05f00*0 m0m00m00m000m0m000*0*m0TEGCholMIMAT0014988 *0*5m0*f0*5m0*0 hsa-miR-3126-3p5′Pm05f0005f005f05f0f005f05f0f05m0*0*0* m0m000m0m000m0m0m0m0*0*m0TEGCholMIMAT0015377 5m0*f0*0*0 hsa-miR-3126-5p5′Pm0005f0f0005f05f05f05f00f05m0*5m0*5 m0m0m000m00m0m0m00m0*m0*m0TEGCholMIMAT0014989 m0*0*5m0*5m0*0 hsa-miR-31275′Pm0000f05f05f00f005f05f0f00*0*0*0*f0*0*m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0014990 hsa-miR-31285′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0014991 m0*5m0*5m0*0 hsa-miR-31295′Pm0005f0f05f005f05f05f05f05f05f05m0*0* m0m0000m00m00m00m0*m0*m0TEGCholMIMAT0014992 5m0*0*f0*0*0 hsa-miR-3130-3p5′Pm05f000f05f05f05f0f005f005f00*5m0*0* m0m0m00m0m0000m0m0m0*0*m0TEGCholMIMAT0014994 5m0*5m0*5m0*0 hsa-miR-3130-5p5′Pm05f000f005f05f05f05f0005f05m0*5m0* m0m0m0m00m000m0m0m0m0*0*m0TEGCholMIMAT0014995 5m0*0*5m0*5m0*0 hsa-miR-31315′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0014996 m0*5m0*5m0*0 hsa-miR-31325′Pm05f05f05f05f05f05f05f0f05f05f05f05f00 m0m0000m0000m000*0*m0TEGCholMIMAT0014997 *0*5m0*5m0*f0*5m0*0 hsa-miR-31335′Pm005f05f05f05f05f05f05f05f05f05f05f00* m0m0000m0000m000*m0*m0TEGCholMIMAT0014998 0*0*0*5m0*0*0 hsa-miR-31345′Pm05f0005f005f05f0f0005f0f00*5m0*5m0 m0m00m0m0m000m0m0m0m0*0*m0TEGCholMIMAT0015000 *0*5m0*5m0*0 hsa-miR-31355′Pm05f000f05f005f0f0005f0f00*5m0*5m0* m0m00m0m0m00m00m0m0m0*0*m0TEGCholMIMAT0015001 5m0*5m0*0*0 hsa-miR-31365′Pm0005f05f05f000f00005f05m0*5m0*5m0m0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0015003 *0*5m0*0*0 hsa-miR-31375′Pm00005f05f000f05f05f00f00*0*0*0*f0**m0m0m000m0m0m00m0m0m0*m0*m0TEGChol MIMAT0015005 hsa-miR-31385′Pm0005f0f05f005f05f05f000f00*0*0*0*f0*m0m0m0m00m00m00m00m0*m0*m0TEGChol MIMAT0015006 0*0 hsa-miR-31395′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0015007 *5m0*0*f0*0*0 hsa-miR-31405′Pm005f005f05f005f0f05f0005f05m0*0*0*5m0m0m0m00m00m00m0m00*m0*m0TEGChol MIMAT0015008 m0*5m0*5m0*0 hsa-miR-31415′Pm005f05f05f0000f00005f00*5m0*5m0*0m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0015010 *f0*5m0*0 hsa-miR-31425′Pm05f0005f0005f05f05f005f0f05m0*0*5m m0m00m00m00m0m0m0m0m0*0*m0TEGCholMIMAT0015011 0*5m0*f0*0*0 hsa-miR-31435′Pm05f000f00005f05f000f00*0*0*0*f0*0*0m0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0015012 hsa-miR-3144-3p5′Pm05f05f00f005f00f05f05f05f0f00*0*5m0* m0m0000m0m00m0m0m00*0*m0TEGCholMIMAT0015015 0*** hsa-miR-3144-5p5′Pm005f00f05f000f05f05f05f0f00*0*5m0*5 m0m0000m0m0m00m0m00*m0*m0TEGCholMIMAT0015014 m0*f0*5m0*0 hsa-miR-31455′Pm05f05f05f05f05f005f05f05f05f005f05m0 m0m0m000m00m00m000*0*m0TEGCholMIMAT0015016 *5m0*0*0*f0*0*0 hsa-miR-31465′Pm05f005f0f0000f0000f05m0*0*5m0*5m0m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0015018 *5m0*5m0*0 hsa-miR-31475′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0015019 *5m0*0*f0*0*0 hsa-miR-31485′Pm05f05f05f0f05f05f00f0005f05f05m0*5m m0m00m0m0m0m000m000*0*m0TEGCholMIMAT0015021 0*5m0*0*** hsa-miR-31495′Pm05f05f05f0f05f000f0000f00*0*5m0*0*fm0m0m0m0m0m0m0m00m000*0*m0TEGChol MIMAT0015022 0*0*0 hsa-miR-31505′Pm0000f0000f0000f00*5m0*0*0*f0*0* m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0015023 Chol hsa-miR-3150b5′Pm05f05f05f0f05f005f05f05f05f05f05f00*0 m0m0000m00m00m000*0*m0TEGCholMIMAT0018194 *0*5m0*5m0*0*0 hsa-miR-31515′Pm05f05f05f0f05f005f0f05f05f00f05m0*5 m0m0m000m00m00m000*0*m0TEGCholMIMAT0015024 m0*5m0*0*f0*0*0 hsa-miR-31525′Pm05f05f05f0f0000f0005f0f05m0*0*5m0* m0m00m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0015025 5m0*5m0*5m0*0 hsa-miR-31535′Pm005f05f05f005f05f0f05f05f00f00*0*0*5 m0m0m000m000m0m000*m0*m0TEGCholMIMAT0015026 m0*f0*5m0*0 hsa-miR-31545′Pm05f0005f05f005f05f005f05f05f05m0*5m m0m000m0m00m00m0m0m0*0*m0TEGCholMIMAT0015028 0*0*5m0*5m0*0*0 hsa-miR-31555′Pm05f000f005f05f05f005f005f00*0*5m0*0m0m0m00m0m000m0m0m0m0*0*m0TEGChol MIMAT0015029 *5m0*5m0*0 hsa-miR-31565′Pm0005f05f0005f05f00005f00*0*5m0*5mm0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0015030 0*f0*0*0 hsa-miR-31575′Pm0005f0f005f05f05f005f00f05m0*0*5m0 m0m0m00m0m000m0m00m0*m0*m0TEGCholMIMAT0015031 *0*5m0*5m0*0 hsa-miR-31585′Pm05f05f005f05f05f00f05f05f005f05m0*5 m0m0m000m0m000m0m00*0*m0TEGCholMIMAT0015032 m0*0*0*f0*5m0*0 hsa-miR-31595′Pm05f005f0f005f05f0f05f05f05f0f00*5m0* m0m0000m000m0m00m0*0*m0TEGCholMIMAT0015033 5m0*0*f0*5m0*0 hsa-miR-31605′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0015034 m0*5m0*5m0*0 hsa-miR-31615′Pm005f005f0005f05f05f05f05f05f05m0*0* m0m0000m00m0m0m0m00*m0*m0TEGCholMIMAT0015035 0*0*f0*5m0* hsa-miR-31625′Pm005f00f05f05f05f0f05f05f05f0f00*0*5m m0m0000m0000m0m00*m0*m0TEGCholMIMAT0015036 0*5m0*f0*5m0*0 hsa-miR-31635′Pm005f00f0005f05f0000f05m0*5m0*0*0*m0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0015037 5m0*0*0 hsa-miR-31645′Pm005f05f05f0005f05f0005f0f00*5m0*5m m0m00m0m0m00m0m0m000*m0*m0TEGCholMIMAT0015038 0*0*5m0** hsa-miR-3165 5′Pm0000f0000f00005f05m0*5m0*5m0*0*5m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0015039 m0*5m0*0 Cholhsa-miR-3166 5′Pm05f005f05f05f05f05f05f0005f0f00*0*5mm0m00m0m0m0000m00m0*0*m0TEGChol MIMAT0015040 0*0*f0** hsa-miR-31675′Pm05f005f0f0005f05f05f05f05f0f00*0*5m0 m0m0000m00m0m0m00m0*0*m0TEGCholMIMAT0015042 *0*f0*0*0 hsa-miR-31685′Pm005f00f05f05f005f005f05f0f05m0*0*0* m0m000m0m0m000m0m00*m0*m0TEGCholMIMAT0015043 0*f0*0*0 hsa-miR-31695′Pm05f05f00f005f00f005f005f05m0*5m0*0 m0m0m00m0m0m00m0m0m00*0*m0TEGCholMIMAT0015044 *5m0*f0*5m0*0 hsa-miR-31705′Pm0005f0f005f05f05f05f05f05f05f05m0*5 m0m0000m000m0m00m0*m0*m0TEGCholMIMAT0015045 m0*5m0*5m0*f0** hsa-miR-31715′Pm05f05f05f05f0000f0000f05m0*0*5m0*5m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0015046 m0*5m0*5m0*0hsa-miR-3173 5′Pm05f0005f05f005f05f005f05f0f05m0*5m0m0m000m0m00m00m0m0m0*0*m0TEGChol MIMAT0015048 *5m0*5m0*5m0*5m0*0hsa-miR-3174 5′Pm05f05f00f005f05f0f005f005f05m0*0*5mm0m0m00m0m000m0m0m00*0*m0TEGChol MIMAT0015051 0*5m0*f0*0* hsa-miR-31755′Pm05f0005f0000f0000f00*0*0*5m0*5m0*m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0015052 0*0 hsa-miR-31765′Pm05f05f00f05f005f0f05f0005f05m0*0*0* m0m0m0m00m00m00m0m00*0*m0TEGCholMIMAT0015053 5m0*5m0*5m0*0 hsa-miR-31775′Pm05f0005f05f005f05f005f05f05f05m0*5m m0m000m0m00m00m0m0m0*0*m0TEGCholMIMAT0015054 0*5m0*5m0*** hsa-miR-31785′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0015055 *5m0*0*f0*0*0 hsa-miR-31795′Pm05f05f05f0f05f005f05f05f05f00f05m0*5 m0m0m000m00m00m000*0*m0TEGCholMIMAT0015056 m0*5m0*5m0*5m0*5m0*0 hsa-miR-31805′Pm05f005f0f0000f0000f05m0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0018178 m0*5m0*5m0*0hsa-miR-3180-3p 5′Pm05f05f05f05f05f005f0f05f05f05f0f00*0*m0m0000m00m00m000*0*m0TEGChol MIMAT0015058 0*5m0*5m0*5m0*0hsa-miR-3180-5p 5′Pm05f05f05f0f00005f05f05f05f0f05m0*0*5m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0015057 m0*0*f0*0*0 hsa-miR-31815′Pm05f05f05f05f005f005f005f05f0f00*5m0* m0m000m0m0m00m0m000*0*m0TEGCholMIMAT0015061 0*5m0*5m0*0*0 hsa-miR-31825′Pm0005f0f005f005f005f00f05m0*0*0*5m0m0m0m00m0m0m00m0m00m0*m0*m0TEGChol MIMAT0015062 *5m0*5m0*0 hsa-miR-31835′Pm00005f05f05f05f0f05f05f05f0f00*0*5m0 m0m0000m0000m0m0m0*m0*m0TEGCholMIMAT0015063 *0*5m0*5m0*0 hsa-miR-31845′Pm005f005f05f05f05f0f0005f0f05m0*0*0* m0m00m0m0m0000m0m00*m0*m0TEGCholMIMAT0015064 0*f0*5m0*0 hsa-miR-31855′Pm005f05f0f05f005f05f05f05f05f05f05m0* m0m0000m00m00m000*m0*m0TEGCholMIMAT0015065 5m0*0*5m0*f0*5m0*0 hsa-miR-3186-3p5′Pm05f005f0f005f05f05f005f05f05f00*0*0* m0m000m0m000m0m00m0*0*m0TEGCholMIMAT0015068 0*5m0*5m0*0 hsa-miR-3186-5p5′Pm0005f05f05f05f05f0f005f05f05f05m0*0* m0m000m0m0000m00m0*m0*m0TEGCholMIMAT0015067 0*5m0*f0*0*0 hsa-miR-31875′Pm05f05f00f05f0005f05f05f005f00*5m0*0 m0m0m000m0m0m00m0m00*0*m0TEGCholMIMAT0015069 *5m0*** hsa-miR-3188 5′Pm005f00f0000f005f05f05f05m0*0*5m0*5m0m000m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0015070 m0*f0*5m0*0 hsa-miR-31895′Pm00005f05f005f0f05f05f005f00*5m0*5m m0m0m000m00m00m0m0m0*m0*m0TEGCholMIMAT0015071 0*0*5m0*5m0*0 hsa-miR-31905′Pm05f005f05f005f05f0f05f05f00f05m0*5m m0m0m000m000m0m00m0*0*m0TEGCholMIMAT0015073 0*5m0*5m0*f0*0*0 hsa-miR-31915′Pm00005f005f005f05f05f005f00*5m0*0*5m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0015075 m0*5m0*0* hsa-miR-31925′Pm05f05f005f005f00f0005f05f05m0*5m0* m0m00m0m0m0m00m0m0m00*0*m0TEGCholMIMAT0015076 5m0*5m0*5m0*5m0*0 hsa-miR-31935′Pm0005f05f005f05f05f005f00f05m0*0*0*0m0m0m00m0m000m0m00m0*m0*m0TEGChol MIMAT0015077 *5m0*5m0*0 hsa-miR-31945′Pm05f05f005f05f05f05f0f0005f0f05m0*5m m0m00m0m0m0000m0m00*0*m0TEGCholMIMAT0015078 0*0*5m0*5m0*0*0 hsa-miR-31955′Pm005f005f05f05f05f05f05f000f00*5m0*0 m0m0m0m00m0000m0m00*m0*m0TEGCholMIMAT0015079 *5m0*5m0*0*0 hsa-miR-31965′Pm005f05f0f005f05f05f05f05f05f05f05m0* m0m0000m000m0m000*m0*m0TEGCholMIMAT0015080 5m0*0*0*f0*5m0*0 hsa-miR-31975′Pm0000f0005f05f005f05f05f05m0*5m0*0*m0m000m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0015082 0*5m0*0*0 hsa-miR-31985′Pm05f0005f05f05f05f0f0005f0f05m0*0*0* m0m00m0m0m0000m0m0m0*0*m0TEGCholMIMAT0015083 5m0*f0*5m0*0 hsa-miR-31995′Pm05f05f00f05f000f05f005f05f05m0*0*0* m0m00m00m0m0m00m0m00*0*m0TEGCholMIMAT0015084 5m0*f0*0*0 hsa-miR-325′Pm05f05f00f05f005f05f05f000f05m0*5m0* m0m0m0m00m00m00m0m00*0*m0TEGCholMIMAT0000090 0*5m0*5m0*5m0*0 hsa-miR-32*5′Pm05f000f00005f005f00f05m0*0*5m0*5mm0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004505 0*f0*5m0*0hsa-miR-3200-3p 5′Pm05f005f0f005f05f0f05f05f05f0f00*0*0*0m0m0000m000m0m00m0*0*m0TEGChol MIMAT0015085 *5m0*0*0 hsa-miR-3200-5p5′Pm005f005f005f05f0f05f005f05f05m0*5m0 m0m00m00m000m0m0m00*m0*m0TEGCholMIMAT0017392 *5m0*0*f0*0*0 hsa-miR-32015′Pm05f05f05f05f0005f05f005f05f05f00*0*5 m0m000m0m00m0m0m000*0*m0TEGCholMIMAT0015086 m0*5m0*f0*5m0*0 hsa-miR-32025′Pm00005f05f05f005f05f05f05f05f00*5m0* m0m0000m0m000m0m0m0*m0*m0TEGCholMIMAT0015089 0*0*f0*5m0*0 hsa-miR-320a5′Pm0005f0f0005f0f05f000f00*5m0*5m0*5 m0m0m0m00m00m0m0m00m0*m0*m0TEGCholMIMAT0000510 m0*f0*0*0 hsa-miR-320b5′Pm0000f005f05f05f05f005f05f00*5m0*5m m0m00m00m000m0m0m0m0*m0*m0TEGCholMIMAT0005792 0*0*f0*5m0*0 hsa-miR-320c5′Pm005f00f05f000f05f05f00f05m0*0*0*5m m0m0m000m0m0m00m0m00*m0*m0TEGCholMIMAT0005793 0*5m0*0*0 hsa-miR-320d5′Pm05f000f0005f05f005f05f0f05m0*0*5m0 m0m000m0m00m0m0m0m0m0*0*m0TEGCholMIMAT0006764 *5m0*f0*5m0*0 hsa-miR-320e5′Pm0005f0f05f05f05f0f05f0005f00*5m0*0* m0m0m0m00m0000m00m0*m0*m0TEGCholMIMAT0015072 5m0*5m0*5m0*0 hsa-miR-323-3p5′Pm05f05f05f05f00005f05f05f05f05f05m0*5 m0m0000m0m0m0m0m000*0*m0TEGCholMIMAT0000755 m0*5m0*5m0*5m0*0*0 hsa-miR-323-5p5′Pm005f00f05f005f05f005f00f05m0*5m0*5 m0m0m00m0m00m00m0m00*m0*m0TEGCholMIMAT0004696 m0*5m0*5m0*0*0 hsa-miR-323b-3p5′Pm05f0005f05f05f05f05f05f05f05f0f05m0* m0m0000m0000m0m0m0*0*m0TEGCholMIMAT0015050 5m0*5m0*5m0*5m0*5m0*0 hsa-miR-323b-5p5′Pm005f00f05f000f05f005f0f00*0*5m0*0*fm0m00m00m0m0m00m0m00*m0*m0TEGChol MIMAT0001630 0*0*0 hsa-miR-324-3p5′Pm0005f0f005f005f005f05f0f05m0*0*0*5 m0m000m0m0m00m0m00m0*m0*m0TEGCholMIMAT0000762 m0*5m0*5m0*0 hsa-miR-324-5p5′Pm005f005f00005f05f05f005f00*5m0*0*0m0m0m000m0m0m0m0m0m00*m0*m0TEGChol MIMAT0000761 *f0*0*0 hsa-miR-3255′Pm005f005f005f05f05f0005f05f00*0*5m0*m0m00m0m0m000m0m0m00*m0*m0TEGChol MIMAT0000771 5m0*5m0*5m0*0 hsa-miR-3265′Pm05f05f05f05f005f05f0f05f05f005f05m0* m0m0m000m000m0m000*0*m0TEGCholMIMAT0000756 5m0*5m0*5m0*5m0*5m0*0 hsa-miR-3285′Pm05f05f005f0005f0f005f05f05f00*0*5m0 m0m000m0m00m0m0m0m00*0*m0TEGCholMIMAT0000752 *0*f0*5m0*0 hsa-miR-3295′Pm00005f0000f05f000f05m0*0*0*0*f0*0*0m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0001629 hsa-miR-330-3p5′Pm005f00f0000f05f05f05f05f05m0*5m0*5 m0m0000m0m0m0m0m0m00*m0*m0TEGCholMIMAT0000751 m0*0*5m0*0*0 hsa-miR-330-5p5′Pm00005f05f005f05f005f05f05f00*5m0*5 m0m000m0m00m00m0m0m0*m0*m0TEGCholMIMAT0004693 m0*0*5m0*5m0*0 hsa-miR-331-3p5′Pm0000f05f005f0f005f05f0f00*0*5m0*0*5m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0000760 m0*5m0*0 hsa-miR-331-5p5′Pm05f000f005f005f005f00f05m0*5m0*5m m0m0m00m0m0m00m0m0m0m0*0*m0TEGCholMIMAT0004700 0*0*5m0*0*0 hsa-miR-3355′Pm05f05f05f05f005f00f005f00f05m0*0*0* m0m0m00m0m0m00m0m000*0*m0TEGCholMIMAT0000765 0*5m0*5m0*0 hsa-miR-335*5′Pm0000f005f005f05f05f05f05f05m0*0*5m m0m0000m0m00m0m0m0m0*m0*m0TEGCholMIMAT0004703 0*0*5m0*0*0 hsa-miR-337-3p5′Pm0005f0f005f005f005f00f00*5m0*0*5m0m0m0m00m0m0m00m0m00m0*m0*m0TEGChol MIMAT0000754 *5m0*0*0 hsa-miR-337-5p5′Pm05f05f00f0005f0f0000f00*0*5m0*0*f0*m0m0m0m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0004695 5m0*0 hsa-miR-338-3p5′Pm05f05f05f05f00005f05f05f005f00*5m0* m0m0m000m0m0m0m0m000*0*m0TEGCholMIMAT0000763 5m0*5m0*5m0*0*0 hsa-miR-338-5p5′Pm0000f0005f05f005f05f05f00*0*5m0*5mm0m000m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004701 0*** hsa-miR-339-3p5′Pm005f00f05f005f05f005f00f05m0*5m0*5 m0m0m00m0m00m00m0m00*m0*m0TEGCholMIMAT0004702 m0*5m0*5m0*0*0 hsa-miR-339-5p5′Pm0000f05f005f0f0000f00*0*5m0*0*5m0m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0000764 *0*0 hsa-miR-33a5′Pm05f05f005f00005f0000f00*5m0*0*0*f0m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0000091 *0*0 hsa-miR-33a*5′Pm005f05f05f05f005f0f05f0005f05m0*0*5 m0m0m0m00m00m00m000*m0*m0TEGCholMIMAT0004506 m0*0*5m0*5m0*0 hsa-miR-33b5′Pm05f0005f005f05f0f005f05f0f05m0*0*5m m0m000m0m000m0m0m0m0*0*m0TEGCholMIMAT0003301 0*5m0*f0*5m0*0 hsa-miR-33b*5′Pm05f05f05f05f05f000f05f05f05f0f05m0*5 m0m0000m0m0m00m000*0*m0TEGCholMIMAT0004811 m0*5m0*5m0*f0*0*0 hsa-miR-3405′Pm05f05f05f05f005f005f05f05f05f05f00*0 m0m0000m0m00m0m000*0*m0TEGCholMIMAT0004692 *5m0*0*f0*0*0 hsa-miR-340*5′Pm05f05f05f0f00005f05f005f0f00*0*0*5m m0m00m00m0m0m0m0m000*0*m0TEGCholMIMAT0000750 0*f0*0*0 hsa-miR-342-3p5′Pm05f000f00005f005f00f05m0*0*5m0*5mm0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0000753 0*f0*5m0*0hsa-miR-342-5p 5′Pm05f05f05f0f0005f05f05f0005f00*5m0*0m0m0m0m00m00m0m0m000*0*m0TEGChol MIMAT0004694 *0*f0*5m0*0 hsa-miR-3455′Pm05f000f005f005f005f05f05f00*5m0*0*5m0m000m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0000772 m0*5m0*0*0 hsa-miR-3465′Pm05f0005f005f05f0f05f05f005f00*5m0*5 m0m0m000m000m0m0m0m0*0*m0TEGCholMIMAT0000773 m0*0*5m0*5m0*0 hsa-miR-34a5′Pm05f000f05f005f0f005f05f05f05m0*0*0* m0m000m0m00m00m0m0m0*0*m0TEGCholMIMAT0000255 0*f0*0*0 hsa-miR-34a*5′Pm00005f05f05f005f0000f05m0*0*0*0*f0m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004557 *5m0*0 hsa-miR-34b5′Pm005f005f00005f05f05f005f00*5m0*0*0m0m0m000m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004676 *f0*0*0 hsa-miR-34b*5′Pm05f000f00005f05f05f005f05m0*5m0*5 m0m0m000m0m0m0m0m0m0m0*0*m0TEGCholMIMAT0000685 m0*5m0*f0** hsa-miR-34c-3p5′Pm0000f0000f05f05f005f00*0*0*0*f0*0*0m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004677 hsa-miR-34c-5p5′Pm0000f005f05f05f005f05f0f05m0*0*5m0 m0m000m0m000m0m0m0m0*m0*m0TEGCholMIMAT0000686 *0*5m0*5m0*0 hsa-miR-3605-3p5′Pm05f005f05f05f000f05f000f05m0*0*0*5 m0m0m0m00m0m0m00m00m0*0*m0TEGCholMIMAT0017982 m0*5m0*0*0 hsa-miR-3605-5p5′Pm05f05f005f0005f05f05f0005f05m0*5m0 m0m0m0m00m00m0m0m0m00*0*m0TEGCholMIMAT0017981 *0*5m0*5m0*0*0 hsa-miR-36065′Pm05f005f0f05f005f0f005f00f00*5m0*5m0 m0m0m00m0m00m00m00m0*0*m0TEGCholMIMAT0017983 *5m0*5m0*5m0*0 hsa-miR-3607-3p5′Pm005f05f05f05f005f0f0005f05f05m0*0*5 m0m00m0m0m00m00m000*m0*m0TEGCholMIMAT0017985 m0*0*5m0*5m0*0 hsa-miR-3607-5p5′Pm0000f05f005f0f05f005f0f00*0*0*0*f0*5m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0017984 m0*0 hsa-miR-36095′Pm05f000f005f005f00005f00*0*5m0*5m0m0m0m0m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0017986 *5m0*5m0*0 hsa-miR-36105′Pm05f000f005f05f0f0005f0f00*5m0*5m0* m0m00m0m0m000m0m0m0m0*0*m0TEGCholMIMAT0017987 0*f0*0*0 hsa-miR-36115′Pm0000f005f05f0f05f000f00*0*5m0*0*f0*m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0017988 5m0*0 hsa-miR-36125′Pm05f05f05f05f05f05f05f05f05f0005f05m0 m0m0m0m00m0000m000*0*m0TEGCholMIMAT0017989 *5m0*5m0**** hsa-miR-3613-3p5′Pm005f05f05f05f05f00f00005f00*0*0*5m0m0m0m0m0m0m0m000m000*m0*m0TEGChol MIMAT0017991 *5m0*5m0*0hsa-miR-3613-5p 5′Pm00005f05f05f05f0f05f05f05f05f05m0*5m0m0000m0000m0m0m0*m0*m0TEGChol MIMAT0017990 m0*5m0*0*5m0*0*0hsa-miR-361-3p 5′Pm005f05f05f05f005f0f0005f05f05m0*0*5m0m00m0m0m00m00m000*m0*m0TEGChol MIMAT0004682 m0*0*5m0*5m0*0hsa-miR-3614-3p 5′Pm0005f0f05f05f005f05f05f00f05m0*0*0*m0m0m000m0m000m00m0*m0*m0TEGChol MIMAT0017993 5m0*f0*0*0 hsa-miR-3614-5p5′Pm005f05f05f05f005f05f00005f00*0*5m0*m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0017992 0*5m0*5m0*0 hsa-miR-36155′Pm005f05f05f005f00f005f05f05f00*0*0*5 m0m000m0m0m00m0m000*m0*m0TEGCholMIMAT0017994 m0*5m0*5m0*0 hsa-miR-361-5p5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0000703 5m0*f0*0*0 hsa-miR-3616-3p5′Pm005f00f005f00f05f000f00*0*5m0*5m0*m0m0m0m00m0m00m0m0m00*m0*m0TEGChol MIMAT0017996 5m0*0*0 hsa-miR-3616-5p5′Pm05f05f05f05f005f005f05f0005f00*5m0* m0m0m0m00m0m00m0m000*0*m0TEGCholMIMAT0017995 5m0*0*5m0*0*0 hsa-miR-36175′Pm0005f0f0005f0f05f0005f00*5m0*0*5m0m0m0m0m00m00m0m0m00m0*m0*m0TEGChol MIMAT0017997 *5m0*5m0*0 hsa-miR-36185′Pm005f05f05f0005f0f05f05f05f0f05m0*5m m0m0000m00m0m0m000*m0*m0TEGCholMIMAT0017998 0*0*5m0*f0*5m0*0 hsa-miR-36195′Pm05f05f05f0f00005f05f005f0f05m0*0*5m m0m00m00m0m0m0m0m000*0*m0TEGCholMIMAT0017999 0*5m0*5m0*5m0*0 hsa-miR-36205′Pm05f0005f05f05f00f05f05f005f05m0*5m0 m0m0m000m0m000m0m0m0*0*m0TEGCholMIMAT0018001 *0*5m0*5m0*5m0*0 hsa-miR-36215′Pm05f0005f00005f005f05f05f00*5m0*5m0m0m000m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018002 *0*5m0*0*0hsa-miR-3622a- 5′Pm05f05f05f05f05f05f05f05f05f05f05f0f05m0m0000m0000m000*0*m0TEGChol 3p m0*5m0*5m0*5m0*5m0*5m0*0 MIMAT0018004hsa-miR-3622a- 5′Pm0005f0f005f05f0f05f05f05f05f05m0*0*0m0m0000m000m0m00m0*m0*m0TEGChol 5p *0*f0*5m0* MIMAT0018003hsa-miR-3622b- 5′Pm05f05f00f00005f0000f05m0*5m0*5m0*m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol 3p 5m0*f0*5m0*0 MIMAT0018006hsa-miR-3622b- 5′Pm05f0005f05f005f0f05f05f05f0f05m0*5mm0m0000m00m00m0m0m0*0*m0TEGChol 5p 0*5m0*5m0*5m0*5m0*0 MIMAT0018005hsa-miR-362-3p 5′Pm0000f05f005f05f05f005f0f00*5m0*0*5m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0004683 m0*f0*0*0 hsa-miR-362-5p5′Pm005f05f05f05f005f05f00005f00*0*5m0*m0m0m0m0m0m00m00m000*m0*m0TEGChol MIMAT0000705 0*5m0*5m0*0 hsa-miR-3635′Pm05f000f0005f0f005f00f05m0*0*0*0*f0*m0m0m00m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0000707 0*0 hsa-miR-363*5′Pm05f0005f00005f005f05f05f00*5m0*5m0m0m000m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003385 *0*f0*0*0 hsa-miR-36465′Pm0005f05f05f05f00f005f05f05f00*5m0*0 m0m000m0m0m000m00m0*m0*m0TEGCholMIMAT0018065 *0*f0*0*0 hsa-miR-3647-3p5′Pm05f05f005f05f0005f05f000f00*0*5m0*0m0m0m0m00m0m0m00m0m00*0*m0TEGChol MIMAT0018067 *f0*0*0 hsa-miR-3647-5p5′Pm0000f05f05f00f05f0005f05m0*0*5m0*5m0m0m0m00m0m000m0m0m0*m0*m0TEGChol MIMAT0018066 m0*5m0*5m0*0hsa-miR-3648 5′Pm00005f005f05f0f05f005f0f00*5m0*5m0m0m00m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018068 *0*f0*5m0*0 hsa-miR-36495′Pm0005f0f005f005f005f05f0f05m0*0*0*5 m0m000m0m0m00m0m00m0*m0*m0TEGCholMIMAT0018069 m0*5m0*5m0*0 hsa-miR-3655′Pm05f05f05f05f05f005f05f005f05f0f05m0* m0m000m0m00m00m000*0*m0TEGCholMIMAT0000710 5m0*5m0*5m0*5m0*0*0 hsa-miR-365*5′Pm0005f0f05f0005f05f05f05f0f00*0*5m0* m0m0000m0m0m00m00m0*m0*m0TEGCholMIMAT0009199 0*f0*0*0 hsa-miR-36505′Pm05f05f05f05f005f005f0005f0f05m0*5m0 m0m00m0m0m0m00m0m000*0*m0TEGCholMIMAT0018070 *5m0*5m0*5m0*5m0*0 hsa-miR-36515′Pm0000f0005f0f0005f0f05m0*5m0*0*0*f0m0m00m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018071 *0*0 hsa-miR-36525′Pm05f0005f05f005f0f005f00f00*5m0*5m0 m0m0m00m0m00m00m0m0m0*0*m0TEGCholMIMAT0018072 *0*f0*0*0 hsa-miR-36535′Pm0000f05f0005f05f005f0f00*0*5m0*5m0m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018073 *5m0*5m0*0 hsa-miR-36545′Pm00005f05f005f0f05f05f005f00*0*5m0*0m0m0m000m00m00m0m0m0*m0*m0TEGChol MIMAT0018074 *5m0*5m0*0 hsa-miR-36555′Pm05f05f00f0005f05f005f00f05m0*0*0*0*m0m0m00m0m00m0m0m0m00*0*m0TEGChol MIMAT0018075 f0*5m0*0 hsa-miR-36565′Pm0005f0f05f005f0f00005f00*5m0*5m0*0m0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0018076 *f0*5m0* hsa-miR-36575′Pm05f05f05f05f0005f05f05f05f00f05m0*0* m0m0m000m00m0m0m000*0*m0TEGCholMIMAT0018077 0*0*f0*0*0 hsa-miR-36585′Pm0000f05f05f005f0005f05f00*5m0*5m0*m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0018078 5m0*5m0*5m0*0hsa-miR-3659 5′Pm05f05f00f0005f05f05f005f0f00*0*0*5mm0m00m00m00m0m0m0m00*0*m0TEGChol MIMAT0018080 0*f0*0*0 hsa-miR-36605′Pm0000f005f05f0f05f005f05f05m0*0*5m0 m0m00m00m000m0m0m0m0*m0*m0TEGCholMIMAT0018081 *5m0*5m0*5m0*0 hsa-miR-36615′Pm005f00f05f005f0f05f0005f05m0*0*0*5 m0m0m0m00m00m00m0m00*m0*m0TEGCholMIMAT0018082 m0*5m0*5m0*0 hsa-miR-36625′Pm05f0005f0000f05f000f00*5m0*5m0*0*fm0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018083 0*5m0*0 hsa-miR-3663-3p5′Pm0005f05f05f05f00f0000f00*0*0*0*f0**m0m0m0m0m0m0m000m00m0*m0*m0TEGChol MIMAT0018085 hsa-miR-3663-5p5′Pm0005f0f05f05f005f05f000f05m0*0*0*5 m0m0m0m00m0m000m00m0*m0*m0TEGCholMIMAT0018084 m0*f0*0*0 hsa-miR-36645′Pm00005f0005f0f0005f05f00*0*5m0*0*f0m0m00m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018086 *5m0*0 hsa-miR-36655′Pm05f000f005f00f005f005f05m0*0*0*5m0m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0018087 *5m0*5m0*0 hsa-miR-36665′Pm0000f005f05f05f05f0005f05m0*0*5m0*m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018088 5m0*5m0*5m0*0hsa-miR-3667-3p 5′Pm0000f05f0005f00005f05m0*0*5m0*0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018090 m0*0*0 hsa-miR-3667-5p5′Pm0000f05f05f05f0f05f005f05f05m0*0*0* m0m00m00m0000m0m0m0*m0*m0TEGCholMIMAT0018089 0*f0** hsa-miR-3668 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018091 m0*5m0*0*0 hsa-miR-36695′Pm05f05f05f0f0005f05f0000f00*0*5m0*0*m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0018092 5m0*5m0*0 hsa-miR-3675′Pm05f05f005f0005f0f0000f05m0*0*5m0*5m0m0m0m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0000719 m0*5m0*0*0 hsa-miR-367*5′Pm005f005f05f05f00f05f005f05f00*5m0*5 m0m00m00m0m000m0m00*m0*m0TEGCholMIMAT0004686 m0*0*f0*5m0*0 hsa-miR-36705′Pm0005f05f0005f05f005f005f05m0*0*5m0m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0018093 *0*5m0*5m0*0hsa-miR-3671 5′Pm0000f005f05f05f05f0005f05m0*0*5m0*m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018094 5m0*5m0*5m0*0hsa-miR-3672 5′Pm05f05f05f0f05f05f00f0005f0f00*0*0*5mm0m00m0m0m0m000m000*0*m0TEGChol MIMAT0018095 0*5m0*5m0*0 hsa-miR-36735′Pm005f005f05f005f0f005f00f00*5m0*5m0 m0m0m00m0m00m00m0m00*m0*m0TEGCholMIMAT0018096 *5m0*f0*5m0*0 hsa-miR-36745′Pm0005f0f005f05f05f05f005f0f05m0*0*0* m0m00m00m000m0m00m0*m0*m0TEGCholMIMAT0018097 0*f0*0*0 hsa-miR-3675-3p5′Pm005f005f05f05f005f05f05f00f00*0*0*5 m0m0m000m0m000m0m00*m0*m0TEGCholMIMAT0018099 m0*f0*0*0 hsa-miR-3675-5p5′Pm05f05f00f05f000f05f000f00*0*0*5m0*5m0m0m0m00m0m0m00m0m00*0*m0TEGChol MIMAT0018098 m0*5m0*0 hsa-miR-36765′Pm0000f05f005f0f05f0005f05m0*5m0*0*5m0m0m0m00m00m00m0m0m0*m0*m0TEGChol MIMAT0018100 m0*5m0*5m0*0hsa-miR-3677 5′Pm005f05f05f05f005f05f05f0005f00*0*5mm0m0m0m00m00m00m000*m0*m0TEGChol MIMAT0018101 0*0*5m0*5m0*0hsa-miR-3678-3p 5′Pm0005f0f05f05f005f05f005f05f05m0*5m0m0m00m00m0m000m00m0*m0*m0TEGChol MIMAT0018103 *5m0*5m0*f0*0*0hsa-miR-3678-5p 5′Pm0000f05f005f0f00005f00*5m0*0*0*f0*m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0018102 0*0 hsa-miR-3679-3p5′Pm05f05f05f05f05f05f005f05f05f05f0f05m m0m0000m0m000m000*0*m0TEGCholMIMAT0018105 0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-3679-5p5′Pm0005f05f05f005f0f05f05f005f05m0*5m0 m0m0m000m00m00m00m0*m0*m0TEGCholMIMAT0018104 *0*0*f0*0*0 hsa-miR-36805′Pm05f05f05f05f005f005f005f005f00*5m0* m0m0m00m0m0m00m0m000*0*m0TEGCholMIMAT0018106 5m0*5m0*5m0*5m0*0 hsa-miR-3680*5′Pm05f005f05f0005f05f05f05f00f05m0*0*0 m0m0m000m00m0m0m00m0*0*m0TEGCholMIMAT0018107 *5m0*f0** hsa-miR-36815′Pm0005f05f05f05f005f005f005f00*0*0*5mm0m0m00m0m0m000m00m0*m0*m0TEGChol MIMAT0018108 0*5m0*0*0 hsa-miR-3681*5′Pm05f05f005f05f0005f05f005f05f00*0*5m m0m00m00m0m0m00m0m00*0*m0TEGCholMIMAT0018109 0*5m0*f0*5m0*0 hsa-miR-36825′Pm0005f05f05f005f05f05f005f0f00*0*0*0*m0m00m00m00m00m00m0*m0*m0TEGChol MIMAT0018110 5m0*0*0 hsa-miR-36835′Pm0000f05f0005f05f005f0f00*5m0*5m0*5m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018111 m0*5m0*5m0*0hsa-miR-3684 5′Pm0000f05f0005f0005f0f05m0*5m0*5m0*m0m00m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018112 5m0*5m0*5m0*0hsa-miR-3685 5′Pm00005f05f05f005f005f05f05f00*5m0*0*m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0018113 0*f0*5m0*0 hsa-miR-36865′Pm0000f005f05f0f05f0005f05m0*5m0*5m m0m0m0m00m000m0m0m0m0*m0*m0TEGCholMIMAT0018114 0*5m0*5m0*5m0*0 hsa-miR-36875′Pm0000f05f05f05f0f005f00f00*5m0*5m0* m0m0m00m0m0000m0m0m0*m0*m0TEGCholMIMAT0018115 5m0*** hsa-miR-3688 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018116 m0*5m0*5m0*0hsa-miR-3689a- 5′Pm0005f05f005f00f005f05f05f05m0*5m0*m0m000m0m0m00m0m00m0*m0*m0TEGChol 3p 0*5m0*5m0*0*0 MIMAT0018118hsa-miR-3689a- 5′Pm05f05f05f0f0005f05f005f00f00*0*0*5mm0m0m00m0m00m0m0m000*0*m0TEGChol 5p 0*f0*5m0*0 MIMAT0018117hsa-miR-3689b 5′Pm00005f005f05f0f05f0005f00*5m0*5m0*m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0018180 5m0*f0*0*0hsa-miR-3689b* 5′Pm05f005f0f05f05f00f05f005f0f05m0*0*0*m0m00m00m0m000m00m0*0*m0TEGChol MIMAT0018181 5m0*f0*0*0 hsa-miR-36905′Pm05f0005f0005f0f05f000f00*0*5m0*5m0m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0018119 *f0*0*0 hsa-miR-36915′Pm0000f005f00f05f005f05f05m0*5m0*5m m0m00m00m0m00m0m0m0m0*m0*m0TEGCholMIMAT0018120 0*0*f0*0*0 hsa-miR-36925′Pm05f05f005f05f0005f05f005f05f00*0*5m m0m00m00m0m0m00m0m00*0*m0TEGCholMIMAT0018122 0*5m0*f0*5m0*0 hsa-miR-3692*5′Pm05f05f00f05f005f05f0005f0f00*5m0*5m m0m00m0m0m00m00m0m00*0*m0TEGCholMIMAT0018121 0*5m0*5m0*0*0 hsa-miR-369-3p5′Pm0005f05f05f005f0f05f05f005f05m0*5m0 m0m0m000m00m00m00m0*m0*m0TEGCholMIMAT0000721 *5m0*0*5m0** hsa-miR-369-5p5′Pm005f00f05f005f05f05f05f00f05m0*0*5m m0m0m000m00m00m0m00*m0*m0TEGCholMIMAT0001621 0*5m0*f0*0*0 hsa-miR-3705′Pm00005f005f05f05f05f0005f00*0*5m0*0m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0000722 *f0*0*0 hsa-miR-37135′Pm05f000f005f005f05f05f00f00*0*5m0*5 m0m0m000m0m00m0m0m0m0*0*m0TEGCholMIMAT0018164 m0*f0*5m0*0 hsa-miR-371-3p5′Pm05f05f05f05f05f05f05f0f05f05f005f05m m0m0m000m0000m000*0*m0TEGCholMIMAT0000723 0*5m0*5m0*0*5m0*0*0 hsa-miR-37145′Pm005f05f05f05f05f005f05f000f00*5m0*5 m0m0m0m00m0m000m000*m0*m0TEGCholMIMAT0018165 m0*5m0*5m0*5m0* hsa-miR-371-5p5′Pm05f05f05f05f005f05f05f05f05f05f0f00*0 m0m0000m000m0m000*0*m0TEGCholMIMAT0004687 *0*0*5m0*5m0*0 hsa-miR-3725′Pm05f000f005f05f05f005f00f05m0*0*0*5 m0m0m00m0m000m0m0m0m0*0*m0TEGCholMIMAT0000724 m0*f0*5m0*0 hsa-miR-3735′Pm05f005f0f05f05f005f0005f05f00*5m0*0 m0m00m0m0m0m000m00m0*0*m0TEGCholMIMAT0000726 *5m0*5m0*0*0 hsa-miR-373*5′Pm0000f05f05f00f0005f05f00*5m0*5m0*5m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000725 m0*5m0*5m0*0hsa-miR-374a 5′Pm0005f0f05f05f05f05f05f005f0f00*5m0*0m0m00m00m0000m00m0*m0*m0TEGChol MIMAT0000727 *5m0*f0*5m0*0 hsa-miR-374a*5′Pm05f05f005f005f05f0f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGCholMIMAT0004688 *0*f0*5m0*0 hsa-miR-374b5′Pm05f005f0f05f05f005f05f005f05f00*5m0* m0m00m00m0m000m00m0*0*m0TEGCholMIMAT0004955 0*5m0*5m0*0*0 hsa-miR-374b*5′Pm00005f005f05f05f05f0005f05m0*5m0*5m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0004956 m0*0*f0*0*0 hsa-miR-374c5′Pm005f05f05f0005f05f05f05f05f0f00*5m0* m0m0000m00m0m0m000*m0*m0TEGCholMIMAT0018443 0*5m0*f0*0*0 hsa-miR-3755′Pm05f05f005f05f000f005f005f00*0*5m0*5m0m0m00m0m0m0m00m0m00*0*m0TEGChol MIMAT0000728 m0*5m0*5m0*0 hsa-miR-376a5′Pm05f05f00f0005f0f0005f05f05m0*0*0*5 m0m00m0m0m00m0m0m0m00*0*m0TEGCholMIMAT0000729 m0*5m0*5m0*0 hsa-miR-376a*5′Pm05f05f05f05f05f05f005f05f05f005f05m0 m0m0m000m0m000m000*0*m0TEGCholMIMAT0003386 *5m0*0*5m0*5m0*5m0*0 hsa-miR-376b5′Pm005f00f05f005f05f005f05f0f00*0*0*5m m0m000m0m00m00m0m00*m0*m0TEGCholMIMAT0002172 0*5m0*0*0 hsa-miR-376c5′Pm00005f05f000f005f05f0f00*0*0*5m0*5m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000720 m0*0*0 hsa-miR-3775′Pm0005f05f05f05f05f0f05f05f005f05m0*5 m0m0m000m0000m00m0*m0*m0TEGCholMIMAT0000730 m0*0*0*f0*5m0*0 hsa-miR-377*5′Pm05f000f0005f05f0005f0f00*0*0*0*f0*0m0m00m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0004689 *0 hsa-miR-3785′Pm05f05f05f0f00005f0000f00*5m0*0*5m0m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0000732 *5m0*5m0*0 hsa-miR-378*5′Pm05f05f05f0f005f005f0005f0f05m0*5m0* m0m00m0m0m0m00m0m000*0*m0TEGCholMIMAT0000731 0*0*5m0*5m0*0 hsa-miR-378b5′Pm05f0005f00005f05f05f00f05m0*5m0*5 m0m0m000m0m0m0m0m0m0m0*0*m0TEGCholMIMAT0014999 m0*0*5m0** hsa-miR-378c5′Pm05f005f0f005f005f0005f05f05m0*0*0*5m0m00m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0016847 m0*f0*0*0 hsa-miR-3795′Pm0000f05f05f005f0005f05f00*5m0*5m0*m0m00m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0000733 5m0*5m0*5m0*hsa-miR-379* 5′Pm05f05f05f05f005f05f05f05f05f00f05m0*m0m0m000m000m0m000*0*m0TEGChol MIMAT0004690 0*5m0*5m0*** hsa-miR-3805′Pm05f05f05f05f05f05f05f0f0000f05m0*0*5 m0m0m0m0m0m0000m000*0*m0TEGCholMIMAT0000735 m0*5m0*5m0*5m0* hsa-miR-380*5′Pm05f005f05f05f005f05f00005f05m0*5m0 m0m0m0m0m0m00m00m00m0*0*m0TEGCholMIMAT0000734 *5m0*5m0*** hsa-miR-3815′Pm05f005f05f0000f05f0005f05m0*5m0*5 m0m0m0m00m0m0m0m0m00m0*0*m0TEGCholMIMAT0000736 m0*5m0*f0*5m0*0 hsa-miR-3825′Pm0005f0f05f05f05f05f0005f0f00*5m0*0* m0m00m0m0m0000m00m0*m0*m0TEGCholMIMAT0000737 5m0*f0*0*0 hsa-miR-3835′Pm005f005f05f05f005f05f0005f05m0*0*5 m0m0m0m00m0m000m0m00*m0*m0TEGCholMIMAT0000738 m0*5m0*f0*5m0*0 hsa-miR-3845′Pm00005f0000f0000f00*0*5m0*5m0*5m0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0001075 *0*0 Chol hsa-miR-39075′Pm05f005f0f00005f0005f0f00*0*0*5m0*5m0m00m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0018179 m0*0*0 hsa-miR-39085′Pm0005f0f05f05f00f05f05f00f00*5m0*0*5 m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0018182 m0*5m0*0*0 hsa-miR-39095′Pm05f05f05f05f05f005f05f05f05f005f05m0 m0m0m000m00m00m000*0*m0TEGCholMIMAT0018183 *0*0*0*f0*5m0*0 hsa-miR-39105′Pm0005f0f0005f05f005f00f00*0*5m0*0*5m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0018184 m0*0*0 hsa-miR-39115′Pm05f05f005f05f05f05f0f005f05f0f05m0*5 m0m000m0m0000m0m00*0*m0TEGCholMIMAT0018185 m0*5m0*5m0*f0*5m0*0 hsa-miR-39125′Pm05f005f0f05f05f05f0f0005f0f00*0*0*0* m0m00m0m0m0000m00m0*0*m0TEGCholMIMAT0018186 5m0*5m0*0 hsa-miR-39135′Pm05f05f05f0f05f005f0f0000f05m0*5m0*0 m0m0m0m0m0m00m00m000*0*m0TEGCholMIMAT0018187 *5m0*f0*5m0*0 hsa-miR-39145′Pm05f0005f0000f0005f0f00*0*0*5m0*5mm0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018188 0*0*0 hsa-miR-39155′Pm0000f0005f05f0000f05m0*5m0*5m0*5m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018189 m0*f0*0*0 hsa-miR-39165′Pm0000f05f0005f00005f05m0*0*5m0*0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018190 m0*5m0*0 hsa-miR-39175′Pm05f05f005f05f000f05f05f005f00*5m0*5 m0m0m000m0m0m00m0m00*0*m0TEGCholMIMAT0018191 m0*0*5m0*0*0 hsa-miR-39185′Pm005f05f05f05f05f005f05f005f05f05m0*0 m0m00m00m0m000m000*m0*m0TEGCholMIMAT0018192 *0*0*5m0** hsa-miR-39195′Pm05f0005f0000f0005f0f00*0*0*5m0*5mm0m00m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0018193 0*0*0 hsa-miR-39205′Pm0005f0f05f0005f005f05f0f00*0*0*0*f0*m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0018195 0*0 hsa-miR-39215′Pm005f005f05f05f005f05f005f05f00*5m0* m0m00m00m0m000m0m00*m0*m0TEGCholMIMAT0018196 5m0*0*f0*5m0*0 hsa-miR-39225′Pm05f05f005f005f05f0f05f005f05f00*5m0* m0m00m00m000m0m0m00*0*m0TEGCholMIMAT0018197 5m0*0*5m0*5m0*0 hsa-miR-39235′Pm05f005f0f005f005f0005f05f05m0*0*5m m0m00m0m0m0m00m0m00m0*0*m0TEGCholMIMAT0018198 0*5m0*f0*0*0 hsa-miR-39245′Pm0000f05f005f05f005f05f05f00*5m0*0*0m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0018199 *5m0*5m0*0 hsa-miR-39255′Pm00005f05f05f05f0f05f0005f00*5m0*5m m0m0m0m00m0000m0m0m0*m0*m0TEGCholMIMAT0018200 0*5m0*5m0*0*0 hsa-miR-39265′Pm05f0005f005f005f0005f05f00*0*5m0*5m0m00m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0018201 m0*5m0*5m0*0hsa-miR-3927 5′Pm005f005f005f05f05f00005f00*0*0*0*f0m0m0m0m0m0m000m0m0m00*m0*m0TEGChol MIMAT0018202 *5m0*0 hsa-miR-39285′Pm00005f05f005f0f005f05f0f05m0*5m0*5 m0m000m0m00m00m0m0m0*m0*m0TEGCholMIMAT0018205 m0*5m0*5m0*0*0 hsa-miR-39295′Pm0000f05f0005f05f005f0f00*5m0*5m0*5m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0018206 m0*5m0*5m0*0hsa-miR-3934 5′Pm00005f005f005f05f005f0f00*5m0*0*5mm0m00m00m0m00m0m0m0m0*m0*m0TEGChol MIMAT0018349 0*f0*5m0*0 hsa-miR-39355′Pm0005f05f05f005f05f05f0005f05m0*5m0 m0m0m0m00m00m00m00m0*m0*m0TEGCholMIMAT0018350 *5m0*5m0*5m0*0*0 hsa-miR-39365′Pm005f005f05f005f0f05f0005f05m0*0*0*5m0m0m0m00m00m00m0m00*m0*m0TEGChol MIMAT0018351 m0*5m0*5m0*0 hsa-miR-39375′Pm05f005f05f005f005f0000f05m0*5m0*0*m0m0m0m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0018352 5m0*5m0*0* hsa-miR-39385′Pm0005f0f05f0005f0005f0f00*0*0*0*f0*0m0m00m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0018353 *0 hsa-miR-39395′Pm05f05f00f05f000f05f05f005f00*5m0*5m m0m0m000m0m0m00m0m00*0*m0TEGCholMIMAT0018355 0*0*5m0*5m0*0 hsa-miR-39405′Pm0000f0005f05f05f05f05f0f00*0*0*5m0*m0m0000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018356 5m0*5m0*0 hsa-miR-39415′Pm05f05f00f05f05f05f05f05f0005f05m0*5 m0m0m0m00m0000m0m00*0*m0TEGCholMIMAT0018357 m0*0*0*f0*0*0 hsa-miR-39425′Pm05f0005f005f00f05f05f05f0f05m0*5m0* m0m0000m0m00m0m0m0m0*0*m0TEGCholMIMAT0018358 0*0*f0*5m0*0 hsa-miR-39435′Pm005f05f05f05f0005f0000f05m0*0*0*0*fm0m0m0m0m0m0m0m00m000*m0*m0TEGChol MIMAT0018359 0*5m0*0 hsa-miR-39445′Pm0005f0f0005f0f0000f00*5m0*5m0*0*5m0m0m0m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0018360 m0*0*0 hsa-miR-39455′Pm005f05f0f05f005f05f05f005f05f05m0*5 m0m00m00m00m00m000*m0*m0TEGCholMIMAT0018361 m0*0*0*5m0*5m0*0 hsa-miR-409-3p5′Pm005f05f05f00005f05f000f00*5m0*5m0*m0m0m0m00m0m0m0m0m000*m0*m0TEGChol MIMAT0001639 0*5m0*0*0 hsa-miR-409-5p5′Pm05f05f005f05f05f005f05f05f00f05m0*5 m0m0m000m0m000m0m00*0*m0TEGCholMIMAT0001638 m0*5m0*0*5m0*0*0 hsa-miR-4105′Pm005f05f05f05f05f05f0f05f05f05f05f05m m0m0000m0000m000*m0*m0TEGCholMIMAT0002171 0*0*0*0*5m0*0*0 hsa-miR-4115′Pm005f005f005f05f05f00005f00*0*0*0*f0m0m0m0m0m0m000m0m0m00*m0*m0TEGChol MIMAT0003329 *5m0*0 hsa-miR-411*5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0004813 0*f0*5m0*0 hsa-miR-4125′Pm0000f05f005f0f05f0005f00*0*0*5m0*f0m0m0m0m00m00m00m0m0m0*m0*m0TEGChol MIMAT0002170 *5m0*0 hsa-miR-4215′Pm05f05f005f0000f0000f00*5m0*5m0*5mm0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0003339 0*f0*5m0*0 hsa-miR-422a5′Pm05f000f05f05f05f05f05f05f05f05f05m0* m0m0000m0000m0m0m0*0*m0TEGCholMIMAT0001339 5m0*0*5m0*f0*0*0 hsa-miR-423-3p5′Pm005f05f05f005f05f05f005f005f00*5m0* m0m0m00m0m000m0m000*m0*m0TEGCholMIMAT0001340 5m0*5m0*f0*5m0*0 hsa-miR-423-5p5′Pm0005f05f005f05f0f05f005f0f05m0*5m0* m0m00m00m000m0m00m0*m0*m0TEGCholMIMAT0004748 0*0*f0*5m0*0 hsa-miR-4245′Pm05f05f005f0000f0000f00*5m0*5m0*5mm0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0001341 0*f0*5m0*0 hsa-miR-424*5′Pm05f000f05f005f05f05f005f05f05m0*0*5 m0m00m00m00m00m0m0m0*0*m0TEGCholMIMAT0004749 m0*5m0*5m0*5m0*0 hsa-miR-4255′Pm005f005f0000f0000f05m0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0003393 m0*f0*5m0*0hsa-miR-425* 5′Pm05f05f005f005f00f00005f00*0*5m0*5mm0m0m0m0m0m0m00m0m0m00*0*m0TEGChol MIMAT0001343 0*5m0*5m0*0 hsa-miR-42515′Pm0000f0000f0000f00*0*0*5m0*f0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0016883 Chol hsa-miR-4252 5′Pm0005f0f005f005f05f05f05f0f00*5m0*5mm0m0000m0m00m0m00m0*m0*m0TEGChol MIMAT0016886 0*0*f0*5m0*0 hsa-miR-42535′Pm005f05f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m000*m0*m0TEGCholMIMAT0016882 m0*5m0*5m0*5m0*5m0*5m0* hsa-miR-42545′Pm005f05f05f05f0005f0005f0f00*5m0*0*0m0m00m0m0m0m0m00m000*m0*m0TEGChol MIMAT0016884 *5m0*0*0 hsa-miR-42555′Pm05f05f05f05f05f005f05f005f05f05f00*0 m0m000m0m00m00m000*0*m0TEGCholMIMAT0016885 *0*5m0*f0*5m0*0 hsa-miR-42565′Pm05f005f05f0005f05f00005f05m0*5m0*5m0m0m0m0m0m00m0m0m00m0*0*m0TEGChol MIMAT0016877 m0*5m0*f0*5m0*0hsa-miR-4257 5′Pm05f05f05f05f0005f05f05f05f005f00*0*5m0m0m000m00m0m0m000*0*m0TEGChol MIMAT0016878 m0*5m0*5m0*5m0*0hsa-miR-4258 5′Pm005f005f05f05f005f0005f0f00*0*5m0*5m0m00m0m0m0m000m0m00*m0*m0TEGChol MIMAT0016879 m0*5m0*5m0*0 hsa-miR-42595′Pm05f05f00f05f000f0005f0f00*5m0*5m0* m0m00m0m0m0m0m00m0m00*0*m0TEGCholMIMAT0016880 *** hsa-miR-4260 5′Pm0000f05f0005f05f005f0f00*0*5m0*5m0m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0016881 *5m0*5m0*0 hsa-miR-42615′Pm0005f05f0000f05f05f00f05m0*5m0*0*5m0m0m000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0016890 m0*f0*0*0 hsa-miR-42625′Pm05f0005f05f000f05f000f05m0*0*0*0*f0m0m0m0m00m0m0m00m0m0m0*0*m0TEGChol MIMAT0016894 *5m0*0 hsa-miR-42635′Pm05f05f05f05f05f05f05f05f05f05f005f05 m0m0m000m0000m000*0*m0TEGCholMIMAT0016898 m0*0*5m0*0*5m0*5m0*0 hsa-miR-42645′Pm05f005f0f005f005f00005f05m0*5m0*0*m0m0m0m0m0m0m00m0m00m0*0*m0TEGChol MIMAT0016899 0*5m0*5m0*0 hsa-miR-42655′Pm0005f05f0005f0f0005f0f05m0*0*5m0*5m0m00m0m0m00m0m0m00m0*m0*m0TEGChol MIMAT0016891 m0*f0*5m0*0 hsa-miR-42665′Pm05f05f05f05f00005f05f0005f05m0*5m0 m0m0m0m00m0m0m0m0m000*0*m0TEGCholMIMAT0016892 *5m0*0*f0** hsa-miR-42675′Pm05f05f005f0005f05f05f000f00*0*5m0*0m0m0m0m00m00m0m0m0m00*0*m0TEGChol MIMAT0016893 *f0*5m0*0 hsa-miR-42685′Pm0000f05f0005f00005f05m0*0*5m0*0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0016896 m0*0*0 hsa-miR-42695′Pm0000f05f0005f05f005f0f00*5m0*5m0*5m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0016897 m0*5m0*5m0*0hsa-miR-4270 5′Pm005f00f005f05f05f05f05f005f05m0*5m0m0m0m000m000m0m0m00*m0*m0TEGChol MIMAT0016900 *5m0*5m0*5m0*5m0*0hsa-miR-4271 5′Pm005f05f05f005f00f0005f05f00*0*5m0*5m0m00m0m0m0m00m0m000*m0*m0TEGChol MIMAT0016901 m0*5m0*5m0*0 hsa-miR-42725′Pm0005f05f005f05f0f005f05f05f05m0*0*5 m0m000m0m000m0m00m0*m0*m0TEGCholMIMAT0016902 m0*5m0*f0*5m0*0 hsa-miR-42735′Pm0005f0f005f05f05f005f00f05m0*5m0*0 m0m0m00m0m000m0m00m0*m0*m0TEGCholMIMAT0016903 *5m0*f0*0*0 hsa-miR-42745′Pm05f05f005f0005f05f05f05f05f0f00*5m0* m0m0000m00m0m0m0m00*0*m0TEGCholMIMAT0016906 5m0*0*5m0*5m0*0 hsa-miR-42755′Pm0000f00005f00005f00*5m0*0*0*5m0** m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0016905 Chol hsa-miR-4276 5′Pm005f00f005f00f05f000f00*5m0*0*0*f0*m0m0m0m00m0m00m0m0m00*m0*m0TEGChol MIMAT0016904 0*0 hsa-miR-42775′Pm0000f005f05f05f0005f0f00*0*5m0*0*5m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0016908 m0*5m0*0 hsa-miR-42785′Pm0005f05f05f0005f0000f00*5m0*0*0***m0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0016910 hsa-miR-42795′Pm005f00f05f005f05f005f00f05m0*0*0*5 m0m0m00m0m00m00m0m00*m0*m0TEGCholMIMAT0016909 m0*5m0*0*0 hsa-miR-42805′Pm00005f0005f0f05f05f005f05m0*0*0*5mm0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0016911 0*5m0*0*0 hsa-miR-42815′Pm0000f05f005f05f05f005f0f00*0*5m0*5 m0m00m00m00m00m0m0m0*m0*m0TEGCholMIMAT0016907 m0*5m0*5m0*0 hsa-miR-42825′Pm005f05f0f05f05f00f05f05f005f00*5m0*0 m0m0m000m0m000m000*m0*m0TEGCholMIMAT0016912 *0*5m0*5m0*0 hsa-miR-42835′Pm0000f05f005f05f05f005f0f00*0*5m0*5 m0m00m00m00m00m0m0m0*m0*m0TEGCholMIMAT0016914 m0*5m0*5m0*0 hsa-miR-42845′Pm0000f05f005f0f0000f00*0*5m0*0*5m0m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0016915 *0*0 hsa-miR-42855′Pm0000f05f05f005f05f05f05f05f00*0*5m0 m0m0000m0m000m0m0m0*m0*m0TEGCholMIMAT0016913 *0*f0*0*0 hsa-miR-42865′Pm05f05f05f05f00005f05f005f05f05m0*5m m0m00m00m0m0m0m0m000*0*m0TEGCholMIMAT0016916 0*0*0*f0*5m0*0 hsa-miR-42875′Pm005f005f05f05f00f05f05f05f0f05m0*5m m0m0000m0m000m0m00*m0*m0TEGCholMIMAT0016917 0*0*0*5m0*0*0 hsa-miR-42885′Pm05f000f005f00f005f00f00*0*0*0*5m0*m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0016918 5m0*0 hsa-miR-42895′Pm05f05f00f005f05f05f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGCholMIMAT0016920 *0*f0*0*0 hsa-miR-4295′Pm005f05f05f05f05f00f00005f05m0*5m0* m0m0m0m0m0m0m000m000*m0*m0TEGCholMIMAT0001536 0*0*f0*5m0*0 hsa-miR-42905′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGCholMIMAT0016921 m0*5m0*5m0*5m0*0 hsa-miR-42915′Pm0000f005f005f05f05f005f00*0*5m0*5mm0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016922 0*5m0*5m0*0 hsa-miR-42925′Pm05f000f005f00f005f00f00*0*0*0*5m0*m0m0m00m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0016919 5m0*0 hsa-miR-42935′Pm0000f005f00f05f05f005f00*0*0*5m0*5m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016848 m0*5m0*0 hsa-miR-42945′Pm0005f0f005f00f00005f00*0*5m0*5m0*m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0016849 5m0*5m0*0 hsa-miR-42955′Pm0005f0f005f005f0005f05f00*0*5m0*5mm0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0016844 0*f0*0*0 hsa-miR-42965′Pm05f05f05f05f0005f05f05f05f00f00*5m0* m0m0m000m00m0m0m000*0*m0TEGCholMIMAT0016845 5m0*5m0*5m0*0*0 hsa-miR-42975′Pm05f005f05f0005f05f005f00f05m0*0*0*0m0m0m00m0m00m0m0m00m0*0*m0TEGChol MIMAT0016846 *f0*0*0 hsa-miR-42985′Pm0005f0f0000f05f05f05f0f05m0*5m0*0* m0m0000m0m0m0m0m00m0*m0*m0TEGCholMIMAT0016852 5m0*f0*5m0*0 hsa-miR-42995′Pm0000f05f05f05f0f05f0005f00*0*0*0***m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0016851 hsa-miR-43005′Pm005f005f05f005f05f05f0005f00*0*5m0*m0m0m0m00m00m00m0m00*m0*m0TEGChol MIMAT0016853 5m0*f0*5m0*0 hsa-miR-43015′Pm05f05f00f0005f05f0000f05m0*0*5m0*0m0m0m0m0m0m00m0m0m0m00*0*m0TEGChol MIMAT0016850 *f0*5m0*0 hsa-miR-43025′Pm05f05f05f05f005f005f05f005f05f05m0*0 m0m00m00m0m00m0m000*0*m0TEGCholMIMAT0016855 *5m0*5m0*5m0*5m0*0 hsa-miR-43035′Pm0005f0f05f0005f005f05f05f05m0*5m0* m0m000m0m0m0m00m00m0*m0*m0TEGCholMIMAT0016856 5m0*5m0*5m0** hsa-miR-43045′Pm0000f005f00f005f00f05m0*0*0*0*f0*0m0m0m00m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016854 *0 hsa-miR-43055′Pm005f05f0f05f05f00f05f05f005f05m0*0*0 m0m0m000m0m000m000*m0*m0TEGCholMIMAT0016857 *0*5m0*0*0 hsa-miR-43065′Pm005f05f05f005f00f005f05f05f00*0*5m0 m0m000m0m0m00m0m000*m0*m0TEGCholMIMAT0016858 *5m0*5m0*5m0*0 hsa-miR-43075′Pm05f005f0f005f05f05f0005f05f05m0*5m0 m0m00m0m0m000m0m00m0*0*m0TEGCholMIMAT0016860 *5m0*0*5m0*5m0*0 hsa-miR-43085′Pm005f00f05f005f05f005f05f0f00*5m0*0* m0m000m0m00m00m0m00*m0*m0TEGCholMIMAT0016861 5m0*5m0*0* hsa-miR-43095′Pm0005f05f05f05f00f05f05f05f0f05m0*0*5 m0m0000m0m000m00m0*m0*m0TEGCholMIMAT0016859 m0*5m0*5m0*5m0*0 hsa-miR-4315′Pm0000f05f000f05f000f00*0*0*0*f0*0*m0m0m0m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0001625 hsa-miR-431*5′Pm00005f05f05f05f05f05f05f00f00*5m0*5 m0m0m000m0000m0m0m0*m0*m0TEGCholMIMAT0004757 m0*5m0*5m0*5m0*0 hsa-miR-43105′Pm0000f05f005f05f05f005f0f00*5m0*0*5 m0m00m00m00m00m0m0m0*m0*m0TEGCholMIMAT0016862 m0*f0*0*0 hsa-miR-43115′Pm005f05f0f05f005f05f05f005f05f05m0*5 m0m00m00m00m00m000*m0*m0TEGCholMIMAT0016863 m0*0*0*5m0*5m0*0 hsa-miR-43125′Pm05f05f005f0000f05f05f05f0f05m0*5m0* m0m0000m0m0m0m0m0m00*0*m0TEGCholMIMAT0016864 5m0*5m0*f0*0*0 hsa-miR-43135′Pm005f05f0f0005f05f0005f05f00*5m0*0*0m0m00m0m0m00m0m0m000*m0*m0TEGChol MIMAT0016865 *f0*0*0 hsa-miR-43145′Pm05f000f005f05f0f05f0005f05m0*0*5m0 m0m0m0m00m000m0m0m0m0*0*m0TEGCholMIMAT0016868 *5m0*5m0*5m0*0 hsa-miR-43155′Pm05f000f005f05f0f0000f00*5m0*0*5m0*m0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0016866 5m0*5m0*0 hsa-miR-43165′Pm005f05f0f005f005f05f05f005f05m0*0*0 m0m0m000m0m00m0m000*m0*m0TEGCholMIMAT0016867 *5m0*5m0*5m0*0 hsa-miR-43175′Pm05f005f0f0005f05f05f000f05m0*5m0*5 m0m0m0m00m00m0m0m00m0*0*m0TEGCholMIMAT0016872 m0*0*** hsa-miR-43185′Pm05f05f00f005f05f05f0000f00*5m0*0*0*m0m0m0m0m0m000m0m0m00*0*m0TEGChol MIMAT0016869 f0*0* hsa-miR-43195′Pm05f05f00f005f05f05f0000f05m0*5m0*0 m0m0m0m0m0m000m0m0m00*0*m0TEGCholMIMAT0016870 *0*f0*0*0 hsa-miR-4325′Pm005f05f05f05f05f05f05f005f05f05f00*5 m0m000m0m0000m000*m0*m0TEGCholMIMAT0002814 m0*0**** hsa-miR-432*5′Pm05f05f005f005f05f0f05f000f05m0*0*5m m0m0m0m00m000m0m0m00*0*m0TEGCholMIMAT0002815 0*5m0*5m0*0*0 hsa-miR-43205′Pm05f0005f0000f005f05f0f05m0*5m0*5m m0m000m0m0m0m0m0m0m0m0*0*m0TEGCholMIMAT0016871 0*5m0*f0*0*0 hsa-miR-43215′Pm0000f05f05f00f0000f05m0*0*5m0*5m0m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0016874 *f0*0*0 hsa-miR-43225′Pm0005f0f0005f05f005f00f00*0*5m0*0*5m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0016873 m0*0*0 hsa-miR-43235′Pm0000f05f005f05f05f005f0f00*5m0*0*5 m0m00m00m00m00m0m0m0*m0*m0TEGCholMIMAT0016875 m0*f0*0*0 hsa-miR-43245′Pm05f05f005f0005f0f05f000f05m0*0*5m0 m0m0m0m00m00m0m0m0m00*0*m0TEGCholMIMAT0016876 *5m0*5m0*5m0*0 hsa-miR-43255′Pm00005f005f00f05f0005f00*0*0*0*f0**m0m0m0m00m0m00m0m0m0m0*m0*m0TEGChol MIMAT0016887 hsa-miR-43265′Pm0005f05f005f05f0f05f0005f00*5m0*5m m0m0m0m00m000m0m00m0*m0*m0TEGCholMIMAT0016888 0*0*f0*5m0*0 hsa-miR-43275′Pm05f000f005f00f0000f00*0*0*0*f0*0*0m0m0m0m0m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0016889 hsa-miR-43285′Pm05f000f05f000f005f05f05f05m0*0*5m0 m0m000m0m0m0m00m0m0m0*0*m0TEGCholMIMAT0016926 *0*5m0*0*0 hsa-miR-43295′Pm05f0005f005f05f0f05f000f00*5m0*0*5 m0m0m0m00m000m0m0m0m0*0*m0TEGCholMIMAT0016923 m0*5m0*5m0*0 hsa-miR-4335′Pm05f05f005f00005f005f05f05f05m0*5m0 m0m000m0m0m0m0m0m0m00*0*m0TEGCholMIMAT0001627 *5m0*0*f0*5m0*0 hsa-miR-43305′Pm005f005f0005f0f05f0005f05m0*5m0*0*m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0016924 5m0*5m0*0*0 hsa-miR-4485′Pm05f05f00f05f0005f005f00f00*0*0*0*5mm0m0m00m0m0m0m00m0m00*0*m0TEGChol MIMAT0001532 0** hsa-miR-449a5′Pm005f005f0005f0f05f0005f05m0*5m0*0*m0m0m0m00m00m0m0m0m00*m0*m0TEGChol MIMAT0001541 5m0*f0*5m0*0hsa-miR-449b 5′Pm0005f05f0005f05f005f00f00*0*5m0*0*m0m0m00m0m00m0m0m00m0*m0*m0TEGChol MIMAT0003327 5m0*0*0 hsa-miR-449b*5′Pm05f005f0f05f0005f0000f05m0*0*0*0*5m0m0m0m0m0m0m0m00m00m0*0*m0TEGChol MIMAT0009203 m0*5m0*0 hsa-miR-449c5′Pm0000f05f005f05f05f05f05f05f05m0*0*0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0010251 *0*5m0*0*0 hsa-miR-449c*5′Pm0005f05f05f005f05f00005f05m0*0*0*5m0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0013771 m0*f0*5m0*0 hsa-miR-450a5′Pm0005f0f05f05f00f05f05f00f05m0*0*0*0 m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0001545 *5m0*5m0*0 hsa-miR-450b-3p5′Pm05f005f0f05f05f05f0f05f05f05f0f00*5m m0m0000m0000m00m0*0*m0TEGCholMIMAT0004910 0*5m0*5m0*5m0*5m0*0 hsa-miR-450b-5p5′Pm05f005f0f05f005f0f05f0005f00*0*5m0* m0m0m0m00m00m00m00m0*0*m0TEGCholMIMAT0004909 0*f0*5m0*0 hsa-miR-4515′Pm05f05f05f05f05f05f05f0f05f05f005f05m m0m0m000m0000m000*0*m0TEGCholMIMAT0001631 0*5m0*5m0*5m0*5m0*0*0 hsa-miR-4525′Pm0000f05f0005f00005f00*0*5m0*0*5m0m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0001635 *5m0*0 hsa-miR-452*5′Pm0005f05f0000f0000f00*0*5m0*0*5m0*m0m0m0m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0001636 5m0*0 hsa-miR-4545′Pm005f005f0000f005f00f00*5m0*5m0*5mm0m0m00m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0003885 0*5m0*5m0*0hsa-miR-454* 5′Pm05f05f00f05f05f05f05f05f05f05f05f00*0m0m0000m0000m0m00*0*m0TEGChol MIMAT0003884 *5m0*5m0*f0*0*0hsa-miR-455-3p 5′Pm00005f05f005f05f05f005f0f00*5m0*0*0m0m00m00m00m00m0m0m0*m0*m0TEGChol MIMAT0004784 *f0*5m0*0 hsa-miR-455-5p5′Pm05f000f0000f05f0005f05m0*0*5m0*5mm0m0m0m00m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003150 0*f0*0*0 hsa-miR-4665′Pm0000f005f05f0f0000f00*0*5m0*0*5m0m0m0m0m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0015002 *0*0 hsa-miR-483-3p5′Pm0000f05f0005f00005f05m0*0*5m0*0*5m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0002173 m0*0*0 hsa-miR-483-5p5′Pm05f05f00f05f000f05f005f05f05m0*0*5m m0m00m00m0m0m00m0m00*0*m0TEGCholMIMAT0004761 0*5m0*f0*0*0 hsa-miR-4845′Pm05f05f05f0f05f005f05f05f0005f05m0*5 m0m0m0m00m00m00m000*0*m0TEGCholMIMAT0002174 m0*5m0*0*5m0*5m0*0 hsa-miR-485-3p5′Pm0005f05f05f05f05f05f05f05f05f05f00*0 m0m0000m0000m00m0*m0*m0TEGCholMIMAT0002176 *0*0*5m0*0*0 hsa-miR-485-5p5′Pm05f05f05f0f05f005f05f05f05f05f05f00*0 m0m0000m00m00m000*0*m0TEGCholMIMAT0002175 *0*0*5m0*0*0 hsa-miR-486-3p5′Pm0005f05f005f00f05f05f05f05f05m0*5m0 m0m0000m0m00m0m00m0*m0*m0TEGCholMIMAT0004762 *0*0*f0*0*0 hsa-miR-486-5p5′Pm00005f05f05f05f0f0005f0f00*0*0*0*f0*m0m00m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0002177 5m0*0 hsa-miR-487a5′Pm005f05f05f05f000f00005f00*5m0*5m0*m0m0m0m0m0m0m0m00m000*m0*m0TEGChol MIMAT0002178 0*5m0*5m0*0 hsa-miR-487b5′Pm0000f005f05f0f0005f05f00*5m0*5m0*5m0m00m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0003180 m0*5m0** hsa-miR-4885′Pm05f05f05f0f05f05f005f05f05f05f0f05m0 m0m0000m0m000m000*0*m0TEGCholMIMAT0004763 *5m0*5m0*0*5m0*0*0 hsa-miR-488*5′Pm005f05f0f05f000f05f005f0f00*5m0*0*0 m0m00m00m0m0m00m000*m0*m0TEGCholMIMAT0002804 *5m0*5m0*0 hsa-miR-4895′Pm0005f0f05f05f05f05f00005f00*5m0*5m m0m0m0m0m0m0000m00m0*m0*m0TEGCholMIMAT0002805 0*5m0*f0*0*0 hsa-miR-490-3p5′Pm0005f0f0000f05f05f005f00*0*5m0*5m0m0m0m000m0m0m0m0m00m0*m0*m0TEGChol MIMAT0002806 *f0*5m0*0 hsa-miR-490-5p5′Pm005f05f05f05f05f005f0005f05f05m0*5m m0m00m0m0m0m000m000*m0*m0TEGCholMIMAT0004764 0*5m0*0*f0*5m0*0 hsa-miR-491-3p5′Pm05f005f0f0000f0000f00*0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0004765 m0*5m0*0 hsa-miR-491-5p5′Pm05f0005f005f00f05f05f05f0f00*5m0*0* m0m0000m0m00m0m0m0m0*0*m0TEGCholMIMAT0002807 0*f0** hsa-miR-492 5′Pm0005f05f0005f0f05f005f05f05m0*0*5mm0m00m00m00m0m0m00m0*m0*m0TEGChol MIMAT0002812 0*0*f0*0*0 hsa-miR-4935′Pm0005f05f0000f0005f0f00*5m0*5m0*0*m0m00m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0003161 5m0*0*0 hsa-miR-493*5′Pm05f05f05f0f0005f05f0000f00*5m0*0*0*m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0002813 ** hsa-miR-4945′Pm05f05f00f05f005f0f0000f05m0*0*0*5m m0m0m0m0m0m00m00m0m00*0*m0TEGCholMIMAT0002816 0*f0*0*0 hsa-miR-4955′Pm005f005f05f005f05f005f05f0f05m0*5m0 m0m000m0m00m00m0m00*m0*m0TEGCholMIMAT0002817 *0*5m0*5m0*0*0 hsa-miR-4965′Pm05f0005f005f005f05f05f00f00*0*5m0*0m0m0m000m0m00m0m0m0m0*0*m0TEGChol MIMAT0002818 *** hsa-miR-4975′Pm05f05f05f05f05f000f0005f05f00*5m0*5 m0m00m0m0m0m0m00m000*0*m0TEGCholMIMAT0002820 m0*5m0*f0*5m0*0 hsa-miR-497*5′Pm0005f0f05f05f05f05f00005f05m0*0*0*5m0m0m0m0m0m0000m00m0*m0*m0TEGChol MIMAT0004768 m0*5m0*5m0*0 hsa-miR-4985′Pm05f05f00f005f005f05f05f05f05f00*0*5m m0m0000m0m00m0m0m00*0*m0TEGCholMIMAT0002824 0*5m0*5m0** hsa-miR-499-3p5′Pm0000f0000f00005f00*0*5m0*0*** m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0004772 Chol hsa-miR-499-5p 5′Pm0005f0f005f005f00005f00*0*0*5m0*5m0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002870 m0*0*0 hsa-miR-500a5′Pm05f05f00f05f05f05f05f05f05f05f05f00*0 m0m0000m0000m0m00*0*m0TEGCholMIMAT0004773 *5m0*5m0*f0*0*0 hsa-miR-500a*5′Pm0000f005f005f05f05f05f0f00*0*0*0*f0*m0m0000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0002871 5m0*0 hsa-miR-500b5′Pm0005f0f005f05f0f005f05f05f00*5m0*0* m0m000m0m000m0m00m0*m0*m0TEGCholMIMAT0016925 5m0*f0*0*0 hsa-miR-501-3p5′Pm005f05f05f05f05f05f0f00005f05m0*5m0 m0m0m0m0m0m0000m000*m0*m0TEGCholMIMAT0004774 *0*5m0*f0*0*0 hsa-miR-501-5p5′Pm005f00f05f005f05f005f005f00*0*0*0*5m0m0m00m0m00m00m0m00*m0*m0TEGChol MIMAT0002872 m0*5m0*0 hsa-miR-502-3p5′Pm0000f05f005f0f00005f05m0*0*0*0*f0*m0m0m0m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004775 5m0*0 hsa-miR-502-5p5′Pm005f05f05f005f005f00005f00*5m0*5m0m0m0m0m0m0m0m00m0m000*m0*m0TEGChol MIMAT0002873 *5m0*f0*0*0 hsa-miR-5035′Pm05f05f005f05f05f005f005f05f05f05m0*0 m0m000m0m0m000m0m00*0*m0TEGCholMIMAT0002874 *5m0*0*f0*5m0*0 hsa-miR-5045′Pm005f005f05f05f005f05f005f05f00*5m0* m0m00m00m0m000m0m00*m0*m0TEGCholMIMAT0002875 5m0*0*f0*5m0*0 hsa-miR-5055′Pm005f05f0f00005f05f05f005f00*0*0*0*f0m0m0m000m0m0m0m0m000*m0*m0TEGChol MIMAT0002876 *5m0*0 hsa-miR-505*5′Pm005f005f05f005f0f005f05f0f05m0*5m0* m0m000m0m00m00m0m00*m0*m0TEGCholMIMAT0004776 5m0*0*f0*0*0 hsa-miR-5065′Pm005f05f05f05f05f00f05f005f0f00*0*0*0 m0m00m00m0m000m000*m0*m0TEGCholMIMAT0002878 *f0*5m0*0 hsa-miR-5075′Pm05f0005f05f0005f05f05f05f05f00*5m0* m0m0000m0m0m00m0m0m0*0*m0TEGCholMIMAT0002879 5m0*5m0*5m0** hsa-miR-508-3p5′Pm05f05f05f05f05f005f0f05f05f00f00*0*0* m0m0m000m00m00m000*0*m0TEGCholMIMAT0002880 5m0*5m0*5m0*0 hsa-miR-508-5p5′Pm005f05f0f05f000f05f0005f00*0*5m0*0*m0m0m0m00m0m0m00m000*m0*m0TEGChol MIMAT0004778 f0*5m0*0 hsa-miR-509-3-5p5′Pm005f005f05f05f05f05f05f05f05f05f00*5 m0m0000m0000m0m00*m0*m0TEGCholMIMAT0004975 m0*5m0*5m0*5m0*5m0* hsa-miR-509-3p5′Pm05f000f0000f0000f05m0*5m0*5m0*0*fm0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0002881 0*5m0*0 hsa-miR-509-5p5′Pm005f05f05f0000f00005f00*0*5m0*0*f0m0m0m0m0m0m0m0m0m0m000*m0*m0TEGChol MIMAT0004779 *5m0*0 hsa-miR-5105′Pm05f05f005f005f05f0f005f05f05f00*5m0* m0m000m0m000m0m0m00*0*m0TEGCholMIMAT0002882 5m0*0*f0*0*0 hsa-miR-5115′Pm005f05f05f05f05f05f05f005f00f05m0*0* m0m0m00m0m0000m000*m0*m0TEGCholMIMAT0002808 5m0*5m0*f0*5m0*0 hsa-miR-512-3p5′Pm005f05f0f05f005f05f05f05f05f05f05m0* m0m0000m00m00m000*m0*m0TEGCholMIMAT0002823 5m0*5m0*5m0*5m0*0*0 hsa-miR-512-5p5′Pm005f05f05f05f05f05f05f05f005f05f00*0 m0m00m00m0000m000*m0*m0TEGCholMIMAT0002822 *0*0*f0*5m0*0 hsa-miR-513a-3p5′Pm005f00f05f05f00f05f05f00f05m0*5m0*0 m0m0m000m0m000m0m00*m0*m0TEGCholMIMAT0004777 *0*f0*0*0 hsa-miR-513a-5p5′Pm05f05f05f0f05f000f05f000f00*0*5m0*5 m0m0m0m00m0m0m00m000*0*m0TEGCholMIMAT0002877 m0*5m0*5m0*0 hsa-miR-513b5′Pm0005f05f05f000f005f05f0f05m0*5m0*0 m0m000m0m0m0m00m00m0*m0*m0TEGCholMIMAT0005788 *0*f0*0*0 hsa-miR-513c5′Pm05f005f05f05f05f05f05f005f05f05f05m0 m0m000m0m0000m00m0*0*m0TEGCholMIMAT0005789 *0*5m0*0*f0*5m0*0 hsa-miR-5145′Pm05f000f05f05f00f005f05f0f05m0*0*5m0 m0m000m0m0m000m0m0m0*0*m0TEGCholMIMAT0002883 *5m0*f0*5m0*0 hsa-miR-514b-3p5′Pm05f000f0005f0f05f000f00*0*0*0*5m0*m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0015088 5m0*0 hsa-miR-514b-5p5′Pm05f0005f05f000f005f05f0f05m0*0*0*5 m0m000m0m0m0m00m0m0m0*0*m0TEGCholMIMAT0015087 m0*5m0*0*0 hsa-miR-515-3p5′Pm0005f0f005f05f05f0000f00*5m0*5m0*5m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0002827 m0*f0*5m0*0hsa-miR-515-5p 5′Pm05f05f05f05f0000f05f05f05f05f05m0*5m0m0000m0m0m0m0m000*0*m0TEGChol MIMAT0002826 m0*5m0*5m0*5m0**hsa-miR-516a-3p 5′Pm005f00f005f05f05f05f05f00f00*0*5m0*m0m0m000m000m0m0m00*m0*m0TEGChol MIMAT0006778 0*f0*0* hsa-miR-516a-5p5′Pm0000f005f00f05f05f005f00*0*5m0*5m0m0m0m000m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004770 *5m0*5m0*0 hsa-miR-516b5′Pm0000f005f05f0f05f0005f05m0*0*5m0*5m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0002859 m0*5m0*5m0*0hsa-miR-516b* 5′Pm05f05f05f0f05f05f05f05f005f05f05f00*5m0m000m0m0000m000*0*m0TEGChol MIMAT0002860 m0*5m0*5m0*5m0*5m0*0hsa-miR-517* 5′Pm05f000f005f05f05f0000f05m0*5m0*5mm0m0m0m0m0m000m0m0m0m0*0*m0TEGChol MIMAT0002851 0*5m0*f0** hsa-miR-517a5′Pm05f05f05f05f05f05f05f0f05f005f0f00*0* m0m00m00m0000m000*0*m0TEGCholMIMAT0002852 5m0*0*5m0*5m0*0 hsa-miR-517b5′Pm05f005f05f05f05f05f05f05f05f05f05f05 m0m0000m0000m00m0*0*m0TEGCholMIMAT0002857 m0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-517c5′Pm05f0005f005f05f0f0005f0f05m0*0*0*5 m0m00m0m0m000m0m0m0m0*0*m0TEGCholMIMAT0002866 m0*5m0*5m0*0 hsa-miR-518a-3p5′Pm0005f0f005f05f05f05f05f00f05m0*5m0* m0m0m000m000m0m00m0*m0*m0TEGCholMIMAT0002863 0*5m0*f0*0*0 hsa-miR-518a-5p5′Pm05f000f005f05f05f05f05f00f00*0*5m0* m0m0m000m000m0m0m0m0*0*m0TEGCholMIMAT0005457 5m0*5m0*5m0*0 hsa-miR-518b5′Pm05f0005f00005f005f00f00*5m0*0*0*f0m0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0002844 *5m0*0 hsa-miR-518c5′Pm005f05f05f005f05f05f005f005f05m0*5m m0m0m00m0m000m0m000*m0*m0TEGCholMIMAT0002848 0*0*5m0*5m0*0*0 hsa-miR-518c*5′Pm005f05f0f05f0005f05f005f05f05m0*5m0 m0m00m00m0m0m00m000*m0*m0TEGCholMIMAT0002847 *5m0*0*5m0*0*0 hsa-miR-518d-3p5′Pm05f0005f05f05f005f00005f05m0*0*0*5m0m0m0m0m0m0m000m0m0m0*0*m0TEGChol MIMAT0002864 m0*f0*0*0hsa-miR-518d-5p 5′Pm005f005f00005f0005f0f00*5m0*5m0*0m0m00m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0005456 *5m0*0*0 hsa-miR-518e5′Pm005f00f05f05f05f05f05f05f005f05m0*5 m0m0m000m0000m0m00*m0*m0TEGCholMIMAT0002861 m0*5m0*5m0*f0*5m0*0 hsa-miR-518e*5′Pm005f005f005f05f0f05f0005f05m0*0*5m m0m0m0m00m000m0m0m00*m0*m0TEGCholMIMAT0005450 0*5m0*5m0*5m0*0 hsa-miR-518f5′Pm0005f05f05f05f00f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0002842 5m0*5m0*0*0 hsa-miR-518f*5′Pm0005f05f005f00f0005f05f05m0*0*0*0*fm0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002841 0*5m0* hsa-miR-519a5′Pm0005f05f05f05f05f0f05f000f05m0*0*0* m0m0m0m00m0000m00m0*m0*m0TEGCholMIMAT0002869 0*5m0*0*0 hsa-miR-519a*5′Pm00005f05f05f05f0f05f0005f00*5m0*5m m0m0m0m00m0000m0m0m0*m0*m0TEGCholMIMAT0005452 0*5m0*5m0*5m0*0 hsa-miR-519b-3p5′Pm005f05f0f05f005f05f0000f00*5m0*5m0 m0m0m0m0m0m00m00m000*m0*m0TEGCholMIMAT0002837 *0*f0*5m0*0 hsa-miR-519b-5p5′Pm0005f05f005f05f0f0000f05m0*5m0*0*0m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0005454 *f0*0*0 hsa-miR-519c-3p5′Pm05f005f0f05f05f05f0f005f05f05f00*0*5 m0m000m0m0000m00m0*0*m0TEGCholMIMAT0002832 m0*5m0*f0*5m0*0 hsa-miR-519c-5p5′Pm05f05f05f0f0005f05f05f000f05m0*5m0* m0m0m0m00m00m0m0m000*0*m0TEGCholMIMAT0002831 5m0*0*5m0*0*0 hsa-miR-519d5′Pm05f0005f05f05f05f0f05f05f00f00*5m0*0 m0m0m000m0000m0m0m0*0*m0TEGCholMIMAT0002853 *5m0*5m0*0*0 hsa-miR-519e5′Pm05f05f05f05f0005f05f005f05f0f00*0*0* m0m000m0m00m0m0m000*0*m0TEGCholMIMAT0002829 0*5m0*0*0 hsa-miR-519e*5′Pm005f05f05f05f005f0f0005f05f00*5m0*5 m0m00m0m0m00m00m000*m0*m0TEGCholMIMAT0002828 m0*0*5m0*0*0 hsa-miR-520a-3p5′Pm005f00f00005f05f000f00*5m0*5m0*0*m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0002834 5m0*0*0 hsa-miR-520a-5p5′Pm0000f05f0005f005f05f0f00*0*0*5m0*f0m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0002833 *0*0 hsa-miR-520b5′Pm005f00f05f05f05f05f05f05f005f05m0*5 m0m0m000m0000m0m00*m0*m0TEGCholMIMAT0002843 m0*5m0*5m0*f0*5m0*0 hsa-miR-520c-3p5′Pm05f005f0f00005f05f000f00*0*5m0*5m0m0m0m0m00m0m0m0m0m00m0*0*m0TEGChol MIMAT0002846 *f0*5m0*0hsa-miR-520c-5p 5′Pm00005f005f05f05f05f05f05f05f05m0*0*m0m0000m000m0m0m0m0*m0*m0TEGChol MIMAT0005455 5m0*5m0*5m0*5m0*0hsa-miR-520d-3p 5′Pm05f05f05f05f005f05f05f005f05f05f05m0m0m000m0m000m0m000*0*m0TEGChol MIMAT0002856 *0*0*5m0*f0*0*0hsa-miR-520d-5p 5′Pm0000f05f05f05f05f05f000f05m0*5m0*5m0m0m0m00m0000m0m0m0*m0*m0TEGChol MIMAT0002855 m0*5m0*f0*0*0hsa-miR-520e 5′Pm005f05f0f05f05f005f05f05f05f0f00*0*5m0m0000m0m000m000*m0*m0TEGChol MIMAT0002825 m0*0*f0*0*0 hsa-miR-520f5′Pm0000f0000f05f05f00f00*5m0*5m0*5m0m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0002830 *f0*5m0*0 hsa-miR-520g5′Pm005f00f05f05f05f05f005f05f0f00*0*5m0 m0m000m0m0000m0m00*m0*m0TEGCholMIMAT0002858 *0*5m0*5m0*0 hsa-miR-520h5′Pm00005f05f000f05f05f05f0f00*0*5m0*0*m0m0000m0m0m00m0m0m0*m0*m0TEGChol MIMAT0002867 5m0*5m0*0 hsa-miR-5215′Pm0000f0000f0005f05f00*0*5m0*5m0*5m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0002854 m0*0*0 hsa-miR-5225′Pm00005f05f005f0f005f05f0f00*0*5m0*0*m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0002868 5m0*5m0*0 hsa-miR-522*5′Pm00005f05f000f05f005f0f05m0*0*5m0*5m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0005451 m0*f0*0*0 hsa-miR-5235′Pm05f005f05f005f05f05f0000f00*5m0*0*5m0m0m0m0m0m000m0m00m0*0*m0TEGChol MIMAT0002840 m0*f0*5m0*0 hsa-miR-523*5′Pm05f000f0005f05f05f05f05f05f00*0*0*0*m0m0000m00m0m0m0m0m0*0*m0TEGChol MIMAT0005449 5m0*5m0*0 hsa-miR-524-3p5′Pm0005f05f005f05f05f00005f00*5m0*0*0m0m0m0m0m0m000m0m00m0*m0*m0TEGChol MIMAT0002850 *5m0*5m0*0hsa-miR-524-5p 5′Pm05f05f00f05f005f05f005f005f00*5m0*5m0m0m00m0m00m00m0m00*0*m0TEGChol MIMAT0002849 m0*0*f0*0*0 hsa-miR-525-3p5′Pm0005f05f005f05f0f005f05f0f00*0*0*0*fm0m000m0m000m0m00m0*m0*m0TEGChol MIMAT0002839 0*5m0*0 hsa-miR-525-5p5′Pm0005f0f05f05f005f05f005f0f00*5m0*5m m0m00m00m0m000m00m0*m0*m0TEGCholMIMAT0002838 0*0*f0*0*0 hsa-miR-526a5′Pm05f05f00f005f00f0005f05f05m0*5m0*5 m0m00m0m0m0m00m0m0m00*0*m0TEGCholMIMAT0002845 m0*0*f0*0*0 hsa-miR-526b5′Pm005f05f05f0005f05f05f05f00f00*0*0*5 m0m0m000m00m0m0m000*m0*m0TEGCholMIMAT0002835 m0*f0*5m0*0 hsa-miR-526b*5′Pm005f05f05f05f05f05f0f005f00f05m0*0*0 m0m0m00m0m0000m000*m0*m0TEGCholMIMAT0002836 *0*5m0*5m0*0 hsa-miR-5275′Pm0005f0f005f00f00005f05m0*5m0*0*5mm0m0m0m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0002862 0*5m0*5m0*0hsa-miR-532-3p 5′Pm005f05f05f0000f005f05f0f00*0*0*5m0*m0m000m0m0m0m0m0m000*m0*m0TEGChol MIMAT0004780 5m0*5m0*0 hsa-miR-532-5p5′Pm005f005f05f000f005f00f00*0*0*0*f0*0m0m0m00m0m0m0m00m0m00*m0*m0TEGChol MIMAT0002888 *0 hsa-miR-5395′Pm00005f05f005f05f05f05f005f00*0*0*0*m0m0m000m00m00m0m0m0*m0*m0TEGChol MIMAT0003163 5m0*5m0*0 hsa-miR-5415′Pm005f00f0000f00005f00*0*0*5m0*5m0*m0m0m0m0m0m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004920 5m0*0 hsa-miR-541*5′Pm005f005f00005f05f05f05f0f00*0*0*0*f0m0m0000m0m0m0m0m0m00*m0*m0TEGChol MIMAT0004919 *0*0 hsa-miR-542-3p5′Pm00005f05f05f05f0f05f05f05f05f05m0*5 m0m0000m0000m0m0m0*m0*m0TEGCholMIMAT0003389 m0*5m0*0*f0*0*0 hsa-miR-542-5p5′Pm0005f0f05f005f0f005f005f00*0*0*5m0*m0m0m00m0m00m00m00m0*m0*m0TEGChol MIMAT0003340 f0*5m0*0 hsa-miR-5435′Pm05f05f00f0005f05f0005f05f05m0*5m0* m0m00m0m0m00m0m0m0m00*0*m0TEGCholMIMAT0004954 0*0*5m0*0*0 hsa-miR-5445′Pm0005f0f0000f0005f05f00*0*0*0*f0*0*0m0m00m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0003164 hsa-miR-544b5′Pm005f05f0f0005f0f005f00f00*0*0*0*f0*0m0m0m00m0m00m0m0m000*m0*m0TEGChol MIMAT0015004 *0 hsa-miR-5455′Pm0000f005f05f0f0000f00*5m0*0*0*f0*0m0m0m0m0m0m000m0m0m0m0*m0*m0TEGChol MIMAT0003165 *0 hsa-miR-545*5′Pm05f000f0000f00005f00*0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004785 m0*5m0*0hsa-miR-548a-3p 5′Pm0000f05f0005f05f005f0f00*5m0*5m0*5m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003251 m0*5m0*5m0*0hsa-miR-548a-5p 5′Pm0000f005f05f0f05f0005f05m0*0*5m0*5m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0004803 m0*5m0*5m0*0hsa-miR-548aa 5′Pm05f05f005f0000f00005f00*5m0*5m0*0m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0018447 *5m0** hsa-miR-548b-3p5′Pm05f0005f005f05f05f005f005f05m0*5m0 m0m0m00m0m000m0m0m0m0*0*m0TEGCholMIMAT0003254 *5m0**** hsa-miR-548b-5p5′Pm0000f05f0005f05f005f05f00*5m0*5m0*m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0004798 5m0*5m0*5m0*0hsa-miR-548c-3p 5′Pm0000f0000f05f05f00f00*5m0*0*5m0*f0m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003285 ** hsa-miR-548c-5p5′Pm0000f005f05f0f05f0005f05m0*0*5m0*5m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0004806 m0*5m0*5m0*0hsa-miR-548d-3p 5′Pm0005f0f005f05f0f05f000f05m0*0*0*0*5m0m0m0m00m000m0m00m0*m0*m0TEGChol MIMAT0003323 m0*5m0*0 hsa-miR-548d-5p5′Pm005f005f05f05f00f0000f00*5m0*0*0*f0m0m0m0m0m0m0m000m0m00*m0*m0TEGChol MIMAT0004812 *0*0 hsa-miR-548e5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0005874 *5m0*5m0*f0*5m0*0 hsa-miR-548f5′Pm05f05f005f0000f00005f00*5m0*5m0*0m0m0m0m0m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0005895 *5m0*5m0*0 hsa-miR-548g5′Pm0000f0000f00005f00*0*5m0*5m0*f0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0005912 *0 Chol hsa-miR-548h5′Pm005f05f05f05f005f05f05f05f05f05f05m0 m0m0000m00m00m000*m0*m0TEGCholMIMAT0005928 *0*0*0*5m0*0*0 hsa-miR-548i5′Pm05f05f05f0f05f05f05f05f05f05f05f0f00* m0m0000m0000m000*0*m0TEGCholMIMAT0005935 0*5m0*0*5m0*5m0*0 hsa-miR-548j5′Pm05f0005f05f05f005f05f05f05f05f00*0*5 m0m0000m0m000m0m0m0*0*m0TEGCholMIMAT0005875 m0*5m0*5m0*5m0*0 hsa-miR-548k5′Pm005f05f05f05f005f05f05f05f05f0f05m0* m0m0000m00m00m000*m0*m0TEGCholMIMAT0005882 5m0*5m0*5m0*5m0*0* hsa-miR-548l5′Pm005f05f05f05f05f05f0f005f05f05f05m0* m0m000m0m0000m000*m0*m0TEGCholMIMAT0005889 0*0*0*5m0*5m0*0 hsa-miR-548m5′Pm05f05f05f05f0000f00005f00*5m0*5m0*m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0005917 0*5m0*5m0*0 hsa-miR-548n5′Pm0005f0f05f05f05f0f05f05f05f05f05m0*0 m0m0000m0000m00m0*m0*m0TEGCholMIMAT0005916 *5m0*5m0*f0*0*0 hsa-miR-548o5′Pm05f05f05f0f0000f005f00f00*0*5m0*0*fm0m0m00m0m0m0m0m0m000*0*m0TEGChol MIMAT0005919 0** hsa-miR-548p5′Pm05f05f00f005f05f05f00005f05m0*5m0* m0m0m0m0m0m000m0m0m00*0*m0TEGCholMIMAT0005934 5m0*5m0*5m0*5m0*0 hsa-miR-548q5′Pm05f05f00f05f005f05f05f05f05f0f05m0*0 m0m0000m00m00m0m00*0*m0TEGCholMIMAT0011163 *0*0*5m0*0*0 hsa-miR-548s5′Pm05f05f05f0f0005f05f00005f00*0*0*5m0m0m0m0m0m0m00m0m0m000*0*m0TEGChol MIMAT0014987 *f0*0*0 hsa-miR-548t5′Pm0000f05f05f05f05f05f0005f00*5m0*5m m0m0m0m00m0000m0m0m0*m0*m0TEGCholMIMAT0015009 0*5m0*f0*0*0 hsa-miR-548u5′Pm05f0005f05f05f005f005f05f05f00*0*5m m0m000m0m0m000m0m0m0*0*m0TEGCholMIMAT0015013 0*5m0*5m0*5m0*0 hsa-miR-548v5′Pm005f05f0f05f005f05f005f05f05f00*5m0* m0m000m0m00m00m000*m0*m0TEGCholMIMAT0015020 5m0*0*f0*0*0 hsa-miR-548w5′Pm00005f05f000f05f005f0f00*0*5m0*0*f0m0m00m00m0m0m00m0m0m0*m0*m0TEGChol MIMAT0015060 *0*0 hsa-miR-548x5′Pm005f00f005f00f05f05f00f05m0*5m0*0* m0m0m000m0m00m0m0m00*m0*m0TEGCholMIMAT0015081 0*f0*5m0*0 hsa-miR-548y5′Pm05f05f00f05f005f05f05f05f05f0f05m0*0 m0m0000m00m00m0m00*0*m0TEGCholMIMAT0018354 *0*0*5m0*0*0 hsa-miR-548z5′Pm00005f0005f0f00005f05m0*5m0*5m0*m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0018446 0*5m0*5m0*0hsa-miR-549 5′Pm05f05f05f05f0000f0000f00*0*5m0*0*f0m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003333 *5m0*0 hsa-miR-550a5′Pm05f05f00f05f05f05f05f0005f05f05m0*0* m0m00m0m0m0000m0m00*0*m0TEGCholMIMAT0004800 0*5m0*5m0*0*0 hsa-miR-550a*5′Pm05f005f0f005f05f05f05f005f0f05m0*0*0 m0m00m00m000m0m00m0*0*m0TEGCholMIMAT0003257 *5m0*f0*5m0*0 hsa-miR-550b5′Pm05f000f05f005f05f05f000f05m0*5m0*5 m0m0m0m00m00m00m0m0m0*0*m0TEGCholMIMAT0018445 m0*5m0*5m0*0*0 hsa-miR-551a5′Pm05f05f00f05f005f05f05f0005f00*0*0*5 m0m0m0m00m00m00m0m00*0*m0TEGCholMIMAT0003214 m0*f0*5m0*0 hsa-miR-551b5′Pm05f05f00f05f0005f0005f0f00*0*0*5m0*m0m00m0m0m0m0m00m0m00*0*m0TEGChol MIMAT0003233 5m0*5m0*0 hsa-miR-551b*5′Pm00005f00005f05f000f05m0*5m0*5m0*m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004794 5m0*5m0*0*0hsa-miR-552 5′Pm0005f0f05f05f05f05f05f05f05f05f05m0*m0m0000m0000m00m0*m0*m0TEGChol MIMAT0003215 0*0*0*f0*5m0*0 hsa-miR-5535′Pm05f05f00f05f05f05f0f0000f00*0*0*5m0 m0m0m0m0m0m0000m0m00*0*m0TEGCholMIMAT0003216 *5m0*5m0*0 hsa-miR-5545′Pm005f05f0f005f005f05f005f0f00*0*5m0* m0m00m00m0m00m0m000*m0*m0TEGCholMIMAT0003217 5m0*f0*0*0 hsa-miR-5555′Pm005f05f0f05f05f00f0000f05m0*5m0*5m m0m0m0m0m0m0m000m000*m0*m0TEGCholMIMAT0003219 0*0*f0*0*0 hsa-miR-556-3p5′Pm0005f05f05f05f00f005f05f05f00*5m0*5 m0m000m0m0m000m00m0*m0*m0TEGCholMIMAT0004793 m0*0*f0*5m0*0 hsa-miR-556-5p5′Pm0000f0000f05f05f00f05m0*0*5m0*0*5m0m0m000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003220 m0*0*0 hsa-miR-5575′Pm05f05f05f05f05f000f05f005f0f00*5m0*5 m0m00m00m0m0m00m000*0*m0TEGCholMIMAT0003221 m0*5m0*5m0*0*0 hsa-miR-5585′Pm0005f05f05f05f05f0f0005f05f05m0*5m0 m0m00m0m0m0000m00m0*m0*m0TEGCholMIMAT0003222 *0*0*5m0*0*0 hsa-miR-5595′Pm05f05f05f0f00005f05f05f05f05f05m0*0* m0m0000m0m0m0m0m000*0*m0TEGCholMIMAT0003223 0*5m0*f0*0*0 hsa-miR-5615′Pm05f005f05f005f05f0f05f05f00f05m0*5m m0m0m000m000m0m00m0*0*m0TEGCholMIMAT0003225 0*5m0*0*5m0*5m0*0 hsa-miR-5625′Pm05f005f05f05f05f05f05f00005f05m0*0* m0m0m0m0m0m0000m00m0*0*m0TEGCholMIMAT0003226 0*0*5m0** hsa-miR-5635′Pm05f000f005f05f0f05f000f05m0*0*0*0*fm0m0m0m00m000m0m0m0m0*0*m0TEGChol MIMAT0003227 0*0*0 hsa-miR-5645′Pm005f00f0005f05f0005f05f00*0*5m0*0*m0m00m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0003228 ** hsa-miR-5665′Pm05f005f05f05f000f05f05f05f0f00*0*0*0 m0m0000m0m0m00m00m0*0*m0TEGCholMIMAT0003230 *5m0*5m0*0 hsa-miR-5675′Pm005f00f05f0005f0005f0f00*5m0*0*0*f0m0m00m0m0m0m0m00m0m00*m0*m0TEGChol MIMAT0003231 *5m0*0 hsa-miR-5685′Pm05f000f00005f0000f00*0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003232 m0*0*0 hsa-miR-5695′Pm05f05f05f05f05f0005f05f05f05f05f05m0 m0m0000m0m0m00m000*0*m0TEGCholMIMAT0003234 *0*5m0*0*f0*5m0*0 hsa-miR-5705′Pm005f05f05f005f05f0f05f005f0f05m0*5m m0m00m00m000m0m000*m0*m0TEGCholMIMAT0003235 0*0*0*f0*0*0 hsa-miR-5715′Pm05f005f05f0000f05f05f05f05f05m0*0*0 m0m0000m0m0m0m0m00m0*0*m0TEGCholMIMAT0003236 *0*f0*0*0 hsa-miR-5725′Pm05f05f00f05f005f05f05f05f05f05f05m0* m0m0000m00m00m0m00*0*m0TEGCholMIMAT0003237 5m0*5m0*5m0*5m0** hsa-miR-5735′Pm05f05f05f05f05f000f0000f00*0*5m0*0*m0m0m0m0m0m0m0m00m000*0*m0TEGChol MIMAT0003238 5m0*5m0*0 hsa-miR-574-3p5′Pm05f05f005f005f00f005f005f00*5m0*0*5m0m0m00m0m0m00m0m0m00*0*m0TEGChol MIMAT0003239 m0*f0*5m0*0hsa-miR-574-5p 5′Pm005f05f05f05f05f05f05f05f05f00f00*0*m0m0m000m0000m000*m0*m0TEGChol MIMAT0004795 0*0*5m0** hsa-miR-5755′Pm05f05f05f05f0000f0000f00*0*0*5m0*f0m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003240 *5m0*0 hsa-miR-576-3p5′Pm005f05f0f005f00f005f05f05f05m0*0*0* m0m000m0m0m00m0m000*m0*m0TEGCholMIMAT0004796 0*f0*0*0 hsa-miR-576-5p5′Pm05f000f05f005f05f05f000f05m0*0*5m0 m0m0m0m00m00m00m0m0m0*0*m0TEGCholMIMAT0003241 *0*5m0*0*0 hsa-miR-5775′Pm0005f05f05f05f05f05f005f05f05f00*0*0 m0m000m0m0000m00m0*m0*m0TEGCholMIMAT0003242 *0*f0*5m0*0 hsa-miR-5785′Pm05f005f05f005f05f05f00005f00*0*0*5mm0m0m0m0m0m000m0m00m0*0*m0TEGChol MIMAT0003243 0*f0*0*0 hsa-miR-5795′Pm05f05f05f0f005f005f005f00f05m0*0*5m m0m0m00m0m0m00m0m000*0*m0TEGCholMIMAT0003244 0*0*f0*0*0 hsa-miR-5805′Pm005f05f05f00005f05f05f05f05f00*0*5m m0m0000m0m0m0m0m000*m0*m0TEGCholMIMAT0003245 0*5m0*5m0*0*0 hsa-miR-5815′Pm0000f05f005f0f005f00f05m0*0*0*5m0*m0m0m00m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003246 f0*5m0*0 hsa-miR-582-3p5′Pm05f05f05f0f0000f05f000f00*0*0*5m0*fm0m0m0m00m0m0m0m0m000*0*m0TEGChol MIMAT0004797 0*5m0*0 hsa-miR-582-5p5′Pm005f05f0f05f005f05f05f0005f05m0*0*5 m0m0m0m00m00m00m000*m0*m0TEGCholMIMAT0003247 m0*5m0*f0*0*0 hsa-miR-5835′Pm05f05f00f05f005f05f0005f0f05m0*0*5m m0m00m0m0m00m00m0m00*0*m0TEGCholMIMAT0003248 0*5m0*5m0*5m0*0 hsa-miR-5845′Pm0000f05f0005f00005f05m0*0*0*0*5m0m0m0m0m0m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003249 ** hsa-miR-5855′Pm05f05f00f05f05f005f05f05f05f0f00*5m0 m0m0000m0m000m0m00*0*m0TEGCholMIMAT0003250 *5m0*5m0*5m0*5m0*0 hsa-miR-5865′Pm05f05f00f05f0005f05f0005f00*5m0*0*0m0m0m0m00m0m0m00m0m00*0*m0TEGChol MIMAT0003252 *f0*5m0*0 hsa-miR-5875′Pm05f000f0000f05f05f05f05f05m0*0*0*0*m0m0000m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003253 f0*5m0*0 hsa-miR-5885′Pm05f005f05f005f05f0f0000f00*5m0*5m0 m0m0m0m0m0m000m0m00m0*0*m0TEGCholMIMAT0003255 *5m0*** hsa-miR-589 5′Pm005f05f0f05f000f05f005f0f05m0*0*5m0m0m00m00m0m0m00m000*m0*m0TEGChol MIMAT0004799 *5m0*** hsa-miR-589*5′Pm005f00f005f05f05f005f05f0f05m0*0*0* m0m000m0m000m0m0m00*m0*m0TEGCholMIMAT0003256 5m0*f0*5m0*0 hsa-miR-590-3p5′Pm0000f00005f05f005f05f00*0*0*0*5m0*m0m00m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0004801 5m0*0 hsa-miR-590-5p5′Pm005f05f0f005f05f05f005f05f0f00*0*5m0 m0m000m0m000m0m000*m0*m0TEGCholMIMAT0003258 *0*5m0*5m0*0 hsa-miR-5915′Pm0000f005f005f05f05f05f0f05m0*0*0*5 m0m0000m0m00m0m0m0m0*m0*m0TEGCholMIMAT0003259 m0*f0*5m0*0 hsa-miR-5925′Pm005f00f0005f0f005f00f00*0*5m0*5m0*m0m0m00m0m00m0m0m0m00*m0*m0TEGChol MIMAT0003260 f0*0*0 hsa-miR-5935′Pm005f005f005f05f05f0005f0f00*0*5m0*5m0m00m0m0m000m0m0m00*m0*m0TEGChol MIMAT0004802 m0*f0*0*0 hsa-miR-593*5′Pm05f05f05f05f00005f0000f05m0*5m0*0*m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003261 5m0*** hsa-miR-5955′Pm05f05f05f0f00005f00005f05m0*0*5m0*m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003263 5m0*f0*0*0 hsa-miR-5965′Pm00005f05f005f05f0005f0f00*5m0*5m0*m0m00m0m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003264 5m0*5m0*0*0 hsa-miR-5975′Pm005f005f05f000f005f00f00*0*0*5m0*f0m0m0m00m0m0m0m00m0m00*m0*m0TEGChol MIMAT0003265 *0*0 hsa-miR-5985′Pm005f00f05f005f05f0005f0f00*0*0*5m0*m0m00m0m0m00m00m0m00*m0*m0TEGChol MIMAT0003266 5m0*5m0*0 hsa-miR-5995′Pm05f000f05f05f005f05f000f00*0*0*5m0*m0m0m0m00m0m000m0m0m0*0*m0TEGChol MIMAT0003267 5m0*0*0 hsa-miR-6005′Pm05f000f05f0005f05f05f05f05f05m0*5m0 m0m0000m0m0m00m0m0m0*0*m0TEGCholMIMAT0003268 *0*5m0*f0*5m0*0 hsa-miR-6015′Pm05f05f05f05f00005f005f05f0f05m0*0*5 m0m000m0m0m0m0m0m000*0*m0TEGCholMIMAT0003269 m0*0*5m0*5m0*0 hsa-miR-6025′Pm05f05f05f0f05f005f0f0005f0f00*0*5m0* m0m00m0m0m00m00m000*0*m0TEGCholMIMAT0003270 5m0*5m0*5m0*0 hsa-miR-6035′Pm05f000f005f005f005f05f05f00*5m0*0*0m0m000m0m0m00m0m0m0m0*0*m0TEGChol MIMAT0003271 *5m0*0*0 hsa-miR-6045′Pm00005f05f05f05f0f05f0005f05m0*5m0* m0m0m0m00m0000m0m0m0*m0*m0TEGCholMIMAT0003272 5m0*5m0*5m0** hsa-miR-6055′Pm05f05f00f05f05f05f05f0005f05f05m0*0* m0m00m0m0m0000m0m00*0*m0TEGCholMIMAT0003273 0*5m0*5m0*5m0*0 hsa-miR-6065′Pm005f05f05f05f05f05f05f05f05f00f00*0* m0m0m000m0000m000*m0*m0TEGCholMIMAT0003274 0*0*5m0** hsa-miR-6075′Pm0000f00005f00005f00*0*0*0*f0*5m0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0003275 Chol hsa-miR-608 5′Pm00005f05f005f05f005f005f05m0*0*0*0m0m0m00m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003276 *f0*5m0* hsa-miR-6095′Pm05f05f005f05f05f05f0f05f0005f00*5m0* m0m0m0m00m0000m0m00*0*m0TEGCholMIMAT0003277 5m0*0*f0*0*0 hsa-miR-6105′Pm05f05f05f05f00005f0000f00*5m0*0*5mm0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0003278 0*5m0*0*0 hsa-miR-6115′Pm0000f0000f0005f05f00*0*0*0*f0*5m0*0m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003279 hsa-miR-6125′Pm05f0005f0005f0f0005f05f00*5m0*5m0*m0m00m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0003280 5m0*5m0*0*0 hsa-miR-6135′Pm00005f0005f0f05f05f05f05f00*0*5m0*0m0m0000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0003281 *f0*5m0*0 hsa-miR-6145′Pm05f05f005f05f05f05f0f05f0005f00*5m0* m0m0m0m00m0000m0m00*0*m0TEGCholMIMAT0003282 5m0*0*f0*0*0 hsa-miR-615-3p5′Pm0000f05f005f0f005f05f0f05m0*0*0*0*fm0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0003283 0*5m0*0 hsa-miR-615-5p5′Pm005f05f0f005f00f05f005f05f00*0*0*5m m0m00m00m0m00m0m000*m0*m0TEGCholMIMAT0004804 0*5m0*0*0 hsa-miR-6165′Pm05f05f005f005f005f05f05f05f05f05m0*5 m0m0000m0m00m0m0m00*0*m0TEGCholMIMAT0004805 m0*0*0*f0*0*0 hsa-miR-616*5′Pm0000f05f005f0f005f05f05f05m0*0*5m0 m0m000m0m00m00m0m0m0*m0*m0TEGCholMIMAT0003284 *5m0*f0*0*0 hsa-miR-6175′Pm0005f0f005f00f0005f0f00*0*0*5m0*5mm0m00m0m0m0m00m0m00m0*m0*m0TEGChol MIMAT0003286 0*5m0*0 hsa-miR-6185′Pm05f05f005f0005f0f05f005f0f05m0*0*5m m0m00m00m00m0m0m0m00*0*m0TEGCholMIMAT0003287 0*5m0*5m0*5m0*0 hsa-miR-6195′Pm005f05f05f005f005f05f0005f00*0*0*0*fm0m0m0m00m0m00m0m000*m0*m0TEGChol MIMAT0003288 0*0*0 hsa-miR-6205′Pm0005f05f05f05f005f05f05f005f05m0*5m m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0003289 0*5m0*5m0*5m0*5m0*0 hsa-miR-6215′Pm05f005f0f05f005f05f05f05f05f05f05m0* m0m0000m00m00m00m0*0*m0TEGCholMIMAT0003290 0*0*0*f0*5m0*0 hsa-miR-6225′Pm05f0005f00005f00005f05m0*0*0*5m0*m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003291 f0*5m0*0 hsa-miR-6235′Pm05f05f005f00005f005f05f0f00*0*0*0*5m0m000m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0003292 m0*0*0 hsa-miR-6245′Pm05f05f005f005f005f05f05f05f05f05m0*5 m0m0000m0m00m0m0m00*0*m0TEGCholMIMAT0004807 m0*0*0*f0*0*0 hsa-miR-624*5′Pm05f005f05f05f05f005f005f05f05f05m0*0 m0m000m0m0m000m00m0*0*m0TEGCholMIMAT0003293 *5m0*0*5m0*5m0*0 hsa-miR-6255′Pm05f05f05f0f05f005f05f005f00f05m0*5m m0m0m00m0m00m00m000*0*m0TEGCholMIMAT0003294 0*5m0*0*f0*5m0*0 hsa-miR-625*5′Pm005f00f005f05f0f00005f05m0*5m0*0*5m0m0m0m0m0m000m0m0m00*m0*m0TEGChol MIMAT0004808 m0*f0*0*0 hsa-miR-6265′Pm05f005f0f05f005f0f05f005f0f00*5m0*5 m0m00m00m00m00m00m0*0*m0TEGCholMIMAT0003295 m0*0*5m0*5m0*0 hsa-miR-6275′Pm05f005f05f05f0005f05f05f05f05f05m0*0 m0m0000m0m0m00m00m0*0*m0TEGCholMIMAT0003296 *5m0*0*5m0*5m0*0 hsa-miR-628-3p5′Pm0000f05f000f05f005f0f05m0*0*5m0*5 m0m00m00m0m0m00m0m0m0*m0*m0TEGCholMIMAT0003297 m0*f0*0*0 hsa-miR-628-5p5′Pm0005f0f005f005f05f05f05f0f05m0*5m0* m0m0000m0m00m0m00m0*m0*m0TEGCholMIMAT0004809 5m0*0*f0*5m0*0 hsa-miR-6295′Pm00005f005f00f00005f05m0*5m0*0*0*fm0m0m0m0m0m0m00m0m0m0m0*m0*m0TEGChol MIMAT0004810 0*5m0*0 hsa-miR-629*5′Pm005f00f05f000f005f00f00*0*5m0*5m0*m0m0m00m0m0m0m00m0m00*m0*m0TEGChol MIMAT0003298 5m0*5m0*0 hsa-miR-6305′Pm00005f0000f0005f05f00*0*5m0*0*f0*0m0m00m0m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003299 *0 hsa-miR-6315′Pm05f005f05f05f000f05f05f05f05f05m0*0* m0m0000m0m0m00m00m0*0*m0TEGCholMIMAT0003300 5m0*0*5m0*5m0*0 hsa-miR-6325′Pm005f005f05f005f05f005f05f0f05m0*0*5 m0m000m0m00m00m0m00*m0*m0TEGCholMIMAT0003302 m0*5m0*f0*0*0 hsa-miR-6335′Pm05f000f05f05f05f05f005f00f05m0*0*0* m0m0m00m0m0000m0m0m0*0*m0TEGCholMIMAT0003303 0*f0*0*0 hsa-miR-634 5′Pm005f005f00005f05f000f05m0*0*5m0*5m0m0m0m00m0m0m0m0m0m00*m0*m0TEGChol MIMAT0003304 m0*f0*5m0*0 hsa-miR-6355′Pm0005f0f05f000f00005f05m0*0*0*0*5mm0m0m0m0m0m0m0m00m00m0*m0*m0TEGChol MIMAT0003305 0*0*0 hsa-miR-6365′Pm005f05f0f05f000f005f00f00*0*5m0*5m m0m0m00m0m0m0m00m000*m0*m0TEGCholMIMAT0003306 0*f0*5m0*0 hsa-miR-6375′Pm0000f05f05f05f0f0000f05m0*0*0*0*f0*m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0003307 0*0 hsa-miR-6385′Pm005f05f05f00005f005f005f05m0*5m0*0m0m0m00m0m0m0m0m0m000*m0*m0TEGChol MIMAT0003308 *5m0*f0*5m0*0hsa-miR-639 5′Pm0000f0000f00005f00*0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEG MIMAT0003309 *5m0*0 Chol hsa-miR-6405′Pm05f005f0f0005f05f05f0005f00*5m0*0*5m0m0m0m00m00m0m0m00m0*0*m0TEGChol MIMAT0003310 m0*f0*0*0 hsa-miR-6415′Pm05f000f0005f05f05f005f0f00*0*5m0*5 m0m00m00m00m0m0m0m0m0*0*m0TEGCholMIMAT0003311 m0*5m0*5m0*0 hsa-miR-642a5′Pm05f05f05f0f05f05f05f05f05f05f05f05f05 m0m0000m0000m000*0*m0TEGCholMIMAT0003312 m0*5m0*5m0*5m0*5m0*5m0*0 hsa-miR-642b5′Pm0005f05f05f05f005f0005f05f05m0*5m0 m0m00m0m0m0m000m00m0*m0*m0TEGCholMIMAT0018444 *0*0*f0** hsa-miR-6435′Pm0000f05f05f00f05f05f05f05f05m0*5m0* m0m0000m0m000m0m0m0*m0*m0TEGCholMIMAT0003313 5m0*5m0*5m0*0*0 hsa-miR-6445′Pm0005f0f005f05f05f05f005f05f05m0*5m0 m0m00m00m000m0m00m0*m0*m0TEGCholMIMAT0003314 *0*5m0*f0*0*0 hsa-miR-6455′Pm005f005f005f05f05f005f05f05f00*0*0*0m0m000m0m000m0m0m00*m0*m0TEGChol MIMAT0003315 *f0*5m0*0 hsa-miR-6465′Pm0000f05f0005f005f005f00*5m0*5m0*0m0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003316 *5m0*5m0*0 hsa-miR-6475′Pm0000f0005f05f05f05f05f05f05m0*5m0* m0m0000m00m0m0m0m0m0*m0*m0TEGCholMIMAT0003317 5m0*5m0*f0*0*0 hsa-miR-6485′Pm05f000f0005f0f0005f0f05m0*0*0*0*f0*m0m00m0m0m00m0m0m0m0m0*0*m0TEGChol MIMAT0003318 0*0 hsa-miR-6495′Pm05f05f005f05f05f05f05f005f05f0f05m0* m0m000m0m0000m0m00*0*m0TEGCholMIMAT0003319 5m0*5m0*0*f0*0*0 hsa-miR-6505′Pm0000f05f05f05f0f00005f05m0*5m0*5m m0m0m0m0m0m0000m0m0m0*m0*m0TEGCholMIMAT0003320 0*5m0*f0*0*0 hsa-miR-6515′Pm05f05f05f0f00005f05f05f05f0f00*5m0*5 m0m0000m0m0m0m0m000*0*m0TEGCholMIMAT0003321 m0*5m0*5m0*0*0 hsa-miR-6525′Pm005f05f05f05f05f00f0005f05f05m0*0*0 m0m00m0m0m0m000m000*m0*m0TEGCholMIMAT0003322 *0*5m0*0*0 hsa-miR-6535′Pm05f005f0f05f05f05f0f05f05f05f05f00*0* m0m0000m0000m00m0*0*m0TEGCholMIMAT0003328 5m0*0*f0** hsa-miR-654-3p5′Pm05f05f05f05f05f000f05f005f0f00*5m0*0 m0m00m00m0m0m00m000*0*m0TEGCholMIMAT0004814 *0*f0*5m0*0 hsa-miR-654-5p5′Pm00005f0005f05f005f005f05m0*0*5m0*m0m0m00m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0003330 5m0*5m0*0*0 hsa-miR-6555′Pm0000f0005f05f0000f00*5m0*0*0*f0*0*0m0m0m0m0m0m00m0m0m0m0m0*m0*m0TEGChol MIMAT0003331 hsa-miR-6565′Pm005f05f0f05f005f0f005f005f05m0*5m0* m0m0m00m0m00m00m000*m0*m0TEGCholMIMAT0003332 0*5m0*5m0*5m0*0 hsa-miR-6575′Pm05f05f005f005f05f0f05f05f00f00*0*0*5 m0m0m000m000m0m0m00*0*m0TEGCholMIMAT0003335 m0*5m0*5m0*0 hsa-miR-6585′Pm00005f0000f05f05f05f05f05m0*0*5m0*m0m0000m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003336 5m0*5m0*5m0*0hsa-miR-659 5′Pm005f05f05f05f05f05f05f005f05f05f05m0m0m000m0m0000m000*m0*m0TEGChol MIMAT0003337 *5m0*5m0*0*f0*0*0hsa-miR-660 5′Pm05f05f05f0f0000f05f000f05m0*5m0*5mm0m0m0m00m0m0m0m0m000*0*m0TEGChol MIMAT0003338 0*5m0*5m0*5m0*0hsa-miR-661 5′Pm05f005f0f05f05f05f05f005f005f05m0*0*m0m0m00m0m0000m00m0*0*m0TEGChol MIMAT0003324 5m0*0*f0*5m0*0 hsa-miR-6625′Pm005f05f0f05f0005f005f00f00*0*5m0*5 m0m0m00m0m0m0m00m000*m0*m0TEGCholMIMAT0003325 m0*5m0*0*0 hsa-miR-6635′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0003326 *5m0*0*5m0*5m0*0 hsa-miR-663b5′Pm05f05f00f05f05f00f005f05f0f00*5m0*0* m0m000m0m0m000m0m00*0*m0TEGCholMIMAT0005867 5m0*f0*0*0 hsa-miR-6645′Pm00005f00005f0000f00*0*0*0*5m0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0005949 Chol hsa-miR-664* 5′Pm0005f05f0005f0f05f005f0f05m0*5m0*5m0m00m00m00m0m0m00m0*m0*m0TEGChol MIMAT0005948 m0*5m0*5m0*5m0*hsa-miR-665 5′Pm0005f0f05f0005f005f05f0f00*5m0*0*0*m0m000m0m0m0m00m00m0*m0*m0TEGChol MIMAT0004952 f0*5m0* hsa-miR-6685′Pm05f05f05f05f005f005f005f00f00*0*5m0 m0m0m00m0m0m00m0m000*0*m0TEGCholMIMAT0003881 *5m0*5m0*0*0 hsa-miR-6705′Pm005f05f05f05f05f05f0f05f005f0f00*5m0 m0m00m00m0000m000*m0*m0TEGCholMIMAT0010357 *0*0*f0*0*0 hsa-miR-671-3p5′Pm00005f05f05f05f05f0000f00*5m0*0*0*fm0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004819 0*0*0 hsa-miR-671-5p5′Pm0005f0f05f05f05f0f05f0005f05m0*5m0* m0m0m0m00m0000m00m0*m0*m0TEGCholMIMAT0003880 5m0*0*f0*5m0* hsa-miR-6755′Pm0000f05f000f005f005f00*0*5m0*0*5mm0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0004284 0*0*0 hsa-miR-675*5′Pm0005f05f05f005f0f00005f05m0*0*0*0*fm0m0m0m0m0m00m00m00m0*m0*m0TEGChol MIMAT0006790 0*5m0*0 hsa-miR-6765′Pm0000f05f05f05f05f05f05f05f05f05m0*5 m0m0000m0000m0m0m0*m0*m0TEGCholMIMAT0018204 m0*0*5m0*f0*0*0 hsa-miR-676*5′Pm0005f0f05f05f005f05f05f00f05m0*0*0* m0m0m000m0m000m00m0*m0*m0TEGCholMIMAT0018203 0*f0*0*0 hsa-miR-7 5′Pm0005f0f00005f005f05f0f05m0*0*0*0*f0m0m000m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0000252 *5m0*0 hsa-miR-7085′Pm05f005f0f0000f0000f05m0*5m0*5m0*5m0m0m0m0m0m0m0m0m0m00m0*0*m0TEGChol MIMAT0004926 m0*5m0*5m0*0hsa-miR-708* 5′Pm005f05f05f005f005f0000f00*0*5m0*5mm0m0m0m0m0m0m00m0m000*m0*m0TEGChol MIMAT0004927 0*f0*0* hsa-miR-7-1*5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0004553 *5m0*0*f0*0*0 hsa-miR-7115′Pm005f00f05f05f05f0f005f05f0f05m0*0*5 m0m000m0m0000m0m00*m0*m0TEGCholMIMAT0012734 m0*5m0*5m0*0*0 hsa-miR-7185′Pm05f000f0005f05f05f000f00*0*0*5m0*f0m0m0m0m00m00m0m0m0m0m0*0*m0TEGChol MIMAT0012735 *0* hsa-miR-7-2*5′Pm0005f05f0000f0005f0f00*0*5m0*0*f0*m0m00m0m0m0m0m0m0m00m0*m0*m0TEGChol MIMAT0004554 0*0 hsa-miR-7205′Pm05f05f005f005f05f0f05f05f00f00*0*0*5 m0m0m000m000m0m0m00*0*m0TEGCholMIMAT0005954 m0*5m0*0*0 hsa-miR-7445′Pm005f05f0f005f00f05f0005f00*5m0*5m0 m0m0m0m00m0m00m0m000*m0*m0TEGCholMIMAT0004945 *5m0*f0*5m0*0 hsa-miR-744*5′Pm0000f05f005f0f05f05f05f0f00*5m0*0*5 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0004946 m0*f0*0*0 hsa-miR-7585′Pm00005f05f05f05f05f0005f0f05m0*0*5m m0m00m0m0m0000m0m0m0*m0*m0TEGCholMIMAT0003879 0*5m0*f0*0*0 hsa-miR-7595′Pm05f0005f05f05f005f05f000f00*5m0*5m m0m0m0m00m0m000m0m0m0*0*m0TEGCholMIMAT0010497 0*0*f0*0*0 hsa-miR-7605′Pm0000f05f05f005f00005f00*5m0*5m0*0m0m0m0m0m0m0m000m0m0m0*m0*m0TEGChol MIMAT0004957 *f0*5m0*0 hsa-miR-7615′Pm005f05f05f005f05f05f005f05f05f05m0*5 m0m000m0m000m0m000*m0*m0TEGCholMIMAT0010364 m0*0*0*5m0*5m0*0 hsa-miR-7625′Pm005f005f005f05f05f05f05f05f05f00*0*0 m0m0000m000m0m0m00*m0*m0TEGCholMIMAT0010313 *0*5m0*0*0 hsa-miR-7645′Pm05f05f005f005f05f0f05f05f00f05m0*0*0 m0m0m000m000m0m0m00*0*m0TEGCholMIMAT0010367 *5m0*5m0*0*0 hsa-miR-7655′Pm00005f05f05f005f005f05f05f00*5m0*0*m0m000m0m0m000m0m0m0*m0*m0TEGChol MIMAT0003945 0*f0*5m0*0 hsa-miR-7665′Pm05f005f05f05f000f05f05f05f0f00*0*0*0 m0m0000m0m0m00m00m0*0*m0TEGCholMIMAT0003888 *f0*5m0*0 hsa-miR-767-3p5′Pm00005f00005f0000f00*0*0*0*5m0*0*0 m0m0m0m0m0m0m0m0m0m0m0m0*m0*m0TEGMIMAT0003883 Chol hsa-miR-767-5p 5′Pm00005f05f000f005f05f0f00*0*0*0*f0*5m0m000m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0003882 m0*0 hsa-miR-769-3p5′Pm00005f00005f05f005f0f00*5m0*0*5m0m0m00m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003887 *f0*0*0 hsa-miR-769-5p5′Pm00005f00005f005f05f05f00*0*5m0*0*fm0m000m0m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0003886 0*0*0 hsa-miR-770-5p5′Pm05f0005f0000f005f00f00*0*0*5m0*5mm0m0m00m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0003948 0*5m0*0 hsa-miR-8025′Pm05f05f00f05f05f00f0000f00*0*5m0*0*fm0m0m0m0m0m0m000m0m00*0*m0TEGChol MIMAT0004185 0*5m0*0 hsa-miR-8735′Pm05f0005f05f05f05f05f05f05f00f00*0*5m m0m0m000m0000m0m0m0*0*m0TEGCholMIMAT0004953 0*5m0*** hsa-miR-8745′Pm005f05f05f05f05f05f0f005f005f00*0*5m m0m0m00m0m0000m000*m0*m0TEGCholMIMAT0004911 0*0*5m0*5m0*0 hsa-miR-875-3p5′Pm05f05f00f0005f05f05f05f00f05m0*5m0* m0m0m000m00m0m0m0m00*0*m0TEGCholMIMAT0004923 5m0*5m0*f0*5m0* hsa-miR-875-5p5′Pm005f00f05f005f05f05f05f05f05f00*5m0* m0m0000m00m00m0m00*m0*m0TEGCholMIMAT0004922 5m0*5m0*5m0*0*0 hsa-miR-876-3p5′Pm05f05f005f0005f0f0005f05f05m0*5m0* m0m00m0m0m00m0m0m0m00*0*m0TEGCholMIMAT0004925 5m0*5m0*f0*0*0 hsa-miR-876-5p5′Pm05f05f005f05f05f05f0f0005f0f05m0*5m m0m00m0m0m0000m0m00*0*m0TEGCholMIMAT0004924 0*5m0*5m0*5m0*5m0*0 hsa-miR-8775′Pm05f005f05f05f05f00f05f05f05f0f00*0*0* m0m0000m0m000m00m0*0*m0TEGCholMIMAT0004949 0*f0*5m0*0 hsa-miR-877*5′Pm00005f005f00f0000f00*5m0*5m0*0*f0 m0m0m0m0m0m00m0m0m0m0*m0*m0TEGCholMIMAT0004950 *0*0 hsa-miR-885-3p 5′Pm05f05f05f05f05f05f005f0000f00*5m0*5m0m0m0m0m0m0m000m000*0*m0TEGChol MIMAT0004948 m0*0*5m0*5m0*0hsa-miR-885-5p 5′Pm005f00f0005f0f0000f00*5m0*0*5m0*5m0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0004947 m0*0*0 hsa-miR-8875′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0004951 *5m0*0*f0*0*0 hsa-miR-8885′Pm05f05f05f05f0000f0000f00*5m0*0*5m0m0m0m0m0m0m0m0m0m0m000*0*m0TEGChol MIMAT0004916 *5m0*5m0*0 hsa-miR-888*5′Pm0000f05f000f005f005f05m0*0*5m0*0*fm0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0004917 0*5m0*0 hsa-miR-8895′Pm05f05f05f0f0005f05f0000f05m0*5m0*5 m0m0m0m0m0m00m0m0m000*0*m0TEGCholMIMAT0004921 m0*5m0*f0*5m0* hsa-miR-8905′Pm005f00f0005f0f05f05f00f05m0*0*5m0* m0m0m000m00m0m0m0m00*m0*m0TEGCholMIMAT0004912 5m0*f0*5m0*0 hsa-miR-891a5′Pm05f005f0f05f005f0f05f000f00*5m0*0*5 m0m0m0m00m00m00m00m0*0*m0TEGCholMIMAT0004902 m0*5m0*5m0*0 hsa-miR-891b5′Pm0005f05f05f0005f05f05f00f05m0*0*0*0m0m0m000m0m0m00m00m0*m0*m0TEGChol MIMAT0004913 *f0*0*0 hsa-miR-892a5′Pm0005f0f05f05f00f05f05f05f05f05m0*5m m0m0000m0m000m00m0*m0*m0TEGCholMIMAT0004907 0*0*5m0*5m0*0*0 hsa-miR-892b5′Pm005f00f005f00f05f000f05m0*5m0*5m0 m0m0m0m00m0m00m0m0m00*m0*m0TEGCholMIMAT0004918 *5m0*f0*0*0 hsa-miR-95′Pm05f000f05f05f05f0f05f05f05f0f00*0*5m m0m0000m0000m0m0m0*0*m0TEGCholMIMAT0000441 0*5m0*5m0*0*0 hsa-miR-9*5′Pm05f005f0f05f000f05f005f0f05m0*0*5m0 m0m00m00m0m0m00m00m0*0*m0TEGCholMIMAT0000442 *0*5m0*0*0 hsa-miR-9205′Pm05f05f00f0000f05f05f00f00*0*5m0*5m m0m0m000m0m0m0m0m0m00*0*m0TEGCholMIMAT0004970 0*5m0*5m0*0 hsa-miR-9215′Pm005f05f0f05f05f05f0f005f05f05f00*0*5 m0m000m0m0000m000*m0*m0TEGCholMIMAT0004971 m0*5m0*5m0*0*0 hsa-miR-9225′Pm05f05f05f05f05f000f05f005f0f05m0*0*5 m0m00m00m0m0m00m000*0*m0TEGCholMIMAT0004972 m0*0*f0*5m0*0 hsa-miR-9245′Pm0000f0005f05f05f05f00f00*0*5m0*5m0m0m0m000m00m0m0m0m0m0*m0*m0TEGChol MIMAT0004974 *5m0*5m0*0 hsa-miR-92a5′Pm005f005f0005f0f05f05f005f00*5m0*5m m0m0m000m00m0m0m0m00*m0*m0TEGCholMIMAT0000092 0*5m0*5m0*5m0*0 hsa-miR-92a-1*5′Pm0000f05f005f05f05f05f05f05f05m0*5m0 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0004507 *5m0*0*f0*0*0 hsa-miR-92a-2*5′Pm05f05f05f0f0000f0000f05m0*0*5m0*5 m0m0m0m0m0m0m0m0m0m000*0*m0TEGCholMIMAT0004508 m0*5m0*5m0*0 hsa-miR-92b5′Pm005f00f05f005f0f0005f0f00*5m0*0*5m m0m00m0m0m00m00m0m00*m0*m0TEGCholMIMAT0003218 0*f0*5m0*0 hsa-miR-92b*5′Pm05f05f00f00005f005f05f0f00*0*0*5m0*m0m000m0m0m0m0m0m0m00*0*m0TEGChol MIMAT0004792 5m0*0*0 hsa-miR-935′Pm00005f05f0005f005f00f00*5m0*0*0*f0m0m0m00m0m0m0m00m0m0m0*m0*m0TEGChol MIMAT0000093 *5m0*0 hsa-miR-93*5′Pm05f000f00005f0000f00*0*0*5m0*f0*0*0m0m0m0m0m0m0m0m0m0m0m0m0*0*m0TEGChol MIMAT0004509 hsa-miR-9335′Pm05f05f00f05f05f05f05f05f000f00*5m0*5 m0m0m0m00m0000m0m00*0*m0TEGCholMIMAT0004976 m0*5m0*5m0*0*0 hsa-miR-9345′Pm005f05f05f005f05f0f0005f05f00*0*5m0 m0m00m0m0m000m0m000*m0*m0TEGCholMIMAT0004977 *0*5m0*5m0*0 hsa-miR-9355′Pm0005f0f05f05f005f05f005f0f05m0*0*5m m0m00m00m0m000m00m0*m0*m0TEGCholMIMAT0004978 0*5m0*f0*5m0*0 hsa-miR-9365′Pm0000f05f005f05f005f05f05f00*5m0*0*5m0m000m0m00m00m0m0m0*m0*m0TEGChol MIMAT0004979 m0*f0*0*0 hsa-miR-9375′Pm05f05f05f05f05f005f05f05f000f05m0*0* m0m0m0m00m00m00m000*0*m0TEGCholMIMAT0004980 5m0*5m0*f0** hsa-miR-9385′Pm05f000f05f005f0f0000f05m0*5m0*0*0*m0m0m0m0m0m00m00m0m0m0*0*m0TEGChol MIMAT0004981 f0*0*0 hsa-miR-9395′Pm005f005f05f05f05f0f005f05f05f05m0*0* m0m000m0m0000m0m00*m0*m0TEGCholMIMAT0004982 5m0*5m0*f0*0*0 hsa-miR-9405′Pm0005f0f005f005f005f05f0f05m0*5m0*0 m0m000m0m0m00m0m00m0*m0*m0TEGCholMIMAT0004983 *0*5m0*5m0*0 hsa-miR-9415′Pm005f00f0005f0f0000f05m0*0*0*5m0*f0m0m0m0m0m0m00m0m0m0m00*m0*m0TEGChol MIMAT0004984 *0*0 hsa-miR-9425′Pm05f005f0f05f0005f05f05f005f05m0*0*5 m0m0m000m0m0m00m00m0*0*m0TEGCholMIMAT0004985 m0*5m0*5m0*5m0*0 hsa-miR-9435′Pm0000f05f005f0f05f05f05f0f00*5m0*0*5 m0m0000m00m00m0m0m0*m0*m0TEGCholMIMAT0004986 m0*f0*0*0 hsa-miR-9445′Pm005f00f05f05f05f05f0000f00*0*0*0*5mm0m0m0m0m0m0000m0m00*m0*m0TEGChol MIMAT0004987 0*0*0 hsa-miR-955′Pm00005f0000f05f000f05m0*5m0*5m0*0m0m0m0m00m0m0m0m0m0m0m0*m0*m0TEGChol MIMAT0000094 *f0*5m0*0 hsa-miR-965′Pm0005f0f0005f0f05f0005f00*5m0*0*0*5m0m0m0m00m00m0m0m00m0*m0*m0TEGChol MIMAT0000095 m0*5m0*0 hsa-miR-96*5′Pm005f00f005f005f00005f00*5m0*5m0*0m0m0m0m0m0m0m00m0m0m00*m0*m0TEGChol MIMAT0004510 *f0*5m0*0 hsa-miR-985′Pm0000f005f05f05f05f000f00*0*0*0*5m0m0m0m0m00m000m0m0m0m0*m0*m0TEGChol MIMAT0000096 *5m0*0 hsa-miR-99a5′Pm005f00f005f00f05f005f05f05m0*0*5m0 m0m00m00m0m00m0m0m00*m0*m0TEGCholMIMAT0000097 *5m0*f0*0*0 hsa-miR-99a*5′Pm005f05f05f05f000f05f005f05f05m0*5m0 m0m00m00m0m0m00m000*m0*m0TEGCholMIMAT0004511 *5m0*5m0*5m0*5m0*0 hsa-miR-99b5′Pm0000f0005f0f05f005f0f00*5m0*0*0*f0*m0m00m00m00m0m0m0m0m0*m0*m0TEGChol MIMAT0000689 5m0*0 hsa-miR-99b*5′Pm00005f05f05f05f0f0000f05m0*0*5m0*5m0m0m0m0m0m0000m0m0m0*m0*m0TEGChol MIMAT0004678 m0*f0*0*0

Having thus described several aspects of at least one embodiment of thisinvention, it is to be appreciated various alterations, modifications,and improvements will readily occur to those skilled in the art. Suchalterations, modifications, and improvements are intended to be part ofthis disclosure, and are intended to be within the spirit and scope ofthe invention. Accordingly, the foregoing description and drawings areby way of example only.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents areintended to be encompassed by the following claims.

All references, including patent documents, disclosed herein areincorporated by reference in their entirety. This applicationincorporates by reference the entire contents, including all thedrawings and all parts of the specification.

1. An isolated nucleic acid molecule comprising a guide strand of 18-23nucleotides in length that has complementarity to a miRNA sequence, apassenger strand of 8-16 nucleotides in length, wherein the guide strandand the passenger strand form the nucleic acid molecule such that thenucleic acid has a double stranded region and a single stranded region,wherein the single stranded region is the 3′ end of the guide strand andis 2-13 nucleotides in length and comprises at least twophosphorothioate modifications, and wherein at least 50% of thepyrimidines in the nucleic acid molecule are modified.
 2. The nucleicacid molecule of claim 1, wherein the nucleotide in position one of theguide strand has a 2′-O-methyl modification, optionally wherein the2′-O-methyl modification is a 5P-2′O-methyl U modification. 3.(canceled)
 4. The nucleic acid molecule of claim 2, wherein at least60%, at least 80%, at least 90% or wherein 100% of the pyrimidines inthe nucleic acid molecule are modified. 5.-7. (canceled)
 8. The nucleicacid molecule of claim 2, wherein modified pyrimidines are 2′fluoro or2′O methyl modified.
 9. The nucleic acid molecule of claim 2, wherein atleast one U or C includes a hydrophobic modification, optionally whereina plurality of U's and/or C's include a hydrophobic modification. 10.(canceled)
 11. The nucleic acid molecule of claim 9, wherein thehydrophobic modification is a methyl or ethyl hydrophobic basemodification.
 12. The nucleic acid molecule of claim 2, wherein theguide strand contains 6-8 phosphorothioate modifications, optionallywherein the 3′ terminal 10 nucleotides of the guide strand include atleast eight phosphorothioate modifications.
 13. (canceled)
 14. Thenucleic acid molecule of claim 2, wherein the guide strand includes 4-14phosphate modifications.
 15. The nucleic acid molecule of claim 2,wherein the single stranded region of the guide strand is 6 nucleotideslong or 8 nucleotides long.
 16. (canceled)
 17. The nucleic acid moleculeof claim 2, wherein the double stranded region is 13 nucleotides long.18. The nucleic acid molecule of claim 2, wherein the double strandednucleic acid molecule has one end that is blunt or includes a onenucleotide overhang.
 19. The nucleic acid molecule of claim 2, whereinthe passenger strand is linked at the 3′ end to a lipophilic group. 20.The nucleic acid molecule of claim 19, wherein the lipophilic group is asterol, optionally wherein the sterol is cholesterol.
 21. (canceled) 22.The nucleic acid molecule of claim 2, wherein the isolated doublestranded nucleic acid molecule is an miRNA mimic and wherein the miRNAsequence to which the guide strand is complementary is a miRNArecognition element, optionally wherein the miRNA mimic is a mimic of amiRNA selected from the group consisting of miR21, miR 139, miR 7,miR29, miR 122, miR 302-367 cluster, miR 221, miR-96, miR 126, miR 225and miR
 206. 23. (canceled)
 24. The nucleic acid molecule of claim 2,wherein the isolated double stranded nucleic acid molecule is an miRNAinhibitor and wherein the miRNA sequence to which the guide strand iscomplementary is an antisense strand of a mature miRNA.
 25. The nucleicacid molecule of claim 24, wherein the guide strand is at least 50%chemically modified.
 26. The nucleic acid molecule of claim 24, whereinthe mature miRNA is miR 17-92.
 27. A method for modulatingmiRNA-mediated gene expression in a mammalian cell, comprisingcontacting the mammalian cell with an isolated double stranded nucleicacid molecule of claim 1 in an effective amount to modulatemiRNA-mediated gene expression. 28.-29. (canceled)
 30. The method ofclaim 27, wherein the mammalian cell is contacted with the isolatednucleic acid in vivo or ex vivo.
 31. (canceled)
 32. A method formodulating miRNA-mediated gene expression in a stem cell, comprisingcontacting the stem cell with an isolated double stranded nucleic acidmolecule of claim 1 in an effective amount to modulate miRNA-mediatedgene expression in the stem cell.